primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
124601402,12460140,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2019,Q1,Drug hypersensitivity,,2019,Q1,2,F,,20190124.0,20160613,20190205,PER,,US-PFIZER INC-2016297037,PFIZER,,61.0,YR,,M,Y,,,20190205.0,,MD,US,US,2019,Q1,Adult
130693853,13069385,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Urine ketone body present,,2019,Q1,3,F,20160627.0,20190207.0,20161228,20190214,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001697",BOEHRINGER INGELHEIM,,60.0,YR,,M,Y,79.0,KG,20190214.0,,MD,JP,JP,2019,Q1,Adult
133797574,13379757,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Blood ketone body increased,,2019,Q1,4,F,20160701.0,20190320.0,20170328,20190327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20190327.0,,MD,JP,JP,2019,Q1,Adult
133797574,13379757,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Blood uric acid increased,,2019,Q1,4,F,20160701.0,20190320.0,20170328,20190327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20190327.0,,MD,JP,JP,2019,Q1,Adult
133797574,13379757,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Red blood cell count increased,,2019,Q1,4,F,20160701.0,20190320.0,20170328,20190327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20190327.0,,MD,JP,JP,2019,Q1,Adult
133797574,13379757,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Urine ketone body present,,2019,Q1,4,F,20160701.0,20190320.0,20170328,20190327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20190327.0,,MD,JP,JP,2019,Q1,Adult
133797574,13379757,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Blood ketone body increased,,2019,Q1,4,F,20160701.0,20190320.0,20170328,20190327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20190327.0,,MD,JP,JP,2019,Q1,Adult
133797574,13379757,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Blood uric acid increased,,2019,Q1,4,F,20160701.0,20190320.0,20170328,20190327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20190327.0,,MD,JP,JP,2019,Q1,Adult
133797574,13379757,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Red blood cell count increased,,2019,Q1,4,F,20160701.0,20190320.0,20170328,20190327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20190327.0,,MD,JP,JP,2019,Q1,Adult
133797574,13379757,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Urine ketone body present,,2019,Q1,4,F,20160701.0,20190320.0,20170328,20190327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20190327.0,,MD,JP,JP,2019,Q1,Adult
134179163,13417916,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Blood ketone body increased,,2019,Q1,3,F,20170113.0,20190314.0,20170406,20190320,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001692",BOEHRINGER INGELHEIM,,46.0,YR,,F,Y,74.1,KG,20190320.0,,MD,JP,JP,2019,Q1,Adult
134179163,13417916,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Urine ketone body present,,2019,Q1,3,F,20170113.0,20190314.0,20170406,20190320,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001692",BOEHRINGER INGELHEIM,,46.0,YR,,F,Y,74.1,KG,20190320.0,,MD,JP,JP,2019,Q1,Adult
134179163,13417916,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Blood ketone body increased,,2019,Q1,3,F,20170113.0,20190314.0,20170406,20190320,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001692",BOEHRINGER INGELHEIM,,46.0,YR,,F,Y,74.1,KG,20190320.0,,MD,JP,JP,2019,Q1,Adult
134179163,13417916,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Urine ketone body present,,2019,Q1,3,F,20170113.0,20190314.0,20170406,20190320,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001692",BOEHRINGER INGELHEIM,,46.0,YR,,F,Y,74.1,KG,20190320.0,,MD,JP,JP,2019,Q1,Adult
135438543,13543854,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Thrombotic cerebral infarction,,2019,Q1,3,F,20170415.0,20190207.0,20170515,20190214,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-002589",BOEHRINGER INGELHEIM,,46.0,YR,,M,Y,95.0,KG,20190214.0,,MD,JP,JP,2019,Q1,Adult
139963343,13996334,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Urine ketone body present,,2019,Q1,3,F,20161025.0,20190207.0,20170921,20190214,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005393",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,85.4,KG,20190214.0,,MD,JP,JP,2019,Q1,Adult
140886817,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Asthma,,2019,Q1,7,F,20160620.0,20190318.0,20171013,20190325,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20190325.0,,MD,JP,JP,2019,Q1,Adult
140886817,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Back pain,,2019,Q1,7,F,20160620.0,20190318.0,20171013,20190325,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20190325.0,,MD,JP,JP,2019,Q1,Adult
140886817,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Blood urea increased,,2019,Q1,7,F,20160620.0,20190318.0,20171013,20190325,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20190325.0,,MD,JP,JP,2019,Q1,Adult
140886817,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Bronchitis,,2019,Q1,7,F,20160620.0,20190318.0,20171013,20190325,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20190325.0,,MD,JP,JP,2019,Q1,Adult
140886817,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Constipation,,2019,Q1,7,F,20160620.0,20190318.0,20171013,20190325,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20190325.0,,MD,JP,JP,2019,Q1,Adult
140886817,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Cystitis,,2019,Q1,7,F,20160620.0,20190318.0,20171013,20190325,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20190325.0,,MD,JP,JP,2019,Q1,Adult
140886817,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Haematocrit increased,,2019,Q1,7,F,20160620.0,20190318.0,20171013,20190325,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20190325.0,,MD,JP,JP,2019,Q1,Adult
140886817,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Herpes zoster,,2019,Q1,7,F,20160620.0,20190318.0,20171013,20190325,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20190325.0,,MD,JP,JP,2019,Q1,Adult
140886817,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Ligament sprain,,2019,Q1,7,F,20160620.0,20190318.0,20171013,20190325,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20190325.0,,MD,JP,JP,2019,Q1,Adult
140886817,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Low density lipoprotein increased,,2019,Q1,7,F,20160620.0,20190318.0,20171013,20190325,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20190325.0,,MD,JP,JP,2019,Q1,Adult
140886817,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Polyuria,,2019,Q1,7,F,20160620.0,20190318.0,20171013,20190325,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20190325.0,,MD,JP,JP,2019,Q1,Adult
140886817,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Red blood cell count increased,,2019,Q1,7,F,20160620.0,20190318.0,20171013,20190325,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20190325.0,,MD,JP,JP,2019,Q1,Adult
140886817,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Road traffic accident,,2019,Q1,7,F,20160620.0,20190318.0,20171013,20190325,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20190325.0,,MD,JP,JP,2019,Q1,Adult
140886817,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Upper respiratory tract inflammation,,2019,Q1,7,F,20160620.0,20190318.0,20171013,20190325,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20190325.0,,MD,JP,JP,2019,Q1,Adult
140886817,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Urine ketone body present,,2019,Q1,7,F,20160620.0,20190318.0,20171013,20190325,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20190325.0,,MD,JP,JP,2019,Q1,Adult
145744333,14574433,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2019,Q1,Pulmonary embolism,,2019,Q1,3,F,20180207.0,20190318.0,20180226,20190319,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-010077",BOEHRINGER INGELHEIM,,42.0,YR,,M,Y,116.4,KG,20190320.0,,MD,GB,GB,2019,Q1,Adult
1459376314,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,QD,2019,Q1,Acute kidney injury,,2019,Q1,14,F,20170822.0,20190219.0,20180302,20190222,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,98.2,KG,20190222.0,,MD,US,US,2019,Q1,Elderly
1459376314,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,QD,2019,Q1,Ascites,,2019,Q1,14,F,20170822.0,20190219.0,20180302,20190222,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,98.2,KG,20190222.0,,MD,US,US,2019,Q1,Elderly
1459376314,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,QD,2019,Q1,Cardiac failure,,2019,Q1,14,F,20170822.0,20190219.0,20180302,20190222,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,98.2,KG,20190222.0,,MD,US,US,2019,Q1,Elderly
1459376314,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,QD,2019,Q1,Dyspnoea,,2019,Q1,14,F,20170822.0,20190219.0,20180302,20190222,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,98.2,KG,20190222.0,,MD,US,US,2019,Q1,Elderly
1459376314,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,QD,2019,Q1,Fall,,2019,Q1,14,F,20170822.0,20190219.0,20180302,20190222,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,98.2,KG,20190222.0,,MD,US,US,2019,Q1,Elderly
1459376314,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,QD,2019,Q1,Metabolic acidosis,,2019,Q1,14,F,20170822.0,20190219.0,20180302,20190222,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,98.2,KG,20190222.0,,MD,US,US,2019,Q1,Elderly
1459376314,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,QD,2019,Q1,Renal impairment,,2019,Q1,14,F,20170822.0,20190219.0,20180302,20190222,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,98.2,KG,20190222.0,,MD,US,US,2019,Q1,Elderly
1459376314,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,QD,2019,Q1,Subdural haematoma,,2019,Q1,14,F,20170822.0,20190219.0,20180302,20190222,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,98.2,KG,20190222.0,,MD,US,US,2019,Q1,Elderly
146354118,14635411,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q1,Dehydration,,2019,Q1,8,F,20180308.0,20190219.0,20180314,20190222,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-013543",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,56.0,KG,20190222.0,,MD,DE,DE,2019,Q1,Elderly
146354118,14635411,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q1,Extranodal marginal zone B-cell lymphoma (MALT type),,2019,Q1,8,F,20180308.0,20190219.0,20180314,20190222,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-013543",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,56.0,KG,20190222.0,,MD,DE,DE,2019,Q1,Elderly
146354118,14635411,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q1,Macular degeneration,,2019,Q1,8,F,20180308.0,20190219.0,20180314,20190222,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-013543",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,56.0,KG,20190222.0,,MD,DE,DE,2019,Q1,Elderly
146354118,14635411,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q1,Dehydration,,2019,Q1,8,F,20180308.0,20190219.0,20180314,20190222,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-013543",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,56.0,KG,20190222.0,,MD,DE,DE,2019,Q1,Elderly
146354118,14635411,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q1,Extranodal marginal zone B-cell lymphoma (MALT type),,2019,Q1,8,F,20180308.0,20190219.0,20180314,20190222,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-013543",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,56.0,KG,20190222.0,,MD,DE,DE,2019,Q1,Elderly
146354118,14635411,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q1,Macular degeneration,,2019,Q1,8,F,20180308.0,20190219.0,20180314,20190222,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-013543",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,56.0,KG,20190222.0,,MD,DE,DE,2019,Q1,Elderly
146689755,14668975,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,QD,2019,Q1,Aortic thrombosis,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,QD,2019,Q1,Aphasia,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,QD,2019,Q1,Disorientation,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,QD,2019,Q1,Drug ineffective,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,QD,2019,Q1,Dysarthria,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,QD,2019,Q1,Dysstasia,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,QD,2019,Q1,Hemiparesis,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,QD,2019,Q1,Ischaemic stroke,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,QD,2019,Q1,Paraesthesia,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Aortic thrombosis,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Aphasia,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Disorientation,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Drug ineffective,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Dysarthria,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Dysstasia,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Hemiparesis,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Ischaemic stroke,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
146689755,14668975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Paraesthesia,,2019,Q1,5,F,20180318.0,20190220.0,20180322,20190227,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20190227.0,,MD,BR,BR,2019,Q1,Elderly
148277014,14827701,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"20 MG, QD",,,D,,,,,20.0,MG,TABLET,QD,2019,Q1,Atrial fibrillation,,2019,Q1,4,F,20171002.0,20190115.0,20180430,20190121,EXP,,JP-009507513-1803JPN000430J,MERCK,"MURAKAMI R, MIYAWAKI M, KAMIKO I, TSURUMAKI Y, TADA A, MORIMOTO J, ET AL.. O36-7 A CASE OF DESTRUCTIVE THYROIDITIS AFTER ADMINISTRATION OF PEMBROLIZUMAB IN A PATIENT WITH BASEDOW^S DISEASE.. THE 61ST ANNUAL MEETING OF THE JAPAN THYROID ASSOCIATION OF THE JAPANESE ENDOCRI. 2018;94:1259",76.0,YR,,M,Y,73.0,KG,20190121.0,,MD,JP,JP,2019,Q1,Elderly
148277014,14827701,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"20 MG, QD",,,D,,,,,20.0,MG,TABLET,QD,2019,Q1,Malignant neoplasm progression,,2019,Q1,4,F,20171002.0,20190115.0,20180430,20190121,EXP,,JP-009507513-1803JPN000430J,MERCK,"MURAKAMI R, MIYAWAKI M, KAMIKO I, TSURUMAKI Y, TADA A, MORIMOTO J, ET AL.. O36-7 A CASE OF DESTRUCTIVE THYROIDITIS AFTER ADMINISTRATION OF PEMBROLIZUMAB IN A PATIENT WITH BASEDOW^S DISEASE.. THE 61ST ANNUAL MEETING OF THE JAPAN THYROID ASSOCIATION OF THE JAPANESE ENDOCRI. 2018;94:1259",76.0,YR,,M,Y,73.0,KG,20190121.0,,MD,JP,JP,2019,Q1,Elderly
148277014,14827701,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"20 MG, QD",,,D,,,,,20.0,MG,TABLET,QD,2019,Q1,Thyroiditis,,2019,Q1,4,F,20171002.0,20190115.0,20180430,20190121,EXP,,JP-009507513-1803JPN000430J,MERCK,"MURAKAMI R, MIYAWAKI M, KAMIKO I, TSURUMAKI Y, TADA A, MORIMOTO J, ET AL.. O36-7 A CASE OF DESTRUCTIVE THYROIDITIS AFTER ADMINISTRATION OF PEMBROLIZUMAB IN A PATIENT WITH BASEDOW^S DISEASE.. THE 61ST ANNUAL MEETING OF THE JAPAN THYROID ASSOCIATION OF THE JAPANESE ENDOCRI. 2018;94:1259",76.0,YR,,M,Y,73.0,KG,20190121.0,,MD,JP,JP,2019,Q1,Elderly
150934973,15093497,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q1,Renal impairment,,2019,Q1,3,F,20180202.0,20190311.0,20180629,20190315,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-008515",BOEHRINGER INGELHEIM,,78.0,YR,,F,Y,60.0,KG,20190315.0,,MD,DE,DE,2019,Q1,Elderly
150934973,15093497,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q1,Urosepsis,,2019,Q1,3,F,20180202.0,20190311.0,20180629,20190315,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-008515",BOEHRINGER INGELHEIM,,78.0,YR,,F,Y,60.0,KG,20190315.0,,MD,DE,DE,2019,Q1,Elderly
151346755,15134675,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",4290.0,MG,Y,,,,,10.0,MG,,QD,2019,Q1,Lower respiratory tract infection,,2019,Q1,5,F,20180102.0,20190128.0,20180712,20190201,EXP,,PHHO2018GB000903,NOVARTIS,,62.0,YR,,M,Y,99.1,KG,20190201.0,,OT,GB,GB,2019,Q1,Adult
151346755,15134675,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",4290.0,MG,Y,,,,,10.0,MG,,QD,2019,Q1,Pancreatitis acute,,2019,Q1,5,F,20180102.0,20190128.0,20180712,20190201,EXP,,PHHO2018GB000903,NOVARTIS,,62.0,YR,,M,Y,99.1,KG,20190201.0,,OT,GB,GB,2019,Q1,Adult
151832394,15183239,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q1,Pyelonephritis acute,,2019,Q1,4,F,20180228.0,20190225.0,20180723,20190227,EXP,,"CZ-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-037658",BOEHRINGER INGELHEIM,,70.0,YR,,F,Y,80.0,KG,20190227.0,,MD,CZ,CZ,2019,Q1,Elderly
1524040410,15240404,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,,,2019,Q1,Presyncope,,2019,Q1,10,F,20180723.0,20190116.0,20180804,20190117,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-038855",BOEHRINGER INGELHEIM,,88.0,YR,,M,Y,73.0,KG,20190117.0,,MD,CA,CA,2019,Q1,Elderly
1524040410,15240404,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,,,2019,Q1,Subdural haematoma,,2019,Q1,10,F,20180723.0,20190116.0,20180804,20190117,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-038855",BOEHRINGER INGELHEIM,,88.0,YR,,M,Y,73.0,KG,20190117.0,,MD,CA,CA,2019,Q1,Elderly
152455573,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q1,Acute myocardial infarction,,2019,Q1,3,F,200508.0,20190117.0,20180806,20190123,EXP,,PHHY2018SK058557,SANDOZ,,66.0,YR,,M,Y,,,20190123.0,,OT,SK,SK,2019,Q1,Elderly
152455573,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q1,Diabetes mellitus,,2019,Q1,3,F,200508.0,20190117.0,20180806,20190123,EXP,,PHHY2018SK058557,SANDOZ,,66.0,YR,,M,Y,,,20190123.0,,OT,SK,SK,2019,Q1,Elderly
152455573,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q1,Drug ineffective,,2019,Q1,3,F,200508.0,20190117.0,20180806,20190123,EXP,,PHHY2018SK058557,SANDOZ,,66.0,YR,,M,Y,,,20190123.0,,OT,SK,SK,2019,Q1,Elderly
152455573,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q1,Glycosylated haemoglobin decreased,,2019,Q1,3,F,200508.0,20190117.0,20180806,20190123,EXP,,PHHY2018SK058557,SANDOZ,,66.0,YR,,M,Y,,,20190123.0,,OT,SK,SK,2019,Q1,Elderly
152455573,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q1,Glycosylated haemoglobin increased,,2019,Q1,3,F,200508.0,20190117.0,20180806,20190123,EXP,,PHHY2018SK058557,SANDOZ,,66.0,YR,,M,Y,,,20190123.0,,OT,SK,SK,2019,Q1,Elderly
152455573,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q1,Hyperlipidaemia,,2019,Q1,3,F,200508.0,20190117.0,20180806,20190123,EXP,,PHHY2018SK058557,SANDOZ,,66.0,YR,,M,Y,,,20190123.0,,OT,SK,SK,2019,Q1,Elderly
152455573,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q1,Hypertension,,2019,Q1,3,F,200508.0,20190117.0,20180806,20190123,EXP,,PHHY2018SK058557,SANDOZ,,66.0,YR,,M,Y,,,20190123.0,,OT,SK,SK,2019,Q1,Elderly
152455573,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q1,Myocardial infarction,,2019,Q1,3,F,200508.0,20190117.0,20180806,20190123,EXP,,PHHY2018SK058557,SANDOZ,,66.0,YR,,M,Y,,,20190123.0,,OT,SK,SK,2019,Q1,Elderly
152455573,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q1,Weight increased,,2019,Q1,3,F,200508.0,20190117.0,20180806,20190123,EXP,,PHHY2018SK058557,SANDOZ,,66.0,YR,,M,Y,,,20190123.0,,OT,SK,SK,2019,Q1,Elderly
152969422,15296942,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,,,TABLET,,2019,Q1,Hypokalaemia,,2019,Q1,2,F,20180809.0,20190219.0,20180820,20190227,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-041179",BOEHRINGER INGELHEIM,,77.0,YR,,F,Y,77.6,KG,20190227.0,,MD,US,US,2019,Q1,Elderly
153320912,15332091,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD  (DAILY DOSE)",,,,,,,,25.0,MG,,QD,2019,Q1,Colitis microscopic,,2019,Q1,2,F,20180414.0,20190301.0,20180829,20190309,EXP,,PHHY2018DE079229,SANDOZ,,77.0,YR,,F,Y,87.0,KG,20190310.0,,OT,DE,DE,2019,Q1,Elderly
153320912,15332091,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD  (DAILY DOSE)",,,,,,,,25.0,MG,,QD,2019,Q1,Contusion,,2019,Q1,2,F,20180414.0,20190301.0,20180829,20190309,EXP,,PHHY2018DE079229,SANDOZ,,77.0,YR,,F,Y,87.0,KG,20190310.0,,OT,DE,DE,2019,Q1,Elderly
153320912,15332091,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD  (DAILY DOSE)",,,,,,,,25.0,MG,,QD,2019,Q1,Fall,,2019,Q1,2,F,20180414.0,20190301.0,20180829,20190309,EXP,,PHHY2018DE079229,SANDOZ,,77.0,YR,,F,Y,87.0,KG,20190310.0,,OT,DE,DE,2019,Q1,Elderly
153320912,15332091,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD  (DAILY DOSE)",,,,,,,,25.0,MG,,QD,2019,Q1,Gastrointestinal haemorrhage,,2019,Q1,2,F,20180414.0,20190301.0,20180829,20190309,EXP,,PHHY2018DE079229,SANDOZ,,77.0,YR,,F,Y,87.0,KG,20190310.0,,OT,DE,DE,2019,Q1,Elderly
153320912,15332091,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD  (DAILY DOSE)",,,,,,,,25.0,MG,,QD,2019,Q1,Pseudomonas test positive,,2019,Q1,2,F,20180414.0,20190301.0,20180829,20190309,EXP,,PHHY2018DE079229,SANDOZ,,77.0,YR,,F,Y,87.0,KG,20190310.0,,OT,DE,DE,2019,Q1,Elderly
153320912,15332091,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD  (DAILY DOSE)",,,,,,,,25.0,MG,,QD,2019,Q1,Spinal instability,,2019,Q1,2,F,20180414.0,20190301.0,20180829,20190309,EXP,,PHHY2018DE079229,SANDOZ,,77.0,YR,,F,Y,87.0,KG,20190310.0,,OT,DE,DE,2019,Q1,Elderly
154113132,15411313,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2019,Q1,Drug hypersensitivity,,2019,Q1,2,F,,20190104.0,20180921,20190109,PER,,US-PFIZER INC-2018380693,PFIZER,,62.0,YR,,M,Y,,,20190109.0,,MD,US,US,2019,Q1,Adult
154594367,15459436,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Cardiac dysfunction,,2019,Q1,7,F,2018.0,20190103.0,20181003,20190111,EXP,,PHHY2018CO008285,SANDOZ,,61.0,YR,,M,Y,65.0,KG,20190111.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Adult
154594367,15459436,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Cardiac failure,,2019,Q1,7,F,2018.0,20190103.0,20181003,20190111,EXP,,PHHY2018CO008285,SANDOZ,,61.0,YR,,M,Y,65.0,KG,20190111.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Adult
154594367,15459436,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Choking,,2019,Q1,7,F,2018.0,20190103.0,20181003,20190111,EXP,,PHHY2018CO008285,SANDOZ,,61.0,YR,,M,Y,65.0,KG,20190111.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Adult
154594367,15459436,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Contraindicated product administered,,2019,Q1,7,F,2018.0,20190103.0,20181003,20190111,EXP,,PHHY2018CO008285,SANDOZ,,61.0,YR,,M,Y,65.0,KG,20190111.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Adult
154594367,15459436,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Decreased appetite,,2019,Q1,7,F,2018.0,20190103.0,20181003,20190111,EXP,,PHHY2018CO008285,SANDOZ,,61.0,YR,,M,Y,65.0,KG,20190111.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Adult
154594367,15459436,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Discoloured vomit,,2019,Q1,7,F,2018.0,20190103.0,20181003,20190111,EXP,,PHHY2018CO008285,SANDOZ,,61.0,YR,,M,Y,65.0,KG,20190111.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Adult
154594367,15459436,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Fatigue,,2019,Q1,7,F,2018.0,20190103.0,20181003,20190111,EXP,,PHHY2018CO008285,SANDOZ,,61.0,YR,,M,Y,65.0,KG,20190111.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Adult
154594367,15459436,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Fluid retention,,2019,Q1,7,F,2018.0,20190103.0,20181003,20190111,EXP,,PHHY2018CO008285,SANDOZ,,61.0,YR,,M,Y,65.0,KG,20190111.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Adult
154594367,15459436,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Gastritis,,2019,Q1,7,F,2018.0,20190103.0,20181003,20190111,EXP,,PHHY2018CO008285,SANDOZ,,61.0,YR,,M,Y,65.0,KG,20190111.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Adult
154594367,15459436,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Hernia,,2019,Q1,7,F,2018.0,20190103.0,20181003,20190111,EXP,,PHHY2018CO008285,SANDOZ,,61.0,YR,,M,Y,65.0,KG,20190111.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Adult
154594367,15459436,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Malaise,,2019,Q1,7,F,2018.0,20190103.0,20181003,20190111,EXP,,PHHY2018CO008285,SANDOZ,,61.0,YR,,M,Y,65.0,KG,20190111.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Adult
154594367,15459436,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Pruritus,,2019,Q1,7,F,2018.0,20190103.0,20181003,20190111,EXP,,PHHY2018CO008285,SANDOZ,,61.0,YR,,M,Y,65.0,KG,20190111.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Adult
154594367,15459436,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Pulmonary oedema,,2019,Q1,7,F,2018.0,20190103.0,20181003,20190111,EXP,,PHHY2018CO008285,SANDOZ,,61.0,YR,,M,Y,65.0,KG,20190111.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Adult
155372413,15537241,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,U, UNKNONWN,,,,,,,2019,Q1,Breast cancer,,2019,Q1,3,F,201712.0,20190108.0,20181022,20190116,EXP,,IT-NOVOPROD-627518,NOVO NORDISK,,64.0,YR,A,F,Y,,,20190117.0,,CN,IT,IT,2019,Q1,Adult
155430893,15543089,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q1,Acute kidney injury,,2019,Q1,3,F,20180912.0,20190301.0,20181023,20190307,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-047249",BOEHRINGER INGELHEIM,,66.0,YR,,F,Y,80.3,KG,20190307.0,,MD,BR,BR,2019,Q1,Elderly
155430893,15543089,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q1,Hypertensive encephalopathy,,2019,Q1,3,F,20180912.0,20190301.0,20181023,20190307,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-047249",BOEHRINGER INGELHEIM,,66.0,YR,,F,Y,80.3,KG,20190307.0,,MD,BR,BR,2019,Q1,Elderly
155610262,15561026,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q1,Asthenia,,2019,Q1,2,F,,20190227.0,20181029,20190305,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190305.0,,CN,US,US,2019,Q1,Elderly
155610262,15561026,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q1,Emotional disorder,,2019,Q1,2,F,,20190227.0,20181029,20190305,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190305.0,,CN,US,US,2019,Q1,Elderly
155610262,15561026,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q1,Fatigue,,2019,Q1,2,F,,20190227.0,20181029,20190305,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190305.0,,CN,US,US,2019,Q1,Elderly
155610262,15561026,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q1,Headache,,2019,Q1,2,F,,20190227.0,20181029,20190305,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190305.0,,CN,US,US,2019,Q1,Elderly
155610262,15561026,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q1,Malaise,,2019,Q1,2,F,,20190227.0,20181029,20190305,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190305.0,,CN,US,US,2019,Q1,Elderly
155610262,15561026,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q1,Muscular weakness,,2019,Q1,2,F,,20190227.0,20181029,20190305,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190305.0,,CN,US,US,2019,Q1,Elderly
155610262,15561026,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q1,Nerve injury,,2019,Q1,2,F,,20190227.0,20181029,20190305,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190305.0,,CN,US,US,2019,Q1,Elderly
155610262,15561026,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q1,Neuralgia,,2019,Q1,2,F,,20190227.0,20181029,20190305,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190305.0,,CN,US,US,2019,Q1,Elderly
155610262,15561026,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q1,Peripheral swelling,,2019,Q1,2,F,,20190227.0,20181029,20190305,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190305.0,,CN,US,US,2019,Q1,Elderly
155610262,15561026,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q1,Weight increased,,2019,Q1,2,F,,20190227.0,20181029,20190305,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190305.0,,CN,US,US,2019,Q1,Elderly
155717083,15571708,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,U, UNKNOWN,,,10.0,MG,,,2019,Q1,Breast cancer,,2019,Q1,3,F,201712.0,20190121.0,20181031,20190124,EXP,,PHHY2018IT140527,SANDOZ,,64.0,YR,,F,Y,,,20190124.0,,OT,IT,IT,2019,Q1,Adult
155773364,15577336,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2019,Q1,Breast cancer,,2019,Q1,4,F,201712.0,20190119.0,20181102,20190202,EXP,,IT-AUROBINDO-AUR-APL-2018-053413,AUROBINDO,,64.0,YR,,F,Y,,,20190202.0,,CN,IT,IT,2019,Q1,Adult
155774613,15577461,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Malignant neoplasm of unknown primary site,,2019,Q1,3,F,20170221.0,20190220.0,20181102,20190222,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-005743",BOEHRINGER INGELHEIM,,80.0,YR,,F,Y,49.9,KG,20190222.0,,MD,JP,JP,2019,Q1,Elderly
156196113,15619611,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q1,Breast cancer,,2019,Q1,3,F,201712.0,20190117.0,20181115,20190124,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-100523,BRISTOL MYERS SQUIBB,,64.0,YR,,F,Y,,,20190124.0,,MD,IT,IT,2019,Q1,Adult
156409593,15640959,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Buccal,,,,N,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q1,Back pain,,2019,Q1,3,F,20181018.0,20190125.0,20181120,20190130,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051884",BOEHRINGER INGELHEIM,,85.0,YR,,M,Y,84.7,KG,20190130.0,,MD,GB,GB,2019,Q1,Elderly
156409593,15640959,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Buccal,,,,N,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q1,Fall,,2019,Q1,3,F,20181018.0,20190125.0,20181120,20190130,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051884",BOEHRINGER INGELHEIM,,85.0,YR,,M,Y,84.7,KG,20190130.0,,MD,GB,GB,2019,Q1,Elderly
156409593,15640959,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Buccal,,,,N,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q1,Urinary tract infection,,2019,Q1,3,F,20181018.0,20190125.0,20181120,20190130,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051884",BOEHRINGER INGELHEIM,,85.0,YR,,M,Y,84.7,KG,20190130.0,,MD,GB,GB,2019,Q1,Elderly
156855744,15685574,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q1,Dehydration,,2019,Q1,4,F,2018.0,20190308.0,20181204,20190312,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051737",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,126.0,KG,20190312.0,,MD,AU,AU,2019,Q1,Elderly
156855744,15685574,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q1,Hyperkalaemia,,2019,Q1,4,F,2018.0,20190308.0,20181204,20190312,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051737",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,126.0,KG,20190312.0,,MD,AU,AU,2019,Q1,Elderly
156855744,15685574,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q1,Hypotension,,2019,Q1,4,F,2018.0,20190308.0,20181204,20190312,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051737",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,126.0,KG,20190312.0,,MD,AU,AU,2019,Q1,Elderly
156855744,15685574,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q1,Renal failure,,2019,Q1,4,F,2018.0,20190308.0,20181204,20190312,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051737",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,126.0,KG,20190312.0,,MD,AU,AU,2019,Q1,Elderly
156855744,15685574,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q1,Renal impairment,,2019,Q1,4,F,2018.0,20190308.0,20181204,20190312,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051737",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,126.0,KG,20190312.0,,MD,AU,AU,2019,Q1,Elderly
157458522,15745852,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Liver abscess,,2019,Q1,2,F,20181109.0,20190320.0,20181220,20190329,EXP,,JP-PFIZER INC-2018470268,PFIZER,,71.0,YR,,M,Y,66.3,KG,20190329.0,,MD,JP,JP,2019,Q1,Elderly
157557352,15755735,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Blood urine present,,2019,Q1,2,F,20161001.0,20190110.0,20181224,20190116,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004809",BOEHRINGER INGELHEIM,,44.0,YR,,F,Y,67.5,KG,20190116.0,,MD,JP,JP,2019,Q1,Adult
157557352,15755735,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Visual field defect,,2019,Q1,2,F,20161001.0,20190110.0,20181224,20190116,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004809",BOEHRINGER INGELHEIM,,44.0,YR,,F,Y,67.5,KG,20190116.0,,MD,JP,JP,2019,Q1,Adult
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Anaemia,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Blood cholesterol increased,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Blood glucose increased,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Blood pressure fluctuation,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Blood uric acid increased,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Cardiomegaly,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Carotid arteriosclerosis,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Chest discomfort,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Decreased ventricular preload,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Dyspnoea exertional,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Electrocardiogram abnormal,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Hepatic lesion,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Ischaemia,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Myocardial ischaemia,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Renal impairment,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157758342,15775834,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,,2019,Q1,Transient ischaemic attack,,2019,Q1,2,F,,20190118.0,20181231,20190201,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-194967,RANBAXY,,65.0,YR,,M,Y,,,20190201.0,,OT,GB,HU,2019,Q1,Elderly
157810782,15781078,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Calculus urinary,,2019,Q1,2,F,20170404.0,20190212.0,20190102,20190219,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002776",BOEHRINGER INGELHEIM,,75.0,YR,,M,Y,92.1,KG,20190219.0,,MD,JP,JP,2019,Q1,Elderly
157810782,15781078,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Hyperuricaemia,,2019,Q1,2,F,20170404.0,20190212.0,20190102,20190219,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002776",BOEHRINGER INGELHEIM,,75.0,YR,,M,Y,92.1,KG,20190219.0,,MD,JP,JP,2019,Q1,Elderly
158353741,15835374,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,210.04167,DF,,, UNKNOWN,,,1.0,DF,,,2019,Q1,Hypersensitivity,,2019,Q1,1,I,20181212.0,20190108.0,20190117,20190117,EXP,GB-MHRA-TPP36212716C968805YC1544636905300,GB-TEVA-2019-GB-999219,TEVA,,58.0,YR,,F,Y,75.0,KG,20190117.0,,MD,GB,GB,2019,Q1,Adult
158353741,15835374,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,210.04167,DF,,, UNKNOWN,,,1.0,DF,,,2019,Q1,Lip swelling,,2019,Q1,1,I,20181212.0,20190108.0,20190117,20190117,EXP,GB-MHRA-TPP36212716C968805YC1544636905300,GB-TEVA-2019-GB-999219,TEVA,,58.0,YR,,F,Y,75.0,KG,20190117.0,,MD,GB,GB,2019,Q1,Adult
158353741,15835374,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,210.04167,DF,,, UNKNOWN,,,1.0,DF,,,2019,Q1,Paraesthesia oral,,2019,Q1,1,I,20181212.0,20190108.0,20190117,20190117,EXP,GB-MHRA-TPP36212716C968805YC1544636905300,GB-TEVA-2019-GB-999219,TEVA,,58.0,YR,,F,Y,75.0,KG,20190117.0,,MD,GB,GB,2019,Q1,Adult
158443611,15844361,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Infection,,2019,Q1,1,I,20170715.0,20171104.0,20190118,20190118,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006472",BOEHRINGER INGELHEIM,,36.0,YR,,F,Y,49.0,KG,20190118.0,,MD,JP,JP,2019,Q1,Adult
158443611,15844361,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Polyuria,,2019,Q1,1,I,20170715.0,20171104.0,20190118,20190118,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006472",BOEHRINGER INGELHEIM,,36.0,YR,,F,Y,49.0,KG,20190118.0,,MD,JP,JP,2019,Q1,Adult
158443611,15844361,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Urine ketone body present,,2019,Q1,1,I,20170715.0,20171104.0,20190118,20190118,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006472",BOEHRINGER INGELHEIM,,36.0,YR,,F,Y,49.0,KG,20190118.0,,MD,JP,JP,2019,Q1,Adult
158484862,15848486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q1,Aspiration,,2019,Q1,2,F,20181226.0,20190118.0,20190121,20190123,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-001731",BOEHRINGER INGELHEIM,,63.0,YR,,M,Y,68.3,KG,20190124.0,,MD,US,US,2019,Q1,Adult
158484862,15848486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q1,Cerebrovascular accident,,2019,Q1,2,F,20181226.0,20190118.0,20190121,20190123,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-001731",BOEHRINGER INGELHEIM,,63.0,YR,,M,Y,68.3,KG,20190124.0,,MD,US,US,2019,Q1,Adult
158484862,15848486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q1,Dysphagia,,2019,Q1,2,F,20181226.0,20190118.0,20190121,20190123,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-001731",BOEHRINGER INGELHEIM,,63.0,YR,,M,Y,68.3,KG,20190124.0,,MD,US,US,2019,Q1,Adult
158484862,15848486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q1,Hyperglycaemia,,2019,Q1,2,F,20181226.0,20190118.0,20190121,20190123,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-001731",BOEHRINGER INGELHEIM,,63.0,YR,,M,Y,68.3,KG,20190124.0,,MD,US,US,2019,Q1,Adult
158484862,15848486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q1,Hypertension,,2019,Q1,2,F,20181226.0,20190118.0,20190121,20190123,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-001731",BOEHRINGER INGELHEIM,,63.0,YR,,M,Y,68.3,KG,20190124.0,,MD,US,US,2019,Q1,Adult
158484862,15848486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q1,Infarction,,2019,Q1,2,F,20181226.0,20190118.0,20190121,20190123,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-001731",BOEHRINGER INGELHEIM,,63.0,YR,,M,Y,68.3,KG,20190124.0,,MD,US,US,2019,Q1,Adult
158484862,15848486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q1,Seizure,,2019,Q1,2,F,20181226.0,20190118.0,20190121,20190123,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-001731",BOEHRINGER INGELHEIM,,63.0,YR,,M,Y,68.3,KG,20190124.0,,MD,US,US,2019,Q1,Adult
158522241,15852224,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DOSAGE FORM, DAILY",210.042,DF,,,,,,1.0,DF,,,2019,Q1,Hypersensitivity,,2019,Q1,1,I,20181212.0,20190107.0,20190122,20190122,EXP,,GB-AUROBINDO-AUR-APL-2019-000841,AUROBINDO,,58.0,YR,,F,Y,75.0,KG,20190122.0,,MD,GB,GB,2019,Q1,Adult
158522241,15852224,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DOSAGE FORM, DAILY",210.042,DF,,,,,,1.0,DF,,,2019,Q1,Lip swelling,,2019,Q1,1,I,20181212.0,20190107.0,20190122,20190122,EXP,,GB-AUROBINDO-AUR-APL-2019-000841,AUROBINDO,,58.0,YR,,F,Y,75.0,KG,20190122.0,,MD,GB,GB,2019,Q1,Adult
158522241,15852224,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DOSAGE FORM, DAILY",210.042,DF,,,,,,1.0,DF,,,2019,Q1,Paraesthesia oral,,2019,Q1,1,I,20181212.0,20190107.0,20190122,20190122,EXP,,GB-AUROBINDO-AUR-APL-2019-000841,AUROBINDO,,58.0,YR,,F,Y,75.0,KG,20190122.0,,MD,GB,GB,2019,Q1,Adult
158531161,15853116,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Cardiovascular somatic symptom disorder,,2019,Q1,1,I,20180126.0,20190116.0,20190122,20190122,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-000162",BOEHRINGER INGELHEIM,,84.0,YR,,M,Y,65.7,KG,20190122.0,,MD,JP,JP,2019,Q1,Elderly
158547541,15854754,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q1,Emphysematous pyelonephritis,,2019,Q1,1,I,20161104.0,20170208.0,20190122,20190122,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000713",BOEHRINGER INGELHEIM,,57.0,YR,,F,Y,63.5,KG,20190122.0,,MD,JP,JP,2019,Q1,Adult
158547541,15854754,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q1,Pollakiuria,,2019,Q1,1,I,20161104.0,20170208.0,20190122,20190122,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000713",BOEHRINGER INGELHEIM,,57.0,YR,,F,Y,63.5,KG,20190122.0,,MD,JP,JP,2019,Q1,Adult
158547541,15854754,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q1,Emphysematous pyelonephritis,,2019,Q1,1,I,20161104.0,20170208.0,20190122,20190122,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000713",BOEHRINGER INGELHEIM,,57.0,YR,,F,Y,63.5,KG,20190122.0,,MD,JP,JP,2019,Q1,Adult
158547541,15854754,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q1,Pollakiuria,,2019,Q1,1,I,20161104.0,20170208.0,20190122,20190122,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000713",BOEHRINGER INGELHEIM,,57.0,YR,,F,Y,63.5,KG,20190122.0,,MD,JP,JP,2019,Q1,Adult
158613001,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Anaemia,,2019,Q1,1,I,20161215.0,20180222.0,20190124,20190124,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190124.0,,MD,JP,JP,2019,Q1,Elderly
158613001,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Blood pressure increased,,2019,Q1,1,I,20161215.0,20180222.0,20190124,20190124,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190124.0,,MD,JP,JP,2019,Q1,Elderly
158613001,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Cardiac failure,,2019,Q1,1,I,20161215.0,20180222.0,20190124,20190124,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190124.0,,MD,JP,JP,2019,Q1,Elderly
158613001,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Essential thrombocythaemia,,2019,Q1,1,I,20161215.0,20180222.0,20190124,20190124,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190124.0,,MD,JP,JP,2019,Q1,Elderly
158613001,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Hyperkalaemia,,2019,Q1,1,I,20161215.0,20180222.0,20190124,20190124,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190124.0,,MD,JP,JP,2019,Q1,Elderly
158613001,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Peripheral arterial occlusive disease,,2019,Q1,1,I,20161215.0,20180222.0,20190124,20190124,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190124.0,,MD,JP,JP,2019,Q1,Elderly
158613001,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Sinus node dysfunction,,2019,Q1,1,I,20161215.0,20180222.0,20190124,20190124,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190124.0,,MD,JP,JP,2019,Q1,Elderly
158845592,15884559,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, DAILY DOSE",,,,, UNK,,,25.0,MG,,QD,2019,Q1,Colitis microscopic,,2019,Q1,2,F,20180414.0,20190128.0,20190129,20190205,EXP,,DE-MYLANLABS-2019M1007430,MYLAN,,77.0,YR,,F,Y,87.0,KG,20190205.0,,OT,DE,DE,2019,Q1,Elderly
158845592,15884559,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, DAILY DOSE",,,,, UNK,,,25.0,MG,,QD,2019,Q1,Gastrointestinal haemorrhage,,2019,Q1,2,F,20180414.0,20190128.0,20190129,20190205,EXP,,DE-MYLANLABS-2019M1007430,MYLAN,,77.0,YR,,F,Y,87.0,KG,20190205.0,,OT,DE,DE,2019,Q1,Elderly
158845592,15884559,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, DAILY DOSE",,,,, UNK,,,25.0,MG,,QD,2019,Q1,Pseudomonas test positive,,2019,Q1,2,F,20180414.0,20190128.0,20190129,20190205,EXP,,DE-MYLANLABS-2019M1007430,MYLAN,,77.0,YR,,F,Y,87.0,KG,20190205.0,,OT,DE,DE,2019,Q1,Elderly
158845592,15884559,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, DAILY DOSE",,,,, UNK,,,25.0,MG,,QD,2019,Q1,Spinal instability,,2019,Q1,2,F,20180414.0,20190128.0,20190129,20190205,EXP,,DE-MYLANLABS-2019M1007430,MYLAN,,77.0,YR,,F,Y,87.0,KG,20190205.0,,OT,DE,DE,2019,Q1,Elderly
158945401,15894540,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,?          OTHER FREQUENCY:AM;?,,,,,,,,10.0,MG,,,2019,Q1,Gingival swelling,,2019,Q1,1,I,20181030.0,,20190108,20190108,DIR,,,FDA-CTU,,55.0,YR,,M,N,,,20181218.0,N,PH,US,US,2019,Q1,Adult
159160651,15916065,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,COATED TABLET,QD,2019,Q1,Pollakiuria,,2019,Q1,1,I,201811.0,20190128.0,20190204,20190204,EXP,,"KR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-003741",BOEHRINGER INGELHEIM,,42.0,YR,,M,Y,158.0,KG,20190205.0,,MD,KR,KR,2019,Q1,Adult
159221781,15922178,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2019,Q1,Euglycaemic diabetic ketoacidosis,,2019,Q1,1,I,20190121.0,,20190205,20190205,DIR,,,FDA-CTU,,39.0,YR,,F,N,99.0,KG,20190205.0,N,PH,US,US,2019,Q1,Adult
159265442,15926544,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 UNK, QD",,,,,,,,,,,QD,2019,Q1,Drug ineffective,,2019,Q1,2,F,20180828.0,20181011.0,20190205,20190219,PER,,US-ALLERGAN-1848994US,ALLERGAN,,60.0,YR,,F,Y,86.62,KG,20190219.0,,OT,US,US,2019,Q1,Adult
159265442,15926544,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 UNK, QD",,,,,,,,,,,QD,2019,Q1,Head discomfort,,2019,Q1,2,F,20180828.0,20181011.0,20190205,20190219,PER,,US-ALLERGAN-1848994US,ALLERGAN,,60.0,YR,,F,Y,86.62,KG,20190219.0,,OT,US,US,2019,Q1,Adult
159265442,15926544,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 UNK, QD",,,,,,,,,,,QD,2019,Q1,Headache,,2019,Q1,2,F,20180828.0,20181011.0,20190205,20190219,PER,,US-ALLERGAN-1848994US,ALLERGAN,,60.0,YR,,F,Y,86.62,KG,20190219.0,,OT,US,US,2019,Q1,Adult
159265442,15926544,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 UNK, QD",,,,,,,,,,,QD,2019,Q1,Injection site pain,,2019,Q1,2,F,20180828.0,20181011.0,20190205,20190219,PER,,US-ALLERGAN-1848994US,ALLERGAN,,60.0,YR,,F,Y,86.62,KG,20190219.0,,OT,US,US,2019,Q1,Adult
159265442,15926544,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 UNK, QD",,,,,,,,,,,QD,2019,Q1,Musculoskeletal pain,,2019,Q1,2,F,20180828.0,20181011.0,20190205,20190219,PER,,US-ALLERGAN-1848994US,ALLERGAN,,60.0,YR,,F,Y,86.62,KG,20190219.0,,OT,US,US,2019,Q1,Adult
159265442,15926544,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 UNK, QD",,,,,,,,,,,QD,2019,Q1,Pruritus,,2019,Q1,2,F,20180828.0,20181011.0,20190205,20190219,PER,,US-ALLERGAN-1848994US,ALLERGAN,,60.0,YR,,F,Y,86.62,KG,20190219.0,,OT,US,US,2019,Q1,Adult
159265442,15926544,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 UNK, QD",,,,,,,,,,,QD,2019,Q1,Scab,,2019,Q1,2,F,20180828.0,20181011.0,20190205,20190219,PER,,US-ALLERGAN-1848994US,ALLERGAN,,60.0,YR,,F,Y,86.62,KG,20190219.0,,OT,US,US,2019,Q1,Adult
159411362,15941136,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Hypoaesthesia,,2019,Q1,2,F,20160606.0,20190207.0,20190208,20190214,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002395",BOEHRINGER INGELHEIM,,74.0,YR,,F,Y,76.2,KG,20190214.0,,MD,JP,JP,2019,Q1,Elderly
159411362,15941136,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Neuropathy peripheral,,2019,Q1,2,F,20160606.0,20190207.0,20190208,20190214,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002395",BOEHRINGER INGELHEIM,,74.0,YR,,F,Y,76.2,KG,20190214.0,,MD,JP,JP,2019,Q1,Elderly
159411362,15941136,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Oedema peripheral,,2019,Q1,2,F,20160606.0,20190207.0,20190208,20190214,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002395",BOEHRINGER INGELHEIM,,74.0,YR,,F,Y,76.2,KG,20190214.0,,MD,JP,JP,2019,Q1,Elderly
159411362,15941136,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Thermal burn,,2019,Q1,2,F,20160606.0,20190207.0,20190208,20190214,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002395",BOEHRINGER INGELHEIM,,74.0,YR,,F,Y,76.2,KG,20190214.0,,MD,JP,JP,2019,Q1,Elderly
159411362,15941136,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Hypoaesthesia,,2019,Q1,2,F,20160606.0,20190207.0,20190208,20190214,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002395",BOEHRINGER INGELHEIM,,74.0,YR,,F,Y,76.2,KG,20190214.0,,MD,JP,JP,2019,Q1,Elderly
159411362,15941136,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Neuropathy peripheral,,2019,Q1,2,F,20160606.0,20190207.0,20190208,20190214,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002395",BOEHRINGER INGELHEIM,,74.0,YR,,F,Y,76.2,KG,20190214.0,,MD,JP,JP,2019,Q1,Elderly
159411362,15941136,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Oedema peripheral,,2019,Q1,2,F,20160606.0,20190207.0,20190208,20190214,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002395",BOEHRINGER INGELHEIM,,74.0,YR,,F,Y,76.2,KG,20190214.0,,MD,JP,JP,2019,Q1,Elderly
159411362,15941136,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Thermal burn,,2019,Q1,2,F,20160606.0,20190207.0,20190208,20190214,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002395",BOEHRINGER INGELHEIM,,74.0,YR,,F,Y,76.2,KG,20190214.0,,MD,JP,JP,2019,Q1,Elderly
159458902,15945890,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Ketoacidosis,,2019,Q1,2,F,,20190226.0,20190211,20190307,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-012993,BRISTOL MYERS SQUIBB,THE 56TH LOCAL MEETING OF THE KANTO KOSHINETSU CHAPTER OF THE JAPAN DIABETES SOC,44.0,YR,,F,Y,,,20190307.0,,OT,JP,JP,2019,Q1,Adult
159598821,15959882,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,TABLET,,2019,Q1,Asthenia,,2019,Q1,1,I,201812.0,20190205.0,20190214,20190214,EXP,,US-BEH-2019099216,CSL BEHRING,,54.0,YR,A,F,Y,,,20190214.0,,OT,US,US,2019,Q1,Adult
159598821,15959882,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,TABLET,,2019,Q1,Concussion,,2019,Q1,1,I,201812.0,20190205.0,20190214,20190214,EXP,,US-BEH-2019099216,CSL BEHRING,,54.0,YR,A,F,Y,,,20190214.0,,OT,US,US,2019,Q1,Adult
159598821,15959882,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,TABLET,,2019,Q1,Constipation,,2019,Q1,1,I,201812.0,20190205.0,20190214,20190214,EXP,,US-BEH-2019099216,CSL BEHRING,,54.0,YR,A,F,Y,,,20190214.0,,OT,US,US,2019,Q1,Adult
159598821,15959882,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,TABLET,,2019,Q1,Decreased appetite,,2019,Q1,1,I,201812.0,20190205.0,20190214,20190214,EXP,,US-BEH-2019099216,CSL BEHRING,,54.0,YR,A,F,Y,,,20190214.0,,OT,US,US,2019,Q1,Adult
159598821,15959882,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,TABLET,,2019,Q1,Fall,,2019,Q1,1,I,201812.0,20190205.0,20190214,20190214,EXP,,US-BEH-2019099216,CSL BEHRING,,54.0,YR,A,F,Y,,,20190214.0,,OT,US,US,2019,Q1,Adult
159598821,15959882,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,TABLET,,2019,Q1,Fatigue,,2019,Q1,1,I,201812.0,20190205.0,20190214,20190214,EXP,,US-BEH-2019099216,CSL BEHRING,,54.0,YR,A,F,Y,,,20190214.0,,OT,US,US,2019,Q1,Adult
159598821,15959882,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,TABLET,,2019,Q1,Insomnia,,2019,Q1,1,I,201812.0,20190205.0,20190214,20190214,EXP,,US-BEH-2019099216,CSL BEHRING,,54.0,YR,A,F,Y,,,20190214.0,,OT,US,US,2019,Q1,Adult
159613441,15961344,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"LATER, THE DOSAGE WAS TITRATED TO 25MG/DAY",,,,,,,,10.0,MG,,QD,2019,Q1,Gastrointestinal disorder,,2019,Q1,1,I,,20190204.0,20190214,20190214,EXP,,US-TEVA-2019-US-1010358,TEVA,"JIALAL I, SINGH R. ORAL PHARMACOTHERAPY AS ALTERNATIVE TREATMENT FOR TYPE 2 DIABETES MELLITUS IN A 61 YEAR OLD ETHNIC FILIPINO MAN WITH INSULIN ALLERGIES. LAB-MED 2019;50(1):93-95.",61.0,YR,,M,Y,,,20190214.0,,MD,US,US,2019,Q1,Adult
159613441,15961344,9,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2019,Q1,Gastrointestinal disorder,,2019,Q1,1,I,,20190204.0,20190214,20190214,EXP,,US-TEVA-2019-US-1010358,TEVA,"JIALAL I, SINGH R. ORAL PHARMACOTHERAPY AS ALTERNATIVE TREATMENT FOR TYPE 2 DIABETES MELLITUS IN A 61 YEAR OLD ETHNIC FILIPINO MAN WITH INSULIN ALLERGIES. LAB-MED 2019;50(1):93-95.",61.0,YR,,M,Y,,,20190214.0,,MD,US,US,2019,Q1,Adult
159629452,15962945,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,,2019,Q1,Angina pectoris,,2019,Q1,2,F,20160613.0,20190222.0,20190214,20190301,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005743",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,76.4,KG,20190301.0,,MD,JP,JP,2019,Q1,Adult
159629452,15962945,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,,2019,Q1,Balanoposthitis,,2019,Q1,2,F,20160613.0,20190222.0,20190214,20190301,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005743",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,76.4,KG,20190301.0,,MD,JP,JP,2019,Q1,Adult
159629452,15962945,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,,2019,Q1,Pollakiuria,,2019,Q1,2,F,20160613.0,20190222.0,20190214,20190301,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005743",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,76.4,KG,20190301.0,,MD,JP,JP,2019,Q1,Adult
159629452,15962945,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,,2019,Q1,Polyuria,,2019,Q1,2,F,20160613.0,20190222.0,20190214,20190301,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005743",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,76.4,KG,20190301.0,,MD,JP,JP,2019,Q1,Adult
159629452,15962945,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,,2019,Q1,Angina pectoris,,2019,Q1,2,F,20160613.0,20190222.0,20190214,20190301,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005743",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,76.4,KG,20190301.0,,MD,JP,JP,2019,Q1,Adult
159629452,15962945,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,,2019,Q1,Balanoposthitis,,2019,Q1,2,F,20160613.0,20190222.0,20190214,20190301,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005743",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,76.4,KG,20190301.0,,MD,JP,JP,2019,Q1,Adult
159629452,15962945,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,,2019,Q1,Pollakiuria,,2019,Q1,2,F,20160613.0,20190222.0,20190214,20190301,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005743",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,76.4,KG,20190301.0,,MD,JP,JP,2019,Q1,Adult
159629452,15962945,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,,2019,Q1,Polyuria,,2019,Q1,2,F,20160613.0,20190222.0,20190214,20190301,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005743",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,76.4,KG,20190301.0,,MD,JP,JP,2019,Q1,Adult
159676101,15967610,1,PS,EMPAGLIFLOZIN-METFORMIN XR,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,D,,,,25.0,MG,,QD,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,20190213.0,,20190215,20190215,DIR,,,FDA-CTU,,55.0,YR,,M,N,140.5,KG,20190215.0,N,PH,US,US,2019,Q1,Adult
159676101,15967610,1,PS,EMPAGLIFLOZIN-METFORMIN XR,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,D,,,,25.0,MG,,QD,2019,Q1,Starvation,,2019,Q1,1,I,20190213.0,,20190215,20190215,DIR,,,FDA-CTU,,55.0,YR,,M,N,140.5,KG,20190215.0,N,PH,US,US,2019,Q1,Adult
159791981,15979198,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q1,Blood creatinine increased,,2019,Q1,1,I,20181117.0,,20190124,20190124,DIR,,,FDA-CTU,,73.0,YR,,M,N,,,20190118.0,N,PH,US,US,2019,Q1,Elderly
159791981,15979198,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q1,Hypotension,,2019,Q1,1,I,20181117.0,,20190124,20190124,DIR,,,FDA-CTU,,73.0,YR,,M,N,,,20190118.0,N,PH,US,US,2019,Q1,Elderly
159793321,15979332,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q1,Dysuria,,2019,Q1,1,I,20181120.0,,20190124,20190124,DIR,,,FDA-CTU,,76.0,YR,,M,N,,,20190118.0,N,PH,US,US,2019,Q1,Elderly
159793321,15979332,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q1,Micturition urgency,,2019,Q1,1,I,20181120.0,,20190124,20190124,DIR,,,FDA-CTU,,76.0,YR,,M,N,,,20190118.0,N,PH,US,US,2019,Q1,Elderly
159793321,15979332,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q1,Pollakiuria,,2019,Q1,1,I,20181120.0,,20190124,20190124,DIR,,,FDA-CTU,,76.0,YR,,M,N,,,20190118.0,N,PH,US,US,2019,Q1,Elderly
159853531,15985353,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q1,Gastrointestinal disorder,,2019,Q1,1,I,,20190207.0,20190220,20190220,PER,,US-BAYER-2019-029710,BAYER,JIALAL I; SINGH R. ORAL PHARMACOTHERAPY AS ALTERNATIVE TREATMENT FOR TYPE 2 DIABETES MELLITUS IN A 61 YEAR OLD ETHNIC FILIPINO MAN WITH INSULIN ALLERGIES. LABORATORY MEDICINE. 2019;50 (1):93-95,61.0,YR,A,M,Y,,,20190220.0,,MD,US,US,2019,Q1,Adult
159853531,15985353,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 MG, QD",,,,,,,,25.0,MG,,QD,2019,Q1,Gastrointestinal disorder,,2019,Q1,1,I,,20190207.0,20190220,20190220,PER,,US-BAYER-2019-029710,BAYER,JIALAL I; SINGH R. ORAL PHARMACOTHERAPY AS ALTERNATIVE TREATMENT FOR TYPE 2 DIABETES MELLITUS IN A 61 YEAR OLD ETHNIC FILIPINO MAN WITH INSULIN ALLERGIES. LABORATORY MEDICINE. 2019;50 (1):93-95,61.0,YR,A,M,Y,,,20190220.0,,MD,US,US,2019,Q1,Adult
159863131,15986313,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,FILM-COATED TABLET,,2019,Q1,Cardiac failure,,2019,Q1,1,I,20190107.0,20190208.0,20190220,20190220,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-006107",BOEHRINGER INGELHEIM,,78.0,YR,,F,Y,73.8,KG,20190220.0,,MD,BR,BR,2019,Q1,Elderly
159876593,15987659,1,PS,TRADIANCE (EMPAGLIFLOZIN\LINAGLIPTIN),EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,206073.0,,,TABLET,,2019,Q1,Blood ketone body increased,,2019,Q1,3,F,,20190220.0,20190220,20190226,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-000726",BOEHRINGER INGELHEIM,,60.0,YR,,M,Y,,,20190226.0,,MD,JP,JP,2019,Q1,Adult
159900231,15990023,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,200.417,MG,U,, UNKNOWN,,,10.0,MG,TABLET,,2019,Q1,Cardiac failure,,2019,Q1,1,I,20181019.0,20190214.0,20190221,20190221,EXP,GB-MHRA-INP0B459061-F824-4180-9480-DB82B517A0BD,GB-TORRENT-00020359,TORRENT,,68.0,YR,,F,Y,82.0,KG,20190221.0,,MD,GB,GB,2019,Q1,Elderly
159900231,15990023,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,200.417,MG,U,, UNKNOWN,,,10.0,MG,TABLET,,2019,Q1,Dyspnoea,,2019,Q1,1,I,20181019.0,20190214.0,20190221,20190221,EXP,GB-MHRA-INP0B459061-F824-4180-9480-DB82B517A0BD,GB-TORRENT-00020359,TORRENT,,68.0,YR,,F,Y,82.0,KG,20190221.0,,MD,GB,GB,2019,Q1,Elderly
159900231,15990023,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,200.417,MG,U,, UNKNOWN,,,10.0,MG,TABLET,,2019,Q1,Pericardial effusion,,2019,Q1,1,I,20181019.0,20190214.0,20190221,20190221,EXP,GB-MHRA-INP0B459061-F824-4180-9480-DB82B517A0BD,GB-TORRENT-00020359,TORRENT,,68.0,YR,,F,Y,82.0,KG,20190221.0,,MD,GB,GB,2019,Q1,Elderly
159907141,15990714,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q1,Hypocalcaemia,,2019,Q1,1,I,,20190212.0,20190221,20190221,EXP,,AU-MYLANLABS-2019M1015407,MYLAN,"HAIDER R, GIRGIS C. DELAY IN DIAGNOSIS OF PROTON PUMP INHIBITOR INDUCED HYPOMAGNESAEMIA: A CASE SERIES. J-CLIN-TRANSL-ENDOCRINOL-CASE-REP 2019;11:3-6.",66.0,YR,,M,Y,,,20190221.0,,OT,AU,AU,2019,Q1,Elderly
159907141,15990714,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q1,Hypomagnesaemia,,2019,Q1,1,I,,20190212.0,20190221,20190221,EXP,,AU-MYLANLABS-2019M1015407,MYLAN,"HAIDER R, GIRGIS C. DELAY IN DIAGNOSIS OF PROTON PUMP INHIBITOR INDUCED HYPOMAGNESAEMIA: A CASE SERIES. J-CLIN-TRANSL-ENDOCRINOL-CASE-REP 2019;11:3-6.",66.0,YR,,M,Y,,,20190221.0,,OT,AU,AU,2019,Q1,Elderly
159952271,15995227,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,,,,,12.5,MG,,,2019,Q1,Hypotension,,2019,Q1,1,I,20181106.0,,20190129,20190129,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20190128.0,N,PH,US,US,2019,Q1,Elderly
159955831,15995583,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2019,Q1,Abdominal pain upper,,2019,Q1,1,I,20190215.0,20181120.0,20190222,20190222,EXP,,PHHY2018CO163899,NOVARTIS,,67.0,YR,,M,Y,55.0,KG,20190222.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Elderly
159955831,15995583,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2019,Q1,Choking,,2019,Q1,1,I,20190215.0,20181120.0,20190222,20190222,EXP,,PHHY2018CO163899,NOVARTIS,,67.0,YR,,M,Y,55.0,KG,20190222.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Elderly
159955831,15995583,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2019,Q1,Death,,2019,Q1,1,I,20190215.0,20181120.0,20190222,20190222,EXP,,PHHY2018CO163899,NOVARTIS,,67.0,YR,,M,Y,55.0,KG,20190222.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Elderly
159955831,15995583,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2019,Q1,Gastrooesophageal reflux disease,,2019,Q1,1,I,20190215.0,20181120.0,20190222,20190222,EXP,,PHHY2018CO163899,NOVARTIS,,67.0,YR,,M,Y,55.0,KG,20190222.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Elderly
159955831,15995583,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2019,Q1,Insomnia,,2019,Q1,1,I,20190215.0,20181120.0,20190222,20190222,EXP,,PHHY2018CO163899,NOVARTIS,,67.0,YR,,M,Y,55.0,KG,20190222.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Elderly
159955831,15995583,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2019,Q1,Vomiting,,2019,Q1,1,I,20190215.0,20181120.0,20190222,20190222,EXP,,PHHY2018CO163899,NOVARTIS,,67.0,YR,,M,Y,55.0,KG,20190222.0,,CN,COUNTRY NOT SPECIFIED,CO,2019,Q1,Elderly
159956051,15995605,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q1,Dizziness,,2019,Q1,1,I,20181212.0,,20190129,20190129,DIR,,,FDA-CTU,,52.0,YR,,M,N,95.0,KG,20190117.0,N,PH,US,US,2019,Q1,Adult
159956051,15995605,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q1,Dry mouth,,2019,Q1,1,I,20181212.0,,20190129,20190129,DIR,,,FDA-CTU,,52.0,YR,,M,N,95.0,KG,20190117.0,N,PH,US,US,2019,Q1,Adult
159956051,15995605,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q1,Pollakiuria,,2019,Q1,1,I,20181212.0,,20190129,20190129,DIR,,,FDA-CTU,,52.0,YR,,M,N,95.0,KG,20190117.0,N,PH,US,US,2019,Q1,Adult
159989661,15998966,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",200.417007,MG,U,,,,,10.0,MG,,QD,2019,Q1,Cardiac failure,,2019,Q1,1,I,20181019.0,20190218.0,20190223,20190223,EXP,,PHHY2019GB040219,SANDOZ,,68.0,YR,,F,Y,82.0,KG,20190224.0,,OT,GB,GB,2019,Q1,Elderly
159989661,15998966,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",200.417007,MG,U,,,,,10.0,MG,,QD,2019,Q1,Dyspnoea,,2019,Q1,1,I,20181019.0,20190218.0,20190223,20190223,EXP,,PHHY2019GB040219,SANDOZ,,68.0,YR,,F,Y,82.0,KG,20190224.0,,OT,GB,GB,2019,Q1,Elderly
159989661,15998966,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",200.417007,MG,U,,,,,10.0,MG,,QD,2019,Q1,Pericardial effusion,,2019,Q1,1,I,20181019.0,20190218.0,20190223,20190223,EXP,,PHHY2019GB040219,SANDOZ,,68.0,YR,,F,Y,82.0,KG,20190224.0,,OT,GB,GB,2019,Q1,Elderly
160012981,16001298,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,?          QUANTITY:1 TABLET(S);?,,,Y,D,,,,,,,,2019,Q1,Dizziness,,2019,Q1,1,I,20181115.0,,20190224,20190224,DIR,,,FDA-CTU,,64.0,YR,,M,N,105.75,KG,20190224.0,N,CN,US,US,2019,Q1,Adult
160012981,16001298,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,?          QUANTITY:1 TABLET(S);?,,,Y,D,,,,,,,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,20181115.0,,20190224,20190224,DIR,,,FDA-CTU,,64.0,YR,,M,N,105.75,KG,20190224.0,N,CN,US,US,2019,Q1,Adult
160012981,16001298,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,?          QUANTITY:1 TABLET(S);?,,,Y,D,,,,,,,,2019,Q1,Renal disorder,,2019,Q1,1,I,20181115.0,,20190224,20190224,DIR,,,FDA-CTU,,64.0,YR,,M,N,105.75,KG,20190224.0,N,CN,US,US,2019,Q1,Adult
160059321,16005932,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Cardiac arrest,,2019,Q1,1,I,20190204.0,20190219.0,20190226,20190226,EXP,,PHHY2019GB041213,SANDOZ,,83.0,YR,,F,Y,,,20190226.0,,OT,GB,GB,2019,Q1,Elderly
160059321,16005932,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Malaise,,2019,Q1,1,I,20190204.0,20190219.0,20190226,20190226,EXP,,PHHY2019GB041213,SANDOZ,,83.0,YR,,F,Y,,,20190226.0,,OT,GB,GB,2019,Q1,Elderly
160059321,16005932,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Sinus node dysfunction,,2019,Q1,1,I,20190204.0,20190219.0,20190226,20190226,EXP,,PHHY2019GB041213,SANDOZ,,83.0,YR,,F,Y,,,20190226.0,,OT,GB,GB,2019,Q1,Elderly
160063301,16006330,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2019,Q1,Photosensitivity reaction,,2019,Q1,1,I,,20190218.0,20190225,20190225,EXP,,PHHY2019GB040716,SANDOZ,,69.0,YR,,M,Y,,,20190225.0,,OT,GB,GB,2019,Q1,Elderly
160071872,16007187,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q1,Liver disorder,,2019,Q1,2,F,20190214.0,20190222.0,20190226,20190227,EXP,,"AR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-007787",BOEHRINGER INGELHEIM,,61.0,YR,,M,Y,,,20190227.0,,MD,AR,AR,2019,Q1,Adult
160178401,16017840,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,,,,,12.5,MG,,,2019,Q1,Urine output increased,,2019,Q1,1,I,20180520.0,,20190201,20190201,DIR,,,FDA-CTU,,65.0,YR,,M,N,,,20190131.0,N,PH,US,US,2019,Q1,Elderly
160181231,16018123,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,,2019,Q1,Genital rash,,2019,Q1,1,I,20190101.0,,20190201,20190201,DIR,,,FDA-CTU,,76.0,YR,,M,N,,,20190128.0,N,PH,US,US,2019,Q1,Elderly
160181231,16018123,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,,2019,Q1,Rash,,2019,Q1,1,I,20190101.0,,20190201,20190201,DIR,,,FDA-CTU,,76.0,YR,,M,N,,,20190128.0,N,PH,US,US,2019,Q1,Elderly
160192001,16019200,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q1,Hypocalcaemia,,2019,Q1,1,I,,20190218.0,20190228,20190228,EXP,,AU-TEVA-2019-AU-1017291,TEVA,"HAIDER R, GIRGIS C. DELAY IN DIAGNOSIS OF PROTON PUMP INHIBITOR INDUCED HYPOMAGNESAEMIA: A CASE SERIES. J-CLIN-TRANSL-ENDOCRINOL-CASE-REP 2019;11:3-6.",66.0,YR,,M,Y,,,20190228.0,,OT,AU,AU,2019,Q1,Elderly
160192001,16019200,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q1,Hypomagnesaemia,,2019,Q1,1,I,,20190218.0,20190228,20190228,EXP,,AU-TEVA-2019-AU-1017291,TEVA,"HAIDER R, GIRGIS C. DELAY IN DIAGNOSIS OF PROTON PUMP INHIBITOR INDUCED HYPOMAGNESAEMIA: A CASE SERIES. J-CLIN-TRANSL-ENDOCRINOL-CASE-REP 2019;11:3-6.",66.0,YR,,M,Y,,,20190228.0,,OT,AU,AU,2019,Q1,Elderly
160194021,16019402,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;,200.41667,MG,,, UNKNOWN,,,10.0,MG,TABLET,,2019,Q1,Cardiac failure,,2019,Q1,1,I,20181019.0,20190219.0,20190228,20190228,EXP,GB-MHRA-INP0B459061-F824-4180-9480-DB82B517A0BD,GB-TEVA-2019-GB-1017485,TEVA,,68.0,YR,,F,Y,82.0,KG,20190228.0,,MD,GB,GB,2019,Q1,Elderly
160194021,16019402,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;,200.41667,MG,,, UNKNOWN,,,10.0,MG,TABLET,,2019,Q1,Dyspnoea,,2019,Q1,1,I,20181019.0,20190219.0,20190228,20190228,EXP,GB-MHRA-INP0B459061-F824-4180-9480-DB82B517A0BD,GB-TEVA-2019-GB-1017485,TEVA,,68.0,YR,,F,Y,82.0,KG,20190228.0,,MD,GB,GB,2019,Q1,Elderly
160194021,16019402,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;,200.41667,MG,,, UNKNOWN,,,10.0,MG,TABLET,,2019,Q1,Pericardial effusion,,2019,Q1,1,I,20181019.0,20190219.0,20190228,20190228,EXP,GB-MHRA-INP0B459061-F824-4180-9480-DB82B517A0BD,GB-TEVA-2019-GB-1017485,TEVA,,68.0,YR,,F,Y,82.0,KG,20190228.0,,MD,GB,GB,2019,Q1,Elderly
160199071,16019907,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNKNOWN,,,D,, UNKNOWN,,,,,,,2019,Q1,Hypomagnesaemia,,2019,Q1,1,I,,20190212.0,20190228,20190228,EXP,,AU-PERRIGO-19AU002063,PERRIGO,,66.0,YR,,M,Y,,,20190228.0,,MD,AU,AU,2019,Q1,Elderly
160276112,16027611,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2019,Q1,Urticaria,,2019,Q1,2,F,2019.0,20190306.0,20190304,20190308,EXP,GB-MHRA-TPP554837C3409673YC1550064124149,GB-GLAXOSMITHKLINE-GB2019036609,GLAXOSMITHKLINE,,60.0,YR,,F,Y,90.0,KG,20190308.0,,OT,GB,GB,2019,Q1,Adult
160360062,16036006,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q1,Hepatic function abnormal,,2019,Q1,2,F,20190225.0,20190312.0,20190305,20190314,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-009185",BOEHRINGER INGELHEIM,,79.0,YR,,M,Y,64.0,KG,20190314.0,,MD,JP,JP,2019,Q1,Elderly
160438121,16043812,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Cardiac arrest,,2019,Q1,1,I,20190204.0,20190225.0,20190306,20190306,EXP,GB-MHRA-EYC 00194595,GB-TEVA-2019-GB-1018337,TEVA,,83.0,YR,,F,Y,,,20190306.0,,PH,GB,GB,2019,Q1,Elderly
160438121,16043812,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Malaise,,2019,Q1,1,I,20190204.0,20190225.0,20190306,20190306,EXP,GB-MHRA-EYC 00194595,GB-TEVA-2019-GB-1018337,TEVA,,83.0,YR,,F,Y,,,20190306.0,,PH,GB,GB,2019,Q1,Elderly
160438121,16043812,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Sinus node dysfunction,,2019,Q1,1,I,20190204.0,20190225.0,20190306,20190306,EXP,GB-MHRA-EYC 00194595,GB-TEVA-2019-GB-1018337,TEVA,,83.0,YR,,F,Y,,,20190306.0,,PH,GB,GB,2019,Q1,Elderly
160465591,16046559,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,D,D,,,,12.5,MG,,QD,2019,Q1,Urinary tract infection,,2019,Q1,1,I,20181113.0,,20190207,20190207,DIR,,,FDA-CTU,,59.0,YR,,M,N,129.0,KG,20190207.0,N,PH,US,US,2019,Q1,Adult
160686801,16068680,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,,,FILM-COATED TABLET,,2019,Q1,Chest pain,,2019,Q1,1,I,20180810.0,20190306.0,20190313,20190313,EXP,,"CN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-010013",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,,,20190313.0,,MD,CN,CN,2019,Q1,Elderly
160877011,16087701,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Abdominal distension,,2019,Q1,1,I,201606.0,20170323.0,20190319,20190319,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190319.0,,MD,JP,JP,2019,Q1,Adult
160877011,16087701,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Angina pectoris,,2019,Q1,1,I,201606.0,20170323.0,20190319,20190319,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190319.0,,MD,JP,JP,2019,Q1,Adult
160877011,16087701,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Diabetes mellitus inadequate control,,2019,Q1,1,I,201606.0,20170323.0,20190319,20190319,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190319.0,,MD,JP,JP,2019,Q1,Adult
160877011,16087701,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Gallbladder polyp,,2019,Q1,1,I,201606.0,20170323.0,20190319,20190319,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190319.0,,MD,JP,JP,2019,Q1,Adult
160877011,16087701,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Haemoconcentration,,2019,Q1,1,I,201606.0,20170323.0,20190319,20190319,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190319.0,,MD,JP,JP,2019,Q1,Adult
160877011,16087701,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Hepatic function abnormal,,2019,Q1,1,I,201606.0,20170323.0,20190319,20190319,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190319.0,,MD,JP,JP,2019,Q1,Adult
160877011,16087701,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Occult blood positive,,2019,Q1,1,I,201606.0,20170323.0,20190319,20190319,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190319.0,,MD,JP,JP,2019,Q1,Adult
160877011,16087701,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Abdominal distension,,2019,Q1,1,I,201606.0,20170323.0,20190319,20190319,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190319.0,,MD,JP,JP,2019,Q1,Adult
160877011,16087701,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Angina pectoris,,2019,Q1,1,I,201606.0,20170323.0,20190319,20190319,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190319.0,,MD,JP,JP,2019,Q1,Adult
160877011,16087701,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Diabetes mellitus inadequate control,,2019,Q1,1,I,201606.0,20170323.0,20190319,20190319,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190319.0,,MD,JP,JP,2019,Q1,Adult
160877011,16087701,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Gallbladder polyp,,2019,Q1,1,I,201606.0,20170323.0,20190319,20190319,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190319.0,,MD,JP,JP,2019,Q1,Adult
160877011,16087701,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Haemoconcentration,,2019,Q1,1,I,201606.0,20170323.0,20190319,20190319,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190319.0,,MD,JP,JP,2019,Q1,Adult
160877011,16087701,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Hepatic function abnormal,,2019,Q1,1,I,201606.0,20170323.0,20190319,20190319,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190319.0,,MD,JP,JP,2019,Q1,Adult
160877011,16087701,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q1,Occult blood positive,,2019,Q1,1,I,201606.0,20170323.0,20190319,20190319,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190319.0,,MD,JP,JP,2019,Q1,Adult
160984232,16098423,13,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Acute kidney injury,,2019,Q1,2,F,,20190318.0,20190321,20190322,EXP,,PT-TEVA-2019-PT-1028643,TEVA,"GOUVEIA C, DUQUE S, CAMPOS L. LIPOT IMIA POR HIPOVOLEMIA - UM CASO DE IATROTROGENIA A EMPA GLIFLO ZINA?. BY MARIANA ROCHA. 2019;.",71.0,YR,,M,Y,,,20190322.0,,MD,PT,PT,2019,Q1,Elderly
160984232,16098423,13,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Arrhythmia,,2019,Q1,2,F,,20190318.0,20190321,20190322,EXP,,PT-TEVA-2019-PT-1028643,TEVA,"GOUVEIA C, DUQUE S, CAMPOS L. LIPOT IMIA POR HIPOVOLEMIA - UM CASO DE IATROTROGENIA A EMPA GLIFLO ZINA?. BY MARIANA ROCHA. 2019;.",71.0,YR,,M,Y,,,20190322.0,,MD,PT,PT,2019,Q1,Elderly
160984232,16098423,13,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Bradycardia,,2019,Q1,2,F,,20190318.0,20190321,20190322,EXP,,PT-TEVA-2019-PT-1028643,TEVA,"GOUVEIA C, DUQUE S, CAMPOS L. LIPOT IMIA POR HIPOVOLEMIA - UM CASO DE IATROTROGENIA A EMPA GLIFLO ZINA?. BY MARIANA ROCHA. 2019;.",71.0,YR,,M,Y,,,20190322.0,,MD,PT,PT,2019,Q1,Elderly
160984232,16098423,13,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Dehydration,,2019,Q1,2,F,,20190318.0,20190321,20190322,EXP,,PT-TEVA-2019-PT-1028643,TEVA,"GOUVEIA C, DUQUE S, CAMPOS L. LIPOT IMIA POR HIPOVOLEMIA - UM CASO DE IATROTROGENIA A EMPA GLIFLO ZINA?. BY MARIANA ROCHA. 2019;.",71.0,YR,,M,Y,,,20190322.0,,MD,PT,PT,2019,Q1,Elderly
160984232,16098423,13,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Dizziness,,2019,Q1,2,F,,20190318.0,20190321,20190322,EXP,,PT-TEVA-2019-PT-1028643,TEVA,"GOUVEIA C, DUQUE S, CAMPOS L. LIPOT IMIA POR HIPOVOLEMIA - UM CASO DE IATROTROGENIA A EMPA GLIFLO ZINA?. BY MARIANA ROCHA. 2019;.",71.0,YR,,M,Y,,,20190322.0,,MD,PT,PT,2019,Q1,Elderly
160984232,16098423,13,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Hypotension,,2019,Q1,2,F,,20190318.0,20190321,20190322,EXP,,PT-TEVA-2019-PT-1028643,TEVA,"GOUVEIA C, DUQUE S, CAMPOS L. LIPOT IMIA POR HIPOVOLEMIA - UM CASO DE IATROTROGENIA A EMPA GLIFLO ZINA?. BY MARIANA ROCHA. 2019;.",71.0,YR,,M,Y,,,20190322.0,,MD,PT,PT,2019,Q1,Elderly
160984232,16098423,13,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Syncope,,2019,Q1,2,F,,20190318.0,20190321,20190322,EXP,,PT-TEVA-2019-PT-1028643,TEVA,"GOUVEIA C, DUQUE S, CAMPOS L. LIPOT IMIA POR HIPOVOLEMIA - UM CASO DE IATROTROGENIA A EMPA GLIFLO ZINA?. BY MARIANA ROCHA. 2019;.",71.0,YR,,M,Y,,,20190322.0,,MD,PT,PT,2019,Q1,Elderly
161078911,16107891,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q1,Dyschromatopsia,,2019,Q1,1,I,20181206.0,20190318.0,20190322,20190322,PER,,US-ALLERGAN-1912024US,ALLERGAN,,51.0,YR,,M,Y,105.7,KG,20190322.0,,MD,US,US,2019,Q1,Adult
161099641,16109964,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,1.0,DF,,QD,2019,Q1,C-reactive protein increased,,2019,Q1,1,I,20180521.0,20190225.0,20190325,20190325,EXP,,JP-ASTELLAS-2019JP003433,ASTELLAS,,51.0,YR,,F,Y,,,20190325.0,,CN,JP,JP,2019,Q1,Adult
161099641,16109964,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,1.0,DF,,QD,2019,Q1,Dysphagia,,2019,Q1,1,I,20180521.0,20190225.0,20190325,20190325,EXP,,JP-ASTELLAS-2019JP003433,ASTELLAS,,51.0,YR,,F,Y,,,20190325.0,,CN,JP,JP,2019,Q1,Adult
161099641,16109964,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,1.0,DF,,QD,2019,Q1,Interstitial lung disease,,2019,Q1,1,I,20180521.0,20190225.0,20190325,20190325,EXP,,JP-ASTELLAS-2019JP003433,ASTELLAS,,51.0,YR,,F,Y,,,20190325.0,,CN,JP,JP,2019,Q1,Adult
161099641,16109964,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,1.0,DF,,QD,2019,Q1,Off label use,,2019,Q1,1,I,20180521.0,20190225.0,20190325,20190325,EXP,,JP-ASTELLAS-2019JP003433,ASTELLAS,,51.0,YR,,F,Y,,,20190325.0,,CN,JP,JP,2019,Q1,Adult
161119511,16111951,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,1.25,MG,,QD,2019,Q1,Urinary tract infection,,2019,Q1,1,I,20181113.0,,20190220,20190220,DIR,,,FDA-CTU,,59.0,YR,,M,N,129.0,KG,20190207.0,N,PH,US,US,2019,Q1,Adult
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Anaemia,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Blood cholesterol increased,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Blood glucose increased,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Blood pressure fluctuation,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Blood uric acid increased,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Cardiomegaly,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Carotid arteriosclerosis,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Chest discomfort,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Decreased ventricular preload,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Dyspnoea exertional,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Electrocardiogram abnormal,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Hepatic lesion,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Ischaemia,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Myocardial ischaemia,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Renal impairment,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161223261,16122326,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,TABLET,,2019,Q1,Transient ischaemic attack,,2019,Q1,1,I,,20190315.0,20190327,20190327,EXP,HU-EMA-DD-20181212-SANDEVHP-125722,HU-ACCORD-116150,ACCORD,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190327.0,,OT,HU,HU,2019,Q1,Elderly
161234641,16123464,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Breast cancer,,2019,Q1,1,I,20160603.0,20161031.0,20190327,20190327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-000644",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,67.8,KG,20190327.0,,MD,JP,JP,2019,Q1,Elderly
161234641,16123464,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q1,Hypoglycaemia,,2019,Q1,1,I,20160603.0,20161031.0,20190327,20190327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-000644",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,67.8,KG,20190327.0,,MD,JP,JP,2019,Q1,Elderly
161236881,16123688,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,, UNK,,,,,,,2019,Q1,Dizziness,,2019,Q1,1,I,,20190318.0,20190327,20190327,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C., DUQUE S., CAMPOS L.. HYPOVOLAEMIC LIPOTHYMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1) SUPPL:47-122",71.0,YR,,M,Y,,,20190327.0,,OT,PT,PT,2019,Q1,Elderly
161236881,16123688,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,, UNK,,,,,,,2019,Q1,Renal injury,,2019,Q1,1,I,,20190318.0,20190327,20190327,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C., DUQUE S., CAMPOS L.. HYPOVOLAEMIC LIPOTHYMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1) SUPPL:47-122",71.0,YR,,M,Y,,,20190327.0,,OT,PT,PT,2019,Q1,Elderly
161236881,16123688,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,, UNK,,,,,,,2019,Q1,Syncope,,2019,Q1,1,I,,20190318.0,20190327,20190327,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C., DUQUE S., CAMPOS L.. HYPOVOLAEMIC LIPOTHYMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1) SUPPL:47-122",71.0,YR,,M,Y,,,20190327.0,,OT,PT,PT,2019,Q1,Elderly
161298281,16129828,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNK",,,,,,,,,,,,2019,Q1,Arrhythmia,,2019,Q1,1,I,,20190322.0,20190328,20190328,EXP,,TR-SA-2019SA080421,SANOFI AVENTIS,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLEMIA ? A CASE OF EMPAGLIFLOZIN IATROGENY?. REVISTA PORTUGUESA DE DIABETES.. 2019;14(1)SUP:47-122:1-2",71.0,YR,E,M,Y,,,20190328.0,,OT,TR,TR,2019,Q1,Elderly
161298281,16129828,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNK",,,,,,,,,,,,2019,Q1,Bradycardia,,2019,Q1,1,I,,20190322.0,20190328,20190328,EXP,,TR-SA-2019SA080421,SANOFI AVENTIS,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLEMIA ? A CASE OF EMPAGLIFLOZIN IATROGENY?. REVISTA PORTUGUESA DE DIABETES.. 2019;14(1)SUP:47-122:1-2",71.0,YR,E,M,Y,,,20190328.0,,OT,TR,TR,2019,Q1,Elderly
161298281,16129828,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNK",,,,,,,,,,,,2019,Q1,Dehydration,,2019,Q1,1,I,,20190322.0,20190328,20190328,EXP,,TR-SA-2019SA080421,SANOFI AVENTIS,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLEMIA ? A CASE OF EMPAGLIFLOZIN IATROGENY?. REVISTA PORTUGUESA DE DIABETES.. 2019;14(1)SUP:47-122:1-2",71.0,YR,E,M,Y,,,20190328.0,,OT,TR,TR,2019,Q1,Elderly
161298281,16129828,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNK",,,,,,,,,,,,2019,Q1,Dizziness,,2019,Q1,1,I,,20190322.0,20190328,20190328,EXP,,TR-SA-2019SA080421,SANOFI AVENTIS,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLEMIA ? A CASE OF EMPAGLIFLOZIN IATROGENY?. REVISTA PORTUGUESA DE DIABETES.. 2019;14(1)SUP:47-122:1-2",71.0,YR,E,M,Y,,,20190328.0,,OT,TR,TR,2019,Q1,Elderly
161298281,16129828,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNK",,,,,,,,,,,,2019,Q1,Hypotension,,2019,Q1,1,I,,20190322.0,20190328,20190328,EXP,,TR-SA-2019SA080421,SANOFI AVENTIS,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLEMIA ? A CASE OF EMPAGLIFLOZIN IATROGENY?. REVISTA PORTUGUESA DE DIABETES.. 2019;14(1)SUP:47-122:1-2",71.0,YR,E,M,Y,,,20190328.0,,OT,TR,TR,2019,Q1,Elderly
161298281,16129828,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNK",,,,,,,,,,,,2019,Q1,Hypovolaemia,,2019,Q1,1,I,,20190322.0,20190328,20190328,EXP,,TR-SA-2019SA080421,SANOFI AVENTIS,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLEMIA ? A CASE OF EMPAGLIFLOZIN IATROGENY?. REVISTA PORTUGUESA DE DIABETES.. 2019;14(1)SUP:47-122:1-2",71.0,YR,E,M,Y,,,20190328.0,,OT,TR,TR,2019,Q1,Elderly
161298281,16129828,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNK",,,,,,,,,,,,2019,Q1,Oedema peripheral,,2019,Q1,1,I,,20190322.0,20190328,20190328,EXP,,TR-SA-2019SA080421,SANOFI AVENTIS,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLEMIA ? A CASE OF EMPAGLIFLOZIN IATROGENY?. REVISTA PORTUGUESA DE DIABETES.. 2019;14(1)SUP:47-122:1-2",71.0,YR,E,M,Y,,,20190328.0,,OT,TR,TR,2019,Q1,Elderly
161298281,16129828,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNK",,,,,,,,,,,,2019,Q1,Presyncope,,2019,Q1,1,I,,20190322.0,20190328,20190328,EXP,,TR-SA-2019SA080421,SANOFI AVENTIS,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLEMIA ? A CASE OF EMPAGLIFLOZIN IATROGENY?. REVISTA PORTUGUESA DE DIABETES.. 2019;14(1)SUP:47-122:1-2",71.0,YR,E,M,Y,,,20190328.0,,OT,TR,TR,2019,Q1,Elderly
161298281,16129828,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNK",,,,,,,,,,,,2019,Q1,Pulmonary congestion,,2019,Q1,1,I,,20190322.0,20190328,20190328,EXP,,TR-SA-2019SA080421,SANOFI AVENTIS,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLEMIA ? A CASE OF EMPAGLIFLOZIN IATROGENY?. REVISTA PORTUGUESA DE DIABETES.. 2019;14(1)SUP:47-122:1-2",71.0,YR,E,M,Y,,,20190328.0,,OT,TR,TR,2019,Q1,Elderly
161298281,16129828,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNK",,,,,,,,,,,,2019,Q1,Renal disorder,,2019,Q1,1,I,,20190322.0,20190328,20190328,EXP,,TR-SA-2019SA080421,SANOFI AVENTIS,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLEMIA ? A CASE OF EMPAGLIFLOZIN IATROGENY?. REVISTA PORTUGUESA DE DIABETES.. 2019;14(1)SUP:47-122:1-2",71.0,YR,E,M,Y,,,20190328.0,,OT,TR,TR,2019,Q1,Elderly
161345571,16134557,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q1,Acute hepatic failure,,2019,Q1,1,I,,20190327.0,20190329,20190329,EXP,,KR-ABBVIE-19P-090-2724838-00,ABBVIE,,70.0,YR,,F,Y,,,20190329.0,,OT,KR,KR,2019,Q1,Elderly
161354851,16135485,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD",200.417,MG,,,,,,10.0,MG,,QD,2019,Q1,Cardiac failure,,2019,Q1,1,I,20181019.0,20190326.0,20190329,20190329,EXP,GB-MHRA-INP0B459061-F824-4180-9480-DB82B517A0BD,GB-TAKEDA-2019TEU003094,TAKEDA,,68.0,YR,,F,Y,82.0,KG,20190329.0,,OT,GB,GB,2019,Q1,Elderly
161354851,16135485,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD",200.417,MG,,,,,,10.0,MG,,QD,2019,Q1,Dyspnoea,,2019,Q1,1,I,20181019.0,20190326.0,20190329,20190329,EXP,GB-MHRA-INP0B459061-F824-4180-9480-DB82B517A0BD,GB-TAKEDA-2019TEU003094,TAKEDA,,68.0,YR,,F,Y,82.0,KG,20190329.0,,OT,GB,GB,2019,Q1,Elderly
161354851,16135485,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD",200.417,MG,,,,,,10.0,MG,,QD,2019,Q1,Pericardial effusion,,2019,Q1,1,I,20181019.0,20190326.0,20190329,20190329,EXP,GB-MHRA-INP0B459061-F824-4180-9480-DB82B517A0BD,GB-TAKEDA-2019TEU003094,TAKEDA,,68.0,YR,,F,Y,82.0,KG,20190329.0,,OT,GB,GB,2019,Q1,Elderly
161363221,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Acute kidney injury,,2019,Q1,1,I,,20190322.0,20190329,20190329,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190329.0,,MD,PT,PT,2019,Q1,Elderly
161363221,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Arrhythmia,,2019,Q1,1,I,,20190322.0,20190329,20190329,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190329.0,,MD,PT,PT,2019,Q1,Elderly
161363221,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Bradycardia,,2019,Q1,1,I,,20190322.0,20190329,20190329,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190329.0,,MD,PT,PT,2019,Q1,Elderly
161363221,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Dehydration,,2019,Q1,1,I,,20190322.0,20190329,20190329,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190329.0,,MD,PT,PT,2019,Q1,Elderly
161363221,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Hypotension,,2019,Q1,1,I,,20190322.0,20190329,20190329,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190329.0,,MD,PT,PT,2019,Q1,Elderly
161363221,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Presyncope,,2019,Q1,1,I,,20190322.0,20190329,20190329,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190329.0,,MD,PT,PT,2019,Q1,Elderly
161363221,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q1,Syncope,,2019,Q1,1,I,,20190322.0,20190329,20190329,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190329.0,,MD,PT,PT,2019,Q1,Elderly
127275182,12727518,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,25.0,MG,,QD,2019,Q2,Diabetic ketoacidosis,,2019,Q2,2,F,,20190529.0,20160909,20190603,EXP,,PK-BAUSCH-BL-2016-021856,BAUSCH AND LOMB,"RASHID O, FAROOQ S, KIRAN Z, ISLAM N. EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES STARTED ON EMPAGLIFLOZIN. BMJ CASE REPORTS. 2016;.",42.0,YR,,M,Y,,,20190603.0,,MD,PK,PK,2019,Q2,Adult
127576383,12757638,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, QD",,,Y,U, UNKNOWN,,,25.0,MG,,QD,2019,Q2,Diabetic ketoacidosis,,2019,Q2,3,F,,20190530.0,20160919,20190613,EXP,,PK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-073938,BRISTOL MYERS SQUIBB,,42.0,YR,,M,Y,,,20190613.0,,OT,PK,PK,2019,Q2,Adult
130111944,13011194,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Albumin urine present,,2019,Q2,4,F,20160810.0,20190328.0,20161208,20190403,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20190403.0,,MD,JP,JP,2019,Q2,Adult
130111944,13011194,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Hypertension,,2019,Q2,4,F,20160810.0,20190328.0,20161208,20190403,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20190403.0,,MD,JP,JP,2019,Q2,Adult
130111944,13011194,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Left ventricular hypertrophy,,2019,Q2,4,F,20160810.0,20190328.0,20161208,20190403,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20190403.0,,MD,JP,JP,2019,Q2,Adult
130111944,13011194,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Red blood cell count increased,,2019,Q2,4,F,20160810.0,20190328.0,20161208,20190403,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20190403.0,,MD,JP,JP,2019,Q2,Adult
130111944,13011194,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Urine ketone body present,,2019,Q2,4,F,20160810.0,20190328.0,20161208,20190403,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20190403.0,,MD,JP,JP,2019,Q2,Adult
130111944,13011194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q2,Albumin urine present,,2019,Q2,4,F,20160810.0,20190328.0,20161208,20190403,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20190403.0,,MD,JP,JP,2019,Q2,Adult
130111944,13011194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q2,Hypertension,,2019,Q2,4,F,20160810.0,20190328.0,20161208,20190403,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20190403.0,,MD,JP,JP,2019,Q2,Adult
130111944,13011194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q2,Left ventricular hypertrophy,,2019,Q2,4,F,20160810.0,20190328.0,20161208,20190403,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20190403.0,,MD,JP,JP,2019,Q2,Adult
130111944,13011194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q2,Red blood cell count increased,,2019,Q2,4,F,20160810.0,20190328.0,20161208,20190403,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20190403.0,,MD,JP,JP,2019,Q2,Adult
130111944,13011194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q2,Urine ketone body present,,2019,Q2,4,F,20160810.0,20190328.0,20161208,20190403,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20190403.0,,MD,JP,JP,2019,Q2,Adult
134179744,13417974,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Blood ketone body increased,,2019,Q2,4,F,20161004.0,20190408.0,20170406,20190415,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001675",BOEHRINGER INGELHEIM,,32.0,YR,,F,Y,89.9,KG,20190415.0,,MD,JP,JP,2019,Q2,Young Adult
134179744,13417974,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Urine ketone body present,,2019,Q2,4,F,20161004.0,20190408.0,20170406,20190415,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001675",BOEHRINGER INGELHEIM,,32.0,YR,,F,Y,89.9,KG,20190415.0,,MD,JP,JP,2019,Q2,Young Adult
134179744,13417974,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q2,Blood ketone body increased,,2019,Q2,4,F,20161004.0,20190408.0,20170406,20190415,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001675",BOEHRINGER INGELHEIM,,32.0,YR,,F,Y,89.9,KG,20190415.0,,MD,JP,JP,2019,Q2,Young Adult
134179744,13417974,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q2,Urine ketone body present,,2019,Q2,4,F,20161004.0,20190408.0,20170406,20190415,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001675",BOEHRINGER INGELHEIM,,32.0,YR,,F,Y,89.9,KG,20190415.0,,MD,JP,JP,2019,Q2,Young Adult
135414733,13541473,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Blood ketone body increased,,2019,Q2,3,F,20170120.0,20190422.0,20170512,20190426,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-002478",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,87.7,KG,20190426.0,,MD,JP,JP,2019,Q2,Adult
135414733,13541473,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q2,Blood ketone body increased,,2019,Q2,3,F,20170120.0,20190422.0,20170512,20190426,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-002478",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,87.7,KG,20190426.0,,MD,JP,JP,2019,Q2,Adult
136486455,13648645,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Hyperphosphatasaemia,,2019,Q2,5,F,20161117.0,20190429.0,20170613,20190508,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003274",BOEHRINGER INGELHEIM,,51.0,YR,,M,Y,87.9,KG,20190508.0,,MD,JP,JP,2019,Q2,Adult
136486455,13648645,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Urine ketone body present,,2019,Q2,5,F,20161117.0,20190429.0,20170613,20190508,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003274",BOEHRINGER INGELHEIM,,51.0,YR,,M,Y,87.9,KG,20190508.0,,MD,JP,JP,2019,Q2,Adult
138683895,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Blood ketone body increased,,2019,Q2,5,F,20170728.0,20190619.0,20170815,20190625,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20190625.0,,MD,JP,JP,2019,Q2,Adult
138683895,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Hypercholesterolaemia,,2019,Q2,5,F,20170728.0,20190619.0,20170815,20190625,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20190625.0,,MD,JP,JP,2019,Q2,Adult
138683895,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Hyperuricaemia,,2019,Q2,5,F,20170728.0,20190619.0,20170815,20190625,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20190625.0,,MD,JP,JP,2019,Q2,Adult
138683895,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Leukocytosis,,2019,Q2,5,F,20170728.0,20190619.0,20170815,20190625,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20190625.0,,MD,JP,JP,2019,Q2,Adult
138768765,13876876,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Dizziness,,2019,Q2,5,F,20161213.0,20190517.0,20170817,20190524,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004697",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,69.2,KG,20190524.0,,MD,JP,JP,2019,Q2,Elderly
138768765,13876876,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Myalgia,,2019,Q2,5,F,20161213.0,20190517.0,20170817,20190524,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004697",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,69.2,KG,20190524.0,,MD,JP,JP,2019,Q2,Elderly
138768765,13876876,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Ventricular extrasystoles,,2019,Q2,5,F,20161213.0,20190517.0,20170817,20190524,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004697",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,69.2,KG,20190524.0,,MD,JP,JP,2019,Q2,Elderly
140832185,14083218,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Myocardial ischaemia,,2019,Q2,5,F,20170704.0,20190604.0,20171012,20190611,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005392",BOEHRINGER INGELHEIM,,77.0,YR,,M,Y,55.4,KG,20190611.0,,MD,JP,JP,2019,Q2,Elderly
140832185,14083218,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Spinal stenosis,,2019,Q2,5,F,20170704.0,20190604.0,20171012,20190611,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005392",BOEHRINGER INGELHEIM,,77.0,YR,,M,Y,55.4,KG,20190611.0,,MD,JP,JP,2019,Q2,Elderly
147996205,14799620,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Calculus urinary,,2019,Q2,5,F,20160816.0,20190510.0,20180424,20190517,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002148",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,87.4,KG,20190517.0,,MD,JP,JP,2019,Q2,Adult
147996205,14799620,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Gastric ulcer haemorrhage,,2019,Q2,5,F,20160816.0,20190510.0,20180424,20190517,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002148",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,87.4,KG,20190517.0,,MD,JP,JP,2019,Q2,Adult
147996205,14799620,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Oropharyngeal discomfort,,2019,Q2,5,F,20160816.0,20190510.0,20180424,20190517,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002148",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,87.4,KG,20190517.0,,MD,JP,JP,2019,Q2,Adult
147996205,14799620,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Urinary tract infection,,2019,Q2,5,F,20160816.0,20190510.0,20180424,20190517,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002148",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,87.4,KG,20190517.0,,MD,JP,JP,2019,Q2,Adult
151332763,15133276,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Lip and/or oral cavity cancer,,2019,Q2,3,F,20170921.0,20190619.0,20180712,20190621,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003865",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,75.8,KG,20190621.0,,MD,JP,JP,2019,Q2,Elderly
151332763,15133276,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,TABLET,,2019,Q2,Lip and/or oral cavity cancer,,2019,Q2,3,F,20170921.0,20190619.0,20180712,20190621,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003865",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,75.8,KG,20190621.0,,MD,JP,JP,2019,Q2,Elderly
1514478210,15144782,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2019,Q2,Cardiac arrest,,2019,Q2,10,F,20180704.0,20190412.0,20180713,20190415,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-035148",BOEHRINGER INGELHEIM,,57.0,YR,,M,Y,94.0,KG,20190415.0,,MD,DE,DE,2019,Q2,Adult
1514478210,15144782,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2019,Q2,Hypoglycaemia,,2019,Q2,10,F,20180704.0,20190412.0,20180713,20190415,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-035148",BOEHRINGER INGELHEIM,,57.0,YR,,M,Y,94.0,KG,20190415.0,,MD,DE,DE,2019,Q2,Adult
1514478210,15144782,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2019,Q2,Hyponatraemia,,2019,Q2,10,F,20180704.0,20190412.0,20180713,20190415,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-035148",BOEHRINGER INGELHEIM,,57.0,YR,,M,Y,94.0,KG,20190415.0,,MD,DE,DE,2019,Q2,Adult
1514478210,15144782,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2019,Q2,Hypotension,,2019,Q2,10,F,20180704.0,20190412.0,20180713,20190415,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-035148",BOEHRINGER INGELHEIM,,57.0,YR,,M,Y,94.0,KG,20190415.0,,MD,DE,DE,2019,Q2,Adult
1514478210,15144782,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2019,Q2,Neurological symptom,,2019,Q2,10,F,20180704.0,20190412.0,20180713,20190415,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-035148",BOEHRINGER INGELHEIM,,57.0,YR,,M,Y,94.0,KG,20190415.0,,MD,DE,DE,2019,Q2,Adult
1514478210,15144782,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2019,Q2,Pulmonary embolism,,2019,Q2,10,F,20180704.0,20190412.0,20180713,20190415,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-035148",BOEHRINGER INGELHEIM,,57.0,YR,,M,Y,94.0,KG,20190415.0,,MD,DE,DE,2019,Q2,Adult
152187434,15218743,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,FILM-COATED TABLET,,2019,Q2,Cardiac failure,,2019,Q2,4,F,20180620.0,20190614.0,20180731,20190618,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-037662",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,109.7,KG,20190618.0,,MD,BR,BR,2019,Q2,Elderly
152187434,15218743,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,FILM-COATED TABLET,,2019,Q2,Hemiparesis,,2019,Q2,4,F,20180620.0,20190614.0,20180731,20190618,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-037662",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,109.7,KG,20190618.0,,MD,BR,BR,2019,Q2,Elderly
152823824,15282382,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Decreased appetite,,2019,Q2,4,F,20180126.0,20190527.0,20180816,20190603,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004452",BOEHRINGER INGELHEIM,,63.0,YR,,M,Y,68.1,KG,20190603.0,,MD,JP,JP,2019,Q2,Adult
152823824,15282382,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Gastric cancer,,2019,Q2,4,F,20180126.0,20190527.0,20180816,20190603,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004452",BOEHRINGER INGELHEIM,,63.0,YR,,M,Y,68.1,KG,20190603.0,,MD,JP,JP,2019,Q2,Adult
152823824,15282382,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Malignant neoplasm of unknown primary site,,2019,Q2,4,F,20180126.0,20190527.0,20180816,20190603,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004452",BOEHRINGER INGELHEIM,,63.0,YR,,M,Y,68.1,KG,20190603.0,,MD,JP,JP,2019,Q2,Adult
153467274,15346727,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,Y,,,205832.0,10.0,MG,TABLET,,2019,Q2,Genital herpes,Genital herpes,2019,Q2,4,F,20170909.0,20190530.0,20180904,20190606,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004765",BOEHRINGER INGELHEIM,,49.0,YR,,F,Y,59.7,KG,20190606.0,,MD,JP,JP,2019,Q2,Adult
153467274,15346727,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,Y,,,205832.0,10.0,MG,TABLET,,2019,Q2,Genital herpes,Genital herpes,2019,Q2,4,F,20170909.0,20190530.0,20180904,20190606,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004765",BOEHRINGER INGELHEIM,,49.0,YR,,F,Y,59.7,KG,20190606.0,,MD,JP,JP,2019,Q2,Adult
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Anaemia,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Blood cholesterol increased,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Blood glucose increased,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Blood pressure fluctuation,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Blood uric acid increased,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Cardiomegaly,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Carotid arteriosclerosis,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Chest discomfort,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Decreased ventricular preload,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Dyspnoea exertional,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Electrocardiogram abnormal,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Hepatic lesion,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Ischaemia,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Myocardial ischaemia,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Renal impairment,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155382762,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,, UNK,,,1.0,DF,TABLET,QD,2019,Q2,Transient ischaemic attack,,2019,Q2,2,F,,20190506.0,20181022,20190510,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20190510.0,,OT,HU,HU,2019,Q2,Elderly
155610263,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q2,Anxiety,,2019,Q2,3,F,,20190416.0,20181029,20190423,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190423.0,,CN,US,US,2019,Q2,Elderly
155610263,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q2,Asthenia,,2019,Q2,3,F,,20190416.0,20181029,20190423,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190423.0,,CN,US,US,2019,Q2,Elderly
155610263,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q2,Back pain,,2019,Q2,3,F,,20190416.0,20181029,20190423,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190423.0,,CN,US,US,2019,Q2,Elderly
155610263,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q2,Depression,,2019,Q2,3,F,,20190416.0,20181029,20190423,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190423.0,,CN,US,US,2019,Q2,Elderly
155610263,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q2,Emotional disorder,,2019,Q2,3,F,,20190416.0,20181029,20190423,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190423.0,,CN,US,US,2019,Q2,Elderly
155610263,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q2,Fatigue,,2019,Q2,3,F,,20190416.0,20181029,20190423,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190423.0,,CN,US,US,2019,Q2,Elderly
155610263,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q2,Headache,,2019,Q2,3,F,,20190416.0,20181029,20190423,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190423.0,,CN,US,US,2019,Q2,Elderly
155610263,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q2,Logorrhoea,,2019,Q2,3,F,,20190416.0,20181029,20190423,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190423.0,,CN,US,US,2019,Q2,Elderly
155610263,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q2,Malaise,,2019,Q2,3,F,,20190416.0,20181029,20190423,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190423.0,,CN,US,US,2019,Q2,Elderly
155610263,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q2,Muscular weakness,,2019,Q2,3,F,,20190416.0,20181029,20190423,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190423.0,,CN,US,US,2019,Q2,Elderly
155610263,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q2,Nerve injury,,2019,Q2,3,F,,20190416.0,20181029,20190423,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190423.0,,CN,US,US,2019,Q2,Elderly
155610263,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q2,Neuralgia,,2019,Q2,3,F,,20190416.0,20181029,20190423,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190423.0,,CN,US,US,2019,Q2,Elderly
155610263,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q2,Peripheral swelling,,2019,Q2,3,F,,20190416.0,20181029,20190423,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190423.0,,CN,US,US,2019,Q2,Elderly
155610263,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q2,Spinal cord neoplasm,,2019,Q2,3,F,,20190416.0,20181029,20190423,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190423.0,,CN,US,US,2019,Q2,Elderly
155610263,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q2,Weight increased,,2019,Q2,3,F,,20190416.0,20181029,20190423,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190423.0,,CN,US,US,2019,Q2,Elderly
155656372,15565637,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Blood glucose increased,,2019,Q2,2,F,20160727.0,20190424.0,20181030,20190426,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005581",BOEHRINGER INGELHEIM,,45.0,YR,,F,Y,76.0,KG,20190426.0,,MD,JP,JP,2019,Q2,Adult
155656372,15565637,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Endometritis,,2019,Q2,2,F,20160727.0,20190424.0,20181030,20190426,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005581",BOEHRINGER INGELHEIM,,45.0,YR,,F,Y,76.0,KG,20190426.0,,MD,JP,JP,2019,Q2,Adult
155656372,15565637,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Fibrous histiocytoma,,2019,Q2,2,F,20160727.0,20190424.0,20181030,20190426,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005581",BOEHRINGER INGELHEIM,,45.0,YR,,F,Y,76.0,KG,20190426.0,,MD,JP,JP,2019,Q2,Adult
155656372,15565637,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Vulvovaginal candidiasis,,2019,Q2,2,F,20160727.0,20190424.0,20181030,20190426,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005581",BOEHRINGER INGELHEIM,,45.0,YR,,F,Y,76.0,KG,20190426.0,,MD,JP,JP,2019,Q2,Adult
155656372,15565637,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Blood glucose increased,,2019,Q2,2,F,20160727.0,20190424.0,20181030,20190426,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005581",BOEHRINGER INGELHEIM,,45.0,YR,,F,Y,76.0,KG,20190426.0,,MD,JP,JP,2019,Q2,Adult
155656372,15565637,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Endometritis,,2019,Q2,2,F,20160727.0,20190424.0,20181030,20190426,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005581",BOEHRINGER INGELHEIM,,45.0,YR,,F,Y,76.0,KG,20190426.0,,MD,JP,JP,2019,Q2,Adult
155656372,15565637,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Fibrous histiocytoma,,2019,Q2,2,F,20160727.0,20190424.0,20181030,20190426,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005581",BOEHRINGER INGELHEIM,,45.0,YR,,F,Y,76.0,KG,20190426.0,,MD,JP,JP,2019,Q2,Adult
155656372,15565637,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Vulvovaginal candidiasis,,2019,Q2,2,F,20160727.0,20190424.0,20181030,20190426,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005581",BOEHRINGER INGELHEIM,,45.0,YR,,F,Y,76.0,KG,20190426.0,,MD,JP,JP,2019,Q2,Adult
156855747,15685574,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q2,Acute kidney injury,,2019,Q2,7,F,20181018.0,20190611.0,20181204,20190614,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051737",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,126.0,KG,20190614.0,,MD,AU,AU,2019,Q2,Elderly
156855747,15685574,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q2,Hyperkalaemia,,2019,Q2,7,F,20181018.0,20190611.0,20181204,20190614,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051737",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,126.0,KG,20190614.0,,MD,AU,AU,2019,Q2,Elderly
156855747,15685574,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q2,Hypotension,,2019,Q2,7,F,20181018.0,20190611.0,20181204,20190614,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051737",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,126.0,KG,20190614.0,,MD,AU,AU,2019,Q2,Elderly
156855747,15685574,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q2,Renal impairment,,2019,Q2,7,F,20181018.0,20190611.0,20181204,20190614,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051737",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,126.0,KG,20190614.0,,MD,AU,AU,2019,Q2,Elderly
157203633,15720363,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q2,Liver injury,,2019,Q2,3,F,20181121.0,20190517.0,20181213,20190524,EXP,,"CN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-057672",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,85.0,KG,20190524.0,,MD,CN,CN,2019,Q2,Adult
157458523,15745852,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q2,Liver abscess,,2019,Q2,3,F,20181109.0,20190524.0,20181220,20190531,EXP,,JP-PFIZER INC-2018470268,PFIZER,,71.0,YR,,M,Y,66.3,KG,20190531.0,,MD,JP,JP,2019,Q2,Elderly
158443612,15844361,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Infection,,2019,Q2,2,F,20170715.0,20190530.0,20190118,20190606,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006472",BOEHRINGER INGELHEIM,,36.0,YR,,F,Y,49.0,KG,20190606.0,,MD,JP,JP,2019,Q2,Adult
158443612,15844361,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Polyuria,,2019,Q2,2,F,20170715.0,20190530.0,20190118,20190606,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006472",BOEHRINGER INGELHEIM,,36.0,YR,,F,Y,49.0,KG,20190606.0,,MD,JP,JP,2019,Q2,Adult
158443612,15844361,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Urine ketone body present,,2019,Q2,2,F,20170715.0,20190530.0,20190118,20190606,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006472",BOEHRINGER INGELHEIM,,36.0,YR,,F,Y,49.0,KG,20190606.0,,MD,JP,JP,2019,Q2,Adult
158531162,15853116,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Cardiovascular somatic symptom disorder,,2019,Q2,2,F,20180126.0,20190612.0,20190122,20190618,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-000162",BOEHRINGER INGELHEIM,,84.0,YR,,M,Y,65.7,KG,20190618.0,,MD,JP,JP,2019,Q2,Elderly
158600723,15860072,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,, UNKNOWN,,,,,,,2019,Q2,Dehydration,,2019,Q2,3,F,20190114.0,20190401.0,20190123,20190409,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-004023,BRISTOL MYERS SQUIBB,,58.0,YR,,M,Y,,,20190409.0,,OT,US,US,2019,Q2,Adult
158600723,15860072,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,, UNKNOWN,,,,,,,2019,Q2,Failure to thrive,,2019,Q2,3,F,20190114.0,20190401.0,20190123,20190409,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-004023,BRISTOL MYERS SQUIBB,,58.0,YR,,M,Y,,,20190409.0,,OT,US,US,2019,Q2,Adult
158600723,15860072,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,, UNKNOWN,,,,,,,2019,Q2,Fatigue,,2019,Q2,3,F,20190114.0,20190401.0,20190123,20190409,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-004023,BRISTOL MYERS SQUIBB,,58.0,YR,,M,Y,,,20190409.0,,OT,US,US,2019,Q2,Adult
158603139,15860313,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q2,Necrotising fasciitis,,2019,Q2,9,F,20181226.0,20190619.0,20190123,20190624,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-062218",BOEHRINGER INGELHEIM,,87.0,YR,,M,Y,81.4,KG,20190624.0,,MD,US,US,2019,Q2,Elderly
158603139,15860313,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q2,Urinary tract infection,,2019,Q2,9,F,20181226.0,20190619.0,20190123,20190624,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-062218",BOEHRINGER INGELHEIM,,87.0,YR,,M,Y,81.4,KG,20190624.0,,MD,US,US,2019,Q2,Elderly
158603139,15860313,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,,,FILM-COATED TABLET,,2019,Q2,Necrotising fasciitis,,2019,Q2,9,F,20181226.0,20190619.0,20190123,20190624,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-062218",BOEHRINGER INGELHEIM,,87.0,YR,,M,Y,81.4,KG,20190624.0,,MD,US,US,2019,Q2,Elderly
158603139,15860313,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,,,FILM-COATED TABLET,,2019,Q2,Urinary tract infection,,2019,Q2,9,F,20181226.0,20190619.0,20190123,20190624,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-062218",BOEHRINGER INGELHEIM,,87.0,YR,,M,Y,81.4,KG,20190624.0,,MD,US,US,2019,Q2,Elderly
158613002,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Anaemia,,2019,Q2,2,F,20161215.0,20190522.0,20190124,20190529,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190529.0,,MD,JP,JP,2019,Q2,Elderly
158613002,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Blood pressure increased,,2019,Q2,2,F,20161215.0,20190522.0,20190124,20190529,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190529.0,,MD,JP,JP,2019,Q2,Elderly
158613002,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Cardiac failure,,2019,Q2,2,F,20161215.0,20190522.0,20190124,20190529,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190529.0,,MD,JP,JP,2019,Q2,Elderly
158613002,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Diabetes mellitus,,2019,Q2,2,F,20161215.0,20190522.0,20190124,20190529,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190529.0,,MD,JP,JP,2019,Q2,Elderly
158613002,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Essential thrombocythaemia,,2019,Q2,2,F,20161215.0,20190522.0,20190124,20190529,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190529.0,,MD,JP,JP,2019,Q2,Elderly
158613002,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Hyperkalaemia,,2019,Q2,2,F,20161215.0,20190522.0,20190124,20190529,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190529.0,,MD,JP,JP,2019,Q2,Elderly
158613002,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Peripheral arterial occlusive disease,,2019,Q2,2,F,20161215.0,20190522.0,20190124,20190529,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190529.0,,MD,JP,JP,2019,Q2,Elderly
158613002,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Sinus node dysfunction,,2019,Q2,2,F,20161215.0,20190522.0,20190124,20190529,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190529.0,,MD,JP,JP,2019,Q2,Elderly
160541985,16054198,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,Y,,,,204629.0,,,FILM-COATED TABLET,,2019,Q2,Liver injury,,2019,Q2,5,F,20190222.0,20190621.0,20190308,20190626,EXP,,"CZ-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-009971",BOEHRINGER INGELHEIM,,78.0,YR,,M,Y,80.0,KG,20190625.0,,MD,CZ,CZ,2019,Q2,Elderly
160643885,16064388,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q2,Bowen's disease,,2019,Q2,5,F,201808.0,20190501.0,20190312,20190502,EXP,,"NL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-008545",BOEHRINGER INGELHEIM,,80.0,YR,,F,Y,74.0,KG,20190502.0,,MD,NL,NL,2019,Q2,Elderly
160643885,16064388,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q2,Glaucoma,,2019,Q2,5,F,201808.0,20190501.0,20190312,20190502,EXP,,"NL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-008545",BOEHRINGER INGELHEIM,,80.0,YR,,F,Y,74.0,KG,20190502.0,,MD,NL,NL,2019,Q2,Elderly
160686804,16068680,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,,,FILM-COATED TABLET,,2019,Q2,Angina pectoris,,2019,Q2,4,F,20180810.0,20190524.0,20190313,20190529,EXP,,"CN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-010013",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,,,20190529.0,,MD,CN,CN,2019,Q2,Elderly
160877013,16087701,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,,2019,Q2,Abdominal distension,,2019,Q2,3,F,201606.0,20190529.0,20190319,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
160877013,16087701,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,,2019,Q2,Angina pectoris,,2019,Q2,3,F,201606.0,20190529.0,20190319,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
160877013,16087701,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,,2019,Q2,Diabetes mellitus inadequate control,,2019,Q2,3,F,201606.0,20190529.0,20190319,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
160877013,16087701,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,,2019,Q2,Gallbladder polyp,,2019,Q2,3,F,201606.0,20190529.0,20190319,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
160877013,16087701,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,,2019,Q2,Haemoconcentration,,2019,Q2,3,F,201606.0,20190529.0,20190319,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
160877013,16087701,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,,2019,Q2,Hepatic function abnormal,,2019,Q2,3,F,201606.0,20190529.0,20190319,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
160877013,16087701,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,,2019,Q2,Occult blood positive,,2019,Q2,3,F,201606.0,20190529.0,20190319,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
160877013,16087701,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,TABLET,,2019,Q2,Abdominal distension,,2019,Q2,3,F,201606.0,20190529.0,20190319,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
160877013,16087701,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,TABLET,,2019,Q2,Angina pectoris,,2019,Q2,3,F,201606.0,20190529.0,20190319,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
160877013,16087701,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,TABLET,,2019,Q2,Diabetes mellitus inadequate control,,2019,Q2,3,F,201606.0,20190529.0,20190319,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
160877013,16087701,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,TABLET,,2019,Q2,Gallbladder polyp,,2019,Q2,3,F,201606.0,20190529.0,20190319,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
160877013,16087701,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,TABLET,,2019,Q2,Haemoconcentration,,2019,Q2,3,F,201606.0,20190529.0,20190319,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
160877013,16087701,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,TABLET,,2019,Q2,Hepatic function abnormal,,2019,Q2,3,F,201606.0,20190529.0,20190319,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
160877013,16087701,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,TABLET,,2019,Q2,Occult blood positive,,2019,Q2,3,F,201606.0,20190529.0,20190319,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001666",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,127.0,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
160979672,16097967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Acidosis,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Acute kidney injury,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,C-reactive protein increased,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Food intolerance,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Glycosuria,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Hypokalaemia,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Hypophosphataemia,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Ketonuria,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Leukocytosis,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Metabolic acidosis,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Nausea,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Neutrophilia,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Vomiting,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Acidosis,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Acute kidney injury,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,C-reactive protein increased,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Food intolerance,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Glycosuria,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Hypokalaemia,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Hypophosphataemia,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Ketonuria,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Leukocytosis,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Metabolic acidosis,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Nausea,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Neutrophilia,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160979672,16097967,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Vomiting,,2019,Q2,2,F,,20190329.0,20190320,20190405,EXP,,PHHY2019PT061227,SANDOZ,,70.0,YR,,M,Y,,,20190405.0,,OT,PT,PT,2019,Q2,Elderly
160984233,16098423,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q2,Acute kidney injury,,2019,Q2,3,F,,20190513.0,20190321,20190523,EXP,,PT-TEVA-2019-PT-1028643,TEVA,GOUVEIA C. LIPOTIMIA POR HIPOVOLEMIA - UM CASO DE IATROGENIA A EMPAGLIFLOZINA?. REVISTA PORTUGUESA DE DIABETES. 2019;17:74.,71.0,YR,,M,Y,,,20190523.0,,MD,PT,PT,2019,Q2,Elderly
160984233,16098423,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q2,Arrhythmia,,2019,Q2,3,F,,20190513.0,20190321,20190523,EXP,,PT-TEVA-2019-PT-1028643,TEVA,GOUVEIA C. LIPOTIMIA POR HIPOVOLEMIA - UM CASO DE IATROGENIA A EMPAGLIFLOZINA?. REVISTA PORTUGUESA DE DIABETES. 2019;17:74.,71.0,YR,,M,Y,,,20190523.0,,MD,PT,PT,2019,Q2,Elderly
160984233,16098423,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q2,Bradycardia,,2019,Q2,3,F,,20190513.0,20190321,20190523,EXP,,PT-TEVA-2019-PT-1028643,TEVA,GOUVEIA C. LIPOTIMIA POR HIPOVOLEMIA - UM CASO DE IATROGENIA A EMPAGLIFLOZINA?. REVISTA PORTUGUESA DE DIABETES. 2019;17:74.,71.0,YR,,M,Y,,,20190523.0,,MD,PT,PT,2019,Q2,Elderly
160984233,16098423,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q2,Dehydration,,2019,Q2,3,F,,20190513.0,20190321,20190523,EXP,,PT-TEVA-2019-PT-1028643,TEVA,GOUVEIA C. LIPOTIMIA POR HIPOVOLEMIA - UM CASO DE IATROGENIA A EMPAGLIFLOZINA?. REVISTA PORTUGUESA DE DIABETES. 2019;17:74.,71.0,YR,,M,Y,,,20190523.0,,MD,PT,PT,2019,Q2,Elderly
160984233,16098423,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q2,Dizziness,,2019,Q2,3,F,,20190513.0,20190321,20190523,EXP,,PT-TEVA-2019-PT-1028643,TEVA,GOUVEIA C. LIPOTIMIA POR HIPOVOLEMIA - UM CASO DE IATROGENIA A EMPAGLIFLOZINA?. REVISTA PORTUGUESA DE DIABETES. 2019;17:74.,71.0,YR,,M,Y,,,20190523.0,,MD,PT,PT,2019,Q2,Elderly
160984233,16098423,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q2,Hypotension,,2019,Q2,3,F,,20190513.0,20190321,20190523,EXP,,PT-TEVA-2019-PT-1028643,TEVA,GOUVEIA C. LIPOTIMIA POR HIPOVOLEMIA - UM CASO DE IATROGENIA A EMPAGLIFLOZINA?. REVISTA PORTUGUESA DE DIABETES. 2019;17:74.,71.0,YR,,M,Y,,,20190523.0,,MD,PT,PT,2019,Q2,Elderly
160984233,16098423,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q2,Syncope,,2019,Q2,3,F,,20190513.0,20190321,20190523,EXP,,PT-TEVA-2019-PT-1028643,TEVA,GOUVEIA C. LIPOTIMIA POR HIPOVOLEMIA - UM CASO DE IATROGENIA A EMPAGLIFLOZINA?. REVISTA PORTUGUESA DE DIABETES. 2019;17:74.,71.0,YR,,M,Y,,,20190523.0,,MD,PT,PT,2019,Q2,Elderly
161145972,16114597,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Lung neoplasm malignant,,2019,Q2,2,F,20180507.0,20190402.0,20190325,20190403,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-001321",BOEHRINGER INGELHEIM,,76.0,YR,,F,Y,65.6,KG,20190403.0,,MD,JP,JP,2019,Q2,Elderly
161290003,16129000,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Blood creatinine increased,,2019,Q2,3,F,20160520.0,20190517.0,20190328,20190520,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002657",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,76.3,KG,20190520.0,,MD,JP,JP,2019,Q2,Elderly
161290003,16129000,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Intestinal obstruction,,2019,Q2,3,F,20160520.0,20190517.0,20190328,20190520,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002657",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,76.3,KG,20190520.0,,MD,JP,JP,2019,Q2,Elderly
161290003,16129000,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Pneumonia,,2019,Q2,3,F,20160520.0,20190517.0,20190328,20190520,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002657",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,76.3,KG,20190520.0,,MD,JP,JP,2019,Q2,Elderly
161363222,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Acute kidney injury,,2019,Q2,2,F,,20190509.0,20190329,20190517,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190517.0,,MD,PT,PT,2019,Q2,Elderly
161363222,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Arrhythmia,,2019,Q2,2,F,,20190509.0,20190329,20190517,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190517.0,,MD,PT,PT,2019,Q2,Elderly
161363222,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Atrial fibrillation,,2019,Q2,2,F,,20190509.0,20190329,20190517,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190517.0,,MD,PT,PT,2019,Q2,Elderly
161363222,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Bradycardia,,2019,Q2,2,F,,20190509.0,20190329,20190517,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190517.0,,MD,PT,PT,2019,Q2,Elderly
161363222,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Dehydration,,2019,Q2,2,F,,20190509.0,20190329,20190517,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190517.0,,MD,PT,PT,2019,Q2,Elderly
161363222,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Dizziness,,2019,Q2,2,F,,20190509.0,20190329,20190517,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190517.0,,MD,PT,PT,2019,Q2,Elderly
161363222,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Haematocrit increased,,2019,Q2,2,F,,20190509.0,20190329,20190517,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190517.0,,MD,PT,PT,2019,Q2,Elderly
161363222,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Haemoglobin increased,,2019,Q2,2,F,,20190509.0,20190329,20190517,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190517.0,,MD,PT,PT,2019,Q2,Elderly
161363222,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Hypotension,,2019,Q2,2,F,,20190509.0,20190329,20190517,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190517.0,,MD,PT,PT,2019,Q2,Elderly
161363222,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Hypovolaemia,,2019,Q2,2,F,,20190509.0,20190329,20190517,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190517.0,,MD,PT,PT,2019,Q2,Elderly
161363222,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Left atrial dilatation,,2019,Q2,2,F,,20190509.0,20190329,20190517,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190517.0,,MD,PT,PT,2019,Q2,Elderly
161363222,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Mucosal dryness,,2019,Q2,2,F,,20190509.0,20190329,20190517,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190517.0,,MD,PT,PT,2019,Q2,Elderly
161363222,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Presyncope,,2019,Q2,2,F,,20190509.0,20190329,20190517,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190517.0,,MD,PT,PT,2019,Q2,Elderly
161363222,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Skin disorder,,2019,Q2,2,F,,20190509.0,20190329,20190517,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190517.0,,MD,PT,PT,2019,Q2,Elderly
161363222,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q2,Syncope,,2019,Q2,2,F,,20190509.0,20190329,20190517,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190517.0,,MD,PT,PT,2019,Q2,Elderly
161436522,16143652,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Acidosis,,2019,Q2,2,F,,20190419.0,20190401,20190429,EXP,,PT-BAUSCH-BL-2019-009330,BAUSCH AND LOMB,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161436522,16143652,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,2,F,,20190419.0,20190401,20190429,EXP,,PT-BAUSCH-BL-2019-009330,BAUSCH AND LOMB,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161436522,16143652,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Food intolerance,,2019,Q2,2,F,,20190419.0,20190401,20190429,EXP,,PT-BAUSCH-BL-2019-009330,BAUSCH AND LOMB,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161436522,16143652,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Glycosuria,,2019,Q2,2,F,,20190419.0,20190401,20190429,EXP,,PT-BAUSCH-BL-2019-009330,BAUSCH AND LOMB,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161436522,16143652,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Hypokalaemia,,2019,Q2,2,F,,20190419.0,20190401,20190429,EXP,,PT-BAUSCH-BL-2019-009330,BAUSCH AND LOMB,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161436522,16143652,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Hypophosphataemia,,2019,Q2,2,F,,20190419.0,20190401,20190429,EXP,,PT-BAUSCH-BL-2019-009330,BAUSCH AND LOMB,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161436522,16143652,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Ketonuria,,2019,Q2,2,F,,20190419.0,20190401,20190429,EXP,,PT-BAUSCH-BL-2019-009330,BAUSCH AND LOMB,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161436522,16143652,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Leukocytosis,,2019,Q2,2,F,,20190419.0,20190401,20190429,EXP,,PT-BAUSCH-BL-2019-009330,BAUSCH AND LOMB,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161436522,16143652,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Metabolic acidosis,,2019,Q2,2,F,,20190419.0,20190401,20190429,EXP,,PT-BAUSCH-BL-2019-009330,BAUSCH AND LOMB,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161436522,16143652,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Nausea,,2019,Q2,2,F,,20190419.0,20190401,20190429,EXP,,PT-BAUSCH-BL-2019-009330,BAUSCH AND LOMB,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161436522,16143652,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Neutrophilia,,2019,Q2,2,F,,20190419.0,20190401,20190429,EXP,,PT-BAUSCH-BL-2019-009330,BAUSCH AND LOMB,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161436522,16143652,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Vomiting,,2019,Q2,2,F,,20190419.0,20190401,20190429,EXP,,PT-BAUSCH-BL-2019-009330,BAUSCH AND LOMB,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190429.0,,OT,PT,PT,2019,Q2,Elderly
161467251,16146725,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,,2019,Q2,Confusional state,,2019,Q2,1,I,20190307.0,20190325.0,20190402,20190402,EXP,GB-MHRA-EYC 00196553,GB-TORRENT-00020710,TORRENT,,59.0,YR,A,F,Y,98.0,KG,20190402.0,,CN,GB,GB,2019,Q2,Adult
161467251,16146725,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,,2019,Q2,Diarrhoea,,2019,Q2,1,I,20190307.0,20190325.0,20190402,20190402,EXP,GB-MHRA-EYC 00196553,GB-TORRENT-00020710,TORRENT,,59.0,YR,A,F,Y,98.0,KG,20190402.0,,CN,GB,GB,2019,Q2,Adult
161467251,16146725,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,,2019,Q2,Hallucination,,2019,Q2,1,I,20190307.0,20190325.0,20190402,20190402,EXP,GB-MHRA-EYC 00196553,GB-TORRENT-00020710,TORRENT,,59.0,YR,A,F,Y,98.0,KG,20190402.0,,CN,GB,GB,2019,Q2,Adult
161467251,16146725,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,,2019,Q2,Off label use,,2019,Q2,1,I,20190307.0,20190325.0,20190402,20190402,EXP,GB-MHRA-EYC 00196553,GB-TORRENT-00020710,TORRENT,,59.0,YR,A,F,Y,98.0,KG,20190402.0,,CN,GB,GB,2019,Q2,Adult
161467251,16146725,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,,2019,Q2,Paranoia,,2019,Q2,1,I,20190307.0,20190325.0,20190402,20190402,EXP,GB-MHRA-EYC 00196553,GB-TORRENT-00020710,TORRENT,,59.0,YR,A,F,Y,98.0,KG,20190402.0,,CN,GB,GB,2019,Q2,Adult
161467251,16146725,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,10.0,MG,,,2019,Q2,Suicidal ideation,,2019,Q2,1,I,20190307.0,20190325.0,20190402,20190402,EXP,GB-MHRA-EYC 00196553,GB-TORRENT-00020710,TORRENT,,59.0,YR,A,F,Y,98.0,KG,20190402.0,,CN,GB,GB,2019,Q2,Adult
161477353,16147735,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Acute kidney injury,,2019,Q2,3,F,2018.0,20190521.0,20190402,20190531,EXP,,PT-BAUSCH-BL-2019-009329,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20190531.0,,MD,PT,PT,2019,Q2,Elderly
161477353,16147735,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Arrhythmia,,2019,Q2,3,F,2018.0,20190521.0,20190402,20190531,EXP,,PT-BAUSCH-BL-2019-009329,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20190531.0,,MD,PT,PT,2019,Q2,Elderly
161477353,16147735,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Atrial fibrillation,,2019,Q2,3,F,2018.0,20190521.0,20190402,20190531,EXP,,PT-BAUSCH-BL-2019-009329,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20190531.0,,MD,PT,PT,2019,Q2,Elderly
161477353,16147735,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Bradycardia,,2019,Q2,3,F,2018.0,20190521.0,20190402,20190531,EXP,,PT-BAUSCH-BL-2019-009329,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20190531.0,,MD,PT,PT,2019,Q2,Elderly
161477353,16147735,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Dehydration,,2019,Q2,3,F,2018.0,20190521.0,20190402,20190531,EXP,,PT-BAUSCH-BL-2019-009329,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20190531.0,,MD,PT,PT,2019,Q2,Elderly
161477353,16147735,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Dizziness,,2019,Q2,3,F,2018.0,20190521.0,20190402,20190531,EXP,,PT-BAUSCH-BL-2019-009329,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20190531.0,,MD,PT,PT,2019,Q2,Elderly
161477353,16147735,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Haematocrit increased,,2019,Q2,3,F,2018.0,20190521.0,20190402,20190531,EXP,,PT-BAUSCH-BL-2019-009329,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20190531.0,,MD,PT,PT,2019,Q2,Elderly
161477353,16147735,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Haemoglobin increased,,2019,Q2,3,F,2018.0,20190521.0,20190402,20190531,EXP,,PT-BAUSCH-BL-2019-009329,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20190531.0,,MD,PT,PT,2019,Q2,Elderly
161477353,16147735,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Hypotension,,2019,Q2,3,F,2018.0,20190521.0,20190402,20190531,EXP,,PT-BAUSCH-BL-2019-009329,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20190531.0,,MD,PT,PT,2019,Q2,Elderly
161477353,16147735,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Hypovolaemia,,2019,Q2,3,F,2018.0,20190521.0,20190402,20190531,EXP,,PT-BAUSCH-BL-2019-009329,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20190531.0,,MD,PT,PT,2019,Q2,Elderly
161477353,16147735,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Left atrial dilatation,,2019,Q2,3,F,2018.0,20190521.0,20190402,20190531,EXP,,PT-BAUSCH-BL-2019-009329,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20190531.0,,MD,PT,PT,2019,Q2,Elderly
161477353,16147735,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Mucosal dryness,,2019,Q2,3,F,2018.0,20190521.0,20190402,20190531,EXP,,PT-BAUSCH-BL-2019-009329,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20190531.0,,MD,PT,PT,2019,Q2,Elderly
161477353,16147735,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Presyncope,,2019,Q2,3,F,2018.0,20190521.0,20190402,20190531,EXP,,PT-BAUSCH-BL-2019-009329,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20190531.0,,MD,PT,PT,2019,Q2,Elderly
161477353,16147735,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Skin disorder,,2019,Q2,3,F,2018.0,20190521.0,20190402,20190531,EXP,,PT-BAUSCH-BL-2019-009329,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20190531.0,,MD,PT,PT,2019,Q2,Elderly
161477353,16147735,15,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q2,Syncope,,2019,Q2,3,F,2018.0,20190521.0,20190402,20190531,EXP,,PT-BAUSCH-BL-2019-009329,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20190531.0,,MD,PT,PT,2019,Q2,Elderly
161482151,16148215,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 MG, QD",,,,,,,,25.0,MG,,QD,2019,Q2,Gastric ulcer,,2019,Q2,1,I,20190305.0,20190325.0,20190402,20190402,EXP,,HK-BAYER-2019-062298,BAYER,,64.0,YR,A,M,Y,69.1,KG,20190402.0,,OT,US,HK,2019,Q2,Adult
161511989,16151198,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q2,Urosepsis,,2019,Q2,9,F,20190317.0,20190604.0,20190403,20190606,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-013915",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,91.0,KG,20190606.0,,MD,DE,DE,2019,Q2,Elderly
161518022,16151802,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Colonic abscess,,2019,Q2,2,F,20190208.0,20190329.0,20190403,20190404,EXP,,US-EXELIXIS-XL18418019836,EXELIXIS,,53.0,YR,,F,Y,114.5,KG,20190404.0,,MD,US,US,2019,Q2,Adult
161518022,16151802,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Pneumonitis,,2019,Q2,2,F,20190208.0,20190329.0,20190403,20190404,EXP,,US-EXELIXIS-XL18418019836,EXELIXIS,,53.0,YR,,F,Y,114.5,KG,20190404.0,,MD,US,US,2019,Q2,Adult
161518022,16151802,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Pyrexia,,2019,Q2,2,F,20190208.0,20190329.0,20190403,20190404,EXP,,US-EXELIXIS-XL18418019836,EXELIXIS,,53.0,YR,,F,Y,114.5,KG,20190404.0,,MD,US,US,2019,Q2,Adult
161521151,16152115,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q2,Diabetic nephropathy,,2019,Q2,1,I,20190326.0,20190329.0,20190403,20190403,EXP,,"AR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-014846",BOEHRINGER INGELHEIM,,64.0,YR,,F,Y,91.8,KG,20190403.0,,MD,AR,AR,2019,Q2,Adult
161521172,16152117,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q2,Acute kidney injury,,2019,Q2,2,F,20190131.0,20190612.0,20190403,20190617,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-006842",BOEHRINGER INGELHEIM,,80.0,YR,,M,Y,50.3,KG,20190617.0,,MD,BR,BR,2019,Q2,Elderly
161548645,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q2,Acute kidney injury,,2019,Q2,5,F,2018.0,20190524.0,20190403,20190605,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190605.0,,CN,PT,PT,2019,Q2,Elderly
161548645,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q2,Arrhythmia,,2019,Q2,5,F,2018.0,20190524.0,20190403,20190605,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190605.0,,CN,PT,PT,2019,Q2,Elderly
161548645,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q2,Atrial fibrillation,,2019,Q2,5,F,2018.0,20190524.0,20190403,20190605,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190605.0,,CN,PT,PT,2019,Q2,Elderly
161548645,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q2,Bradycardia,,2019,Q2,5,F,2018.0,20190524.0,20190403,20190605,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190605.0,,CN,PT,PT,2019,Q2,Elderly
161548645,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q2,Dehydration,,2019,Q2,5,F,2018.0,20190524.0,20190403,20190605,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190605.0,,CN,PT,PT,2019,Q2,Elderly
161548645,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q2,Dizziness,,2019,Q2,5,F,2018.0,20190524.0,20190403,20190605,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190605.0,,CN,PT,PT,2019,Q2,Elderly
161548645,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q2,Haematocrit increased,,2019,Q2,5,F,2018.0,20190524.0,20190403,20190605,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190605.0,,CN,PT,PT,2019,Q2,Elderly
161548645,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q2,Haemoglobin increased,,2019,Q2,5,F,2018.0,20190524.0,20190403,20190605,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190605.0,,CN,PT,PT,2019,Q2,Elderly
161548645,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q2,Hypotension,,2019,Q2,5,F,2018.0,20190524.0,20190403,20190605,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190605.0,,CN,PT,PT,2019,Q2,Elderly
161548645,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q2,Hypovolaemia,,2019,Q2,5,F,2018.0,20190524.0,20190403,20190605,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190605.0,,CN,PT,PT,2019,Q2,Elderly
161548645,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q2,Left atrial dilatation,,2019,Q2,5,F,2018.0,20190524.0,20190403,20190605,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190605.0,,CN,PT,PT,2019,Q2,Elderly
161548645,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q2,Mucosal dryness,,2019,Q2,5,F,2018.0,20190524.0,20190403,20190605,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190605.0,,CN,PT,PT,2019,Q2,Elderly
161548645,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q2,Presyncope,,2019,Q2,5,F,2018.0,20190524.0,20190403,20190605,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190605.0,,CN,PT,PT,2019,Q2,Elderly
161548645,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q2,Skin disorder,,2019,Q2,5,F,2018.0,20190524.0,20190403,20190605,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190605.0,,CN,PT,PT,2019,Q2,Elderly
161548645,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q2,Syncope,,2019,Q2,5,F,2018.0,20190524.0,20190403,20190605,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190605.0,,CN,PT,PT,2019,Q2,Elderly
161561811,16156181,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Abdominal discomfort,,2019,Q2,1,I,20190331.0,20190403.0,20190404,20190404,PER,,US-BEH-2019101148,CSL BEHRING,,53.0,YR,A,M,Y,147.39,KG,20190404.0,,OT,US,US,2019,Q2,Adult
161568791,16156879,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,N,,,,12.5,MG,,QD,2019,Q2,Dehydration,,2019,Q2,1,I,20170828.0,,20190228,20190228,DIR,,,FDA-CTU,,65.0,YR,,F,N,80.47,KG,20170831.0,N,PH,US,US,2019,Q2,Elderly
161618733,16161873,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Acute kidney injury,,2019,Q2,3,F,2018.0,20190521.0,20190405,20190527,EXP,,PT-SA-2019SA092645,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20190527.0,,MD,PT,PT,2019,Q2,Elderly
161618733,16161873,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Arrhythmia,,2019,Q2,3,F,2018.0,20190521.0,20190405,20190527,EXP,,PT-SA-2019SA092645,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20190527.0,,MD,PT,PT,2019,Q2,Elderly
161618733,16161873,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Atrial fibrillation,,2019,Q2,3,F,2018.0,20190521.0,20190405,20190527,EXP,,PT-SA-2019SA092645,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20190527.0,,MD,PT,PT,2019,Q2,Elderly
161618733,16161873,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Bradycardia,,2019,Q2,3,F,2018.0,20190521.0,20190405,20190527,EXP,,PT-SA-2019SA092645,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20190527.0,,MD,PT,PT,2019,Q2,Elderly
161618733,16161873,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Dehydration,,2019,Q2,3,F,2018.0,20190521.0,20190405,20190527,EXP,,PT-SA-2019SA092645,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20190527.0,,MD,PT,PT,2019,Q2,Elderly
161618733,16161873,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Dizziness,,2019,Q2,3,F,2018.0,20190521.0,20190405,20190527,EXP,,PT-SA-2019SA092645,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20190527.0,,MD,PT,PT,2019,Q2,Elderly
161618733,16161873,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Haematocrit increased,,2019,Q2,3,F,2018.0,20190521.0,20190405,20190527,EXP,,PT-SA-2019SA092645,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20190527.0,,MD,PT,PT,2019,Q2,Elderly
161618733,16161873,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Haemoglobin increased,,2019,Q2,3,F,2018.0,20190521.0,20190405,20190527,EXP,,PT-SA-2019SA092645,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20190527.0,,MD,PT,PT,2019,Q2,Elderly
161618733,16161873,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Hypotension,,2019,Q2,3,F,2018.0,20190521.0,20190405,20190527,EXP,,PT-SA-2019SA092645,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20190527.0,,MD,PT,PT,2019,Q2,Elderly
161618733,16161873,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Hypovolaemia,,2019,Q2,3,F,2018.0,20190521.0,20190405,20190527,EXP,,PT-SA-2019SA092645,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20190527.0,,MD,PT,PT,2019,Q2,Elderly
161618733,16161873,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Left atrial dilatation,,2019,Q2,3,F,2018.0,20190521.0,20190405,20190527,EXP,,PT-SA-2019SA092645,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20190527.0,,MD,PT,PT,2019,Q2,Elderly
161618733,16161873,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Mucosal dryness,,2019,Q2,3,F,2018.0,20190521.0,20190405,20190527,EXP,,PT-SA-2019SA092645,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20190527.0,,MD,PT,PT,2019,Q2,Elderly
161618733,16161873,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Presyncope,,2019,Q2,3,F,2018.0,20190521.0,20190405,20190527,EXP,,PT-SA-2019SA092645,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20190527.0,,MD,PT,PT,2019,Q2,Elderly
161618733,16161873,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Skin disorder,,2019,Q2,3,F,2018.0,20190521.0,20190405,20190527,EXP,,PT-SA-2019SA092645,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20190527.0,,MD,PT,PT,2019,Q2,Elderly
161618733,16161873,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Syncope,,2019,Q2,3,F,2018.0,20190521.0,20190405,20190527,EXP,,PT-SA-2019SA092645,SANOFI AVENTIS,,71.0,YR,E,M,Y,,,20190527.0,,MD,PT,PT,2019,Q2,Elderly
161627821,16162782,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Renal cell carcinoma,,2019,Q2,1,I,20181026.0,20190404.0,20190405,20190405,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-001568",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,71.4,KG,20190405.0,,MD,JP,JP,2019,Q2,Elderly
161633411,16163341,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2019,Q2,Confusional state,,2019,Q2,1,I,20190307.0,20190325.0,20190405,20190405,EXP,GB-MHRA-EYC 00196553,GB-ELI_LILLY_AND_COMPANY-GB201903014364,ELI LILLY AND CO,,59.0,YR,,F,Y,98.87,KG,20190405.0,,CN,GB,GB,2019,Q2,Adult
161633411,16163341,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2019,Q2,Diarrhoea,,2019,Q2,1,I,20190307.0,20190325.0,20190405,20190405,EXP,GB-MHRA-EYC 00196553,GB-ELI_LILLY_AND_COMPANY-GB201903014364,ELI LILLY AND CO,,59.0,YR,,F,Y,98.87,KG,20190405.0,,CN,GB,GB,2019,Q2,Adult
161633411,16163341,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2019,Q2,Hallucination,,2019,Q2,1,I,20190307.0,20190325.0,20190405,20190405,EXP,GB-MHRA-EYC 00196553,GB-ELI_LILLY_AND_COMPANY-GB201903014364,ELI LILLY AND CO,,59.0,YR,,F,Y,98.87,KG,20190405.0,,CN,GB,GB,2019,Q2,Adult
161633411,16163341,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2019,Q2,Paranoia,,2019,Q2,1,I,20190307.0,20190325.0,20190405,20190405,EXP,GB-MHRA-EYC 00196553,GB-ELI_LILLY_AND_COMPANY-GB201903014364,ELI LILLY AND CO,,59.0,YR,,F,Y,98.87,KG,20190405.0,,CN,GB,GB,2019,Q2,Adult
161633411,16163341,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2019,Q2,Suicidal ideation,,2019,Q2,1,I,20190307.0,20190325.0,20190405,20190405,EXP,GB-MHRA-EYC 00196553,GB-ELI_LILLY_AND_COMPANY-GB201903014364,ELI LILLY AND CO,,59.0,YR,,F,Y,98.87,KG,20190405.0,,CN,GB,GB,2019,Q2,Adult
161637337,16163733,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1X/DAY",,,,,,,,10.0,MG,,QD,2019,Q2,Acute kidney injury,,2019,Q2,7,F,2018.0,20190527.0,20190405,20190530,EXP,,PT-PFIZER INC-2019149489,PFIZER,"GOUVEIA, C.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20190530.0,,MD,PT,PT,2019,Q2,Elderly
161637337,16163733,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1X/DAY",,,,,,,,10.0,MG,,QD,2019,Q2,Arrhythmia,,2019,Q2,7,F,2018.0,20190527.0,20190405,20190530,EXP,,PT-PFIZER INC-2019149489,PFIZER,"GOUVEIA, C.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20190530.0,,MD,PT,PT,2019,Q2,Elderly
161637337,16163733,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1X/DAY",,,,,,,,10.0,MG,,QD,2019,Q2,Atrial fibrillation,,2019,Q2,7,F,2018.0,20190527.0,20190405,20190530,EXP,,PT-PFIZER INC-2019149489,PFIZER,"GOUVEIA, C.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20190530.0,,MD,PT,PT,2019,Q2,Elderly
161637337,16163733,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1X/DAY",,,,,,,,10.0,MG,,QD,2019,Q2,Bradycardia,,2019,Q2,7,F,2018.0,20190527.0,20190405,20190530,EXP,,PT-PFIZER INC-2019149489,PFIZER,"GOUVEIA, C.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20190530.0,,MD,PT,PT,2019,Q2,Elderly
161637337,16163733,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1X/DAY",,,,,,,,10.0,MG,,QD,2019,Q2,Dehydration,,2019,Q2,7,F,2018.0,20190527.0,20190405,20190530,EXP,,PT-PFIZER INC-2019149489,PFIZER,"GOUVEIA, C.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20190530.0,,MD,PT,PT,2019,Q2,Elderly
161637337,16163733,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1X/DAY",,,,,,,,10.0,MG,,QD,2019,Q2,Dizziness,,2019,Q2,7,F,2018.0,20190527.0,20190405,20190530,EXP,,PT-PFIZER INC-2019149489,PFIZER,"GOUVEIA, C.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20190530.0,,MD,PT,PT,2019,Q2,Elderly
161637337,16163733,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1X/DAY",,,,,,,,10.0,MG,,QD,2019,Q2,Haematocrit increased,,2019,Q2,7,F,2018.0,20190527.0,20190405,20190530,EXP,,PT-PFIZER INC-2019149489,PFIZER,"GOUVEIA, C.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20190530.0,,MD,PT,PT,2019,Q2,Elderly
161637337,16163733,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1X/DAY",,,,,,,,10.0,MG,,QD,2019,Q2,Haemoglobin increased,,2019,Q2,7,F,2018.0,20190527.0,20190405,20190530,EXP,,PT-PFIZER INC-2019149489,PFIZER,"GOUVEIA, C.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20190530.0,,MD,PT,PT,2019,Q2,Elderly
161637337,16163733,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1X/DAY",,,,,,,,10.0,MG,,QD,2019,Q2,Hypotension,,2019,Q2,7,F,2018.0,20190527.0,20190405,20190530,EXP,,PT-PFIZER INC-2019149489,PFIZER,"GOUVEIA, C.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20190530.0,,MD,PT,PT,2019,Q2,Elderly
161637337,16163733,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1X/DAY",,,,,,,,10.0,MG,,QD,2019,Q2,Hypovolaemia,,2019,Q2,7,F,2018.0,20190527.0,20190405,20190530,EXP,,PT-PFIZER INC-2019149489,PFIZER,"GOUVEIA, C.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20190530.0,,MD,PT,PT,2019,Q2,Elderly
161637337,16163733,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1X/DAY",,,,,,,,10.0,MG,,QD,2019,Q2,Left atrial dilatation,,2019,Q2,7,F,2018.0,20190527.0,20190405,20190530,EXP,,PT-PFIZER INC-2019149489,PFIZER,"GOUVEIA, C.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20190530.0,,MD,PT,PT,2019,Q2,Elderly
161637337,16163733,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1X/DAY",,,,,,,,10.0,MG,,QD,2019,Q2,Mucosal dryness,,2019,Q2,7,F,2018.0,20190527.0,20190405,20190530,EXP,,PT-PFIZER INC-2019149489,PFIZER,"GOUVEIA, C.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20190530.0,,MD,PT,PT,2019,Q2,Elderly
161637337,16163733,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1X/DAY",,,,,,,,10.0,MG,,QD,2019,Q2,Presyncope,,2019,Q2,7,F,2018.0,20190527.0,20190405,20190530,EXP,,PT-PFIZER INC-2019149489,PFIZER,"GOUVEIA, C.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20190530.0,,MD,PT,PT,2019,Q2,Elderly
161637337,16163733,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1X/DAY",,,,,,,,10.0,MG,,QD,2019,Q2,Skin disorder,,2019,Q2,7,F,2018.0,20190527.0,20190405,20190530,EXP,,PT-PFIZER INC-2019149489,PFIZER,"GOUVEIA, C.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20190530.0,,MD,PT,PT,2019,Q2,Elderly
161637337,16163733,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1X/DAY",,,,,,,,10.0,MG,,QD,2019,Q2,Syncope,,2019,Q2,7,F,2018.0,20190527.0,20190405,20190530,EXP,,PT-PFIZER INC-2019149489,PFIZER,"GOUVEIA, C.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20190530.0,,MD,PT,PT,2019,Q2,Elderly
161654302,16165430,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Cardiac disorder,,2019,Q2,2,F,20180125.0,20190611.0,20190405,20190619,EXP,,US-ASTRAZENECA-2019SE50243,ASTRAZENECA,,22591.0,DY,,M,Y,,,20190619.0,,,US,US,2019,Q2,Elderly
161654302,16165430,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Cardiac failure,,2019,Q2,2,F,20180125.0,20190611.0,20190405,20190619,EXP,,US-ASTRAZENECA-2019SE50243,ASTRAZENECA,,22591.0,DY,,M,Y,,,20190619.0,,,US,US,2019,Q2,Elderly
161654302,16165430,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Cardiac failure congestive,,2019,Q2,2,F,20180125.0,20190611.0,20190405,20190619,EXP,,US-ASTRAZENECA-2019SE50243,ASTRAZENECA,,22591.0,DY,,M,Y,,,20190619.0,,,US,US,2019,Q2,Elderly
161654302,16165430,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Chronic left ventricular failure,,2019,Q2,2,F,20180125.0,20190611.0,20190405,20190619,EXP,,US-ASTRAZENECA-2019SE50243,ASTRAZENECA,,22591.0,DY,,M,Y,,,20190619.0,,,US,US,2019,Q2,Elderly
161654302,16165430,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Left ventricular failure,,2019,Q2,2,F,20180125.0,20190611.0,20190405,20190619,EXP,,US-ASTRAZENECA-2019SE50243,ASTRAZENECA,,22591.0,DY,,M,Y,,,20190619.0,,,US,US,2019,Q2,Elderly
161654302,16165430,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Myocardial infarction,,2019,Q2,2,F,20180125.0,20190611.0,20190405,20190619,EXP,,US-ASTRAZENECA-2019SE50243,ASTRAZENECA,,22591.0,DY,,M,Y,,,20190619.0,,,US,US,2019,Q2,Elderly
161659751,16165975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,200.41667,MG,,,,,,10.0,MG,TABLET,,2019,Q2,Cardiac failure,,2019,Q2,1,I,20181019.0,20190326.0,20190406,20190406,EXP,GB-MHRA-ADR 24378545,GB-ACCORD-118471,ACCORD,,68.0,YR,,F,Y,82.0,KG,20190406.0,,MD,GB,GB,2019,Q2,Elderly
161659751,16165975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,200.41667,MG,,,,,,10.0,MG,TABLET,,2019,Q2,Dyspnoea,,2019,Q2,1,I,20181019.0,20190326.0,20190406,20190406,EXP,GB-MHRA-ADR 24378545,GB-ACCORD-118471,ACCORD,,68.0,YR,,F,Y,82.0,KG,20190406.0,,MD,GB,GB,2019,Q2,Elderly
161659751,16165975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,200.41667,MG,,,,,,10.0,MG,TABLET,,2019,Q2,Pericardial effusion,,2019,Q2,1,I,20181019.0,20190326.0,20190406,20190406,EXP,GB-MHRA-ADR 24378545,GB-ACCORD-118471,ACCORD,,68.0,YR,,F,Y,82.0,KG,20190406.0,,MD,GB,GB,2019,Q2,Elderly
161684451,16168445,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,,,2019,Q2,Leg amputation,,2019,Q2,1,I,20181227.0,20190403.0,20190408,20190408,EXP,GB-MHRA-EYC 00196788,GB-009507513-1904GBR001979,MERCK,,51.0,YR,,M,Y,111.0,KG,20190408.0,,MD,GB,GB,2019,Q2,Adult
161684451,16168445,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,,,2019,Q2,Peripheral embolism,,2019,Q2,1,I,20181227.0,20190403.0,20190408,20190408,EXP,GB-MHRA-EYC 00196788,GB-009507513-1904GBR001979,MERCK,,51.0,YR,,M,Y,111.0,KG,20190408.0,,MD,GB,GB,2019,Q2,Adult
161694951,16169495,1,PS,empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q2,Deep vein thrombosis,,2019,Q2,1,I,20190404.0,,20190406,20190406,DIR,,,FDA-CTU,,73.0,YR,,M,N,67.4,KG,20190406.0,N,PH,US,US,2019,Q2,Elderly
161694951,16169495,1,PS,empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,1,I,20190404.0,,20190406,20190406,DIR,,,FDA-CTU,,73.0,YR,,M,N,67.4,KG,20190406.0,N,PH,US,US,2019,Q2,Elderly
161694951,16169495,1,PS,empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q2,Osteomyelitis,,2019,Q2,1,I,20190404.0,,20190406,20190406,DIR,,,FDA-CTU,,73.0,YR,,M,N,67.4,KG,20190406.0,N,PH,US,US,2019,Q2,Elderly
161694951,16169495,1,PS,empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q2,Pain in extremity,,2019,Q2,1,I,20190404.0,,20190406,20190406,DIR,,,FDA-CTU,,73.0,YR,,M,N,67.4,KG,20190406.0,N,PH,US,US,2019,Q2,Elderly
161708241,16170824,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Deep vein thrombosis,,2019,Q2,1,I,,20190402.0,20190408,20190408,EXP,,ES-MYLANLABS-2019M1031615,MYLAN,,74.0,YR,,F,Y,,,20190408.0,,MD,ES,ES,2019,Q2,Elderly
161708241,16170824,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Hypoglycaemia,,2019,Q2,1,I,,20190402.0,20190408,20190408,EXP,,ES-MYLANLABS-2019M1031615,MYLAN,,74.0,YR,,F,Y,,,20190408.0,,MD,ES,ES,2019,Q2,Elderly
161708241,16170824,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Weight decreased,,2019,Q2,1,I,,20190402.0,20190408,20190408,EXP,,ES-MYLANLABS-2019M1031615,MYLAN,,74.0,YR,,F,Y,,,20190408.0,,MD,ES,ES,2019,Q2,Elderly
161813951,16181395,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,10.0,MG,,,2019,Q2,Confusional state,,2019,Q2,1,I,20190307.0,20190401.0,20190410,20190410,EXP,GB-MHRA-EYC 00196553,GB-TEVA-2019-GB-1034142,TEVA,,59.0,YR,,F,Y,98.87,KG,20190410.0,,CN,GB,GB,2019,Q2,Adult
161813951,16181395,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,10.0,MG,,,2019,Q2,Diarrhoea,,2019,Q2,1,I,20190307.0,20190401.0,20190410,20190410,EXP,GB-MHRA-EYC 00196553,GB-TEVA-2019-GB-1034142,TEVA,,59.0,YR,,F,Y,98.87,KG,20190410.0,,CN,GB,GB,2019,Q2,Adult
161813951,16181395,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,10.0,MG,,,2019,Q2,Hallucination,,2019,Q2,1,I,20190307.0,20190401.0,20190410,20190410,EXP,GB-MHRA-EYC 00196553,GB-TEVA-2019-GB-1034142,TEVA,,59.0,YR,,F,Y,98.87,KG,20190410.0,,CN,GB,GB,2019,Q2,Adult
161813951,16181395,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,10.0,MG,,,2019,Q2,Paranoia,,2019,Q2,1,I,20190307.0,20190401.0,20190410,20190410,EXP,GB-MHRA-EYC 00196553,GB-TEVA-2019-GB-1034142,TEVA,,59.0,YR,,F,Y,98.87,KG,20190410.0,,CN,GB,GB,2019,Q2,Adult
161813951,16181395,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,10.0,MG,,,2019,Q2,Suicidal ideation,,2019,Q2,1,I,20190307.0,20190401.0,20190410,20190410,EXP,GB-MHRA-EYC 00196553,GB-TEVA-2019-GB-1034142,TEVA,,59.0,YR,,F,Y,98.87,KG,20190410.0,,CN,GB,GB,2019,Q2,Adult
161962423,16196242,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Dermatitis,,2019,Q2,3,F,20160506.0,20190529.0,20190415,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-49810NB",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,80.3,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
161962423,16196242,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Diabetes mellitus inadequate control,,2019,Q2,3,F,20160506.0,20190529.0,20190415,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-49810NB",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,80.3,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
161962423,16196242,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Hypertriglyceridaemia,,2019,Q2,3,F,20160506.0,20190529.0,20190415,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-49810NB",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,80.3,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
161962423,16196242,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Injury,,2019,Q2,3,F,20160506.0,20190529.0,20190415,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-49810NB",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,80.3,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
161962423,16196242,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Intervertebral disc protrusion,,2019,Q2,3,F,20160506.0,20190529.0,20190415,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-49810NB",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,80.3,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
161962423,16196242,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Menopausal symptoms,,2019,Q2,3,F,20160506.0,20190529.0,20190415,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-49810NB",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,80.3,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
161962423,16196242,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Nasopharyngitis,,2019,Q2,3,F,20160506.0,20190529.0,20190415,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-49810NB",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,80.3,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
161962423,16196242,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Pharyngitis,,2019,Q2,3,F,20160506.0,20190529.0,20190415,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-49810NB",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,80.3,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
161962423,16196242,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Vulvovaginal candidiasis,,2019,Q2,3,F,20160506.0,20190529.0,20190415,20190605,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-49810NB",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,80.3,KG,20190605.0,,MD,JP,JP,2019,Q2,Adult
162034792,16203479,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Angina pectoris,,2019,Q2,2,F,20180913.0,20190419.0,20190416,20190423,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-001679",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,80.0,KG,20190423.0,,MD,JP,JP,2019,Q2,Elderly
162034792,16203479,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Cerebral infarction,,2019,Q2,2,F,20180913.0,20190419.0,20190416,20190423,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-001679",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,80.0,KG,20190423.0,,MD,JP,JP,2019,Q2,Elderly
162034792,16203479,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Osteoarthritis,,2019,Q2,2,F,20180913.0,20190419.0,20190416,20190423,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-001679",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,80.0,KG,20190423.0,,MD,JP,JP,2019,Q2,Elderly
162036954,16203695,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,U,,,,,25.0,MG,,,2019,Q2,Blood glucose increased,,2019,Q2,4,F,2015.0,20190513.0,20190416,20190520,EXP,,PHHY2019HU084919,NOVARTIS,,63.0,YR,,M,Y,,,20190521.0,,OT,HU,HU,2019,Q2,Adult
162036954,16203695,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,U,,,,,25.0,MG,,,2019,Q2,Blood pressure inadequately controlled,,2019,Q2,4,F,2015.0,20190513.0,20190416,20190520,EXP,,PHHY2019HU084919,NOVARTIS,,63.0,YR,,M,Y,,,20190521.0,,OT,HU,HU,2019,Q2,Adult
162036954,16203695,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,U,,,,,25.0,MG,,,2019,Q2,Blood pressure systolic increased,,2019,Q2,4,F,2015.0,20190513.0,20190416,20190520,EXP,,PHHY2019HU084919,NOVARTIS,,63.0,YR,,M,Y,,,20190521.0,,OT,HU,HU,2019,Q2,Adult
162036954,16203695,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,U,,,,,25.0,MG,,,2019,Q2,Dyslipidaemia,,2019,Q2,4,F,2015.0,20190513.0,20190416,20190520,EXP,,PHHY2019HU084919,NOVARTIS,,63.0,YR,,M,Y,,,20190521.0,,OT,HU,HU,2019,Q2,Adult
162036954,16203695,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,U,,,,,25.0,MG,,,2019,Q2,Eating disorder,,2019,Q2,4,F,2015.0,20190513.0,20190416,20190520,EXP,,PHHY2019HU084919,NOVARTIS,,63.0,YR,,M,Y,,,20190521.0,,OT,HU,HU,2019,Q2,Adult
162036954,16203695,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,U,,,,,25.0,MG,,,2019,Q2,Glycosylated haemoglobin increased,,2019,Q2,4,F,2015.0,20190513.0,20190416,20190520,EXP,,PHHY2019HU084919,NOVARTIS,,63.0,YR,,M,Y,,,20190521.0,,OT,HU,HU,2019,Q2,Adult
162036954,16203695,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,U,,,,,25.0,MG,,,2019,Q2,Mobility decreased,,2019,Q2,4,F,2015.0,20190513.0,20190416,20190520,EXP,,PHHY2019HU084919,NOVARTIS,,63.0,YR,,M,Y,,,20190521.0,,OT,HU,HU,2019,Q2,Adult
162036954,16203695,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,U,,,,,25.0,MG,,,2019,Q2,Obesity,,2019,Q2,4,F,2015.0,20190513.0,20190416,20190520,EXP,,PHHY2019HU084919,NOVARTIS,,63.0,YR,,M,Y,,,20190521.0,,OT,HU,HU,2019,Q2,Adult
162036954,16203695,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,U,,,,,25.0,MG,,,2019,Q2,Sleep apnoea syndrome,,2019,Q2,4,F,2015.0,20190513.0,20190416,20190520,EXP,,PHHY2019HU084919,NOVARTIS,,63.0,YR,,M,Y,,,20190521.0,,OT,HU,HU,2019,Q2,Adult
162036954,16203695,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,U,,,,,25.0,MG,,,2019,Q2,Stress,,2019,Q2,4,F,2015.0,20190513.0,20190416,20190520,EXP,,PHHY2019HU084919,NOVARTIS,,63.0,YR,,M,Y,,,20190521.0,,OT,HU,HU,2019,Q2,Adult
162036954,16203695,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,U,,,,,25.0,MG,,,2019,Q2,Type 2 diabetes mellitus,,2019,Q2,4,F,2015.0,20190513.0,20190416,20190520,EXP,,PHHY2019HU084919,NOVARTIS,,63.0,YR,,M,Y,,,20190521.0,,OT,HU,HU,2019,Q2,Adult
162050943,16205094,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q2,Acute kidney injury,,2019,Q2,3,F,20180717.0,20190524.0,20190416,20190529,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-038274",BOEHRINGER INGELHEIM,,83.0,YR,,F,Y,,,20190529.0,,MD,AU,AU,2019,Q2,Elderly
162050943,16205094,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q2,Fall,,2019,Q2,3,F,20180717.0,20190524.0,20190416,20190529,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-038274",BOEHRINGER INGELHEIM,,83.0,YR,,F,Y,,,20190529.0,,MD,AU,AU,2019,Q2,Elderly
162050943,16205094,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q2,Urinary tract infection,,2019,Q2,3,F,20180717.0,20190524.0,20190416,20190529,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-038274",BOEHRINGER INGELHEIM,,83.0,YR,,F,Y,,,20190529.0,,MD,AU,AU,2019,Q2,Elderly
162070791,16207079,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q2,Glucose urine,,2019,Q2,1,I,,20190405.0,20190417,20190417,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-035476,BRISTOL MYERS SQUIBB,"OHSHIMIZU , ET AL.. A CASE OF TRANSNASAL PITUITARY TUMOR REMOVAL WITHOUT SUFFICIENT CESSATION OF SODIUM GLUCOSE TRANSPORTER 2 INHIBITORS. 2019;P76-5",33.0,YR,,F,Y,71.0,KG,20190417.0,,OT,JP,JP,2019,Q2,Young Adult
162070791,16207079,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q2,Ketoacidosis,,2019,Q2,1,I,,20190405.0,20190417,20190417,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-035476,BRISTOL MYERS SQUIBB,"OHSHIMIZU , ET AL.. A CASE OF TRANSNASAL PITUITARY TUMOR REMOVAL WITHOUT SUFFICIENT CESSATION OF SODIUM GLUCOSE TRANSPORTER 2 INHIBITORS. 2019;P76-5",33.0,YR,,F,Y,71.0,KG,20190417.0,,OT,JP,JP,2019,Q2,Young Adult
162070791,16207079,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q2,Polyuria,,2019,Q2,1,I,,20190405.0,20190417,20190417,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-035476,BRISTOL MYERS SQUIBB,"OHSHIMIZU , ET AL.. A CASE OF TRANSNASAL PITUITARY TUMOR REMOVAL WITHOUT SUFFICIENT CESSATION OF SODIUM GLUCOSE TRANSPORTER 2 INHIBITORS. 2019;P76-5",33.0,YR,,F,Y,71.0,KG,20190417.0,,OT,JP,JP,2019,Q2,Young Adult
162135901,16213590,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q2,Constipation,Constipation,2019,Q2,1,I,20120101.0,20190406.0,20190418,20190418,EXP,,MX-ALVOGEN-2019-ALVOGEN-099463,ALVOGEN,,15739.0,DY,,F,Y,82.0,KG,20190418.0,,CN,MX,MX,2019,Q2,Elderly
162135901,16213590,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q2,Cystitis,Cystitis,2019,Q2,1,I,20120101.0,20190406.0,20190418,20190418,EXP,,MX-ALVOGEN-2019-ALVOGEN-099463,ALVOGEN,,15739.0,DY,,F,Y,82.0,KG,20190418.0,,CN,MX,MX,2019,Q2,Elderly
162135901,16213590,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q2,Drug interaction,Drug interaction,2019,Q2,1,I,20120101.0,20190406.0,20190418,20190418,EXP,,MX-ALVOGEN-2019-ALVOGEN-099463,ALVOGEN,,15739.0,DY,,F,Y,82.0,KG,20190418.0,,CN,MX,MX,2019,Q2,Elderly
162135901,16213590,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q2,Fall,Fall,2019,Q2,1,I,20120101.0,20190406.0,20190418,20190418,EXP,,MX-ALVOGEN-2019-ALVOGEN-099463,ALVOGEN,,15739.0,DY,,F,Y,82.0,KG,20190418.0,,CN,MX,MX,2019,Q2,Elderly
162135901,16213590,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q2,Hypertonic bladder,Hypertonic bladder,2019,Q2,1,I,20120101.0,20190406.0,20190418,20190418,EXP,,MX-ALVOGEN-2019-ALVOGEN-099463,ALVOGEN,,15739.0,DY,,F,Y,82.0,KG,20190418.0,,CN,MX,MX,2019,Q2,Elderly
162135901,16213590,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q2,Impaired healing,Impaired healing,2019,Q2,1,I,20120101.0,20190406.0,20190418,20190418,EXP,,MX-ALVOGEN-2019-ALVOGEN-099463,ALVOGEN,,15739.0,DY,,F,Y,82.0,KG,20190418.0,,CN,MX,MX,2019,Q2,Elderly
162135901,16213590,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q2,Increased appetite,Increased appetite,2019,Q2,1,I,20120101.0,20190406.0,20190418,20190418,EXP,,MX-ALVOGEN-2019-ALVOGEN-099463,ALVOGEN,,15739.0,DY,,F,Y,82.0,KG,20190418.0,,CN,MX,MX,2019,Q2,Elderly
162135901,16213590,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q2,Nephrolithiasis,Nephrolithiasis,2019,Q2,1,I,20120101.0,20190406.0,20190418,20190418,EXP,,MX-ALVOGEN-2019-ALVOGEN-099463,ALVOGEN,,15739.0,DY,,F,Y,82.0,KG,20190418.0,,CN,MX,MX,2019,Q2,Elderly
162135901,16213590,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q2,Pyelonephritis,Pyelonephritis,2019,Q2,1,I,20120101.0,20190406.0,20190418,20190418,EXP,,MX-ALVOGEN-2019-ALVOGEN-099463,ALVOGEN,,15739.0,DY,,F,Y,82.0,KG,20190418.0,,CN,MX,MX,2019,Q2,Elderly
162135901,16213590,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q2,Spinal fracture,Spinal fracture,2019,Q2,1,I,20120101.0,20190406.0,20190418,20190418,EXP,,MX-ALVOGEN-2019-ALVOGEN-099463,ALVOGEN,,15739.0,DY,,F,Y,82.0,KG,20190418.0,,CN,MX,MX,2019,Q2,Elderly
162135901,16213590,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q2,Type 2 diabetes mellitus,Type 2 diabetes mellitus,2019,Q2,1,I,20120101.0,20190406.0,20190418,20190418,EXP,,MX-ALVOGEN-2019-ALVOGEN-099463,ALVOGEN,,15739.0,DY,,F,Y,82.0,KG,20190418.0,,CN,MX,MX,2019,Q2,Elderly
162135901,16213590,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q2,Weight increased,Weight increased,2019,Q2,1,I,20120101.0,20190406.0,20190418,20190418,EXP,,MX-ALVOGEN-2019-ALVOGEN-099463,ALVOGEN,,15739.0,DY,,F,Y,82.0,KG,20190418.0,,CN,MX,MX,2019,Q2,Elderly
162143762,16214376,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Chronic kidney disease,,2019,Q2,2,F,20130708.0,20190610.0,20190418,20190618,EXP,,US-ASTRAZENECA-2019SE55640,ASTRAZENECA,,26048.0,DY,,F,Y,52.6,KG,20190618.0,,,US,US,2019,Q2,Elderly
162143762,16214376,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Renal failure,,2019,Q2,2,F,20130708.0,20190610.0,20190418,20190618,EXP,,US-ASTRAZENECA-2019SE55640,ASTRAZENECA,,26048.0,DY,,F,Y,52.6,KG,20190618.0,,,US,US,2019,Q2,Elderly
162180352,16218035,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Acute kidney injury,,2019,Q2,2,F,2018.0,20190527.0,20190419,20190604,EXP,,PHHY2019PT089405,SANDOZ,,71.0,YR,,M,Y,,,20190604.0,,OT,PT,PT,2019,Q2,Elderly
162180352,16218035,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Arrhythmia,,2019,Q2,2,F,2018.0,20190527.0,20190419,20190604,EXP,,PHHY2019PT089405,SANDOZ,,71.0,YR,,M,Y,,,20190604.0,,OT,PT,PT,2019,Q2,Elderly
162180352,16218035,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Atrial fibrillation,,2019,Q2,2,F,2018.0,20190527.0,20190419,20190604,EXP,,PHHY2019PT089405,SANDOZ,,71.0,YR,,M,Y,,,20190604.0,,OT,PT,PT,2019,Q2,Elderly
162180352,16218035,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Bradycardia,,2019,Q2,2,F,2018.0,20190527.0,20190419,20190604,EXP,,PHHY2019PT089405,SANDOZ,,71.0,YR,,M,Y,,,20190604.0,,OT,PT,PT,2019,Q2,Elderly
162180352,16218035,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Dehydration,,2019,Q2,2,F,2018.0,20190527.0,20190419,20190604,EXP,,PHHY2019PT089405,SANDOZ,,71.0,YR,,M,Y,,,20190604.0,,OT,PT,PT,2019,Q2,Elderly
162180352,16218035,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Dizziness,,2019,Q2,2,F,2018.0,20190527.0,20190419,20190604,EXP,,PHHY2019PT089405,SANDOZ,,71.0,YR,,M,Y,,,20190604.0,,OT,PT,PT,2019,Q2,Elderly
162180352,16218035,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Haematocrit increased,,2019,Q2,2,F,2018.0,20190527.0,20190419,20190604,EXP,,PHHY2019PT089405,SANDOZ,,71.0,YR,,M,Y,,,20190604.0,,OT,PT,PT,2019,Q2,Elderly
162180352,16218035,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Haemoglobin increased,,2019,Q2,2,F,2018.0,20190527.0,20190419,20190604,EXP,,PHHY2019PT089405,SANDOZ,,71.0,YR,,M,Y,,,20190604.0,,OT,PT,PT,2019,Q2,Elderly
162180352,16218035,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Hypotension,,2019,Q2,2,F,2018.0,20190527.0,20190419,20190604,EXP,,PHHY2019PT089405,SANDOZ,,71.0,YR,,M,Y,,,20190604.0,,OT,PT,PT,2019,Q2,Elderly
162180352,16218035,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Hypovolaemia,,2019,Q2,2,F,2018.0,20190527.0,20190419,20190604,EXP,,PHHY2019PT089405,SANDOZ,,71.0,YR,,M,Y,,,20190604.0,,OT,PT,PT,2019,Q2,Elderly
162180352,16218035,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Left atrial dilatation,,2019,Q2,2,F,2018.0,20190527.0,20190419,20190604,EXP,,PHHY2019PT089405,SANDOZ,,71.0,YR,,M,Y,,,20190604.0,,OT,PT,PT,2019,Q2,Elderly
162180352,16218035,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Mucosal dryness,,2019,Q2,2,F,2018.0,20190527.0,20190419,20190604,EXP,,PHHY2019PT089405,SANDOZ,,71.0,YR,,M,Y,,,20190604.0,,OT,PT,PT,2019,Q2,Elderly
162180352,16218035,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Presyncope,,2019,Q2,2,F,2018.0,20190527.0,20190419,20190604,EXP,,PHHY2019PT089405,SANDOZ,,71.0,YR,,M,Y,,,20190604.0,,OT,PT,PT,2019,Q2,Elderly
162180352,16218035,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Skin disorder,,2019,Q2,2,F,2018.0,20190527.0,20190419,20190604,EXP,,PHHY2019PT089405,SANDOZ,,71.0,YR,,M,Y,,,20190604.0,,OT,PT,PT,2019,Q2,Elderly
162180352,16218035,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Syncope,,2019,Q2,2,F,2018.0,20190527.0,20190419,20190604,EXP,,PHHY2019PT089405,SANDOZ,,71.0,YR,,M,Y,,,20190604.0,,OT,PT,PT,2019,Q2,Elderly
162210612,16221061,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Polymyalgia rheumatica,,2019,Q2,2,F,201812.0,20190424.0,20190421,20190425,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-001792",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,74.9,KG,20190425.0,,MD,JP,JP,2019,Q2,Elderly
162281681,16228168,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q2,Hypotension,,2019,Q2,1,I,20180430.0,,20190318,20190318,DIR,,,FDA-CTU,,63.0,YR,,M,N,122.0,KG,20190308.0,N,PH,US,US,2019,Q2,Adult
162281681,16228168,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q2,Tachycardia,,2019,Q2,1,I,20180430.0,,20190318,20190318,DIR,,,FDA-CTU,,63.0,YR,,M,N,122.0,KG,20190308.0,N,PH,US,US,2019,Q2,Adult
162281681,16228168,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q2,Urosepsis,,2019,Q2,1,I,20180430.0,,20190318,20190318,DIR,,,FDA-CTU,,63.0,YR,,M,N,122.0,KG,20190308.0,N,PH,US,US,2019,Q2,Adult
162289421,16228942,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,D,D,,,,10.0,MG,,,2019,Q2,Glomerulonephritis,,2019,Q2,1,I,20190306.0,,20190319,20190319,DIR,,,FDA-CTU,,54.0,YR,,M,N,,,20190311.0,N,PH,US,US,2019,Q2,Adult
162289421,16228942,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,D,D,,,,10.0,MG,,,2019,Q2,Haematuria,,2019,Q2,1,I,20190306.0,,20190319,20190319,DIR,,,FDA-CTU,,54.0,YR,,M,N,,,20190311.0,N,PH,US,US,2019,Q2,Adult
162289421,16228942,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,D,D,,,,10.0,MG,,,2019,Q2,Vasculitis necrotising,,2019,Q2,1,I,20190306.0,,20190319,20190319,DIR,,,FDA-CTU,,54.0,YR,,M,N,,,20190311.0,N,PH,US,US,2019,Q2,Adult
162373607,16237360,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,,,FILM-COATED TABLET,,2019,Q2,Acute kidney injury,,2019,Q2,7,F,20190414.0,20190524.0,20190425,20190527,EXP,,"IN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-018872",BOEHRINGER INGELHEIM,,45.0,YR,,F,Y,,,20190527.0,,MD,IN,IN,2019,Q2,Adult
162373607,16237360,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,,,FILM-COATED TABLET,,2019,Q2,Hyperkalaemia,,2019,Q2,7,F,20190414.0,20190524.0,20190425,20190527,EXP,,"IN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-018872",BOEHRINGER INGELHEIM,,45.0,YR,,F,Y,,,20190527.0,,MD,IN,IN,2019,Q2,Adult
162373607,16237360,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,,,FILM-COATED TABLET,,2019,Q2,Renal impairment,,2019,Q2,7,F,20190414.0,20190524.0,20190425,20190527,EXP,,"IN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-018872",BOEHRINGER INGELHEIM,,45.0,YR,,F,Y,,,20190527.0,,MD,IN,IN,2019,Q2,Adult
162460321,16246032,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Abdominal pain,,2019,Q2,1,I,20181021.0,20190419.0,20190426,20190426,EXP,GB-MHRA-EYC 00198104,GB-NOVOPROD-659161,NOVO NORDISK,,57.0,YR,,M,Y,100.5,KG,20190426.0,,PH,GB,GB,2019,Q2,Adult
162460321,16246032,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Hepatic steatosis,,2019,Q2,1,I,20181021.0,20190419.0,20190426,20190426,EXP,GB-MHRA-EYC 00198104,GB-NOVOPROD-659161,NOVO NORDISK,,57.0,YR,,M,Y,100.5,KG,20190426.0,,PH,GB,GB,2019,Q2,Adult
162460321,16246032,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Pancreatitis acute,,2019,Q2,1,I,20181021.0,20190419.0,20190426,20190426,EXP,GB-MHRA-EYC 00198104,GB-NOVOPROD-659161,NOVO NORDISK,,57.0,YR,,M,Y,100.5,KG,20190426.0,,PH,GB,GB,2019,Q2,Adult
162596691,16259669,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,0.5,DF,TABLET,QD,2019,Q2,Rash,,2019,Q2,1,I,,,20190326,20190326,DIR,,,FDA-CTU,,68.0,YR,,M,N,113.85,KG,20190304.0,N,PH,US,US,2019,Q2,Elderly
162652722,16265272,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q2,Alanine aminotransferase increased,,2019,Q2,2,F,20190406.0,20190528.0,20190502,20190531,EXP,,"AR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-019144",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,60.5,KG,20190531.0,,MD,AR,AR,2019,Q2,Elderly
162652722,16265272,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q2,Diabetic foot,,2019,Q2,2,F,20190406.0,20190528.0,20190502,20190531,EXP,,"AR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-019144",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,60.5,KG,20190531.0,,MD,AR,AR,2019,Q2,Elderly
162652722,16265272,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q2,Peripheral arterial occlusive disease,,2019,Q2,2,F,20190406.0,20190528.0,20190502,20190531,EXP,,"AR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-019144",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,60.5,KG,20190531.0,,MD,AR,AR,2019,Q2,Elderly
162688991,16268899,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D, 855464,20200801.0,,25.0,MG,,QD,2019,Q2,Acute kidney injury,,2019,Q2,1,I,20181212.0,,20190328,20190328,DIR,,,FDA-CTU,,58.0,YR,,P,N,,,20190318.0,N,PH,US,US,2019,Q2,Adult
162688991,16268899,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D, 855464,20200801.0,,25.0,MG,,QD,2019,Q2,Azotaemia,,2019,Q2,1,I,20181212.0,,20190328,20190328,DIR,,,FDA-CTU,,58.0,YR,,P,N,,,20190318.0,N,PH,US,US,2019,Q2,Adult
162688991,16268899,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D, 855464,20200801.0,,25.0,MG,,QD,2019,Q2,Hypovolaemia,,2019,Q2,1,I,20181212.0,,20190328,20190328,DIR,,,FDA-CTU,,58.0,YR,,P,N,,,20190318.0,N,PH,US,US,2019,Q2,Adult
162688991,16268899,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D, 855464,20200801.0,,25.0,MG,,QD,2019,Q2,Orthostatic hypotension,,2019,Q2,1,I,20181212.0,,20190328,20190328,DIR,,,FDA-CTU,,58.0,YR,,P,N,,,20190318.0,N,PH,US,US,2019,Q2,Adult
162713593,16271359,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q2,Blood glucose increased,,2019,Q2,3,F,,20190506.0,20190503,20190513,EXP,,HU-PFIZER INC-2019185018,PFIZER,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20190513.0,,MD,HU,HU,2019,Q2,Adult
162713593,16271359,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q2,Blood pressure inadequately controlled,,2019,Q2,3,F,,20190506.0,20190503,20190513,EXP,,HU-PFIZER INC-2019185018,PFIZER,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20190513.0,,MD,HU,HU,2019,Q2,Adult
162713593,16271359,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q2,Blood pressure systolic increased,,2019,Q2,3,F,,20190506.0,20190503,20190513,EXP,,HU-PFIZER INC-2019185018,PFIZER,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20190513.0,,MD,HU,HU,2019,Q2,Adult
162713593,16271359,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q2,Dyslipidaemia,,2019,Q2,3,F,,20190506.0,20190503,20190513,EXP,,HU-PFIZER INC-2019185018,PFIZER,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20190513.0,,MD,HU,HU,2019,Q2,Adult
162713593,16271359,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q2,Eating disorder,,2019,Q2,3,F,,20190506.0,20190503,20190513,EXP,,HU-PFIZER INC-2019185018,PFIZER,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20190513.0,,MD,HU,HU,2019,Q2,Adult
162713593,16271359,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q2,Glycosylated haemoglobin increased,,2019,Q2,3,F,,20190506.0,20190503,20190513,EXP,,HU-PFIZER INC-2019185018,PFIZER,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20190513.0,,MD,HU,HU,2019,Q2,Adult
162713593,16271359,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q2,Mobility decreased,,2019,Q2,3,F,,20190506.0,20190503,20190513,EXP,,HU-PFIZER INC-2019185018,PFIZER,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20190513.0,,MD,HU,HU,2019,Q2,Adult
162713593,16271359,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q2,Stress,,2019,Q2,3,F,,20190506.0,20190503,20190513,EXP,,HU-PFIZER INC-2019185018,PFIZER,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20190513.0,,MD,HU,HU,2019,Q2,Adult
162756541,16275654,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q2,Cholecystitis,,2019,Q2,1,I,20190322.0,,20190401,20190401,DIR,,,FDA-CTU,,70.0,YR,,M,N,95.25,KG,20190328.0,N,PH,US,US,2019,Q2,Elderly
162756541,16275654,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,1,I,20190322.0,,20190401,20190401,DIR,,,FDA-CTU,,70.0,YR,,M,N,95.25,KG,20190328.0,N,PH,US,US,2019,Q2,Elderly
162886311,16288631,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q2,Cholecystitis,,2019,Q2,1,I,20190322.0,,20190402,20190402,DIR,,,FDA-CTU,,70.0,YR,,M,N,95.25,KG,20190328.0,N,PH,US,US,2019,Q2,Elderly
162886311,16288631,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,1,I,20190322.0,,20190402,20190402,DIR,,,FDA-CTU,,70.0,YR,,M,N,95.25,KG,20190328.0,N,PH,US,US,2019,Q2,Elderly
162891311,16289131,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Colon cancer,,2019,Q2,1,I,20180619.0,20190306.0,20190509,20190509,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-001061",BOEHRINGER INGELHEIM,,73.0,YR,,F,Y,54.5,KG,20190509.0,,MD,JP,JP,2019,Q2,Elderly
162894912,16289491,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Iron deficiency anaemia,,2019,Q2,2,F,20171229.0,20190517.0,20190509,20190522,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002038",BOEHRINGER INGELHEIM,,61.0,YR,,M,Y,78.6,KG,20190522.0,,MD,JP,JP,2019,Q2,Adult
162894912,16289491,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Meningioma,,2019,Q2,2,F,20171229.0,20190517.0,20190509,20190522,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002038",BOEHRINGER INGELHEIM,,61.0,YR,,M,Y,78.6,KG,20190522.0,,MD,JP,JP,2019,Q2,Adult
162898951,16289895,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Urticaria,,2019,Q2,1,I,20190508.0,,20190508,20190508,DIR,,,FDA-CTU,,64.0,YR,,M,N,107.0,KG,20190508.0,N,PH,US,US,2019,Q2,Adult
163035942,16303594,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, DAILY",,,U,,,,,10.0,MG,TABLET,,2019,Q2,Pruritus,,2019,Q2,2,F,20190426.0,20190604.0,20190513,20190619,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-045706,BRISTOL MYERS SQUIBB,,88.0,YR,,F,Y,,,20190619.0,,OT,US,US,2019,Q2,Elderly
163035942,16303594,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, DAILY",,,U,,,,,10.0,MG,TABLET,,2019,Q2,Rash pruritic,,2019,Q2,2,F,20190426.0,20190604.0,20190513,20190619,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-045706,BRISTOL MYERS SQUIBB,,88.0,YR,,F,Y,,,20190619.0,,OT,US,US,2019,Q2,Elderly
163048371,16304837,11,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Asthenia,,2019,Q2,1,I,20190430.0,,20190510,20190510,DIR,,,FDA-CTU,,68.0,YR,,M,N,112.5,KG,20190510.0,N,PH,US,US,2019,Q2,Elderly
163048371,16304837,11,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Fatigue,,2019,Q2,1,I,20190430.0,,20190510,20190510,DIR,,,FDA-CTU,,68.0,YR,,M,N,112.5,KG,20190510.0,N,PH,US,US,2019,Q2,Elderly
163048371,16304837,11,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Hallucination,,2019,Q2,1,I,20190430.0,,20190510,20190510,DIR,,,FDA-CTU,,68.0,YR,,M,N,112.5,KG,20190510.0,N,PH,US,US,2019,Q2,Elderly
163048371,16304837,11,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Nausea,,2019,Q2,1,I,20190430.0,,20190510,20190510,DIR,,,FDA-CTU,,68.0,YR,,M,N,112.5,KG,20190510.0,N,PH,US,US,2019,Q2,Elderly
163048371,16304837,11,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Vomiting,,2019,Q2,1,I,20190430.0,,20190510,20190510,DIR,,,FDA-CTU,,68.0,YR,,M,N,112.5,KG,20190510.0,N,PH,US,US,2019,Q2,Elderly
163052411,16305241,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2019,Q2,Abdominal pain,,2019,Q2,1,I,20190508.0,,20190511,20190511,DIR,,,FDA-CTU,,48.0,YR,,F,N,91.9,KG,20190511.0,N,PH,US,US,2019,Q2,Adult
163052411,16305241,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2019,Q2,Asthenia,,2019,Q2,1,I,20190508.0,,20190511,20190511,DIR,,,FDA-CTU,,48.0,YR,,F,N,91.9,KG,20190511.0,N,PH,US,US,2019,Q2,Adult
163052411,16305241,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2019,Q2,Chills,,2019,Q2,1,I,20190508.0,,20190511,20190511,DIR,,,FDA-CTU,,48.0,YR,,F,N,91.9,KG,20190511.0,N,PH,US,US,2019,Q2,Adult
163052411,16305241,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2019,Q2,Dizziness,,2019,Q2,1,I,20190508.0,,20190511,20190511,DIR,,,FDA-CTU,,48.0,YR,,F,N,91.9,KG,20190511.0,N,PH,US,US,2019,Q2,Adult
163052411,16305241,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2019,Q2,Nausea,,2019,Q2,1,I,20190508.0,,20190511,20190511,DIR,,,FDA-CTU,,48.0,YR,,F,N,91.9,KG,20190511.0,N,PH,US,US,2019,Q2,Adult
163052411,16305241,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2019,Q2,Necrotising fasciitis,,2019,Q2,1,I,20190508.0,,20190511,20190511,DIR,,,FDA-CTU,,48.0,YR,,F,N,91.9,KG,20190511.0,N,PH,US,US,2019,Q2,Adult
163052411,16305241,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2019,Q2,Pyrexia,,2019,Q2,1,I,20190508.0,,20190511,20190511,DIR,,,FDA-CTU,,48.0,YR,,F,N,91.9,KG,20190511.0,N,PH,US,US,2019,Q2,Adult
163052411,16305241,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2019,Q2,Sepsis,,2019,Q2,1,I,20190508.0,,20190511,20190511,DIR,,,FDA-CTU,,48.0,YR,,F,N,91.9,KG,20190511.0,N,PH,US,US,2019,Q2,Adult
163052411,16305241,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2019,Q2,Vomiting,,2019,Q2,1,I,20190508.0,,20190511,20190511,DIR,,,FDA-CTU,,48.0,YR,,F,N,91.9,KG,20190511.0,N,PH,US,US,2019,Q2,Adult
163062891,16306289,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q2,Abdominal pain upper,,2019,Q2,1,I,201902.0,20190430.0,20190513,20190513,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20190513.0,,CN,GT,GT,2019,Q2,Elderly
163062891,16306289,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q2,Cardiac failure,,2019,Q2,1,I,201902.0,20190430.0,20190513,20190513,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20190513.0,,CN,GT,GT,2019,Q2,Elderly
163062891,16306289,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q2,Decreased appetite,,2019,Q2,1,I,201902.0,20190430.0,20190513,20190513,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20190513.0,,CN,GT,GT,2019,Q2,Elderly
163062891,16306289,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q2,Dizziness,,2019,Q2,1,I,201902.0,20190430.0,20190513,20190513,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20190513.0,,CN,GT,GT,2019,Q2,Elderly
163062891,16306289,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q2,Hypoglycaemia,,2019,Q2,1,I,201902.0,20190430.0,20190513,20190513,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20190513.0,,CN,GT,GT,2019,Q2,Elderly
163062891,16306289,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q2,Insomnia,,2019,Q2,1,I,201902.0,20190430.0,20190513,20190513,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20190513.0,,CN,GT,GT,2019,Q2,Elderly
163062891,16306289,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q2,Nausea,,2019,Q2,1,I,201902.0,20190430.0,20190513,20190513,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20190513.0,,CN,GT,GT,2019,Q2,Elderly
163062891,16306289,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q2,Red blood cell count decreased,,2019,Q2,1,I,201902.0,20190430.0,20190513,20190513,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20190513.0,,CN,GT,GT,2019,Q2,Elderly
163096321,16309632,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2019,Q2,Diarrhoea,,2019,Q2,1,I,20190327.0,,20190408,20190408,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20190405.0,N,PH,US,US,2019,Q2,Elderly
163096321,16309632,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2019,Q2,Dizziness,,2019,Q2,1,I,20190327.0,,20190408,20190408,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20190405.0,N,PH,US,US,2019,Q2,Elderly
163096321,16309632,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2019,Q2,Dry mouth,,2019,Q2,1,I,20190327.0,,20190408,20190408,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20190405.0,N,PH,US,US,2019,Q2,Elderly
163183611,16318361,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,, UNKNOWN,,,10.0,MG,,QD,2019,Q2,Polycythaemia,,2019,Q2,1,I,,20190315.0,20190516,20190516,PER,,IT-LUPIN PHARMACEUTICALS INC.-2019-01797,LUPIN,,52.0,YR,,M,Y,,,20190516.0,,OT,IT,IT,2019,Q2,Adult
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Anaemia,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Blood cholesterol increased,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Blood glucose increased,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Blood pressure fluctuation,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Blood uric acid increased,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Cardiomegaly,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Carotid arteriosclerosis,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Chest discomfort,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Decreased ventricular preload,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Dyspnoea exertional,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Electrocardiogram abnormal,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Hepatic lesion,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Ischaemia,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Myocardial ischaemia,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Renal impairment,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163184311,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q2,Transient ischaemic attack,,2019,Q2,1,I,,20190507.0,20190516,20190516,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190516.0,,CN,HU,HU,2019,Q2,Elderly
163354731,16335473,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Aortic occlusion,,2019,Q2,1,I,201902.0,20190411.0,20190521,20190521,EXP,,US-ABBVIE-19K-163-2742840-00,ABBVIE,,72.0,YR,,M,Y,73.55,KG,20190521.0,,CN,US,US,2019,Q2,Elderly
163354731,16335473,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Blood pressure increased,,2019,Q2,1,I,201902.0,20190411.0,20190521,20190521,EXP,,US-ABBVIE-19K-163-2742840-00,ABBVIE,,72.0,YR,,M,Y,73.55,KG,20190521.0,,CN,US,US,2019,Q2,Elderly
163418251,16341825,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,U,,,,,,,FORMULATION UNKNOWN,,2019,Q2,Bronchial disorder,,2019,Q2,1,I,20190315.0,20190515.0,20190522,20190522,EXP,,US-ASTELLAS-2019US021247,ASTELLAS,,69.0,YR,,M,Y,106.0,KG,20190522.0,,PH,US,US,2019,Q2,Elderly
163445682,16344568,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q2,Cholestasis,,2019,Q2,2,F,20181204.0,20190613.0,20190522,20190617,EXP,,"PL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-061174",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,99.2,KG,20190617.0,,MD,PL,PL,2019,Q2,Elderly
163663771,16366377,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,25.0,MG,UNSPECIFIED,QD,2019,Q2,Chest pain,,2019,Q2,1,I,,20190521.0,20190529,20190529,EXP,,CA-JNJFOC-20190536880,JANSSEN,,80.0,YR,E,M,Y,,,20190529.0,,CN,CA,CA,2019,Q2,Elderly
163663771,16366377,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,25.0,MG,UNSPECIFIED,QD,2019,Q2,Electrocardiogram ST segment depression,,2019,Q2,1,I,,20190521.0,20190529,20190529,EXP,,CA-JNJFOC-20190536880,JANSSEN,,80.0,YR,E,M,Y,,,20190529.0,,CN,CA,CA,2019,Q2,Elderly
163663771,16366377,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,25.0,MG,UNSPECIFIED,QD,2019,Q2,Troponin I increased,,2019,Q2,1,I,,20190521.0,20190529,20190529,EXP,,CA-JNJFOC-20190536880,JANSSEN,,80.0,YR,E,M,Y,,,20190529.0,,CN,CA,CA,2019,Q2,Elderly
163669871,16366987,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q2,Cholecystitis chronic,,2019,Q2,1,I,20190322.0,,20190422,20190422,DIR,,,FDA-CTU,,70.0,YR,,M,N,95.25,KG,20190328.0,N,PH,US,US,2019,Q2,Elderly
163669871,16366987,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,1,I,20190322.0,,20190422,20190422,DIR,,,FDA-CTU,,70.0,YR,,M,N,95.25,KG,20190328.0,N,PH,US,US,2019,Q2,Elderly
163693523,16369352,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q2,Vomiting,,2019,Q2,3,F,20190508.0,20190626.0,20190529,20190627,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-022262",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,77.0,KG,20190627.0,,MD,DE,DE,2019,Q2,Adult
163739622,16373962,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q2,Anaemia,,2019,Q2,2,F,20190522.0,20190604.0,20190530,20190607,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-023714",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,82.9,KG,20190607.0,,MD,DE,DE,2019,Q2,Elderly
163739622,16373962,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q2,Aortic valve stenosis,,2019,Q2,2,F,20190522.0,20190604.0,20190530,20190607,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-023714",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,82.9,KG,20190607.0,,MD,DE,DE,2019,Q2,Elderly
163739622,16373962,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q2,Cardiac arrest,,2019,Q2,2,F,20190522.0,20190604.0,20190530,20190607,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-023714",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,82.9,KG,20190607.0,,MD,DE,DE,2019,Q2,Elderly
163739622,16373962,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q2,Cardiac failure,,2019,Q2,2,F,20190522.0,20190604.0,20190530,20190607,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-023714",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,82.9,KG,20190607.0,,MD,DE,DE,2019,Q2,Elderly
163739622,16373962,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q2,Hypoglycaemia,,2019,Q2,2,F,20190522.0,20190604.0,20190530,20190607,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-023714",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,82.9,KG,20190607.0,,MD,DE,DE,2019,Q2,Elderly
163739622,16373962,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q2,Pulmonary embolism,,2019,Q2,2,F,20190522.0,20190604.0,20190530,20190607,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-023714",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,82.9,KG,20190607.0,,MD,DE,DE,2019,Q2,Elderly
163777761,16377776,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,1,I,20190408.0,,20190408,20190408,DIR,,,FDA-CTU,,36.0,YR,,F,N,105.2,KG,20190408.0,N,,US,US,2019,Q2,Adult
163777761,16377776,2,SS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,1,I,20190408.0,,20190408,20190408,DIR,,,FDA-CTU,,36.0,YR,,F,N,105.2,KG,20190408.0,N,,US,US,2019,Q2,Adult
163826042,16382604,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Cerebral infarction,,2019,Q2,2,F,20170802.0,20190611.0,20190603,20190613,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002973",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,80.6,KG,20190614.0,,MD,JP,JP,2019,Q2,Elderly
163826042,16382604,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Fall,,2019,Q2,2,F,20170802.0,20190611.0,20190603,20190613,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002973",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,80.6,KG,20190614.0,,MD,JP,JP,2019,Q2,Elderly
163826042,16382604,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Renal cell carcinoma,,2019,Q2,2,F,20170802.0,20190611.0,20190603,20190613,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002973",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,80.6,KG,20190614.0,,MD,JP,JP,2019,Q2,Elderly
163826042,16382604,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Subdural haematoma,,2019,Q2,2,F,20170802.0,20190611.0,20190603,20190613,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002973",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,80.6,KG,20190614.0,,MD,JP,JP,2019,Q2,Elderly
163870671,16387067,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2019,Q2,Blood creatinine increased,,2019,Q2,1,I,20190405.0,,20190426,20190426,DIR,,,FDA-CTU,,63.0,YR,,M,N,133.0,KG,20190426.0,N,PH,US,US,2019,Q2,Adult
163870671,16387067,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2019,Q2,Blood urea increased,,2019,Q2,1,I,20190405.0,,20190426,20190426,DIR,,,FDA-CTU,,63.0,YR,,M,N,133.0,KG,20190426.0,N,PH,US,US,2019,Q2,Adult
163870671,16387067,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2019,Q2,Muscle spasms,,2019,Q2,1,I,20190405.0,,20190426,20190426,DIR,,,FDA-CTU,,63.0,YR,,M,N,133.0,KG,20190426.0,N,PH,US,US,2019,Q2,Adult
163982124,16398212,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Pancreatitis acute,,2019,Q2,4,F,20180520.0,20190627.0,20190606,20190628,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002390",BOEHRINGER INGELHEIM,,73.0,YR,,M,Y,91.0,KG,20190628.0,,MD,JP,JP,2019,Q2,Elderly
163982124,16398212,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,5.0,MG,TABLET,,2019,Q2,Pancreatitis acute,,2019,Q2,4,F,20180520.0,20190627.0,20190606,20190628,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002390",BOEHRINGER INGELHEIM,,73.0,YR,,M,Y,91.0,KG,20190628.0,,MD,JP,JP,2019,Q2,Elderly
163982124,16398212,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Pancreatitis acute,,2019,Q2,4,F,20180520.0,20190627.0,20190606,20190628,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002390",BOEHRINGER INGELHEIM,,73.0,YR,,M,Y,91.0,KG,20190628.0,,MD,JP,JP,2019,Q2,Elderly
163992191,16399219,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q2,Nausea,,2019,Q2,1,I,20190321.0,,20190501,20190501,DIR,,,FDA-CTU,,72.0,YR,,M,N,76.0,KG,20190402.0,N,PH,US,US,2019,Q2,Elderly
163992191,16399219,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q2,Vomiting,,2019,Q2,1,I,20190321.0,,20190501,20190501,DIR,,,FDA-CTU,,72.0,YR,,M,N,76.0,KG,20190402.0,N,PH,US,US,2019,Q2,Elderly
164003541,16400354,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Injection site reaction,,2019,Q2,1,I,20181102.0,20181128.0,20190606,20190606,EXP,,GB-NOVOPROD-635761,NOVO NORDISK,,50.0,YR,,F,Y,78.0,KG,20190606.0,,OT,GB,GB,2019,Q2,Adult
164003541,16400354,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Rash generalised,,2019,Q2,1,I,20181102.0,20181128.0,20190606,20190606,EXP,,GB-NOVOPROD-635761,NOVO NORDISK,,50.0,YR,,F,Y,78.0,KG,20190606.0,,OT,GB,GB,2019,Q2,Adult
164003541,16400354,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q2,Skin irritation,,2019,Q2,1,I,20181102.0,20181128.0,20190606,20190606,EXP,,GB-NOVOPROD-635761,NOVO NORDISK,,50.0,YR,,F,Y,78.0,KG,20190606.0,,OT,GB,GB,2019,Q2,Adult
164066282,16406628,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Dizziness,,2019,Q2,2,F,20190215.0,20190614.0,20190607,20190619,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002477",BOEHRINGER INGELHEIM,,63.0,YR,,F,Y,65.6,KG,20190619.0,,MD,JP,JP,2019,Q2,Adult
164066282,16406628,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Pain in extremity,,2019,Q2,2,F,20190215.0,20190614.0,20190607,20190619,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002477",BOEHRINGER INGELHEIM,,63.0,YR,,F,Y,65.6,KG,20190619.0,,MD,JP,JP,2019,Q2,Adult
164066282,16406628,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q2,Dizziness,,2019,Q2,2,F,20190215.0,20190614.0,20190607,20190619,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002477",BOEHRINGER INGELHEIM,,63.0,YR,,F,Y,65.6,KG,20190619.0,,MD,JP,JP,2019,Q2,Adult
164066282,16406628,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q2,Pain in extremity,,2019,Q2,2,F,20190215.0,20190614.0,20190607,20190619,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002477",BOEHRINGER INGELHEIM,,63.0,YR,,F,Y,65.6,KG,20190619.0,,MD,JP,JP,2019,Q2,Adult
164196551,16419655,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,20190209.0,,20190503,20190503,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20190418.0,N,PH,US,US,2019,Q2,Elderly
164206051,16420605,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q2,Lichenification,,2019,Q2,1,I,201711.0,20190603.0,20190612,20190612,EXP,CH-SM-2019-13952,CH-NOVOPROD-666318,NOVO NORDISK,,60.0,YR,,M,Y,,,20190612.0,,MD,CH,CH,2019,Q2,Adult
164260761,16426076,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,,QD,2019,Q2,Blood creatinine increased,,2019,Q2,1,I,20190424.0,,20190506,20190506,DIR,,,FDA-CTU,,72.0,YR,,M,N,107.95,KG,20190502.0,N,PH,US,US,2019,Q2,Elderly
164260761,16426076,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,,QD,2019,Q2,Blood urea increased,,2019,Q2,1,I,20190424.0,,20190506,20190506,DIR,,,FDA-CTU,,72.0,YR,,M,N,107.95,KG,20190502.0,N,PH,US,US,2019,Q2,Elderly
164319662,16431966,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q2,Rectal cancer,,2019,Q2,2,F,20181126.0,20190620.0,20190614,20190621,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002669",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,68.5,KG,20190621.0,,MD,JP,JP,2019,Q2,Elderly
164386321,16438632,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q2,Acute kidney injury,,2019,Q2,1,I,2018.0,20190605.0,20190617,20190617,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,E,M,Y,,,20190617.0,,OT,PT,PT,2019,Q2,Elderly
164386321,16438632,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q2,Arrhythmia,,2019,Q2,1,I,2018.0,20190605.0,20190617,20190617,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,E,M,Y,,,20190617.0,,OT,PT,PT,2019,Q2,Elderly
164386321,16438632,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q2,Atrial fibrillation,,2019,Q2,1,I,2018.0,20190605.0,20190617,20190617,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,E,M,Y,,,20190617.0,,OT,PT,PT,2019,Q2,Elderly
164386321,16438632,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q2,Bradycardia,,2019,Q2,1,I,2018.0,20190605.0,20190617,20190617,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,E,M,Y,,,20190617.0,,OT,PT,PT,2019,Q2,Elderly
164386321,16438632,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q2,Dehydration,,2019,Q2,1,I,2018.0,20190605.0,20190617,20190617,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,E,M,Y,,,20190617.0,,OT,PT,PT,2019,Q2,Elderly
164386321,16438632,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q2,Dizziness,,2019,Q2,1,I,2018.0,20190605.0,20190617,20190617,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,E,M,Y,,,20190617.0,,OT,PT,PT,2019,Q2,Elderly
164386321,16438632,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q2,Haematocrit increased,,2019,Q2,1,I,2018.0,20190605.0,20190617,20190617,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,E,M,Y,,,20190617.0,,OT,PT,PT,2019,Q2,Elderly
164386321,16438632,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q2,Haemoglobin increased,,2019,Q2,1,I,2018.0,20190605.0,20190617,20190617,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,E,M,Y,,,20190617.0,,OT,PT,PT,2019,Q2,Elderly
164386321,16438632,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q2,Hypotension,,2019,Q2,1,I,2018.0,20190605.0,20190617,20190617,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,E,M,Y,,,20190617.0,,OT,PT,PT,2019,Q2,Elderly
164386321,16438632,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q2,Hypovolaemia,,2019,Q2,1,I,2018.0,20190605.0,20190617,20190617,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,E,M,Y,,,20190617.0,,OT,PT,PT,2019,Q2,Elderly
164386321,16438632,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q2,Left atrial dilatation,,2019,Q2,1,I,2018.0,20190605.0,20190617,20190617,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,E,M,Y,,,20190617.0,,OT,PT,PT,2019,Q2,Elderly
164386321,16438632,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q2,Mucosal dryness,,2019,Q2,1,I,2018.0,20190605.0,20190617,20190617,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,E,M,Y,,,20190617.0,,OT,PT,PT,2019,Q2,Elderly
164386321,16438632,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q2,Presyncope,,2019,Q2,1,I,2018.0,20190605.0,20190617,20190617,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,E,M,Y,,,20190617.0,,OT,PT,PT,2019,Q2,Elderly
164386321,16438632,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q2,Skin disorder,,2019,Q2,1,I,2018.0,20190605.0,20190617,20190617,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,E,M,Y,,,20190617.0,,OT,PT,PT,2019,Q2,Elderly
164386321,16438632,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q2,Syncope,,2019,Q2,1,I,2018.0,20190605.0,20190617,20190617,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN?. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,E,M,Y,,,20190617.0,,OT,PT,PT,2019,Q2,Elderly
164590701,16459070,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2019,Q2,Ventricular extrasystoles,,2019,Q2,1,I,20180903.0,20190605.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002551",BOEHRINGER INGELHEIM,,65.0,YR,,M,Y,78.0,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Cerebral infarction,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Cholangitis acute,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Cholelithiasis,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Dermatitis,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Cerebral infarction,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Cholangitis acute,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Cholelithiasis,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q2,Dermatitis,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q2,Cerebral infarction,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q2,Cholangitis acute,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q2,Cholelithiasis,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q2,Dermatitis,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q2,Cerebral infarction,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q2,Cholangitis acute,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q2,Cholelithiasis,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q2,Dermatitis,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q2,Cerebral infarction,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q2,Cholangitis acute,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q2,Cholelithiasis,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164604571,16460457,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q2,Dermatitis,,2019,Q2,1,I,20170322.0,20170804.0,20190620,20190620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190620.0,,MD,JP,JP,2019,Q2,Elderly
164724581,16472458,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,Y, 851894,20200501.0,,25.0,MG,,QD,2019,Q2,Blood creatinine increased,,2019,Q2,1,I,20180807.0,,20190514,20190514,DIR,,,FDA-CTU,,72.0,YR,,M,N,142.56,KG,20180807.0,N,PH,US,US,2019,Q2,Elderly
164724581,16472458,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,Y, 851894,20200501.0,,25.0,MG,,QD,2019,Q2,Blood urea increased,,2019,Q2,1,I,20180807.0,,20190514,20190514,DIR,,,FDA-CTU,,72.0,YR,,M,N,142.56,KG,20180807.0,N,PH,US,US,2019,Q2,Elderly
164724991,16472499,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,, 856425,20201001.0,,12.5,MG,,QD,2019,Q2,Fungal infection,,2019,Q2,1,I,20180913.0,,20190514,20190514,DIR,,,FDA-CTU,,62.0,YR,,M,N,97.07,KG,20180914.0,N,PH,US,US,2019,Q2,Adult
164724991,16472499,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,, 856425,20201001.0,,12.5,MG,,QD,2019,Q2,Urinary tract infection,,2019,Q2,1,I,20180913.0,,20190514,20190514,DIR,,,FDA-CTU,,62.0,YR,,M,N,97.07,KG,20180914.0,N,PH,US,US,2019,Q2,Adult
164727901,16472790,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,, 702863C,20181027.0,,12.5,MG,,,2019,Q2,Urinary tract infection,,2019,Q2,1,I,20171206.0,,20190514,20190514,DIR,,,FDA-CTU,,86.0,YR,,M,N,84.82,KG,20180110.0,N,PH,US,US,2019,Q2,Elderly
164745581,16474558,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5MG AM PO,,,Y,D, 860713,20210501.0,,12.5,MG,,QD,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,20190515.0,,20190515,20190515,DIR,,,FDA-CTU,,46.0,YR,,M,N,66.95,KG,20190515.0,N,PH,US,US,2019,Q2,Adult
164745581,16474558,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5MG AM PO,,,Y,D, 860713,20210501.0,,12.5,MG,,QD,2019,Q2,Hyperglycaemia,,2019,Q2,1,I,20190515.0,,20190515,20190515,DIR,,,FDA-CTU,,46.0,YR,,M,N,66.95,KG,20190515.0,N,PH,US,US,2019,Q2,Adult
164750571,16475057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Sepsis,,2019,Q2,1,I,20190415.0,,20190515,20190515,DIR,,,FDA-CTU,,65.0,YR,,M,N,113.0,KG,20190515.0,N,PH,US,US,2019,Q2,Elderly
164750571,16475057,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Urinary tract infection,,2019,Q2,1,I,20190415.0,,20190515,20190515,DIR,,,FDA-CTU,,65.0,YR,,M,N,113.0,KG,20190515.0,N,PH,US,US,2019,Q2,Elderly
164775741,16477574,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,134810.0,10.0,MG,TABLET,,2019,Q2,Cerebral infarction,,2019,Q2,1,I,20180919.0,20190624.0,20190626,20190626,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002911",BOEHRINGER INGELHEIM,,79.0,YR,,M,Y,66.8,KG,20190626.0,,MD,JP,JP,2019,Q2,Elderly
164887561,16488756,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Cardiac failure chronic,,2019,Q2,1,I,,20190620.0,20190627,20190627,EXP,,PHHY2019AU144207,SANDOZ,,76.0,YR,,F,Y,,,20190628.0,,MD,AU,AU,2019,Q2,Elderly
164887561,16488756,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Conjunctival pallor,,2019,Q2,1,I,,20190620.0,20190627,20190627,EXP,,PHHY2019AU144207,SANDOZ,,76.0,YR,,F,Y,,,20190628.0,,MD,AU,AU,2019,Q2,Elderly
164887561,16488756,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Decreased appetite,,2019,Q2,1,I,,20190620.0,20190627,20190627,EXP,,PHHY2019AU144207,SANDOZ,,76.0,YR,,F,Y,,,20190628.0,,MD,AU,AU,2019,Q2,Elderly
164887561,16488756,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Dyspnoea,,2019,Q2,1,I,,20190620.0,20190627,20190627,EXP,,PHHY2019AU144207,SANDOZ,,76.0,YR,,F,Y,,,20190628.0,,MD,AU,AU,2019,Q2,Elderly
164887561,16488756,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Fatigue,,2019,Q2,1,I,,20190620.0,20190627,20190627,EXP,,PHHY2019AU144207,SANDOZ,,76.0,YR,,F,Y,,,20190628.0,,MD,AU,AU,2019,Q2,Elderly
164887561,16488756,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q2,Iron deficiency anaemia,,2019,Q2,1,I,,20190620.0,20190627,20190627,EXP,,PHHY2019AU144207,SANDOZ,,76.0,YR,,F,Y,,,20190628.0,,MD,AU,AU,2019,Q2,Elderly
164913181,16491318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,5.0,MG,TABLET,,2019,Q2,Cerebral haematoma,,2019,Q2,1,I,20170912.0,20180721.0,20190628,20190628,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004115",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,66.0,KG,20190628.0,,MD,JP,JP,2019,Q2,Elderly
164913181,16491318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,5.0,MG,TABLET,,2019,Q2,Cerebral haemorrhage,,2019,Q2,1,I,20170912.0,20180721.0,20190628,20190628,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004115",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,66.0,KG,20190628.0,,MD,JP,JP,2019,Q2,Elderly
164913181,16491318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,5.0,MG,TABLET,,2019,Q2,Cholelithiasis,,2019,Q2,1,I,20170912.0,20180721.0,20190628,20190628,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004115",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,66.0,KG,20190628.0,,MD,JP,JP,2019,Q2,Elderly
164913181,16491318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,5.0,MG,TABLET,,2019,Q2,Fall,,2019,Q2,1,I,20170912.0,20180721.0,20190628,20190628,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004115",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,66.0,KG,20190628.0,,MD,JP,JP,2019,Q2,Elderly
164913181,16491318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,5.0,MG,TABLET,,2019,Q2,Hypoglycaemia,,2019,Q2,1,I,20170912.0,20180721.0,20190628,20190628,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004115",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,66.0,KG,20190628.0,,MD,JP,JP,2019,Q2,Elderly
164940421,16494042,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Pancreatic carcinoma,Pancreatic carcinoma,2019,Q2,1,I,20190619.0,20190619.0,20190628,20190628,EXP,,US-ALVOGEN-2019-ALVOGEN-100318,ALVOGEN,,69.0,YR,,M,Y,,,20190628.0,,OT,US,US,2019,Q2,Elderly
164960631,16496063,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,U,,,,25.0,MG,,QD,2019,Q2,Creatinine renal clearance decreased,,2019,Q2,1,I,2019.0,20190619.0,20190628,20190628,EXP,,US-NOVOPROD-669943,NOVO NORDISK,,76.0,YR,,F,Y,101.15,KG,20190628.0,,PH,US,US,2019,Q2,Elderly
164960631,16496063,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,U,,,,25.0,MG,,QD,2019,Q2,Decreased appetite,,2019,Q2,1,I,2019.0,20190619.0,20190628,20190628,EXP,,US-NOVOPROD-669943,NOVO NORDISK,,76.0,YR,,F,Y,101.15,KG,20190628.0,,PH,US,US,2019,Q2,Elderly
164960631,16496063,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,U,,,,25.0,MG,,QD,2019,Q2,Dizziness postural,,2019,Q2,1,I,2019.0,20190619.0,20190628,20190628,EXP,,US-NOVOPROD-669943,NOVO NORDISK,,76.0,YR,,F,Y,101.15,KG,20190628.0,,PH,US,US,2019,Q2,Elderly
164960631,16496063,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,U,,,,25.0,MG,,QD,2019,Q2,Nausea,,2019,Q2,1,I,2019.0,20190619.0,20190628,20190628,EXP,,US-NOVOPROD-669943,NOVO NORDISK,,76.0,YR,,F,Y,101.15,KG,20190628.0,,PH,US,US,2019,Q2,Elderly
164960631,16496063,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,U,,,,25.0,MG,,QD,2019,Q2,Vertigo,,2019,Q2,1,I,2019.0,20190619.0,20190628,20190628,EXP,,US-NOVOPROD-669943,NOVO NORDISK,,76.0,YR,,F,Y,101.15,KG,20190628.0,,PH,US,US,2019,Q2,Elderly
164960631,16496063,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,U,,,,25.0,MG,,QD,2019,Q2,Vomiting,,2019,Q2,1,I,2019.0,20190619.0,20190628,20190628,EXP,,US-NOVOPROD-669943,NOVO NORDISK,,76.0,YR,,F,Y,101.15,KG,20190628.0,,PH,US,US,2019,Q2,Elderly
165001361,16500136,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,N,,,,,,,,2019,Q2,Blood creatine increased,,2019,Q2,1,I,20190328.0,,20190520,20190520,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20190517.0,N,PH,US,US,2019,Q2,Elderly
165068951,16506895,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q2,Fungal infection,,2019,Q2,1,I,,,20190520,20190520,DIR,,,FDA-CTU,,59.0,YR,,M,N,118.0,KG,20190504.0,N,PH,US,US,2019,Q2,Adult
165068951,16506895,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q2,Malaise,,2019,Q2,1,I,,,20190520,20190520,DIR,,,FDA-CTU,,59.0,YR,,M,N,118.0,KG,20190504.0,N,PH,US,US,2019,Q2,Adult
165068951,16506895,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q2,Pollakiuria,,2019,Q2,1,I,,,20190520,20190520,DIR,,,FDA-CTU,,59.0,YR,,M,N,118.0,KG,20190504.0,N,PH,US,US,2019,Q2,Adult
130432425,13043242,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Blood creatine phosphokinase increased,,2019,Q3,5,F,20160917.0,20190723.0,20161219,20190731,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001374",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,60.4,KG,20190731.0,,MD,JP,JP,2019,Q3,Elderly
130432425,13043242,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Blood ketone body increased,,2019,Q3,5,F,20160917.0,20190723.0,20161219,20190731,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001374",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,60.4,KG,20190731.0,,MD,JP,JP,2019,Q3,Elderly
130432425,13043242,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Urine ketone body present,,2019,Q3,5,F,20160917.0,20190723.0,20161219,20190731,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001374",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,60.4,KG,20190731.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Arrhythmia,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Cerebral infarction,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Decreased appetite,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Diabetes mellitus,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Electrocardiogram T wave abnormal,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Myocardial infarction,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Sleep disorder,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Arrhythmia,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Cerebral infarction,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Decreased appetite,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Diabetes mellitus,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Electrocardiogram T wave abnormal,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Myocardial infarction,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Sleep disorder,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,23,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,1.0,DF,,,2019,Q3,Arrhythmia,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,23,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,1.0,DF,,,2019,Q3,Cerebral infarction,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,23,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,1.0,DF,,,2019,Q3,Decreased appetite,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,23,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,1.0,DF,,,2019,Q3,Diabetes mellitus,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,23,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,1.0,DF,,,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,23,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,1.0,DF,,,2019,Q3,Electrocardiogram T wave abnormal,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,23,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,1.0,DF,,,2019,Q3,Myocardial infarction,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
130852956,13085295,23,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,1.0,DF,,,2019,Q3,Sleep disorder,,2019,Q3,6,F,20160930.0,20190918.0,20170104,20190924,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20190924.0,,MD,JP,JP,2019,Q3,Elderly
135787343,13578734,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Fall,,2019,Q3,3,F,20170316.0,20190829.0,20170524,20190904,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-002855",BOEHRINGER INGELHEIM,,61.0,YR,,M,Y,,,20190904.0,,MD,JP,JP,2019,Q3,Adult
135787343,13578734,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Fracture,,2019,Q3,3,F,20170316.0,20190829.0,20170524,20190904,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-002855",BOEHRINGER INGELHEIM,,61.0,YR,,M,Y,,,20190904.0,,MD,JP,JP,2019,Q3,Adult
137825374,13782537,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Angina pectoris,,2019,Q3,4,F,201610.0,20190702.0,20170724,20190709,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003360",BOEHRINGER INGELHEIM,,60.0,YR,,M,Y,87.4,KG,20190709.0,,MD,JP,JP,2019,Q3,Adult
137825374,13782537,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Angina pectoris,,2019,Q3,4,F,201610.0,20190702.0,20170724,20190709,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003360",BOEHRINGER INGELHEIM,,60.0,YR,,M,Y,87.4,KG,20190709.0,,MD,JP,JP,2019,Q3,Adult
137825374,13782537,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Angina pectoris,,2019,Q3,4,F,201610.0,20190702.0,20170724,20190709,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003360",BOEHRINGER INGELHEIM,,60.0,YR,,M,Y,87.4,KG,20190709.0,,MD,JP,JP,2019,Q3,Adult
137825374,13782537,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Angina pectoris,,2019,Q3,4,F,201610.0,20190702.0,20170724,20190709,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003360",BOEHRINGER INGELHEIM,,60.0,YR,,M,Y,87.4,KG,20190709.0,,MD,JP,JP,2019,Q3,Adult
138683896,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Blood ketone body increased,,2019,Q3,6,F,20170728.0,20190717.0,20170815,20190724,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20190724.0,,MD,JP,JP,2019,Q3,Adult
138683896,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Hypercholesterolaemia,,2019,Q3,6,F,20170728.0,20190717.0,20170815,20190724,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20190724.0,,MD,JP,JP,2019,Q3,Adult
138683896,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Hyperuricaemia,,2019,Q3,6,F,20170728.0,20190717.0,20170815,20190724,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20190724.0,,MD,JP,JP,2019,Q3,Adult
138683896,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Leukocytosis,,2019,Q3,6,F,20170728.0,20190717.0,20170815,20190724,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20190724.0,,MD,JP,JP,2019,Q3,Adult
138768766,13876876,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Dizziness,,2019,Q3,6,F,20161213.0,20190722.0,20170817,20190730,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004697",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,69.2,KG,20190730.0,,MD,JP,JP,2019,Q3,Elderly
138768766,13876876,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Myalgia,,2019,Q3,6,F,20161213.0,20190722.0,20170817,20190730,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004697",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,69.2,KG,20190730.0,,MD,JP,JP,2019,Q3,Elderly
138768766,13876876,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Ventricular extrasystoles,,2019,Q3,6,F,20161213.0,20190722.0,20170817,20190730,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004697",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,69.2,KG,20190730.0,,MD,JP,JP,2019,Q3,Elderly
145830262,14583026,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2019,Q3,Euglycaemic diabetic ketoacidosis,,2019,Q3,2,F,,20190617.0,20180228,20190701,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-016617,BRISTOL MYERS SQUIBB,YOKOYAMA A. A CASE OF EUGLYCAEMIC DIABETIC KETOACIDOSIS WHICH DEVELOPED AFTER STARTING SODIUM-GLUCOSE LINKED TRANSPORTER (SGLT) 2 INHIBITORS.. FOLIA ENDOCRINOLOGICA JAPONICA. 2017;93(3):846,33.0,YR,,M,Y,,,20190701.0,,OT,JP,JP,2019,Q3,Young Adult
1459376321,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,,,TABLET,QD,2019,Q3,Acute kidney injury,,2019,Q3,21,F,20170822.0,20190913.0,20180302,20190917,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,103.0,KG,20190917.0,,MD,US,US,2019,Q3,Elderly
1459376321,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,,,TABLET,QD,2019,Q3,Ascites,,2019,Q3,21,F,20170822.0,20190913.0,20180302,20190917,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,103.0,KG,20190917.0,,MD,US,US,2019,Q3,Elderly
1459376321,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,,,TABLET,QD,2019,Q3,Cardiac failure,,2019,Q3,21,F,20170822.0,20190913.0,20180302,20190917,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,103.0,KG,20190917.0,,MD,US,US,2019,Q3,Elderly
1459376321,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,,,TABLET,QD,2019,Q3,Fall,,2019,Q3,21,F,20170822.0,20190913.0,20180302,20190917,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,103.0,KG,20190917.0,,MD,US,US,2019,Q3,Elderly
1459376321,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,,,TABLET,QD,2019,Q3,Metabolic acidosis,,2019,Q3,21,F,20170822.0,20190913.0,20180302,20190917,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,103.0,KG,20190917.0,,MD,US,US,2019,Q3,Elderly
1459376321,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,,,TABLET,QD,2019,Q3,Seizure,,2019,Q3,21,F,20170822.0,20190913.0,20180302,20190917,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,103.0,KG,20190917.0,,MD,US,US,2019,Q3,Elderly
1459376321,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,,,TABLET,QD,2019,Q3,Subdural haematoma,,2019,Q3,21,F,20170822.0,20190913.0,20180302,20190917,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,103.0,KG,20190917.0,,MD,US,US,2019,Q3,Elderly
149976074,14997607,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Lung neoplasm malignant,,2019,Q3,4,F,20180221.0,20190815.0,20180611,20190816,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003129",BOEHRINGER INGELHEIM,,72.0,YR,,F,Y,66.1,KG,20190816.0,,MD,JP,JP,2019,Q3,Elderly
149976074,14997607,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Pneumonia bacterial,,2019,Q3,4,F,20180221.0,20190815.0,20180611,20190816,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003129",BOEHRINGER INGELHEIM,,72.0,YR,,F,Y,66.1,KG,20190816.0,,MD,JP,JP,2019,Q3,Elderly
152455575,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q3,Acute myocardial infarction,,2019,Q3,5,F,200508.0,20190823.0,20180806,20190830,EXP,,PHHY2018SK058557,NOVARTIS,,66.0,YR,,M,Y,,,20190830.0,,OT,SK,SK,2019,Q3,Elderly
152455575,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q3,Diabetes mellitus,,2019,Q3,5,F,200508.0,20190823.0,20180806,20190830,EXP,,PHHY2018SK058557,NOVARTIS,,66.0,YR,,M,Y,,,20190830.0,,OT,SK,SK,2019,Q3,Elderly
152455575,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q3,Drug ineffective,,2019,Q3,5,F,200508.0,20190823.0,20180806,20190830,EXP,,PHHY2018SK058557,NOVARTIS,,66.0,YR,,M,Y,,,20190830.0,,OT,SK,SK,2019,Q3,Elderly
152455575,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q3,Glycosylated haemoglobin decreased,,2019,Q3,5,F,200508.0,20190823.0,20180806,20190830,EXP,,PHHY2018SK058557,NOVARTIS,,66.0,YR,,M,Y,,,20190830.0,,OT,SK,SK,2019,Q3,Elderly
152455575,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q3,Glycosylated haemoglobin increased,,2019,Q3,5,F,200508.0,20190823.0,20180806,20190830,EXP,,PHHY2018SK058557,NOVARTIS,,66.0,YR,,M,Y,,,20190830.0,,OT,SK,SK,2019,Q3,Elderly
152455575,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q3,Hyperlipidaemia,,2019,Q3,5,F,200508.0,20190823.0,20180806,20190830,EXP,,PHHY2018SK058557,NOVARTIS,,66.0,YR,,M,Y,,,20190830.0,,OT,SK,SK,2019,Q3,Elderly
152455575,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q3,Hypertension,,2019,Q3,5,F,200508.0,20190823.0,20180806,20190830,EXP,,PHHY2018SK058557,NOVARTIS,,66.0,YR,,M,Y,,,20190830.0,,OT,SK,SK,2019,Q3,Elderly
152455575,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q3,Myocardial infarction,,2019,Q3,5,F,200508.0,20190823.0,20180806,20190830,EXP,,PHHY2018SK058557,NOVARTIS,,66.0,YR,,M,Y,,,20190830.0,,OT,SK,SK,2019,Q3,Elderly
152455575,15245557,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2019,Q3,Weight increased,,2019,Q3,5,F,200508.0,20190823.0,20180806,20190830,EXP,,PHHY2018SK058557,NOVARTIS,,66.0,YR,,M,Y,,,20190830.0,,OT,SK,SK,2019,Q3,Elderly
153443764,15344376,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Emphysema,,2019,Q3,4,F,201805.0,20190805.0,20180903,20190808,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004711",BOEHRINGER INGELHEIM,,62.0,YR,,M,Y,50.7,KG,20190808.0,,MD,JP,JP,2019,Q3,Adult
153443764,15344376,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Hypertension,,2019,Q3,4,F,201805.0,20190805.0,20180903,20190808,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004711",BOEHRINGER INGELHEIM,,62.0,YR,,M,Y,50.7,KG,20190808.0,,MD,JP,JP,2019,Q3,Adult
153443764,15344376,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Interstitial lung disease,,2019,Q3,4,F,201805.0,20190805.0,20180903,20190808,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004711",BOEHRINGER INGELHEIM,,62.0,YR,,M,Y,50.7,KG,20190808.0,,MD,JP,JP,2019,Q3,Adult
154113133,15411313,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2019,Q3,Drug hypersensitivity,,2019,Q3,3,F,,20190723.0,20180921,20190729,PER,,US-PFIZER INC-2018380693,PFIZER,,62.0,YR,,M,Y,,,20190729.0,,MD,US,US,2019,Q3,Adult
155504462,15550446,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Alanine aminotransferase increased,,2019,Q3,2,F,20170613.0,20190911.0,20181025,20190918,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20190918.0,,MD,JP,JP,2019,Q3,Elderly
155504462,15550446,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Blood alkaline phosphatase increased,,2019,Q3,2,F,20170613.0,20190911.0,20181025,20190918,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20190918.0,,MD,JP,JP,2019,Q3,Elderly
155504462,15550446,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Cystitis,,2019,Q3,2,F,20170613.0,20190911.0,20181025,20190918,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20190918.0,,MD,JP,JP,2019,Q3,Elderly
155504462,15550446,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Urine ketone body present,,2019,Q3,2,F,20170613.0,20190911.0,20181025,20190918,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20190918.0,,MD,JP,JP,2019,Q3,Elderly
155504462,15550446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Alanine aminotransferase increased,,2019,Q3,2,F,20170613.0,20190911.0,20181025,20190918,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20190918.0,,MD,JP,JP,2019,Q3,Elderly
155504462,15550446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Blood alkaline phosphatase increased,,2019,Q3,2,F,20170613.0,20190911.0,20181025,20190918,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20190918.0,,MD,JP,JP,2019,Q3,Elderly
155504462,15550446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Cystitis,,2019,Q3,2,F,20170613.0,20190911.0,20181025,20190918,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20190918.0,,MD,JP,JP,2019,Q3,Elderly
155504462,15550446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Urine ketone body present,,2019,Q3,2,F,20170613.0,20190911.0,20181025,20190918,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20190918.0,,MD,JP,JP,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Alopecia,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Anxiety,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Asthenia,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Back pain,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Blood pressure increased,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Depression,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Dizziness,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Dry eye,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Emotional disorder,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Fatigue,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Frustration tolerance decreased,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Hair growth abnormal,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Headache,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Logorrhoea,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Malaise,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Muscular weakness,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Myalgia,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Nerve injury,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Neuralgia,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Pain,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Peripheral swelling,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Spinal cord neoplasm,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155610264,15561026,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q3,Weight increased,,2019,Q3,4,F,,20190730.0,20181029,20190805,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20190805.0,,CN,US,US,2019,Q3,Elderly
155722444,15572244,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q3,Acute myocardial infarction,,2019,Q3,4,F,200508.0,20190620.0,20181031,20190701,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20190701.0,,MD,SK,SK,2019,Q3,Elderly
155722444,15572244,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q3,Diabetes mellitus,,2019,Q3,4,F,200508.0,20190620.0,20181031,20190701,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20190701.0,,MD,SK,SK,2019,Q3,Elderly
155722444,15572244,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q3,Drug ineffective,,2019,Q3,4,F,200508.0,20190620.0,20181031,20190701,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20190701.0,,MD,SK,SK,2019,Q3,Elderly
155722444,15572244,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q3,Glycosylated haemoglobin decreased,,2019,Q3,4,F,200508.0,20190620.0,20181031,20190701,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20190701.0,,MD,SK,SK,2019,Q3,Elderly
155722444,15572244,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q3,Glycosylated haemoglobin increased,,2019,Q3,4,F,200508.0,20190620.0,20181031,20190701,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20190701.0,,MD,SK,SK,2019,Q3,Elderly
155722444,15572244,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q3,Hyperlipidaemia,,2019,Q3,4,F,200508.0,20190620.0,20181031,20190701,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20190701.0,,MD,SK,SK,2019,Q3,Elderly
155722444,15572244,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q3,Hypertension,,2019,Q3,4,F,200508.0,20190620.0,20181031,20190701,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20190701.0,,MD,SK,SK,2019,Q3,Elderly
155722444,15572244,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q3,Myocardial infarction,,2019,Q3,4,F,200508.0,20190620.0,20181031,20190701,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20190701.0,,MD,SK,SK,2019,Q3,Elderly
155722444,15572244,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q3,Weight increased,,2019,Q3,4,F,200508.0,20190620.0,20181031,20190701,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20190701.0,,MD,SK,SK,2019,Q3,Elderly
156409598,15640959,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Back pain,,2019,Q3,8,F,20180605.0,20190828.0,20181120,20190903,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051884",BOEHRINGER INGELHEIM,,85.0,YR,,M,Y,84.7,KG,20190903.0,,MD,GB,GB,2019,Q3,Elderly
156409598,15640959,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Cardiac failure,,2019,Q3,8,F,20180605.0,20190828.0,20181120,20190903,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051884",BOEHRINGER INGELHEIM,,85.0,YR,,M,Y,84.7,KG,20190903.0,,MD,GB,GB,2019,Q3,Elderly
156409598,15640959,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Fall,,2019,Q3,8,F,20180605.0,20190828.0,20181120,20190903,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051884",BOEHRINGER INGELHEIM,,85.0,YR,,M,Y,84.7,KG,20190903.0,,MD,GB,GB,2019,Q3,Elderly
156409598,15640959,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Urinary tract infection,,2019,Q3,8,F,20180605.0,20190828.0,20181120,20190903,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051884",BOEHRINGER INGELHEIM,,85.0,YR,,M,Y,84.7,KG,20190903.0,,MD,GB,GB,2019,Q3,Elderly
1564425419,15644254,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,,,FILM-COATED TABLET,,2019,Q3,Cardiac failure,,2019,Q3,19,F,20180618.0,20190712.0,20181121,20190715,EXP,,"PL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-033334",BOEHRINGER INGELHEIM,,82.0,YR,,M,Y,75.0,KG,20190715.0,,MD,PL,PL,2019,Q3,Elderly
1564425419,15644254,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,,,FILM-COATED TABLET,,2019,Q3,Diabetic nephropathy,Diabetic nephropathy,2019,Q3,19,F,20180618.0,20190712.0,20181121,20190715,EXP,,"PL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-033334",BOEHRINGER INGELHEIM,,82.0,YR,,M,Y,75.0,KG,20190715.0,,MD,PL,PL,2019,Q3,Elderly
1564425419,15644254,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,,,FILM-COATED TABLET,,2019,Q3,Hepatic failure,,2019,Q3,19,F,20180618.0,20190712.0,20181121,20190715,EXP,,"PL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-033334",BOEHRINGER INGELHEIM,,82.0,YR,,M,Y,75.0,KG,20190715.0,,MD,PL,PL,2019,Q3,Elderly
1564425419,15644254,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,,,FILM-COATED TABLET,,2019,Q3,Loss of consciousness,,2019,Q3,19,F,20180618.0,20190712.0,20181121,20190715,EXP,,"PL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-033334",BOEHRINGER INGELHEIM,,82.0,YR,,M,Y,75.0,KG,20190715.0,,MD,PL,PL,2019,Q3,Elderly
1564425419,15644254,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,,,FILM-COATED TABLET,,2019,Q3,Pancreatitis acute,,2019,Q3,19,F,20180618.0,20190712.0,20181121,20190715,EXP,,"PL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-033334",BOEHRINGER INGELHEIM,,82.0,YR,,M,Y,75.0,KG,20190715.0,,MD,PL,PL,2019,Q3,Elderly
1564425419,15644254,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,,,FILM-COATED TABLET,,2019,Q3,Cardiac failure,,2019,Q3,19,F,20180618.0,20190712.0,20181121,20190715,EXP,,"PL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-033334",BOEHRINGER INGELHEIM,,82.0,YR,,M,Y,75.0,KG,20190715.0,,MD,PL,PL,2019,Q3,Elderly
1564425419,15644254,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,,,FILM-COATED TABLET,,2019,Q3,Diabetic nephropathy,Diabetic nephropathy,2019,Q3,19,F,20180618.0,20190712.0,20181121,20190715,EXP,,"PL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-033334",BOEHRINGER INGELHEIM,,82.0,YR,,M,Y,75.0,KG,20190715.0,,MD,PL,PL,2019,Q3,Elderly
1564425419,15644254,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,,,FILM-COATED TABLET,,2019,Q3,Hepatic failure,,2019,Q3,19,F,20180618.0,20190712.0,20181121,20190715,EXP,,"PL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-033334",BOEHRINGER INGELHEIM,,82.0,YR,,M,Y,75.0,KG,20190715.0,,MD,PL,PL,2019,Q3,Elderly
1564425419,15644254,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,,,FILM-COATED TABLET,,2019,Q3,Loss of consciousness,,2019,Q3,19,F,20180618.0,20190712.0,20181121,20190715,EXP,,"PL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-033334",BOEHRINGER INGELHEIM,,82.0,YR,,M,Y,75.0,KG,20190715.0,,MD,PL,PL,2019,Q3,Elderly
1564425419,15644254,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,,,FILM-COATED TABLET,,2019,Q3,Pancreatitis acute,,2019,Q3,19,F,20180618.0,20190712.0,20181121,20190715,EXP,,"PL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-033334",BOEHRINGER INGELHEIM,,82.0,YR,,M,Y,75.0,KG,20190715.0,,MD,PL,PL,2019,Q3,Elderly
157203635,15720363,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Liver injury,,2019,Q3,5,F,20181121.0,20190905.0,20181213,20190920,EXP,,"CN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-057672",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,85.0,KG,20190920.0,,MD,CN,CN,2019,Q3,Adult
157458525,15745852,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Liver abscess,,2019,Q3,5,F,20181109.0,20190830.0,20181220,20190910,EXP,,JP-PFIZER INC-2018470268,PFIZER,,71.0,YR,,M,Y,66.3,KG,20190910.0,,MD,JP,JP,2019,Q3,Elderly
1586031313,15860313,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Fournier's gangrene,,2019,Q3,13,F,20181226.0,20190831.0,20190123,20190904,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-062218",BOEHRINGER INGELHEIM,,87.0,YR,,M,Y,81.4,KG,20190904.0,,MD,US,US,2019,Q3,Elderly
1586031313,15860313,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,,,FILM-COATED TABLET,,2019,Q3,Fournier's gangrene,,2019,Q3,13,F,20181226.0,20190831.0,20190123,20190904,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-062218",BOEHRINGER INGELHEIM,,87.0,YR,,M,Y,81.4,KG,20190904.0,,MD,US,US,2019,Q3,Elderly
158613003,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Anaemia,,2019,Q3,3,F,20161215.0,20190827.0,20190124,20190903,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190903.0,,MD,JP,JP,2019,Q3,Elderly
158613003,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Blood pressure increased,,2019,Q3,3,F,20161215.0,20190827.0,20190124,20190903,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190903.0,,MD,JP,JP,2019,Q3,Elderly
158613003,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Cardiac failure,,2019,Q3,3,F,20161215.0,20190827.0,20190124,20190903,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190903.0,,MD,JP,JP,2019,Q3,Elderly
158613003,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Diabetes mellitus,,2019,Q3,3,F,20161215.0,20190827.0,20190124,20190903,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190903.0,,MD,JP,JP,2019,Q3,Elderly
158613003,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Essential thrombocythaemia,,2019,Q3,3,F,20161215.0,20190827.0,20190124,20190903,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190903.0,,MD,JP,JP,2019,Q3,Elderly
158613003,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Hyperkalaemia,,2019,Q3,3,F,20161215.0,20190827.0,20190124,20190903,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190903.0,,MD,JP,JP,2019,Q3,Elderly
158613003,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Peripheral arterial occlusive disease,,2019,Q3,3,F,20161215.0,20190827.0,20190124,20190903,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190903.0,,MD,JP,JP,2019,Q3,Elderly
158613003,15861300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Sinus node dysfunction,,2019,Q3,3,F,20161215.0,20190827.0,20190124,20190903,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000909",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,49.9,KG,20190903.0,,MD,JP,JP,2019,Q3,Elderly
158845593,15884559,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, DAILY DOSE",,,,, UNK,,,25.0,MG,,QD,2019,Q3,Colitis microscopic,,2019,Q3,3,F,20180414.0,20190729.0,20190129,20190805,EXP,,DE-MYLANLABS-2019M1007430,MYLAN,,77.0,YR,,F,Y,87.0,KG,20190805.0,,OT,DE,DE,2019,Q3,Elderly
158845593,15884559,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, DAILY DOSE",,,,, UNK,,,25.0,MG,,QD,2019,Q3,Contusion,,2019,Q3,3,F,20180414.0,20190729.0,20190129,20190805,EXP,,DE-MYLANLABS-2019M1007430,MYLAN,,77.0,YR,,F,Y,87.0,KG,20190805.0,,OT,DE,DE,2019,Q3,Elderly
158845593,15884559,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, DAILY DOSE",,,,, UNK,,,25.0,MG,,QD,2019,Q3,Fall,,2019,Q3,3,F,20180414.0,20190729.0,20190129,20190805,EXP,,DE-MYLANLABS-2019M1007430,MYLAN,,77.0,YR,,F,Y,87.0,KG,20190805.0,,OT,DE,DE,2019,Q3,Elderly
158845593,15884559,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, DAILY DOSE",,,,, UNK,,,25.0,MG,,QD,2019,Q3,Gastrointestinal haemorrhage,,2019,Q3,3,F,20180414.0,20190729.0,20190129,20190805,EXP,,DE-MYLANLABS-2019M1007430,MYLAN,,77.0,YR,,F,Y,87.0,KG,20190805.0,,OT,DE,DE,2019,Q3,Elderly
158845593,15884559,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, DAILY DOSE",,,,, UNK,,,25.0,MG,,QD,2019,Q3,Pseudomonas test positive,,2019,Q3,3,F,20180414.0,20190729.0,20190129,20190805,EXP,,DE-MYLANLABS-2019M1007430,MYLAN,,77.0,YR,,F,Y,87.0,KG,20190805.0,,OT,DE,DE,2019,Q3,Elderly
158845593,15884559,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, DAILY DOSE",,,,, UNK,,,25.0,MG,,QD,2019,Q3,Spinal instability,,2019,Q3,3,F,20180414.0,20190729.0,20190129,20190805,EXP,,DE-MYLANLABS-2019M1007430,MYLAN,,77.0,YR,,F,Y,87.0,KG,20190805.0,,OT,DE,DE,2019,Q3,Elderly
159863138,15986313,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Abdominal pain,,2019,Q3,8,F,20190107.0,20190905.0,20190220,20190906,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-006107",BOEHRINGER INGELHEIM,,78.0,YR,,F,Y,73.8,KG,20190906.0,,MD,BR,BR,2019,Q3,Elderly
159863138,15986313,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Cardiac failure,,2019,Q3,8,F,20190107.0,20190905.0,20190220,20190906,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-006107",BOEHRINGER INGELHEIM,,78.0,YR,,F,Y,73.8,KG,20190906.0,,MD,BR,BR,2019,Q3,Elderly
159863138,15986313,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Syncope,,2019,Q3,8,F,20190107.0,20190905.0,20190220,20190906,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-006107",BOEHRINGER INGELHEIM,,78.0,YR,,F,Y,73.8,KG,20190906.0,,MD,BR,BR,2019,Q3,Elderly
160071873,16007187,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q3,Liver disorder,,2019,Q3,3,F,20190214.0,20190830.0,20190226,20190904,EXP,,"AR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-007787",BOEHRINGER INGELHEIM,,61.0,YR,,M,Y,54.6,KG,20190905.0,,MD,AR,AR,2019,Q3,Adult
160542256,16054225,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Cardiac failure,,2019,Q3,6,F,20190120.0,20190723.0,20190308,20190725,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-008316",BOEHRINGER INGELHEIM,,72.0,YR,,M,Y,83.7,KG,20190725.0,,MD,BR,BR,2019,Q3,Elderly
160542256,16054225,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Dyspnoea,,2019,Q3,6,F,20190120.0,20190723.0,20190308,20190725,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-008316",BOEHRINGER INGELHEIM,,72.0,YR,,M,Y,83.7,KG,20190725.0,,MD,BR,BR,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Acute kidney injury,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Arrhythmia,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Atrial fibrillation,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Bradycardia,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Dehydration,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Dizziness,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Drug interaction,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Haematocrit increased,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Haemoglobin increased,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Heart rate irregular,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Hypotension,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Hypovolaemia,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Left atrial dilatation,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Mucosal dryness,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Presyncope,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Skin disorder,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,4,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Syncope,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Acute kidney injury,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Arrhythmia,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Atrial fibrillation,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Bradycardia,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Dehydration,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Dizziness,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Drug interaction,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Haematocrit increased,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Haemoglobin increased,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Heart rate irregular,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Hypotension,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Hypovolaemia,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Left atrial dilatation,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Mucosal dryness,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Presyncope,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Skin disorder,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161236885,16123688,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Syncope,,2019,Q3,5,F,2018.0,20190920.0,20190327,20190926,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74",71.0,YR,,M,Y,,,20190926.0,,MD,PT,PT,2019,Q3,Elderly
161290004,16129000,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Blood creatinine increased,,2019,Q3,4,F,20160520.0,20190809.0,20190328,20190813,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002657",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,76.3,KG,20190813.0,,MD,JP,JP,2019,Q3,Elderly
161290004,16129000,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Intestinal obstruction,,2019,Q3,4,F,20160520.0,20190809.0,20190328,20190813,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002657",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,76.3,KG,20190813.0,,MD,JP,JP,2019,Q3,Elderly
161290004,16129000,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Pneumonia,,2019,Q3,4,F,20160520.0,20190809.0,20190328,20190813,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002657",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,76.3,KG,20190813.0,,MD,JP,JP,2019,Q3,Elderly
161363223,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q3,Acute kidney injury,,2019,Q3,3,F,,20190802.0,20190329,20190809,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190809.0,,OT,PT,PT,2019,Q3,Elderly
161363223,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q3,Arrhythmia,,2019,Q3,3,F,,20190802.0,20190329,20190809,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190809.0,,OT,PT,PT,2019,Q3,Elderly
161363223,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q3,Atrial fibrillation,,2019,Q3,3,F,,20190802.0,20190329,20190809,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190809.0,,OT,PT,PT,2019,Q3,Elderly
161363223,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q3,Bradycardia,,2019,Q3,3,F,,20190802.0,20190329,20190809,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190809.0,,OT,PT,PT,2019,Q3,Elderly
161363223,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q3,Dehydration,,2019,Q3,3,F,,20190802.0,20190329,20190809,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190809.0,,OT,PT,PT,2019,Q3,Elderly
161363223,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q3,Dizziness,,2019,Q3,3,F,,20190802.0,20190329,20190809,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190809.0,,OT,PT,PT,2019,Q3,Elderly
161363223,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q3,Haematocrit increased,,2019,Q3,3,F,,20190802.0,20190329,20190809,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190809.0,,OT,PT,PT,2019,Q3,Elderly
161363223,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q3,Haemoglobin increased,,2019,Q3,3,F,,20190802.0,20190329,20190809,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190809.0,,OT,PT,PT,2019,Q3,Elderly
161363223,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q3,Hypotension,,2019,Q3,3,F,,20190802.0,20190329,20190809,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190809.0,,OT,PT,PT,2019,Q3,Elderly
161363223,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q3,Hypovolaemia,,2019,Q3,3,F,,20190802.0,20190329,20190809,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190809.0,,OT,PT,PT,2019,Q3,Elderly
161363223,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q3,Left atrial dilatation,,2019,Q3,3,F,,20190802.0,20190329,20190809,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190809.0,,OT,PT,PT,2019,Q3,Elderly
161363223,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q3,Mucosal dryness,,2019,Q3,3,F,,20190802.0,20190329,20190809,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190809.0,,OT,PT,PT,2019,Q3,Elderly
161363223,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q3,Presyncope,,2019,Q3,3,F,,20190802.0,20190329,20190809,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190809.0,,OT,PT,PT,2019,Q3,Elderly
161363223,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q3,Skin disorder,,2019,Q3,3,F,,20190802.0,20190329,20190809,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190809.0,,OT,PT,PT,2019,Q3,Elderly
161363223,16136322,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2019,Q3,Syncope,,2019,Q3,3,F,,20190802.0,20190329,20190809,EXP,,PT-ASTRAZENECA-2019SE49086,ASTRAZENECA,,71.0,YR,,M,Y,,,20190809.0,,OT,PT,PT,2019,Q3,Elderly
161521152,16152115,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q3,Diabetic nephropathy,,2019,Q3,2,F,20190326.0,20190824.0,20190403,20190828,EXP,,"AR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-014846",BOEHRINGER INGELHEIM,,64.0,YR,,F,Y,91.8,KG,20190828.0,,MD,AR,AR,2019,Q3,Adult
161548646,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q3,Acute kidney injury,,2019,Q3,6,F,2018.0,20190801.0,20190403,20190809,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190809.0,,CN,PT,PT,2019,Q3,Elderly
161548646,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q3,Arrhythmia,,2019,Q3,6,F,2018.0,20190801.0,20190403,20190809,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190809.0,,CN,PT,PT,2019,Q3,Elderly
161548646,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q3,Atrial fibrillation,,2019,Q3,6,F,2018.0,20190801.0,20190403,20190809,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190809.0,,CN,PT,PT,2019,Q3,Elderly
161548646,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q3,Bradycardia,,2019,Q3,6,F,2018.0,20190801.0,20190403,20190809,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190809.0,,CN,PT,PT,2019,Q3,Elderly
161548646,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q3,Dehydration,,2019,Q3,6,F,2018.0,20190801.0,20190403,20190809,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190809.0,,CN,PT,PT,2019,Q3,Elderly
161548646,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q3,Dizziness,,2019,Q3,6,F,2018.0,20190801.0,20190403,20190809,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190809.0,,CN,PT,PT,2019,Q3,Elderly
161548646,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q3,Haematocrit increased,,2019,Q3,6,F,2018.0,20190801.0,20190403,20190809,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190809.0,,CN,PT,PT,2019,Q3,Elderly
161548646,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q3,Haemoglobin increased,,2019,Q3,6,F,2018.0,20190801.0,20190403,20190809,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190809.0,,CN,PT,PT,2019,Q3,Elderly
161548646,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q3,Hypotension,,2019,Q3,6,F,2018.0,20190801.0,20190403,20190809,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190809.0,,CN,PT,PT,2019,Q3,Elderly
161548646,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q3,Hypovolaemia,,2019,Q3,6,F,2018.0,20190801.0,20190403,20190809,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190809.0,,CN,PT,PT,2019,Q3,Elderly
161548646,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q3,Left atrial dilatation,,2019,Q3,6,F,2018.0,20190801.0,20190403,20190809,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190809.0,,CN,PT,PT,2019,Q3,Elderly
161548646,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q3,Mucosal dryness,,2019,Q3,6,F,2018.0,20190801.0,20190403,20190809,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190809.0,,CN,PT,PT,2019,Q3,Elderly
161548646,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q3,Presyncope,,2019,Q3,6,F,2018.0,20190801.0,20190403,20190809,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190809.0,,CN,PT,PT,2019,Q3,Elderly
161548646,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q3,Skin disorder,,2019,Q3,6,F,2018.0,20190801.0,20190403,20190809,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190809.0,,CN,PT,PT,2019,Q3,Elderly
161548646,16154864,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,,10.0,MG,,QD,2019,Q3,Syncope,,2019,Q3,6,F,2018.0,20190801.0,20190403,20190809,EXP,,PT-ELI_LILLY_AND_COMPANY-PT201904001123,ELI LILLY AND CO,,71.0,YR,,M,Y,,,20190809.0,,CN,PT,PT,2019,Q3,Elderly
162032192,16203219,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Bronchitis,,2019,Q3,2,F,20171128.0,20190710.0,20190416,20190716,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-001750",BOEHRINGER INGELHEIM,,85.0,YR,,F,Y,39.5,KG,20190716.0,,MD,JP,JP,2019,Q3,Elderly
162032192,16203219,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Decreased appetite,,2019,Q3,2,F,20171128.0,20190710.0,20190416,20190716,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-001750",BOEHRINGER INGELHEIM,,85.0,YR,,F,Y,39.5,KG,20190716.0,,MD,JP,JP,2019,Q3,Elderly
162249552,16224955,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U, UNKNONWN,,,10.0,MG,,,2019,Q3,Breast cancer,,2019,Q3,2,F,201712.0,20190621.0,20190422,20190701,EXP,,IT-MYLANLABS-2019M1036988,MYLAN,,64.0,YR,,F,Y,,,20190701.0,,CN,IT,IT,2019,Q3,Adult
162366875,16236687,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2019,Q3,Impaired healing,,2019,Q3,5,F,20190326.0,20190624.0,20190425,20190702,EXP,,JP-ASTELLAS-2019JP007355,ASTELLAS,,79.0,YR,,M,Y,,,20190702.0,,MD,COUNTRY NOT SPECIFIED,JP,2019,Q3,Elderly
162366875,16236687,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2019,Q3,Prescribed underdose,,2019,Q3,5,F,20190326.0,20190624.0,20190425,20190702,EXP,,JP-ASTELLAS-2019JP007355,ASTELLAS,,79.0,YR,,M,Y,,,20190702.0,,MD,COUNTRY NOT SPECIFIED,JP,2019,Q3,Elderly
163007792,16300779,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Rectal haemorrhage,,2019,Q3,2,F,20190425.0,20190703.0,20190510,20190703,EXP,,"IT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-020766",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,107.0,KG,20190703.0,,MD,IT,IT,2019,Q3,Elderly
163007792,16300779,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Urinary tract infection,,2019,Q3,2,F,20190425.0,20190703.0,20190510,20190703,EXP,,"IT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-020766",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,107.0,KG,20190703.0,,MD,IT,IT,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Anaemia,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Blood cholesterol increased,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Blood glucose increased,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Blood pressure fluctuation,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Blood uric acid increased,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Cardiomegaly,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Carotid arteriosclerosis,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Chest discomfort,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Decreased ventricular preload,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Dyspnoea exertional,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Electrocardiogram abnormal,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Hepatic lesion,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Ischaemia,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Myocardial ischaemia,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Renal impairment,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163184312,16318431,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,U,,,,1.0,DF,TABLET,,2019,Q3,Transient ischaemic attack,,2019,Q3,2,F,,20190507.0,20190516,20190821,EXP,,HU-APOTEX-2019AP013993,APOTEX,,65.0,YR,,M,Y,,,20190821.0,,CN,HU,HU,2019,Q3,Elderly
163445684,16344568,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Cholestasis,,2019,Q3,4,F,20181204.0,20190715.0,20190522,20190718,EXP,,"PL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-061174",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,99.2,KG,20190718.0,,MD,PL,PL,2019,Q3,Elderly
163610641,16361064,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q3,Euglycaemic diabetic ketoacidosis,,2019,Q3,1,I,20190429.0,,20190524,20190524,DIR,,,FDA-CTU,,71.0,YR,,F,N,97.9,KG,20190524.0,N,PH,US,US,2019,Q3,Elderly
163686453,16368645,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Acute left ventricular failure,,2019,Q3,3,F,20180220.0,20190923.0,20190529,20190927,EXP,,US-ASTRAZENECA-2019SE75941,ASTRAZENECA,,23504.0,DY,,M,Y,106.1,KG,20190927.0,,,US,US,2019,Q3,Elderly
163686453,16368645,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Acute myocardial infarction,,2019,Q3,3,F,20180220.0,20190923.0,20190529,20190927,EXP,,US-ASTRAZENECA-2019SE75941,ASTRAZENECA,,23504.0,DY,,M,Y,106.1,KG,20190927.0,,,US,US,2019,Q3,Elderly
163686453,16368645,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Cardiac failure,,2019,Q3,3,F,20180220.0,20190923.0,20190529,20190927,EXP,,US-ASTRAZENECA-2019SE75941,ASTRAZENECA,,23504.0,DY,,M,Y,106.1,KG,20190927.0,,,US,US,2019,Q3,Elderly
163686453,16368645,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Cardiac failure acute,,2019,Q3,3,F,20180220.0,20190923.0,20190529,20190927,EXP,,US-ASTRAZENECA-2019SE75941,ASTRAZENECA,,23504.0,DY,,M,Y,106.1,KG,20190927.0,,,US,US,2019,Q3,Elderly
163686453,16368645,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Cardiac failure congestive,,2019,Q3,3,F,20180220.0,20190923.0,20190529,20190927,EXP,,US-ASTRAZENECA-2019SE75941,ASTRAZENECA,,23504.0,DY,,M,Y,106.1,KG,20190927.0,,,US,US,2019,Q3,Elderly
163686453,16368645,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Chronic left ventricular failure,,2019,Q3,3,F,20180220.0,20190923.0,20190529,20190927,EXP,,US-ASTRAZENECA-2019SE75941,ASTRAZENECA,,23504.0,DY,,M,Y,106.1,KG,20190927.0,,,US,US,2019,Q3,Elderly
163686453,16368645,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Myocardial infarction,,2019,Q3,3,F,20180220.0,20190923.0,20190529,20190927,EXP,,US-ASTRAZENECA-2019SE75941,ASTRAZENECA,,23504.0,DY,,M,Y,106.1,KG,20190927.0,,,US,US,2019,Q3,Elderly
163724972,16372497,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,,,,,25.0,MG,,,2019,Q3,Acute kidney injury,,2019,Q3,2,F,201904.0,20190625.0,20190530,20190705,EXP,,US-NOVOPROD-663677,NOVO NORDISK,,54.0,YR,,M,Y,116.1,KG,20190705.0,,CN,US,US,2019,Q3,Adult
163724972,16372497,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,,,,,25.0,MG,,,2019,Q3,Amnesia,,2019,Q3,2,F,201904.0,20190625.0,20190530,20190705,EXP,,US-NOVOPROD-663677,NOVO NORDISK,,54.0,YR,,M,Y,116.1,KG,20190705.0,,CN,US,US,2019,Q3,Adult
163724972,16372497,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,,,,,25.0,MG,,,2019,Q3,Pancreatitis,,2019,Q3,2,F,201904.0,20190625.0,20190530,20190705,EXP,,US-NOVOPROD-663677,NOVO NORDISK,,54.0,YR,,M,Y,116.1,KG,20190705.0,,CN,US,US,2019,Q3,Adult
163724972,16372497,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,,,,,25.0,MG,,,2019,Q3,Respiratory failure,,2019,Q3,2,F,201904.0,20190625.0,20190530,20190705,EXP,,US-NOVOPROD-663677,NOVO NORDISK,,54.0,YR,,M,Y,116.1,KG,20190705.0,,CN,US,US,2019,Q3,Adult
163724972,16372497,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,,,,,25.0,MG,,,2019,Q3,Sepsis,,2019,Q3,2,F,201904.0,20190625.0,20190530,20190705,EXP,,US-NOVOPROD-663677,NOVO NORDISK,,54.0,YR,,M,Y,116.1,KG,20190705.0,,CN,US,US,2019,Q3,Adult
163724972,16372497,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,,,,,25.0,MG,,,2019,Q3,Urinary tract infection,,2019,Q3,2,F,201904.0,20190625.0,20190530,20190705,EXP,,US-NOVOPROD-663677,NOVO NORDISK,,54.0,YR,,M,Y,116.1,KG,20190705.0,,CN,US,US,2019,Q3,Adult
163900033,16390003,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Colitis ulcerative,,2019,Q3,3,F,20170703.0,20190726.0,20190604,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-000748",BOEHRINGER INGELHEIM,,36.0,YR,,F,Y,84.5,KG,20190801.0,,MD,JP,JP,2019,Q3,Adult
163900033,16390003,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Hypoglycaemia,,2019,Q3,3,F,20170703.0,20190726.0,20190604,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-000748",BOEHRINGER INGELHEIM,,36.0,YR,,F,Y,84.5,KG,20190801.0,,MD,JP,JP,2019,Q3,Adult
163985301,16398530,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q3,Acidosis,,2019,Q3,1,I,20190604.0,,20190605,20190605,DIR,,,FDA-CTU,,63.0,YR,,M,N,76.0,KG,20190605.0,N,PH,US,US,2019,Q3,Adult
163985301,16398530,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q3,Acute kidney injury,,2019,Q3,1,I,20190604.0,,20190605,20190605,DIR,,,FDA-CTU,,63.0,YR,,M,N,76.0,KG,20190605.0,N,PH,US,US,2019,Q3,Adult
163985301,16398530,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,20190604.0,,20190605,20190605,DIR,,,FDA-CTU,,63.0,YR,,M,N,76.0,KG,20190605.0,N,PH,US,US,2019,Q3,Adult
163985301,16398530,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q3,Hyperglycaemia,,2019,Q3,1,I,20190604.0,,20190605,20190605,DIR,,,FDA-CTU,,63.0,YR,,M,N,76.0,KG,20190605.0,N,PH,US,US,2019,Q3,Adult
164063032,16406303,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Cardiac failure,,2019,Q3,2,F,201802.0,20190628.0,20190607,20190705,EXP,,US-ASTRAZENECA-2019SE83609,ASTRAZENECA,,790.0,MON,,M,Y,,,20190705.0,,,US,US,2019,Q3,Elderly
164063032,16406303,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Cardiac failure congestive,,2019,Q3,2,F,201802.0,20190628.0,20190607,20190705,EXP,,US-ASTRAZENECA-2019SE83609,ASTRAZENECA,,790.0,MON,,M,Y,,,20190705.0,,,US,US,2019,Q3,Elderly
164063032,16406303,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Left ventricular failure,,2019,Q3,2,F,201802.0,20190628.0,20190607,20190705,EXP,,US-ASTRAZENECA-2019SE83609,ASTRAZENECA,,790.0,MON,,M,Y,,,20190705.0,,,US,US,2019,Q3,Elderly
164101701,16410170,4,C,empagliflozin 10mg  daily,,2,,,,,,,,,,,,,,2019,Q3,Anticoagulation drug level below therapeutic,,2019,Q3,1,I,20190217.0,,20190607,20190607,DIR,,,FDA-CTU,,59.0,YR,,M,N,91.7,KG,20190607.0,N,PH,US,US,2019,Q3,Adult
164101701,16410170,4,C,empagliflozin 10mg  daily,,2,,,,,,,,,,,,,,2019,Q3,Cerebral haematoma,,2019,Q3,1,I,20190217.0,,20190607,20190607,DIR,,,FDA-CTU,,59.0,YR,,M,N,91.7,KG,20190607.0,N,PH,US,US,2019,Q3,Adult
164101701,16410170,4,C,empagliflozin 10mg  daily,,2,,,,,,,,,,,,,,2019,Q3,Hypertensive emergency,,2019,Q3,1,I,20190217.0,,20190607,20190607,DIR,,,FDA-CTU,,59.0,YR,,M,N,91.7,KG,20190607.0,N,PH,US,US,2019,Q3,Adult
164101701,16410170,4,C,empagliflozin 10mg  daily,,2,,,,,,,,,,,,,,2019,Q3,Pneumonia,,2019,Q3,1,I,20190217.0,,20190607,20190607,DIR,,,FDA-CTU,,59.0,YR,,M,N,91.7,KG,20190607.0,N,PH,US,US,2019,Q3,Adult
164101701,16410170,4,C,empagliflozin 10mg  daily,,2,,,,,,,,,,,,,,2019,Q3,Pneumonia aspiration,,2019,Q3,1,I,20190217.0,,20190607,20190607,DIR,,,FDA-CTU,,59.0,YR,,M,N,91.7,KG,20190607.0,N,PH,US,US,2019,Q3,Adult
164101701,16410170,4,C,empagliflozin 10mg  daily,,2,,,,,,,,,,,,,,2019,Q3,Shock,,2019,Q3,1,I,20190217.0,,20190607,20190607,DIR,,,FDA-CTU,,59.0,YR,,M,N,91.7,KG,20190607.0,N,PH,US,US,2019,Q3,Adult
164101701,16410170,4,C,empagliflozin 10mg  daily,,2,,,,,,,,,,,,,,2019,Q3,Treatment noncompliance,,2019,Q3,1,I,20190217.0,,20190607,20190607,DIR,,,FDA-CTU,,59.0,YR,,M,N,91.7,KG,20190607.0,N,PH,US,US,2019,Q3,Adult
164241766,16424176,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Disturbance in attention,,2019,Q3,6,F,201906.0,20190910.0,20190613,20190916,EXP,,CA-ABBVIE-19K-028-2811700-00,ABBVIE,,52.0,YR,,F,Y,90.7,KG,20190916.0,,MD,CA,CA,2019,Q3,Adult
164241766,16424176,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Epistaxis,,2019,Q3,6,F,201906.0,20190910.0,20190613,20190916,EXP,,CA-ABBVIE-19K-028-2811700-00,ABBVIE,,52.0,YR,,F,Y,90.7,KG,20190916.0,,MD,CA,CA,2019,Q3,Adult
164241766,16424176,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Hyponatraemia,,2019,Q3,6,F,201906.0,20190910.0,20190613,20190916,EXP,,CA-ABBVIE-19K-028-2811700-00,ABBVIE,,52.0,YR,,F,Y,90.7,KG,20190916.0,,MD,CA,CA,2019,Q3,Adult
164241766,16424176,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Muscle fatigue,,2019,Q3,6,F,201906.0,20190910.0,20190613,20190916,EXP,,CA-ABBVIE-19K-028-2811700-00,ABBVIE,,52.0,YR,,F,Y,90.7,KG,20190916.0,,MD,CA,CA,2019,Q3,Adult
164241766,16424176,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Rash,,2019,Q3,6,F,201906.0,20190910.0,20190613,20190916,EXP,,CA-ABBVIE-19K-028-2811700-00,ABBVIE,,52.0,YR,,F,Y,90.7,KG,20190916.0,,MD,CA,CA,2019,Q3,Adult
164264342,16426434,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Hyperglycaemia,,2019,Q3,2,F,,20190705.0,20190613,20190718,EXP,,CO-NOVOPROD-666793,NOVO NORDISK,,69.0,YR,,F,Y,,,20190718.0,,MD,CO,CO,2019,Q3,Elderly
164264342,16426434,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Medication error,,2019,Q3,2,F,,20190705.0,20190613,20190718,EXP,,CO-NOVOPROD-666793,NOVO NORDISK,,69.0,YR,,F,Y,,,20190718.0,,MD,CO,CO,2019,Q3,Elderly
164264342,16426434,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Off label use,,2019,Q3,2,F,,20190705.0,20190613,20190718,EXP,,CO-NOVOPROD-666793,NOVO NORDISK,,69.0,YR,,F,Y,,,20190718.0,,MD,CO,CO,2019,Q3,Elderly
164264342,16426434,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Pancreatitis,,2019,Q3,2,F,,20190705.0,20190613,20190718,EXP,,CO-NOVOPROD-666793,NOVO NORDISK,,69.0,YR,,F,Y,,,20190718.0,,MD,CO,CO,2019,Q3,Elderly
164386322,16438632,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q3,Acute kidney injury,,2019,Q3,2,F,2018.0,20190731.0,20190617,20190806,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,,71.0,YR,E,M,Y,,,20190806.0,,OT,PT,PT,2019,Q3,Elderly
164386322,16438632,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q3,Arrhythmia,,2019,Q3,2,F,2018.0,20190731.0,20190617,20190806,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,,71.0,YR,E,M,Y,,,20190806.0,,OT,PT,PT,2019,Q3,Elderly
164386322,16438632,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q3,Atrial fibrillation,,2019,Q3,2,F,2018.0,20190731.0,20190617,20190806,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,,71.0,YR,E,M,Y,,,20190806.0,,OT,PT,PT,2019,Q3,Elderly
164386322,16438632,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q3,Bradycardia,,2019,Q3,2,F,2018.0,20190731.0,20190617,20190806,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,,71.0,YR,E,M,Y,,,20190806.0,,OT,PT,PT,2019,Q3,Elderly
164386322,16438632,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q3,Dehydration,,2019,Q3,2,F,2018.0,20190731.0,20190617,20190806,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,,71.0,YR,E,M,Y,,,20190806.0,,OT,PT,PT,2019,Q3,Elderly
164386322,16438632,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q3,Dizziness,,2019,Q3,2,F,2018.0,20190731.0,20190617,20190806,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,,71.0,YR,E,M,Y,,,20190806.0,,OT,PT,PT,2019,Q3,Elderly
164386322,16438632,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q3,Haematocrit increased,,2019,Q3,2,F,2018.0,20190731.0,20190617,20190806,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,,71.0,YR,E,M,Y,,,20190806.0,,OT,PT,PT,2019,Q3,Elderly
164386322,16438632,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q3,Haemoglobin increased,,2019,Q3,2,F,2018.0,20190731.0,20190617,20190806,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,,71.0,YR,E,M,Y,,,20190806.0,,OT,PT,PT,2019,Q3,Elderly
164386322,16438632,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q3,Hypotension,,2019,Q3,2,F,2018.0,20190731.0,20190617,20190806,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,,71.0,YR,E,M,Y,,,20190806.0,,OT,PT,PT,2019,Q3,Elderly
164386322,16438632,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q3,Hypovolaemia,,2019,Q3,2,F,2018.0,20190731.0,20190617,20190806,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,,71.0,YR,E,M,Y,,,20190806.0,,OT,PT,PT,2019,Q3,Elderly
164386322,16438632,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q3,Left atrial dilatation,,2019,Q3,2,F,2018.0,20190731.0,20190617,20190806,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,,71.0,YR,E,M,Y,,,20190806.0,,OT,PT,PT,2019,Q3,Elderly
164386322,16438632,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q3,Mucosal dryness,,2019,Q3,2,F,2018.0,20190731.0,20190617,20190806,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,,71.0,YR,E,M,Y,,,20190806.0,,OT,PT,PT,2019,Q3,Elderly
164386322,16438632,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q3,Presyncope,,2019,Q3,2,F,2018.0,20190731.0,20190617,20190806,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,,71.0,YR,E,M,Y,,,20190806.0,,OT,PT,PT,2019,Q3,Elderly
164386322,16438632,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q3,Skin disorder,,2019,Q3,2,F,2018.0,20190731.0,20190617,20190806,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,,71.0,YR,E,M,Y,,,20190806.0,,OT,PT,PT,2019,Q3,Elderly
164386322,16438632,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,,2019,Q3,Syncope,,2019,Q3,2,F,2018.0,20190731.0,20190617,20190806,EXP,PT-EMA-DD-20190508-HV_A-123303,PT-ACCORD-132410,ACCORD,,71.0,YR,E,M,Y,,,20190806.0,,OT,PT,PT,2019,Q3,Elderly
164604572,16460457,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Cerebral infarction,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Cholangitis acute,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Cholelithiasis,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Dermatitis,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Cerebral infarction,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Cholangitis acute,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Cholelithiasis,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Dermatitis,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q3,Cerebral infarction,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q3,Cholangitis acute,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q3,Cholelithiasis,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q3,Dermatitis,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q3,Cerebral infarction,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q3,Cholangitis acute,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q3,Cholelithiasis,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q3,Dermatitis,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q3,Cerebral infarction,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q3,Cholangitis acute,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q3,Cholelithiasis,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164604572,16460457,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q3,Dermatitis,,2019,Q3,2,F,20170322.0,20190728.0,20190620,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
164866232,16486623,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1000 MILLIGRAM,,,,,,,,1000.0,MG,,,2019,Q3,Cholelithiasis,,2019,Q3,2,F,20190616.0,20190703.0,20190627,20190708,EXP,,DK-AMGEN-DNKCT2019101669,AMGEN,,59.0,YR,A,M,Y,92.0,KG,20190708.0,,MD,DK,DK,2019,Q3,Adult
164913182,16491318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,5.0,MG,TABLET,,2019,Q3,Cerebral haematoma,,2019,Q3,2,F,20170912.0,20190725.0,20190628,20190731,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004115",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,66.0,KG,20190731.0,,MD,JP,JP,2019,Q3,Elderly
164913182,16491318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,5.0,MG,TABLET,,2019,Q3,Cerebral haemorrhage,,2019,Q3,2,F,20170912.0,20190725.0,20190628,20190731,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004115",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,66.0,KG,20190731.0,,MD,JP,JP,2019,Q3,Elderly
164913182,16491318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,5.0,MG,TABLET,,2019,Q3,Cholelithiasis,,2019,Q3,2,F,20170912.0,20190725.0,20190628,20190731,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004115",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,66.0,KG,20190731.0,,MD,JP,JP,2019,Q3,Elderly
164913182,16491318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,5.0,MG,TABLET,,2019,Q3,Fall,,2019,Q3,2,F,20170912.0,20190725.0,20190628,20190731,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004115",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,66.0,KG,20190731.0,,MD,JP,JP,2019,Q3,Elderly
164913182,16491318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,5.0,MG,TABLET,,2019,Q3,Hypoglycaemia,,2019,Q3,2,F,20170912.0,20190725.0,20190628,20190731,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004115",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,66.0,KG,20190731.0,,MD,JP,JP,2019,Q3,Elderly
165004611,16500461,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,,2019,Q3,Asthma,Asthma,2019,Q3,1,I,,20190620.0,20190701,20190701,EXP,,US-ALVOGEN-2019-ALVOGEN-100345,ALVOGEN,,60.0,YR,,F,Y,140.16,KG,20190701.0,,MD,US,US,2019,Q3,Adult
165004611,16500461,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,,2019,Q3,Breast cancer,Breast cancer,2019,Q3,1,I,,20190620.0,20190701,20190701,EXP,,US-ALVOGEN-2019-ALVOGEN-100345,ALVOGEN,,60.0,YR,,F,Y,140.16,KG,20190701.0,,MD,US,US,2019,Q3,Adult
165004611,16500461,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,,2019,Q3,Hot flush,Hot flush,2019,Q3,1,I,,20190620.0,20190701,20190701,EXP,,US-ALVOGEN-2019-ALVOGEN-100345,ALVOGEN,,60.0,YR,,F,Y,140.16,KG,20190701.0,,MD,US,US,2019,Q3,Adult
165004611,16500461,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,,2019,Q3,Memory impairment,Memory impairment,2019,Q3,1,I,,20190620.0,20190701,20190701,EXP,,US-ALVOGEN-2019-ALVOGEN-100345,ALVOGEN,,60.0,YR,,F,Y,140.16,KG,20190701.0,,MD,US,US,2019,Q3,Adult
165004611,16500461,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,,2019,Q3,Nephrolithiasis,Nephrolithiasis,2019,Q3,1,I,,20190620.0,20190701,20190701,EXP,,US-ALVOGEN-2019-ALVOGEN-100345,ALVOGEN,,60.0,YR,,F,Y,140.16,KG,20190701.0,,MD,US,US,2019,Q3,Adult
165004611,16500461,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,,2019,Q3,Type 2 diabetes mellitus,Type 2 diabetes mellitus,2019,Q3,1,I,,20190620.0,20190701,20190701,EXP,,US-ALVOGEN-2019-ALVOGEN-100345,ALVOGEN,,60.0,YR,,F,Y,140.16,KG,20190701.0,,MD,US,US,2019,Q3,Adult
165004611,16500461,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,,2019,Q3,Vision blurred,Vision blurred,2019,Q3,1,I,,20190620.0,20190701,20190701,EXP,,US-ALVOGEN-2019-ALVOGEN-100345,ALVOGEN,,60.0,YR,,F,Y,140.16,KG,20190701.0,,MD,US,US,2019,Q3,Adult
165004611,16500461,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,,2019,Q3,Visual field defect,Visual field defect,2019,Q3,1,I,,20190620.0,20190701,20190701,EXP,,US-ALVOGEN-2019-ALVOGEN-100345,ALVOGEN,,60.0,YR,,F,Y,140.16,KG,20190701.0,,MD,US,US,2019,Q3,Adult
165010862,16501086,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Cataract diabetic,,2019,Q3,2,F,20170807.0,20190703.0,20190701,20190710,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002912",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,84.3,KG,20190710.0,,MD,JP,JP,2019,Q3,Adult
165010862,16501086,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Diabetes mellitus,,2019,Q3,2,F,20170807.0,20190703.0,20190701,20190710,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002912",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,84.3,KG,20190710.0,,MD,JP,JP,2019,Q3,Adult
165010862,16501086,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Tenosynovitis,,2019,Q3,2,F,20170807.0,20190703.0,20190701,20190710,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002912",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,84.3,KG,20190710.0,,MD,JP,JP,2019,Q3,Adult
165010862,16501086,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Cataract diabetic,,2019,Q3,2,F,20170807.0,20190703.0,20190701,20190710,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002912",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,84.3,KG,20190710.0,,MD,JP,JP,2019,Q3,Adult
165010862,16501086,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Diabetes mellitus,,2019,Q3,2,F,20170807.0,20190703.0,20190701,20190710,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002912",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,84.3,KG,20190710.0,,MD,JP,JP,2019,Q3,Adult
165010862,16501086,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Tenosynovitis,,2019,Q3,2,F,20170807.0,20190703.0,20190701,20190710,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002912",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,84.3,KG,20190710.0,,MD,JP,JP,2019,Q3,Adult
165277424,16527742,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q3,Cardiac failure,,2019,Q3,4,F,,20190805.0,20190703,20190807,EXP,,PHHY2019PL151220,SANDOZ,,56.0,YR,,M,Y,120.0,KG,20190807.0,,OT,PL,PL,2019,Q3,Adult
165277424,16527742,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q3,Cardiac failure chronic,,2019,Q3,4,F,,20190805.0,20190703,20190807,EXP,,PHHY2019PL151220,SANDOZ,,56.0,YR,,M,Y,120.0,KG,20190807.0,,OT,PL,PL,2019,Q3,Adult
165277424,16527742,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q3,Concomitant disease aggravated,,2019,Q3,4,F,,20190805.0,20190703,20190807,EXP,,PHHY2019PL151220,SANDOZ,,56.0,YR,,M,Y,120.0,KG,20190807.0,,OT,PL,PL,2019,Q3,Adult
165277424,16527742,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q3,Condition aggravated,,2019,Q3,4,F,,20190805.0,20190703,20190807,EXP,,PHHY2019PL151220,SANDOZ,,56.0,YR,,M,Y,120.0,KG,20190807.0,,OT,PL,PL,2019,Q3,Adult
165277424,16527742,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,4,F,,20190805.0,20190703,20190807,EXP,,PHHY2019PL151220,SANDOZ,,56.0,YR,,M,Y,120.0,KG,20190807.0,,OT,PL,PL,2019,Q3,Adult
165277424,16527742,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q3,Drug ineffective,,2019,Q3,4,F,,20190805.0,20190703,20190807,EXP,,PHHY2019PL151220,SANDOZ,,56.0,YR,,M,Y,120.0,KG,20190807.0,,OT,PL,PL,2019,Q3,Adult
165277424,16527742,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q3,Respiratory tract infection,,2019,Q3,4,F,,20190805.0,20190703,20190807,EXP,,PHHY2019PL151220,SANDOZ,,56.0,YR,,M,Y,120.0,KG,20190807.0,,OT,PL,PL,2019,Q3,Adult
165277424,16527742,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG/DL, UNK",,,,,,,,,,,,2019,Q3,Cardiac failure,,2019,Q3,4,F,,20190805.0,20190703,20190807,EXP,,PHHY2019PL151220,SANDOZ,,56.0,YR,,M,Y,120.0,KG,20190807.0,,OT,PL,PL,2019,Q3,Adult
165277424,16527742,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG/DL, UNK",,,,,,,,,,,,2019,Q3,Cardiac failure chronic,,2019,Q3,4,F,,20190805.0,20190703,20190807,EXP,,PHHY2019PL151220,SANDOZ,,56.0,YR,,M,Y,120.0,KG,20190807.0,,OT,PL,PL,2019,Q3,Adult
165277424,16527742,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG/DL, UNK",,,,,,,,,,,,2019,Q3,Concomitant disease aggravated,,2019,Q3,4,F,,20190805.0,20190703,20190807,EXP,,PHHY2019PL151220,SANDOZ,,56.0,YR,,M,Y,120.0,KG,20190807.0,,OT,PL,PL,2019,Q3,Adult
165277424,16527742,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG/DL, UNK",,,,,,,,,,,,2019,Q3,Condition aggravated,,2019,Q3,4,F,,20190805.0,20190703,20190807,EXP,,PHHY2019PL151220,SANDOZ,,56.0,YR,,M,Y,120.0,KG,20190807.0,,OT,PL,PL,2019,Q3,Adult
165277424,16527742,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG/DL, UNK",,,,,,,,,,,,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,4,F,,20190805.0,20190703,20190807,EXP,,PHHY2019PL151220,SANDOZ,,56.0,YR,,M,Y,120.0,KG,20190807.0,,OT,PL,PL,2019,Q3,Adult
165277424,16527742,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG/DL, UNK",,,,,,,,,,,,2019,Q3,Drug ineffective,,2019,Q3,4,F,,20190805.0,20190703,20190807,EXP,,PHHY2019PL151220,SANDOZ,,56.0,YR,,M,Y,120.0,KG,20190807.0,,OT,PL,PL,2019,Q3,Adult
165277424,16527742,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG/DL, UNK",,,,,,,,,,,,2019,Q3,Respiratory tract infection,,2019,Q3,4,F,,20190805.0,20190703,20190807,EXP,,PHHY2019PL151220,SANDOZ,,56.0,YR,,M,Y,120.0,KG,20190807.0,,OT,PL,PL,2019,Q3,Adult
165287137,16528713,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Cardiac failure congestive,,2019,Q3,7,F,20190416.0,20190819.0,20190703,20190821,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-026253",BOEHRINGER INGELHEIM,,76.0,YR,,F,Y,108.4,KG,20190821.0,,MD,CA,CA,2019,Q3,Elderly
165287137,16528713,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Urosepsis,,2019,Q3,7,F,20190416.0,20190819.0,20190703,20190821,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-026253",BOEHRINGER INGELHEIM,,76.0,YR,,F,Y,108.4,KG,20190821.0,,MD,CA,CA,2019,Q3,Elderly
1653327110,16533271,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG/DL,,,,,,,,,,,,2019,Q3,Cardiac failure,,2019,Q3,10,F,,20190819.0,20190705,20190821,EXP,,PL-PFIZER INC-2019289284,PFIZER,"KOMOROWSKA, A.. CESSATION OF EMPAGLIFLOZIN TREATMENT IN A HOSPITALISED PATIENT WITH EXACERBATED HEART FAILURE AND REDUCED EJECTION FRACTION. FOLIA CARDIOLOGICA. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20190821.0,,MD,PL,PL,2019,Q3,Adult
1653327110,16533271,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG/DL,,,,,,,,,,,,2019,Q3,Cardiac failure chronic,,2019,Q3,10,F,,20190819.0,20190705,20190821,EXP,,PL-PFIZER INC-2019289284,PFIZER,"KOMOROWSKA, A.. CESSATION OF EMPAGLIFLOZIN TREATMENT IN A HOSPITALISED PATIENT WITH EXACERBATED HEART FAILURE AND REDUCED EJECTION FRACTION. FOLIA CARDIOLOGICA. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20190821.0,,MD,PL,PL,2019,Q3,Adult
1653327110,16533271,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG/DL,,,,,,,,,,,,2019,Q3,Concomitant disease aggravated,,2019,Q3,10,F,,20190819.0,20190705,20190821,EXP,,PL-PFIZER INC-2019289284,PFIZER,"KOMOROWSKA, A.. CESSATION OF EMPAGLIFLOZIN TREATMENT IN A HOSPITALISED PATIENT WITH EXACERBATED HEART FAILURE AND REDUCED EJECTION FRACTION. FOLIA CARDIOLOGICA. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20190821.0,,MD,PL,PL,2019,Q3,Adult
1653327110,16533271,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG/DL,,,,,,,,,,,,2019,Q3,Condition aggravated,,2019,Q3,10,F,,20190819.0,20190705,20190821,EXP,,PL-PFIZER INC-2019289284,PFIZER,"KOMOROWSKA, A.. CESSATION OF EMPAGLIFLOZIN TREATMENT IN A HOSPITALISED PATIENT WITH EXACERBATED HEART FAILURE AND REDUCED EJECTION FRACTION. FOLIA CARDIOLOGICA. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20190821.0,,MD,PL,PL,2019,Q3,Adult
1653327110,16533271,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG/DL,,,,,,,,,,,,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,10,F,,20190819.0,20190705,20190821,EXP,,PL-PFIZER INC-2019289284,PFIZER,"KOMOROWSKA, A.. CESSATION OF EMPAGLIFLOZIN TREATMENT IN A HOSPITALISED PATIENT WITH EXACERBATED HEART FAILURE AND REDUCED EJECTION FRACTION. FOLIA CARDIOLOGICA. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20190821.0,,MD,PL,PL,2019,Q3,Adult
1653327110,16533271,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG/DL,,,,,,,,,,,,2019,Q3,Drug ineffective,,2019,Q3,10,F,,20190819.0,20190705,20190821,EXP,,PL-PFIZER INC-2019289284,PFIZER,"KOMOROWSKA, A.. CESSATION OF EMPAGLIFLOZIN TREATMENT IN A HOSPITALISED PATIENT WITH EXACERBATED HEART FAILURE AND REDUCED EJECTION FRACTION. FOLIA CARDIOLOGICA. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20190821.0,,MD,PL,PL,2019,Q3,Adult
1653327110,16533271,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG/DL,,,,,,,,,,,,2019,Q3,Respiratory tract infection,,2019,Q3,10,F,,20190819.0,20190705,20190821,EXP,,PL-PFIZER INC-2019289284,PFIZER,"KOMOROWSKA, A.. CESSATION OF EMPAGLIFLOZIN TREATMENT IN A HOSPITALISED PATIENT WITH EXACERBATED HEART FAILURE AND REDUCED EJECTION FRACTION. FOLIA CARDIOLOGICA. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20190821.0,,MD,PL,PL,2019,Q3,Adult
1653327110,16533271,19,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q3,Cardiac failure,,2019,Q3,10,F,,20190819.0,20190705,20190821,EXP,,PL-PFIZER INC-2019289284,PFIZER,"KOMOROWSKA, A.. CESSATION OF EMPAGLIFLOZIN TREATMENT IN A HOSPITALISED PATIENT WITH EXACERBATED HEART FAILURE AND REDUCED EJECTION FRACTION. FOLIA CARDIOLOGICA. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20190821.0,,MD,PL,PL,2019,Q3,Adult
1653327110,16533271,19,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q3,Cardiac failure chronic,,2019,Q3,10,F,,20190819.0,20190705,20190821,EXP,,PL-PFIZER INC-2019289284,PFIZER,"KOMOROWSKA, A.. CESSATION OF EMPAGLIFLOZIN TREATMENT IN A HOSPITALISED PATIENT WITH EXACERBATED HEART FAILURE AND REDUCED EJECTION FRACTION. FOLIA CARDIOLOGICA. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20190821.0,,MD,PL,PL,2019,Q3,Adult
1653327110,16533271,19,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q3,Concomitant disease aggravated,,2019,Q3,10,F,,20190819.0,20190705,20190821,EXP,,PL-PFIZER INC-2019289284,PFIZER,"KOMOROWSKA, A.. CESSATION OF EMPAGLIFLOZIN TREATMENT IN A HOSPITALISED PATIENT WITH EXACERBATED HEART FAILURE AND REDUCED EJECTION FRACTION. FOLIA CARDIOLOGICA. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20190821.0,,MD,PL,PL,2019,Q3,Adult
1653327110,16533271,19,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q3,Condition aggravated,,2019,Q3,10,F,,20190819.0,20190705,20190821,EXP,,PL-PFIZER INC-2019289284,PFIZER,"KOMOROWSKA, A.. CESSATION OF EMPAGLIFLOZIN TREATMENT IN A HOSPITALISED PATIENT WITH EXACERBATED HEART FAILURE AND REDUCED EJECTION FRACTION. FOLIA CARDIOLOGICA. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20190821.0,,MD,PL,PL,2019,Q3,Adult
1653327110,16533271,19,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,10,F,,20190819.0,20190705,20190821,EXP,,PL-PFIZER INC-2019289284,PFIZER,"KOMOROWSKA, A.. CESSATION OF EMPAGLIFLOZIN TREATMENT IN A HOSPITALISED PATIENT WITH EXACERBATED HEART FAILURE AND REDUCED EJECTION FRACTION. FOLIA CARDIOLOGICA. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20190821.0,,MD,PL,PL,2019,Q3,Adult
1653327110,16533271,19,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q3,Drug ineffective,,2019,Q3,10,F,,20190819.0,20190705,20190821,EXP,,PL-PFIZER INC-2019289284,PFIZER,"KOMOROWSKA, A.. CESSATION OF EMPAGLIFLOZIN TREATMENT IN A HOSPITALISED PATIENT WITH EXACERBATED HEART FAILURE AND REDUCED EJECTION FRACTION. FOLIA CARDIOLOGICA. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20190821.0,,MD,PL,PL,2019,Q3,Adult
1653327110,16533271,19,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q3,Respiratory tract infection,,2019,Q3,10,F,,20190819.0,20190705,20190821,EXP,,PL-PFIZER INC-2019289284,PFIZER,"KOMOROWSKA, A.. CESSATION OF EMPAGLIFLOZIN TREATMENT IN A HOSPITALISED PATIENT WITH EXACERBATED HEART FAILURE AND REDUCED EJECTION FRACTION. FOLIA CARDIOLOGICA. 2019;14(2):206-212",56.0,YR,,M,Y,120.0,KG,20190821.0,,MD,PL,PL,2019,Q3,Adult
165334872,16533487,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,FILM-COATED TABLET,,2019,Q3,Acute kidney injury,,2019,Q3,2,F,20190318.0,20190809.0,20190704,20190812,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-019290",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,65.0,KG,20190812.0,,MD,BR,BR,2019,Q3,Adult
165334872,16533487,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,FILM-COATED TABLET,,2019,Q3,Dehydration,,2019,Q3,2,F,20190318.0,20190809.0,20190704,20190812,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-019290",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,65.0,KG,20190812.0,,MD,BR,BR,2019,Q3,Adult
165342542,16534254,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q3,Blood glucose increased,,2019,Q3,2,F,,20190625.0,20190705,20190926,EXP,,DK-009507513-1906DNK009957,MERCK,,51.0,YR,,M,Y,,,20190926.0,,OT,DK,DK,2019,Q3,Adult
165342542,16534254,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q3,Decreased appetite,,2019,Q3,2,F,,20190625.0,20190705,20190926,EXP,,DK-009507513-1906DNK009957,MERCK,,51.0,YR,,M,Y,,,20190926.0,,OT,DK,DK,2019,Q3,Adult
165342542,16534254,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q3,Euglycaemic diabetic ketoacidosis,,2019,Q3,2,F,,20190625.0,20190705,20190926,EXP,,DK-009507513-1906DNK009957,MERCK,,51.0,YR,,M,Y,,,20190926.0,,OT,DK,DK,2019,Q3,Adult
165342542,16534254,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q3,Hypotension,,2019,Q3,2,F,,20190625.0,20190705,20190926,EXP,,DK-009507513-1906DNK009957,MERCK,,51.0,YR,,M,Y,,,20190926.0,,OT,DK,DK,2019,Q3,Adult
165342542,16534254,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q3,Metabolic acidosis,,2019,Q3,2,F,,20190625.0,20190705,20190926,EXP,,DK-009507513-1906DNK009957,MERCK,,51.0,YR,,M,Y,,,20190926.0,,OT,DK,DK,2019,Q3,Adult
165342542,16534254,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q3,Nausea,,2019,Q3,2,F,,20190625.0,20190705,20190926,EXP,,DK-009507513-1906DNK009957,MERCK,,51.0,YR,,M,Y,,,20190926.0,,OT,DK,DK,2019,Q3,Adult
165369262,16536926,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Metastases to lymph nodes,,2019,Q3,2,F,20190325.0,20190712.0,20190707,20190716,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-003095",BOEHRINGER INGELHEIM,,79.0,YR,,M,Y,60.8,KG,20190716.0,,MD,JP,JP,2019,Q3,Elderly
165369262,16536926,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Thyroid cancer,,2019,Q3,2,F,20190325.0,20190712.0,20190707,20190716,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-003095",BOEHRINGER INGELHEIM,,79.0,YR,,M,Y,60.8,KG,20190716.0,,MD,JP,JP,2019,Q3,Elderly
165443271,16544327,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2019,Q3,Euglycaemic diabetic ketoacidosis,,2019,Q3,1,I,20190707.0,,20190708,20190708,DIR,,,FDA-CTU,,55.0,YR,,M,N,117.0,KG,20190708.0,N,MD,US,US,2019,Q3,Adult
165517491,16551749,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q3,Pruritus,,2019,Q3,1,I,20190502.0,,20190529,20190529,DIR,,,FDA-CTU,,58.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Adult
165517491,16551749,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q3,Rash,,2019,Q3,1,I,20190502.0,,20190529,20190529,DIR,,,FDA-CTU,,58.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Adult
165517491,16551749,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q3,Urticaria,,2019,Q3,1,I,20190502.0,,20190529,20190529,DIR,,,FDA-CTU,,58.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Adult
165547741,16554774,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,,,,,,,,,QD,2019,Q3,Pruritus,,2019,Q3,1,I,20190502.0,,20190529,20190529,DIR,,,FDA-CTU,,58.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Adult
165547741,16554774,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,,,,,,,,,QD,2019,Q3,Urticaria,,2019,Q3,1,I,20190502.0,,20190529,20190529,DIR,,,FDA-CTU,,58.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Adult
165547891,16554789,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,,,,,,,,,QD,2019,Q3,Blood creatinine increased,,2019,Q3,1,I,20190522.0,,20190529,20190529,DIR,,,FDA-CTU,,82.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Elderly
165547891,16554789,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,,,,,,,,,QD,2019,Q3,Blood urea increased,,2019,Q3,1,I,20190522.0,,20190529,20190529,DIR,,,FDA-CTU,,82.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Elderly
165547891,16554789,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,,,,,,,,,QD,2019,Q3,Dehydration,,2019,Q3,1,I,20190522.0,,20190529,20190529,DIR,,,FDA-CTU,,82.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Elderly
165547891,16554789,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,,,,,,,,,QD,2019,Q3,Pollakiuria,,2019,Q3,1,I,20190522.0,,20190529,20190529,DIR,,,FDA-CTU,,82.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Elderly
165548311,16554831,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,,,,,,,,,QD,2019,Q3,Blood creatinine increased,,2019,Q3,1,I,20190522.0,,20190529,20190529,DIR,,,FDA-CTU,,82.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Elderly
165548311,16554831,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,,,,,,,,,QD,2019,Q3,Blood urea increased,,2019,Q3,1,I,20190522.0,,20190529,20190529,DIR,,,FDA-CTU,,82.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Elderly
165548311,16554831,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,,,,,,,,,QD,2019,Q3,Dehydration,,2019,Q3,1,I,20190522.0,,20190529,20190529,DIR,,,FDA-CTU,,82.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Elderly
165548311,16554831,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,,,,,,,,,QD,2019,Q3,Pollakiuria,,2019,Q3,1,I,20190522.0,,20190529,20190529,DIR,,,FDA-CTU,,82.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Elderly
165570101,16557010,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q3,Dry mouth,,2019,Q3,1,I,20190515.0,,20190529,20190529,DIR,,,FDA-CTU,,58.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Adult
165570101,16557010,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q3,Pollakiuria,,2019,Q3,1,I,20190515.0,,20190529,20190529,DIR,,,FDA-CTU,,58.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Adult
165570271,16557027,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q3,Dry mouth,,2019,Q3,1,I,20190515.0,,20190529,20190529,DIR,,,FDA-CTU,,58.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Adult
165570271,16557027,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q3,Pollakiuria,,2019,Q3,1,I,20190515.0,,20190529,20190529,DIR,,,FDA-CTU,,58.0,YR,,M,N,,,20190529.0,N,PH,US,US,2019,Q3,Adult
165572312,16557231,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Peripheral arterial occlusive disease,,2019,Q3,2,F,201802.0,20190717.0,20190711,20190723,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-003138",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,78.0,KG,20190723.0,,MD,JP,JP,2019,Q3,Elderly
165586222,16558622,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Blood glucose increased,,2019,Q3,2,F,20171108.0,20190712.0,20190711,20190719,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002900",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,75.4,KG,20190719.0,,MD,JP,JP,2019,Q3,Elderly
165586222,16558622,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Colon neoplasm,,2019,Q3,2,F,20171108.0,20190712.0,20190711,20190719,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002900",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,75.4,KG,20190719.0,,MD,JP,JP,2019,Q3,Elderly
165586222,16558622,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Enterostomy,,2019,Q3,2,F,20171108.0,20190712.0,20190711,20190719,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002900",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,75.4,KG,20190719.0,,MD,JP,JP,2019,Q3,Elderly
165586222,16558622,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Post procedural complication,,2019,Q3,2,F,20171108.0,20190712.0,20190711,20190719,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002900",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,75.4,KG,20190719.0,,MD,JP,JP,2019,Q3,Elderly
165586222,16558622,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Suture rupture,,2019,Q3,2,F,20171108.0,20190712.0,20190711,20190719,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002900",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,75.4,KG,20190719.0,,MD,JP,JP,2019,Q3,Elderly
165586222,16558622,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Blood glucose increased,,2019,Q3,2,F,20171108.0,20190712.0,20190711,20190719,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002900",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,75.4,KG,20190719.0,,MD,JP,JP,2019,Q3,Elderly
165586222,16558622,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Colon neoplasm,,2019,Q3,2,F,20171108.0,20190712.0,20190711,20190719,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002900",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,75.4,KG,20190719.0,,MD,JP,JP,2019,Q3,Elderly
165586222,16558622,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Enterostomy,,2019,Q3,2,F,20171108.0,20190712.0,20190711,20190719,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002900",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,75.4,KG,20190719.0,,MD,JP,JP,2019,Q3,Elderly
165586222,16558622,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Post procedural complication,,2019,Q3,2,F,20171108.0,20190712.0,20190711,20190719,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002900",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,75.4,KG,20190719.0,,MD,JP,JP,2019,Q3,Elderly
165586222,16558622,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q3,Suture rupture,,2019,Q3,2,F,20171108.0,20190712.0,20190711,20190719,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002900",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,75.4,KG,20190719.0,,MD,JP,JP,2019,Q3,Elderly
165612442,16561244,2,SS,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2019,Q3,Death,,2019,Q3,2,F,20190627.0,20190725.0,20190711,20190730,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201907004407,ELI LILLY AND CO,,76.0,YR,,F,Y,,,20190730.0,,MD,JP,JP,2019,Q3,Elderly
165612442,16561244,2,SS,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2019,Q3,Decreased appetite,,2019,Q3,2,F,20190627.0,20190725.0,20190711,20190730,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201907004407,ELI LILLY AND CO,,76.0,YR,,F,Y,,,20190730.0,,MD,JP,JP,2019,Q3,Elderly
165612442,16561244,2,SS,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2019,Q3,Nausea,,2019,Q3,2,F,20190627.0,20190725.0,20190711,20190730,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201907004407,ELI LILLY AND CO,,76.0,YR,,F,Y,,,20190730.0,,MD,JP,JP,2019,Q3,Elderly
165618911,16561891,7,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2019,Q3,Chills,,2019,Q3,1,I,,20190708.0,20190711,20190711,EXP,,CA-CELGENEUS-CAN-20190702637,CELGENE,,66.0,YR,,M,Y,,,20190711.0,,OT,CA,CA,2019,Q3,Elderly
165618911,16561891,7,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2019,Q3,Sepsis,,2019,Q3,1,I,,20190708.0,20190711,20190711,EXP,,CA-CELGENEUS-CAN-20190702637,CELGENE,,66.0,YR,,M,Y,,,20190711.0,,OT,CA,CA,2019,Q3,Elderly
165618911,16561891,7,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2019,Q3,Vomiting,,2019,Q3,1,I,,20190708.0,20190711,20190711,EXP,,CA-CELGENEUS-CAN-20190702637,CELGENE,,66.0,YR,,M,Y,,,20190711.0,,OT,CA,CA,2019,Q3,Elderly
165636961,16563696,2,C,empagliflozin/linagliptin,,2,,"10/5 MG/ DAY?EMPAGLIFLOXACIN 10 MG DAILY,",,,U,, UNKNOWN,,,,,,,2019,Q3,Hypertension,,2019,Q3,1,I,201807.0,20180918.0,20190712,20190712,PER,,US-TORRENT-00006989,TORRENT,,75.0,YR,E,F,Y,63.0,KG,20190712.0,,CN,US,US,2019,Q3,Elderly
165636961,16563696,2,C,empagliflozin/linagliptin,,2,,"10/5 MG/ DAY?EMPAGLIFLOXACIN 10 MG DAILY,",,,U,, UNKNOWN,,,,,,,2019,Q3,Syncope,,2019,Q3,1,I,201807.0,20180918.0,20190712,20190712,PER,,US-TORRENT-00006989,TORRENT,,75.0,YR,E,F,Y,63.0,KG,20190712.0,,CN,US,US,2019,Q3,Elderly
165653841,16565384,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2019,Q3,Groin pain,,2019,Q3,1,I,20190702.0,,20190711,20190711,DIR,,,FDA-CTU,,65.0,YR,,F,N,64.3,KG,20190711.0,N,PH,US,US,2019,Q3,Elderly
165653841,16565384,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2019,Q3,Necrotising fasciitis,,2019,Q3,1,I,20190702.0,,20190711,20190711,DIR,,,FDA-CTU,,65.0,YR,,F,N,64.3,KG,20190711.0,N,PH,US,US,2019,Q3,Elderly
165653841,16565384,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2019,Q3,Necrotising soft tissue infection,,2019,Q3,1,I,20190702.0,,20190711,20190711,DIR,,,FDA-CTU,,65.0,YR,,F,N,64.3,KG,20190711.0,N,PH,US,US,2019,Q3,Elderly
165666992,16566699,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Alanine aminotransferase increased,,2019,Q3,2,F,2019.0,20190909.0,20190712,20190913,EXP,,GB-PFIZER INC-2019271284,PFIZER,,74.0,YR,,M,Y,77.0,KG,20190913.0,,MD,GB,GB,2019,Q3,Elderly
165666992,16566699,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Blood alkaline phosphatase increased,,2019,Q3,2,F,2019.0,20190909.0,20190712,20190913,EXP,,GB-PFIZER INC-2019271284,PFIZER,,74.0,YR,,M,Y,77.0,KG,20190913.0,,MD,GB,GB,2019,Q3,Elderly
165666992,16566699,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Blood bilirubin increased,,2019,Q3,2,F,2019.0,20190909.0,20190712,20190913,EXP,,GB-PFIZER INC-2019271284,PFIZER,,74.0,YR,,M,Y,77.0,KG,20190913.0,,MD,GB,GB,2019,Q3,Elderly
165666992,16566699,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Cholelithiasis,,2019,Q3,2,F,2019.0,20190909.0,20190712,20190913,EXP,,GB-PFIZER INC-2019271284,PFIZER,,74.0,YR,,M,Y,77.0,KG,20190913.0,,MD,GB,GB,2019,Q3,Elderly
165666992,16566699,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Diarrhoea,,2019,Q3,2,F,2019.0,20190909.0,20190712,20190913,EXP,,GB-PFIZER INC-2019271284,PFIZER,,74.0,YR,,M,Y,77.0,KG,20190913.0,,MD,GB,GB,2019,Q3,Elderly
165715751,16571575,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,?          QUANTITY:1 TABLET(S);?,,,N,D,,20200318.0,,,,,QD,2019,Q3,Dyspnoea,,2019,Q3,1,I,20190401.0,,20190713,20190713,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20190713.0,N,CN,US,US,2019,Q3,Adult
165715751,16571575,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,?          QUANTITY:1 TABLET(S);?,,,N,D,,20200318.0,,,,,QD,2019,Q3,Thirst,,2019,Q3,1,I,20190401.0,,20190713,20190713,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20190713.0,N,CN,US,US,2019,Q3,Adult
165715751,16571575,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,?          QUANTITY:1 TABLET(S);?,,,N,D,,20200318.0,,,,,QD,2019,Q3,Urinary incontinence,,2019,Q3,1,I,20190401.0,,20190713,20190713,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20190713.0,N,CN,US,US,2019,Q3,Adult
165717761,16571776,11,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Fluid retention,,2019,Q3,1,I,20190711.0,,20190714,20190714,DIR,,,FDA-CTU,,48.0,YR,,M,N,138.0,KG,20190714.0,N,PH,US,US,2019,Q3,Adult
165717761,16571776,11,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Gait inability,,2019,Q3,1,I,20190711.0,,20190714,20190714,DIR,,,FDA-CTU,,48.0,YR,,M,N,138.0,KG,20190714.0,N,PH,US,US,2019,Q3,Adult
165717761,16571776,11,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Hypoaesthesia,,2019,Q3,1,I,20190711.0,,20190714,20190714,DIR,,,FDA-CTU,,48.0,YR,,M,N,138.0,KG,20190714.0,N,PH,US,US,2019,Q3,Adult
165717761,16571776,11,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Oedema peripheral,,2019,Q3,1,I,20190711.0,,20190714,20190714,DIR,,,FDA-CTU,,48.0,YR,,M,N,138.0,KG,20190714.0,N,PH,US,US,2019,Q3,Adult
165717761,16571776,11,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Pain in extremity,,2019,Q3,1,I,20190711.0,,20190714,20190714,DIR,,,FDA-CTU,,48.0,YR,,M,N,138.0,KG,20190714.0,N,PH,US,US,2019,Q3,Adult
165717761,16571776,11,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Paraesthesia,,2019,Q3,1,I,20190711.0,,20190714,20190714,DIR,,,FDA-CTU,,48.0,YR,,M,N,138.0,KG,20190714.0,N,PH,US,US,2019,Q3,Adult
165717761,16571776,11,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Peripheral coldness,,2019,Q3,1,I,20190711.0,,20190714,20190714,DIR,,,FDA-CTU,,48.0,YR,,M,N,138.0,KG,20190714.0,N,PH,US,US,2019,Q3,Adult
165717761,16571776,11,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Peripheral swelling,,2019,Q3,1,I,20190711.0,,20190714,20190714,DIR,,,FDA-CTU,,48.0,YR,,M,N,138.0,KG,20190714.0,N,PH,US,US,2019,Q3,Adult
165717761,16571776,11,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Tenderness,,2019,Q3,1,I,20190711.0,,20190714,20190714,DIR,,,FDA-CTU,,48.0,YR,,M,N,138.0,KG,20190714.0,N,PH,US,US,2019,Q3,Adult
165717761,16571776,11,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Urinary hesitation,,2019,Q3,1,I,20190711.0,,20190714,20190714,DIR,,,FDA-CTU,,48.0,YR,,M,N,138.0,KG,20190714.0,N,PH,US,US,2019,Q3,Adult
165725001,16572500,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q3,Acute kidney injury,,2019,Q3,1,I,20190321.0,,20190531,20190531,DIR,,,FDA-CTU,,68.0,YR,,M,N,72.0,KG,20190420.0,N,PH,US,US,2019,Q3,Elderly
165725001,16572500,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,20190321.0,,20190531,20190531,DIR,,,FDA-CTU,,68.0,YR,,M,N,72.0,KG,20190420.0,N,PH,US,US,2019,Q3,Elderly
165733792,16573379,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Asthma,,2019,Q3,2,F,20110121.0,20190816.0,20190715,20190821,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK140497,GLAXOSMITHKLINE,,41.0,YR,,M,Y,93.0,KG,20190821.0,,MD,CA,CA,2019,Q3,Adult
165733792,16573379,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Blood count abnormal,,2019,Q3,2,F,20110121.0,20190816.0,20190715,20190821,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK140497,GLAXOSMITHKLINE,,41.0,YR,,M,Y,93.0,KG,20190821.0,,MD,CA,CA,2019,Q3,Adult
165733792,16573379,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Bronchial hyperreactivity,,2019,Q3,2,F,20110121.0,20190816.0,20190715,20190821,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK140497,GLAXOSMITHKLINE,,41.0,YR,,M,Y,93.0,KG,20190821.0,,MD,CA,CA,2019,Q3,Adult
165733792,16573379,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Chest discomfort,,2019,Q3,2,F,20110121.0,20190816.0,20190715,20190821,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK140497,GLAXOSMITHKLINE,,41.0,YR,,M,Y,93.0,KG,20190821.0,,MD,CA,CA,2019,Q3,Adult
165733792,16573379,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Cough,,2019,Q3,2,F,20110121.0,20190816.0,20190715,20190821,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK140497,GLAXOSMITHKLINE,,41.0,YR,,M,Y,93.0,KG,20190821.0,,MD,CA,CA,2019,Q3,Adult
165733792,16573379,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Dyspnoea,,2019,Q3,2,F,20110121.0,20190816.0,20190715,20190821,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK140497,GLAXOSMITHKLINE,,41.0,YR,,M,Y,93.0,KG,20190821.0,,MD,CA,CA,2019,Q3,Adult
165733792,16573379,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Forced expiratory volume decreased,,2019,Q3,2,F,20110121.0,20190816.0,20190715,20190821,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK140497,GLAXOSMITHKLINE,,41.0,YR,,M,Y,93.0,KG,20190821.0,,MD,CA,CA,2019,Q3,Adult
165733792,16573379,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Inspiratory capacity decreased,,2019,Q3,2,F,20110121.0,20190816.0,20190715,20190821,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK140497,GLAXOSMITHKLINE,,41.0,YR,,M,Y,93.0,KG,20190821.0,,MD,CA,CA,2019,Q3,Adult
165733792,16573379,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Obstructive airways disorder,,2019,Q3,2,F,20110121.0,20190816.0,20190715,20190821,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK140497,GLAXOSMITHKLINE,,41.0,YR,,M,Y,93.0,KG,20190821.0,,MD,CA,CA,2019,Q3,Adult
165733792,16573379,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Sinusitis,,2019,Q3,2,F,20110121.0,20190816.0,20190715,20190821,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK140497,GLAXOSMITHKLINE,,41.0,YR,,M,Y,93.0,KG,20190821.0,,MD,CA,CA,2019,Q3,Adult
165733792,16573379,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Therapeutic product effect incomplete,,2019,Q3,2,F,20110121.0,20190816.0,20190715,20190821,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK140497,GLAXOSMITHKLINE,,41.0,YR,,M,Y,93.0,KG,20190821.0,,MD,CA,CA,2019,Q3,Adult
165733792,16573379,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Total lung capacity decreased,,2019,Q3,2,F,20110121.0,20190816.0,20190715,20190821,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK140497,GLAXOSMITHKLINE,,41.0,YR,,M,Y,93.0,KG,20190821.0,,MD,CA,CA,2019,Q3,Adult
165733792,16573379,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Weight decreased,,2019,Q3,2,F,20110121.0,20190816.0,20190715,20190821,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK140497,GLAXOSMITHKLINE,,41.0,YR,,M,Y,93.0,KG,20190821.0,,MD,CA,CA,2019,Q3,Adult
165733792,16573379,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2019,Q3,Wheezing,,2019,Q3,2,F,20110121.0,20190816.0,20190715,20190821,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK140497,GLAXOSMITHKLINE,,41.0,YR,,M,Y,93.0,KG,20190821.0,,MD,CA,CA,2019,Q3,Adult
165782942,16578294,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Infection,,2019,Q3,2,F,20171122.0,20190726.0,20190716,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003878",BOEHRINGER INGELHEIM,,70.0,YR,,M,Y,69.8,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
165782942,16578294,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Metastases to liver,,2019,Q3,2,F,20171122.0,20190726.0,20190716,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003878",BOEHRINGER INGELHEIM,,70.0,YR,,M,Y,69.8,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
165782942,16578294,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Rectal cancer stage IV,,2019,Q3,2,F,20171122.0,20190726.0,20190716,20190801,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003878",BOEHRINGER INGELHEIM,,70.0,YR,,M,Y,69.8,KG,20190801.0,,MD,JP,JP,2019,Q3,Elderly
165842111,16584211,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0, TABLET",,,,,,,,10.0,MG,TABLET,QD,2019,Q3,Agitation,,2019,Q3,1,I,,20190708.0,20190717,20190717,EXP,DE-BFARM-19007959,DE-ACCORD-138604,ACCORD,,56.0,YR,A,M,Y,84.0,KG,20190717.0,,MD,DE,DE,2019,Q3,Adult
165842111,16584211,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0, TABLET",,,,,,,,10.0,MG,TABLET,QD,2019,Q3,Depressed level of consciousness,,2019,Q3,1,I,,20190708.0,20190717,20190717,EXP,DE-BFARM-19007959,DE-ACCORD-138604,ACCORD,,56.0,YR,A,M,Y,84.0,KG,20190717.0,,MD,DE,DE,2019,Q3,Adult
165842111,16584211,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0, TABLET",,,,,,,,10.0,MG,TABLET,QD,2019,Q3,General physical health deterioration,,2019,Q3,1,I,,20190708.0,20190717,20190717,EXP,DE-BFARM-19007959,DE-ACCORD-138604,ACCORD,,56.0,YR,A,M,Y,84.0,KG,20190717.0,,MD,DE,DE,2019,Q3,Adult
165842111,16584211,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0, TABLET",,,,,,,,10.0,MG,TABLET,QD,2019,Q3,Product prescribing error,,2019,Q3,1,I,,20190708.0,20190717,20190717,EXP,DE-BFARM-19007959,DE-ACCORD-138604,ACCORD,,56.0,YR,A,M,Y,84.0,KG,20190717.0,,MD,DE,DE,2019,Q3,Adult
165842111,16584211,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0, TABLET",,,,,,,,10.0,MG,TABLET,QD,2019,Q3,Syncope,,2019,Q3,1,I,,20190708.0,20190717,20190717,EXP,DE-BFARM-19007959,DE-ACCORD-138604,ACCORD,,56.0,YR,A,M,Y,84.0,KG,20190717.0,,MD,DE,DE,2019,Q3,Adult
165844041,16584404,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,20190706.0,,20190716,20190716,DIR,,,FDA-CTU,,64.0,YR,,F,N,,,20190716.0,N,PH,US,US,2019,Q3,Adult
165844041,16584404,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q3,Therapy cessation,,2019,Q3,1,I,20190706.0,,20190716,20190716,DIR,,,FDA-CTU,,64.0,YR,,F,N,,,20190716.0,N,PH,US,US,2019,Q3,Adult
165955621,16595562,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0, TABLET",,,,,,,,,,TABLET,,2019,Q3,Haematochezia,,2019,Q3,1,I,20180226.0,20190710.0,20190719,20190719,EXP,DE-BFARM-19008123,DE-ACCORD-138845,ACCORD,,74.0,YR,E,M,Y,89.0,KG,20190719.0,,MD,DE,DE,2019,Q3,Elderly
165955621,16595562,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0, TABLET",,,,,,,,,,TABLET,,2019,Q3,Medication error,,2019,Q3,1,I,20180226.0,20190710.0,20190719,20190719,EXP,DE-BFARM-19008123,DE-ACCORD-138845,ACCORD,,74.0,YR,E,M,Y,89.0,KG,20190719.0,,MD,DE,DE,2019,Q3,Elderly
165981761,16598176,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Lung neoplasm malignant,,2019,Q3,1,I,20190108.0,20190718.0,20190719,20190719,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-003335",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,80.3,KG,20190719.0,,MD,JP,JP,2019,Q3,Elderly
165983522,16598352,4,C,EMPAGLIFLOZIN W/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Cerebral infarction,,2019,Q3,2,F,20190708.0,20190730.0,20190719,20190731,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-003339",BOEHRINGER INGELHEIM,,40.0,YR,,M,Y,,,20190731.0,,MD,JP,JP,2019,Q3,Adult
166066882,16606688,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Urine ketone body present,,2019,Q3,2,F,20190116.0,20190816.0,20190722,20190820,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-003333",BOEHRINGER INGELHEIM,,45.0,YR,,M,Y,87.5,KG,20190820.0,,MD,JP,JP,2019,Q3,Adult
166069631,16606963,14,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0, TABLETS",,,,, UNKNOWN,,,,,TABLET,,2019,Q3,Agitation,,2019,Q3,1,I,,20190711.0,20190722,20190722,EXP,,DE-TEVA-2019-DE-1079304,TEVA,,56.0,YR,,M,Y,84.0,KG,20190722.0,,MD,DE,DE,2019,Q3,Adult
166069631,16606963,14,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0, TABLETS",,,,, UNKNOWN,,,,,TABLET,,2019,Q3,Depressed level of consciousness,,2019,Q3,1,I,,20190711.0,20190722,20190722,EXP,,DE-TEVA-2019-DE-1079304,TEVA,,56.0,YR,,M,Y,84.0,KG,20190722.0,,MD,DE,DE,2019,Q3,Adult
166069631,16606963,14,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0, TABLETS",,,,, UNKNOWN,,,,,TABLET,,2019,Q3,General physical health deterioration,,2019,Q3,1,I,,20190711.0,20190722,20190722,EXP,,DE-TEVA-2019-DE-1079304,TEVA,,56.0,YR,,M,Y,84.0,KG,20190722.0,,MD,DE,DE,2019,Q3,Adult
166069631,16606963,14,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0, TABLETS",,,,, UNKNOWN,,,,,TABLET,,2019,Q3,Product prescribing error,,2019,Q3,1,I,,20190711.0,20190722,20190722,EXP,,DE-TEVA-2019-DE-1079304,TEVA,,56.0,YR,,M,Y,84.0,KG,20190722.0,,MD,DE,DE,2019,Q3,Adult
166069631,16606963,14,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0, TABLETS",,,,, UNKNOWN,,,,,TABLET,,2019,Q3,Syncope,,2019,Q3,1,I,,20190711.0,20190722,20190722,EXP,,DE-TEVA-2019-DE-1079304,TEVA,,56.0,YR,,M,Y,84.0,KG,20190722.0,,MD,DE,DE,2019,Q3,Adult
166069851,16606985,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q3,Agitation,,2019,Q3,1,I,,20190710.0,20190722,20190722,EXP,,DE-APOTEX-2019AP018750,APOTEX,,56.0,YR,,M,Y,,,20190722.0,,CN,DE,DE,2019,Q3,Adult
166069851,16606985,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q3,Depressed level of consciousness,,2019,Q3,1,I,,20190710.0,20190722,20190722,EXP,,DE-APOTEX-2019AP018750,APOTEX,,56.0,YR,,M,Y,,,20190722.0,,CN,DE,DE,2019,Q3,Adult
166069851,16606985,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q3,General physical health deterioration,,2019,Q3,1,I,,20190710.0,20190722,20190722,EXP,,DE-APOTEX-2019AP018750,APOTEX,,56.0,YR,,M,Y,,,20190722.0,,CN,DE,DE,2019,Q3,Adult
166069851,16606985,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q3,Product prescribing error,,2019,Q3,1,I,,20190710.0,20190722,20190722,EXP,,DE-APOTEX-2019AP018750,APOTEX,,56.0,YR,,M,Y,,,20190722.0,,CN,DE,DE,2019,Q3,Adult
166069851,16606985,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2019,Q3,Syncope,,2019,Q3,1,I,,20190710.0,20190722,20190722,EXP,,DE-APOTEX-2019AP018750,APOTEX,,56.0,YR,,M,Y,,,20190722.0,,CN,DE,DE,2019,Q3,Adult
166080062,16608006,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG/DL,,,,,,,,10.0,DF,,,2019,Q3,Cardiac failure chronic,,2019,Q3,2,F,,20190820.0,20190722,20190831,EXP,PL-EMA-20190708-AUTODUP-27056000,PL-ACCORD-139157,ACCORD,,56.0,YR,A,M,Y,120.0,KG,20190831.0,,OT,PL,PL,2019,Q3,Adult
166080062,16608006,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG/DL,,,,,,,,10.0,DF,,,2019,Q3,Concomitant disease aggravated,,2019,Q3,2,F,,20190820.0,20190722,20190831,EXP,PL-EMA-20190708-AUTODUP-27056000,PL-ACCORD-139157,ACCORD,,56.0,YR,A,M,Y,120.0,KG,20190831.0,,OT,PL,PL,2019,Q3,Adult
166080062,16608006,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG/DL,,,,,,,,10.0,DF,,,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,2,F,,20190820.0,20190722,20190831,EXP,PL-EMA-20190708-AUTODUP-27056000,PL-ACCORD-139157,ACCORD,,56.0,YR,A,M,Y,120.0,KG,20190831.0,,OT,PL,PL,2019,Q3,Adult
166080062,16608006,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG/DL,,,,,,,,10.0,DF,,,2019,Q3,Drug ineffective,,2019,Q3,2,F,,20190820.0,20190722,20190831,EXP,PL-EMA-20190708-AUTODUP-27056000,PL-ACCORD-139157,ACCORD,,56.0,YR,A,M,Y,120.0,KG,20190831.0,,OT,PL,PL,2019,Q3,Adult
166080062,16608006,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG/DL,,,,,,,,10.0,DF,,,2019,Q3,Respiratory tract infection,,2019,Q3,2,F,,20190820.0,20190722,20190831,EXP,PL-EMA-20190708-AUTODUP-27056000,PL-ACCORD-139157,ACCORD,,56.0,YR,A,M,Y,120.0,KG,20190831.0,,OT,PL,PL,2019,Q3,Adult
166136831,16613683,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Blood pressure decreased,,2019,Q3,1,I,,20190716.0,20190723,20190723,EXP,,JP-SAKK-2019SA193639AA,SANOFI AVENTIS,"OWADA G, OKANO H, KIMURA Y, YOSHIDA T, NANAO T, FUJIMOTO J, ET AL.. BRIEF REPORT: A CASE OF METFORMIN-ASSOCIATED LACTIC ACIDOSIS SUCCESSFULLY TREATED BY CONTINUOUS RENAL REPLACEMENT THERAPY. JOURNAL OF THE JAPANESE SOCIETY OF INTENSIVE CARE MEDICINE. 2019;26:273-274",63.0,YR,A,F,Y,59.0,KG,20190723.0,,MD,JP,JP,2019,Q3,Adult
166136831,16613683,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Diarrhoea,,2019,Q3,1,I,,20190716.0,20190723,20190723,EXP,,JP-SAKK-2019SA193639AA,SANOFI AVENTIS,"OWADA G, OKANO H, KIMURA Y, YOSHIDA T, NANAO T, FUJIMOTO J, ET AL.. BRIEF REPORT: A CASE OF METFORMIN-ASSOCIATED LACTIC ACIDOSIS SUCCESSFULLY TREATED BY CONTINUOUS RENAL REPLACEMENT THERAPY. JOURNAL OF THE JAPANESE SOCIETY OF INTENSIVE CARE MEDICINE. 2019;26:273-274",63.0,YR,A,F,Y,59.0,KG,20190723.0,,MD,JP,JP,2019,Q3,Adult
166136831,16613683,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Dyspnoea,,2019,Q3,1,I,,20190716.0,20190723,20190723,EXP,,JP-SAKK-2019SA193639AA,SANOFI AVENTIS,"OWADA G, OKANO H, KIMURA Y, YOSHIDA T, NANAO T, FUJIMOTO J, ET AL.. BRIEF REPORT: A CASE OF METFORMIN-ASSOCIATED LACTIC ACIDOSIS SUCCESSFULLY TREATED BY CONTINUOUS RENAL REPLACEMENT THERAPY. JOURNAL OF THE JAPANESE SOCIETY OF INTENSIVE CARE MEDICINE. 2019;26:273-274",63.0,YR,A,F,Y,59.0,KG,20190723.0,,MD,JP,JP,2019,Q3,Adult
166136831,16613683,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Enteritis infectious,,2019,Q3,1,I,,20190716.0,20190723,20190723,EXP,,JP-SAKK-2019SA193639AA,SANOFI AVENTIS,"OWADA G, OKANO H, KIMURA Y, YOSHIDA T, NANAO T, FUJIMOTO J, ET AL.. BRIEF REPORT: A CASE OF METFORMIN-ASSOCIATED LACTIC ACIDOSIS SUCCESSFULLY TREATED BY CONTINUOUS RENAL REPLACEMENT THERAPY. JOURNAL OF THE JAPANESE SOCIETY OF INTENSIVE CARE MEDICINE. 2019;26:273-274",63.0,YR,A,F,Y,59.0,KG,20190723.0,,MD,JP,JP,2019,Q3,Adult
166136831,16613683,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Hypocapnia,,2019,Q3,1,I,,20190716.0,20190723,20190723,EXP,,JP-SAKK-2019SA193639AA,SANOFI AVENTIS,"OWADA G, OKANO H, KIMURA Y, YOSHIDA T, NANAO T, FUJIMOTO J, ET AL.. BRIEF REPORT: A CASE OF METFORMIN-ASSOCIATED LACTIC ACIDOSIS SUCCESSFULLY TREATED BY CONTINUOUS RENAL REPLACEMENT THERAPY. JOURNAL OF THE JAPANESE SOCIETY OF INTENSIVE CARE MEDICINE. 2019;26:273-274",63.0,YR,A,F,Y,59.0,KG,20190723.0,,MD,JP,JP,2019,Q3,Adult
166136831,16613683,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Inflammation,,2019,Q3,1,I,,20190716.0,20190723,20190723,EXP,,JP-SAKK-2019SA193639AA,SANOFI AVENTIS,"OWADA G, OKANO H, KIMURA Y, YOSHIDA T, NANAO T, FUJIMOTO J, ET AL.. BRIEF REPORT: A CASE OF METFORMIN-ASSOCIATED LACTIC ACIDOSIS SUCCESSFULLY TREATED BY CONTINUOUS RENAL REPLACEMENT THERAPY. JOURNAL OF THE JAPANESE SOCIETY OF INTENSIVE CARE MEDICINE. 2019;26:273-274",63.0,YR,A,F,Y,59.0,KG,20190723.0,,MD,JP,JP,2019,Q3,Adult
166136831,16613683,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Lactic acidosis,,2019,Q3,1,I,,20190716.0,20190723,20190723,EXP,,JP-SAKK-2019SA193639AA,SANOFI AVENTIS,"OWADA G, OKANO H, KIMURA Y, YOSHIDA T, NANAO T, FUJIMOTO J, ET AL.. BRIEF REPORT: A CASE OF METFORMIN-ASSOCIATED LACTIC ACIDOSIS SUCCESSFULLY TREATED BY CONTINUOUS RENAL REPLACEMENT THERAPY. JOURNAL OF THE JAPANESE SOCIETY OF INTENSIVE CARE MEDICINE. 2019;26:273-274",63.0,YR,A,F,Y,59.0,KG,20190723.0,,MD,JP,JP,2019,Q3,Adult
166136831,16613683,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Prerenal failure,,2019,Q3,1,I,,20190716.0,20190723,20190723,EXP,,JP-SAKK-2019SA193639AA,SANOFI AVENTIS,"OWADA G, OKANO H, KIMURA Y, YOSHIDA T, NANAO T, FUJIMOTO J, ET AL.. BRIEF REPORT: A CASE OF METFORMIN-ASSOCIATED LACTIC ACIDOSIS SUCCESSFULLY TREATED BY CONTINUOUS RENAL REPLACEMENT THERAPY. JOURNAL OF THE JAPANESE SOCIETY OF INTENSIVE CARE MEDICINE. 2019;26:273-274",63.0,YR,A,F,Y,59.0,KG,20190723.0,,MD,JP,JP,2019,Q3,Adult
166174271,16617427,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2019,Q3,Blood glucose decreased,,2019,Q3,1,I,20180410.0,,20190610,20190610,DIR,,,FDA-CTU,,55.0,YR,,F,N,89.36,KG,20190520.0,N,PH,US,US,2019,Q3,Adult
166174271,16617427,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2019,Q3,Dizziness,,2019,Q3,1,I,20180410.0,,20190610,20190610,DIR,,,FDA-CTU,,55.0,YR,,F,N,89.36,KG,20190520.0,N,PH,US,US,2019,Q3,Adult
166174271,16617427,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2019,Q3,Dysuria,,2019,Q3,1,I,20180410.0,,20190610,20190610,DIR,,,FDA-CTU,,55.0,YR,,F,N,89.36,KG,20190520.0,N,PH,US,US,2019,Q3,Adult
166174271,16617427,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2019,Q3,Fall,,2019,Q3,1,I,20180410.0,,20190610,20190610,DIR,,,FDA-CTU,,55.0,YR,,F,N,89.36,KG,20190520.0,N,PH,US,US,2019,Q3,Adult
166174271,16617427,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2019,Q3,Hand fracture,,2019,Q3,1,I,20180410.0,,20190610,20190610,DIR,,,FDA-CTU,,55.0,YR,,F,N,89.36,KG,20190520.0,N,PH,US,US,2019,Q3,Adult
166182981,16618298,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1X/DAY",,,,,,,,10.0,MG,TABLET,QD,2019,Q3,Agitation,,2019,Q3,1,I,,20190711.0,20190723,20190723,EXP,,DE-PFIZER INC-2019311597,PFIZER,,56.0,YR,,M,Y,84.0,KG,20190723.0,,MD,DE,DE,2019,Q3,Adult
166182981,16618298,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1X/DAY",,,,,,,,10.0,MG,TABLET,QD,2019,Q3,Depressed level of consciousness,,2019,Q3,1,I,,20190711.0,20190723,20190723,EXP,,DE-PFIZER INC-2019311597,PFIZER,,56.0,YR,,M,Y,84.0,KG,20190723.0,,MD,DE,DE,2019,Q3,Adult
166182981,16618298,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1X/DAY",,,,,,,,10.0,MG,TABLET,QD,2019,Q3,General physical health deterioration,,2019,Q3,1,I,,20190711.0,20190723,20190723,EXP,,DE-PFIZER INC-2019311597,PFIZER,,56.0,YR,,M,Y,84.0,KG,20190723.0,,MD,DE,DE,2019,Q3,Adult
166182981,16618298,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1X/DAY",,,,,,,,10.0,MG,TABLET,QD,2019,Q3,Product prescribing error,,2019,Q3,1,I,,20190711.0,20190723,20190723,EXP,,DE-PFIZER INC-2019311597,PFIZER,,56.0,YR,,M,Y,84.0,KG,20190723.0,,MD,DE,DE,2019,Q3,Adult
166182981,16618298,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1X/DAY",,,,,,,,10.0,MG,TABLET,QD,2019,Q3,Syncope,,2019,Q3,1,I,,20190711.0,20190723,20190723,EXP,,DE-PFIZER INC-2019311597,PFIZER,,56.0,YR,,M,Y,84.0,KG,20190723.0,,MD,DE,DE,2019,Q3,Adult
166205601,16620560,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, DAILY",,,,,,,,10.0,MG,TABLET,QD,2019,Q3,Haematochezia,,2019,Q3,1,I,20180226.0,20190711.0,20190723,20190723,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201907009435,ELI LILLY AND CO,,74.0,YR,,M,Y,89.0,KG,20190723.0,,CN,DE,DE,2019,Q3,Elderly
166205601,16620560,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, DAILY",,,,,,,,10.0,MG,TABLET,QD,2019,Q3,Medication error,,2019,Q3,1,I,20180226.0,20190711.0,20190723,20190723,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201907009435,ELI LILLY AND CO,,74.0,YR,,M,Y,89.0,KG,20190723.0,,CN,DE,DE,2019,Q3,Elderly
166214041,16621404,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2019,Q3,Pollakiuria,,2019,Q3,1,I,20190606.0,,20190610,20190610,DIR,,,FDA-CTU,,74.0,YR,,M,N,,,20190607.0,N,PH,US,US,2019,Q3,Elderly
166257811,16625781,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD",200.417,MG,,, UNK,,,10.0,MG,TABLET,QD,2019,Q3,Cardiac failure,,2019,Q3,1,I,20181019.0,20190716.0,20190724,20190724,EXP,GB-MHRA-INP0B459061-F824-4180-9480-DB82B517A0BD,GB-MYLANLABS-2019M1068190,MYLAN,,68.0,YR,,F,Y,82.0,KG,20190724.0,,MD,GB,GB,2019,Q3,Elderly
166257811,16625781,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD",200.417,MG,,, UNK,,,10.0,MG,TABLET,QD,2019,Q3,Dyspnoea,,2019,Q3,1,I,20181019.0,20190716.0,20190724,20190724,EXP,GB-MHRA-INP0B459061-F824-4180-9480-DB82B517A0BD,GB-MYLANLABS-2019M1068190,MYLAN,,68.0,YR,,F,Y,82.0,KG,20190724.0,,MD,GB,GB,2019,Q3,Elderly
166257811,16625781,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD",200.417,MG,,, UNK,,,10.0,MG,TABLET,QD,2019,Q3,Pericardial effusion,,2019,Q3,1,I,20181019.0,20190716.0,20190724,20190724,EXP,GB-MHRA-INP0B459061-F824-4180-9480-DB82B517A0BD,GB-MYLANLABS-2019M1068190,MYLAN,,68.0,YR,,F,Y,82.0,KG,20190724.0,,MD,GB,GB,2019,Q3,Elderly
166302901,16630290,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:TAB;?,,,,,,,,,,TABLET,QD,2019,Q3,Genital rash,,2019,Q3,1,I,20190529.0,,20190612,20190612,DIR,,,FDA-CTU,,64.0,YR,,M,N,90.72,KG,20190611.0,N,PH,US,US,2019,Q3,Adult
166302901,16630290,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:TAB;?,,,,,,,,,,TABLET,QD,2019,Q3,Urinary tract infection,,2019,Q3,1,I,20190529.0,,20190612,20190612,DIR,,,FDA-CTU,,64.0,YR,,M,N,90.72,KG,20190611.0,N,PH,US,US,2019,Q3,Adult
166310781,16631078,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,, UNK,,,,,,,2019,Q3,Cardiac arrest,,2019,Q3,1,I,20190204.0,20190718.0,20190725,20190725,EXP,GB-MHRA-EYC 00194595,GB-MYLANLABS-2019M1068870,MYLAN,,83.0,YR,,F,Y,,,20190725.0,,PH,GB,GB,2019,Q3,Elderly
166310781,16631078,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,, UNK,,,,,,,2019,Q3,Malaise,,2019,Q3,1,I,20190204.0,20190718.0,20190725,20190725,EXP,GB-MHRA-EYC 00194595,GB-MYLANLABS-2019M1068870,MYLAN,,83.0,YR,,F,Y,,,20190725.0,,PH,GB,GB,2019,Q3,Elderly
166310781,16631078,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,, UNK,,,,,,,2019,Q3,Sinus node dysfunction,,2019,Q3,1,I,20190204.0,20190718.0,20190725,20190725,EXP,GB-MHRA-EYC 00194595,GB-MYLANLABS-2019M1068870,MYLAN,,83.0,YR,,F,Y,,,20190725.0,,PH,GB,GB,2019,Q3,Elderly
166336421,16633642,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D, UNKNOWN,,99.0,10.0,MG,,QD,2019,Q3,Fournier's gangrene,,2019,Q3,1,I,20190711.0,,20190725,20190725,DIR,,,FDA-CTU,,51.0,YR,,M,N,149.4,KG,20190725.0,Y,MD,US,US,2019,Q3,Adult
166360061,16636006,3,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNKNOWN,,,Y,,,,,,,,,2019,Q3,Acute kidney injury,,2019,Q3,1,I,,20190716.0,20190726,20190726,EXP,,GR-NOVOPROD-674738,NOVO NORDISK,,55.0,YR,,F,Y,,,20190726.0,,MD,GR,GR,2019,Q3,Adult
166360061,16636006,3,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNKNOWN,,,Y,,,,,,,,,2019,Q3,Dehydration,,2019,Q3,1,I,,20190716.0,20190726,20190726,EXP,,GR-NOVOPROD-674738,NOVO NORDISK,,55.0,YR,,F,Y,,,20190726.0,,MD,GR,GR,2019,Q3,Adult
166360061,16636006,3,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNKNOWN,,,Y,,,,,,,,,2019,Q3,Gastroenteritis,,2019,Q3,1,I,,20190716.0,20190726,20190726,EXP,,GR-NOVOPROD-674738,NOVO NORDISK,,55.0,YR,,F,Y,,,20190726.0,,MD,GR,GR,2019,Q3,Adult
166417582,16641758,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Back pain,,2019,Q3,2,F,201804.0,20190731.0,20190729,20190807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004466",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,69.9,KG,20190807.0,,MD,JP,JP,2019,Q3,Elderly
166417582,16641758,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Chest pain,,2019,Q3,2,F,201804.0,20190731.0,20190729,20190807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004466",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,69.9,KG,20190807.0,,MD,JP,JP,2019,Q3,Elderly
166417582,16641758,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Nasopharyngitis,,2019,Q3,2,F,201804.0,20190731.0,20190729,20190807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004466",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,69.9,KG,20190807.0,,MD,JP,JP,2019,Q3,Elderly
166417582,16641758,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Seasonal allergy,,2019,Q3,2,F,201804.0,20190731.0,20190729,20190807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004466",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,69.9,KG,20190807.0,,MD,JP,JP,2019,Q3,Elderly
166417582,16641758,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Therapeutic product effect incomplete,,2019,Q3,2,F,201804.0,20190731.0,20190729,20190807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004466",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,69.9,KG,20190807.0,,MD,JP,JP,2019,Q3,Elderly
166417582,16641758,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Upper respiratory tract inflammation,,2019,Q3,2,F,201804.0,20190731.0,20190729,20190807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004466",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,69.9,KG,20190807.0,,MD,JP,JP,2019,Q3,Elderly
166459852,16645985,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 DOSAGE FORM, 10 MG/DL",,,,,,,,10.0,DF,,,2019,Q3,Cardiac failure chronic,,2019,Q3,2,F,,20190826.0,20190730,20190910,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20190910.0,,OT,PL,PL,2019,Q3,Adult
166459852,16645985,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 DOSAGE FORM, 10 MG/DL",,,,,,,,10.0,DF,,,2019,Q3,Concomitant disease aggravated,,2019,Q3,2,F,,20190826.0,20190730,20190910,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20190910.0,,OT,PL,PL,2019,Q3,Adult
166459852,16645985,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 DOSAGE FORM, 10 MG/DL",,,,,,,,10.0,DF,,,2019,Q3,Condition aggravated,,2019,Q3,2,F,,20190826.0,20190730,20190910,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20190910.0,,OT,PL,PL,2019,Q3,Adult
166459852,16645985,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 DOSAGE FORM, 10 MG/DL",,,,,,,,10.0,DF,,,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,2,F,,20190826.0,20190730,20190910,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20190910.0,,OT,PL,PL,2019,Q3,Adult
166459852,16645985,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 DOSAGE FORM, 10 MG/DL",,,,,,,,10.0,DF,,,2019,Q3,Drug ineffective,,2019,Q3,2,F,,20190826.0,20190730,20190910,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20190910.0,,OT,PL,PL,2019,Q3,Adult
166459852,16645985,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 DOSAGE FORM, 10 MG/DL",,,,,,,,10.0,DF,,,2019,Q3,Respiratory tract infection,,2019,Q3,2,F,,20190826.0,20190730,20190910,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-215650,RANBAXY,,56.0,YR,,M,Y,,,20190910.0,,OT,PL,PL,2019,Q3,Adult
166464021,16646402,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2019,Q3,Death,,2019,Q3,1,I,201906.0,20190726.0,20190730,20190730,EXP,GB-MHRA-EYC 00203409,GB-GLAXOSMITHKLINE-GB2019135973,GLAXOSMITHKLINE,,55.0,YR,,M,Y,97.0,KG,20190730.0,,OT,GB,GB,2019,Q3,Adult
166496612,16649661,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Transient ischaemic attack,,2019,Q3,2,F,20190620.0,20190819.0,20190730,20190820,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-031033",BOEHRINGER INGELHEIM,,70.0,YR,,F,Y,77.0,KG,20190820.0,,MD,US,US,2019,Q3,Elderly
166496612,16649661,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Vertigo,,2019,Q3,2,F,20190620.0,20190819.0,20190730,20190820,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-031033",BOEHRINGER INGELHEIM,,70.0,YR,,F,Y,77.0,KG,20190820.0,,MD,US,US,2019,Q3,Elderly
166530384,16653038,26,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,TABLETS,QD,2019,Q3,Chronic kidney disease,,2019,Q3,4,F,20190611.0,20190905.0,20190731,20190910,EXP,,US-CELGENEUS-USA-20190710913,CELGENE,,78.0,YR,,F,Y,54.0,KG,20190910.0,,MD,US,US,2019,Q3,Elderly
166530384,16653038,26,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,TABLETS,QD,2019,Q3,Hypercalcaemia,,2019,Q3,4,F,20190611.0,20190905.0,20190731,20190910,EXP,,US-CELGENEUS-USA-20190710913,CELGENE,,78.0,YR,,F,Y,54.0,KG,20190910.0,,MD,US,US,2019,Q3,Elderly
166530384,16653038,26,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,TABLETS,QD,2019,Q3,Plasma cell myeloma,,2019,Q3,4,F,20190611.0,20190905.0,20190731,20190910,EXP,,US-CELGENEUS-USA-20190710913,CELGENE,,78.0,YR,,F,Y,54.0,KG,20190910.0,,MD,US,US,2019,Q3,Elderly
166710822,16671082,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Renal impairment,,2019,Q3,2,F,20180903.0,20190904.0,20190805,20190905,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-032214",BOEHRINGER INGELHEIM,,79.0,YR,,M,Y,111.1,KG,20190905.0,,MD,US,US,2019,Q3,Elderly
166933811,16693381,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",330.0,DF,U,,,,,1.0,DF,,QD,2019,Q3,Rash generalised,,2019,Q3,1,I,20190704.0,20190805.0,20190812,20190812,EXP,,PHHY2019GB182565,SANDOZ,,71.0,YR,,M,Y,145.0,KG,20190812.0,,OT,GB,GB,2019,Q3,Elderly
166950741,16695074,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,,,,,2019,Q3,Fournier's gangrene,,2019,Q3,1,I,,20190807.0,20190813,20190813,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-032819",BOEHRINGER INGELHEIM,"ELSHIMY G, CORREA R, ALSAYED M, JYOTHINAGARAM S. EARLY PRESENTATION OF A RARE COMPLICATION OF SODIUM- GLUCOSE COTRANSPORTER-2 INHIBITORS 10 DAYS AFTER INITIATION: CASE REPORT AND LITERATURE REVIEW. CUREUS. 2019 JUL 19;11(7):.",57.0,YR,,M,Y,192.0,KG,20190813.0,,OT,US,US,2019,Q3,Adult
166961243,16696124,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2019,Q3,Haemorrhage,,2019,Q3,3,F,,20190917.0,20190813,20190920,EXP,,JP-SA-2019SA221878,SANOFI AVENTIS,"YAMAMOTO S., IWAMURO M., MIYAKE M., NISHIMURA N., MIZUNO M., OKADA H.. SEVERE BLEEDING DUE TO CYTOMEGALOVIRUS ESOPHAGITIS IN A PATIENT WITH DIABETES AFTER INTERBODY FUSION SURGERY. INTERNAL MEDICINE (TOKYO, JAPAN). 2019;UNK:UNK",49.0,YR,A,M,Y,,,20190920.0,,MD,JP,JP,2019,Q3,Adult
166961243,16696124,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2019,Q3,Mucosal disorder,,2019,Q3,3,F,,20190917.0,20190813,20190920,EXP,,JP-SA-2019SA221878,SANOFI AVENTIS,"YAMAMOTO S., IWAMURO M., MIYAKE M., NISHIMURA N., MIZUNO M., OKADA H.. SEVERE BLEEDING DUE TO CYTOMEGALOVIRUS ESOPHAGITIS IN A PATIENT WITH DIABETES AFTER INTERBODY FUSION SURGERY. INTERNAL MEDICINE (TOKYO, JAPAN). 2019;UNK:UNK",49.0,YR,A,M,Y,,,20190920.0,,MD,JP,JP,2019,Q3,Adult
167020815,16702081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2019,Q3,Haemorrhage,,2019,Q3,5,F,,20190917.0,20190814,20190930,EXP,,JP-PFIZER INC-2019348002,PFIZER,"YAMAMOTO, S.. SEVERE BLEEDING DUE TO CYTOMEGALOVIRUS ESOPHAGITIS IN A PATIENT WITH DIABETES AFTER INTERBODY FUSION SURGERY. INTERNAL MEDICINE (TOKYO, JAPAN). 2019;10.2169/INTERNALMEDICINE.2908-",49.0,YR,,M,Y,,,20190930.0,,MD,JP,JP,2019,Q3,Adult
167020815,16702081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2019,Q3,Mucosal disorder,,2019,Q3,5,F,,20190917.0,20190814,20190930,EXP,,JP-PFIZER INC-2019348002,PFIZER,"YAMAMOTO, S.. SEVERE BLEEDING DUE TO CYTOMEGALOVIRUS ESOPHAGITIS IN A PATIENT WITH DIABETES AFTER INTERBODY FUSION SURGERY. INTERNAL MEDICINE (TOKYO, JAPAN). 2019;10.2169/INTERNALMEDICINE.2908-",49.0,YR,,M,Y,,,20190930.0,,MD,JP,JP,2019,Q3,Adult
167020815,16702081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2019,Q3,Oesophageal haemorrhage,,2019,Q3,5,F,,20190917.0,20190814,20190930,EXP,,JP-PFIZER INC-2019348002,PFIZER,"YAMAMOTO, S.. SEVERE BLEEDING DUE TO CYTOMEGALOVIRUS ESOPHAGITIS IN A PATIENT WITH DIABETES AFTER INTERBODY FUSION SURGERY. INTERNAL MEDICINE (TOKYO, JAPAN). 2019;10.2169/INTERNALMEDICINE.2908-",49.0,YR,,M,Y,,,20190930.0,,MD,JP,JP,2019,Q3,Adult
167020815,16702081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2019,Q3,Oesophageal ulcer,,2019,Q3,5,F,,20190917.0,20190814,20190930,EXP,,JP-PFIZER INC-2019348002,PFIZER,"YAMAMOTO, S.. SEVERE BLEEDING DUE TO CYTOMEGALOVIRUS ESOPHAGITIS IN A PATIENT WITH DIABETES AFTER INTERBODY FUSION SURGERY. INTERNAL MEDICINE (TOKYO, JAPAN). 2019;10.2169/INTERNALMEDICINE.2908-",49.0,YR,,M,Y,,,20190930.0,,MD,JP,JP,2019,Q3,Adult
167020815,16702081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2019,Q3,Oesophagitis,,2019,Q3,5,F,,20190917.0,20190814,20190930,EXP,,JP-PFIZER INC-2019348002,PFIZER,"YAMAMOTO, S.. SEVERE BLEEDING DUE TO CYTOMEGALOVIRUS ESOPHAGITIS IN A PATIENT WITH DIABETES AFTER INTERBODY FUSION SURGERY. INTERNAL MEDICINE (TOKYO, JAPAN). 2019;10.2169/INTERNALMEDICINE.2908-",49.0,YR,,M,Y,,,20190930.0,,MD,JP,JP,2019,Q3,Adult
167057172,16705717,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Acute coronary syndrome,,2019,Q3,2,F,20180614.0,20190825.0,20190815,20190826,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-003798",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,92.6,KG,20190827.0,,MD,JP,JP,2019,Q3,Elderly
167076881,16707688,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,QD,2019,Q3,Asthenia,,2019,Q3,1,I,20180506.0,20180510.0,20190815,20190815,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2018BDSI0204,BIODELIVERY SCIENCES INTERNATIONAL,,70.0,YR,,M,Y,136.2,KG,20190809.0,,CN,US,US,2019,Q3,Elderly
167076881,16707688,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,QD,2019,Q3,Dyspnoea,,2019,Q3,1,I,20180506.0,20180510.0,20190815,20190815,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2018BDSI0204,BIODELIVERY SCIENCES INTERNATIONAL,,70.0,YR,,M,Y,136.2,KG,20190809.0,,CN,US,US,2019,Q3,Elderly
167076881,16707688,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,QD,2019,Q3,Headache,,2019,Q3,1,I,20180506.0,20180510.0,20190815,20190815,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2018BDSI0204,BIODELIVERY SCIENCES INTERNATIONAL,,70.0,YR,,M,Y,136.2,KG,20190809.0,,CN,US,US,2019,Q3,Elderly
167076881,16707688,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,QD,2019,Q3,Nervousness,,2019,Q3,1,I,20180506.0,20180510.0,20190815,20190815,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2018BDSI0204,BIODELIVERY SCIENCES INTERNATIONAL,,70.0,YR,,M,Y,136.2,KG,20190809.0,,CN,US,US,2019,Q3,Elderly
167076881,16707688,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,QD,2019,Q3,Pain,,2019,Q3,1,I,20180506.0,20180510.0,20190815,20190815,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2018BDSI0204,BIODELIVERY SCIENCES INTERNATIONAL,,70.0,YR,,M,Y,136.2,KG,20190809.0,,CN,US,US,2019,Q3,Elderly
167082962,16708296,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2019,Q3,Cardiac failure,,2019,Q3,2,F,20180908.0,20190825.0,20190816,20190826,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-003802",BOEHRINGER INGELHEIM,,88.0,YR,,F,Y,63.4,KG,20190826.0,,MD,JP,JP,2019,Q3,Elderly
167100284,16710028,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,TABLETS,,2019,Q3,Intestinal haemorrhage,,2019,Q3,4,F,20190805.0,20190923.0,20190816,20190925,EXP,,JP-CELGENEUS-JPN-20190804062,CELGENE,,72.0,YR,,M,Y,64.4,KG,20190925.0,,MD,JP,JP,2019,Q3,Elderly
167102495,16710249,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,Y,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Oedema peripheral,Oedema peripheral,2019,Q3,5,F,20180426.0,20190913.0,20190816,20190918,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-033227",BOEHRINGER INGELHEIM,,55.0,YR,,M,Y,83.0,KG,20190918.0,,MD,MX,MX,2019,Q3,Adult
167102495,16710249,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,Y,,,204629.0,,,FILM-COATED TABLET,,2019,Q3,Oedema peripheral,Oedema peripheral,2019,Q3,5,F,20180426.0,20190913.0,20190816,20190918,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-033227",BOEHRINGER INGELHEIM,,55.0,YR,,M,Y,83.0,KG,20190918.0,,MD,MX,MX,2019,Q3,Adult
167145002,16714500,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2019,Q3,Haemorrhage,,2019,Q3,2,F,,20190808.0,20190819,20190819,EXP,,JP-ACCORD-151913,ACCORD,"YAMAMOTO S, IWAMURO M, MIYAKE M, NISHIMURA N, MIZUNO M, OKADA H. SEVERE BLEEDING DUE TO CYTOMEGALOVIRUS ESOPHAGITIS IN A PATIENT WITH DIABETES AFTER INTERBODY FUSION SURGERY. INTERNAL MEDICINE (TOKYO, JAPAN). 2019.",49.0,YR,,M,Y,,,20190819.0,,MD,JP,JP,2019,Q3,Adult
167145002,16714500,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2019,Q3,Mucosal disorder,,2019,Q3,2,F,,20190808.0,20190819,20190819,EXP,,JP-ACCORD-151913,ACCORD,"YAMAMOTO S, IWAMURO M, MIYAKE M, NISHIMURA N, MIZUNO M, OKADA H. SEVERE BLEEDING DUE TO CYTOMEGALOVIRUS ESOPHAGITIS IN A PATIENT WITH DIABETES AFTER INTERBODY FUSION SURGERY. INTERNAL MEDICINE (TOKYO, JAPAN). 2019.",49.0,YR,,M,Y,,,20190819.0,,MD,JP,JP,2019,Q3,Adult
167148234,16714823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Pancreatitis,,2019,Q3,4,F,20190515.0,20190822.0,20190819,20190827,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-033229",BOEHRINGER INGELHEIM,,55.0,YR,,M,Y,135.0,KG,20190827.0,,MD,US,US,2019,Q3,Adult
167192921,16719292,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190808.0,20190820,20190820,EXP,,ES-BAUSCH-BL-2019-023037,BAUSCH AND LOMB,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURRENT DIABETES REVIEWS. 2019;15(04):259-262. DOI:10.2174/1573399814666180726114044",52.0,YR,,M,Y,70.0,KG,20190820.0,,OT,ES,ES,2019,Q3,Adult
167203601,16720360,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,,,,,,25.0,MG,,QD,2019,Q3,Gastrooesophageal reflux disease,,2019,Q3,1,I,201907.0,20190813.0,20190820,20190820,EXP,,MX-NOVOPROD-679957,NOVO NORDISK,,47.0,YR,,F,Y,104.0,KG,20190820.0,,CN,MX,MX,2019,Q3,Adult
167203601,16720360,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,,,,,,25.0,MG,,QD,2019,Q3,Taste disorder,,2019,Q3,1,I,201907.0,20190813.0,20190820,20190820,EXP,,MX-NOVOPROD-679957,NOVO NORDISK,,47.0,YR,,F,Y,104.0,KG,20190820.0,,CN,MX,MX,2019,Q3,Adult
167208721,16720872,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190813.0,20190820,20190820,EXP,,ES-MYLANLABS-2019M1077139,MYLAN,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURR-DIABET-REV 2019;15(4):259-262.",52.0,YR,,M,Y,70.0,KG,20190820.0,,OT,ES,ES,2019,Q3,Adult
167229931,16722993,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2019,Q3,Haemorrhage,,2019,Q3,1,I,,20190808.0,20190821,20190821,EXP,JP-MLMSERVICE-20190802-1879944-1,JP-LUPIN PHARMACEUTICALS INC.-2019-05233,LUPIN,,49.0,YR,,M,Y,,,20190821.0,,OT,JP,JP,2019,Q3,Adult
167229931,16722993,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2019,Q3,Mucosal disorder,,2019,Q3,1,I,,20190808.0,20190821,20190821,EXP,JP-MLMSERVICE-20190802-1879944-1,JP-LUPIN PHARMACEUTICALS INC.-2019-05233,LUPIN,,49.0,YR,,M,Y,,,20190821.0,,OT,JP,JP,2019,Q3,Adult
167246041,16724604,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Renal impairment,,2019,Q3,1,I,20190314.0,,20190704,20190704,DIR,,,FDA-CTU,,62.0,YR,,M,N,,,20190517.0,N,PH,US,US,2019,Q3,Adult
167251881,16725188,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2019,Q3,Euglycaemic diabetic ketoacidosis,,2019,Q3,1,I,20190617.0,,20190704,20190704,DIR,,,FDA-CTU,,64.0,YR,,M,N,116.0,KG,20190619.0,N,PH,US,US,2019,Q3,Adult
167261381,16726138,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,330.0,DF,,," UNKNOWN,UNKNOWN",,,1.0,DF,,,2019,Q3,Rash generalised,,2019,Q3,1,I,20190704.0,20190814.0,20190821,20190821,EXP,GB-MHRA-TPP25652474C5314990YC1563261007240,GB-TEVA-2019-GB-1093936,TEVA,,71.0,YR,,M,Y,145.0,KG,20190821.0,,OT,GB,GB,2019,Q3,Elderly
167277671,16727767,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,IN THE MORNING.,,,,,,,,25.0,MG,TABLET,,2019,Q3,Dyspnoea,,2019,Q3,1,I,20190416.0,20190816.0,20190822,20190822,EXP,GB-MHRA-ADR 24410679,GB-ACCORD-152269,ACCORD,,69.0,YR,,F,Y,,,20190822.0,,PH,GB,GB,2019,Q3,Elderly
167277671,16727767,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,IN THE MORNING.,,,,,,,,25.0,MG,TABLET,,2019,Q3,Interstitial lung disease,,2019,Q3,1,I,20190416.0,20190816.0,20190822,20190822,EXP,GB-MHRA-ADR 24410679,GB-ACCORD-152269,ACCORD,,69.0,YR,,F,Y,,,20190822.0,,PH,GB,GB,2019,Q3,Elderly
167277671,16727767,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,IN THE MORNING.,,,,,,,,25.0,MG,TABLET,,2019,Q3,Left ventricular dysfunction,,2019,Q3,1,I,20190416.0,20190816.0,20190822,20190822,EXP,GB-MHRA-ADR 24410679,GB-ACCORD-152269,ACCORD,,69.0,YR,,F,Y,,,20190822.0,,PH,GB,GB,2019,Q3,Elderly
167281611,16728161,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2019,Q3,Diabetic foot infection,,2019,Q3,1,I,20190411.0,,20190704,20190704,DIR,,,FDA-CTU,,66.0,YR,,M,N,121.0,KG,20190628.0,N,PH,US,US,2019,Q3,Elderly
167322001,16732200,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,152.958,DF,,,,,,,,,,2019,Q3,Confusional state,,2019,Q3,1,I,20190701.0,20190816.0,20190822,20190822,EXP,GB-MHRA-TPP979367C579002YC1561971754336,GB-GILEAD-2019-0424575,GILEAD,,75.0,YR,E,M,Y,94.0,KG,20190822.0,,MD,GB,GB,2019,Q3,Elderly
167322001,16732200,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,152.958,DF,,,,,,,,,,2019,Q3,Dizziness,,2019,Q3,1,I,20190701.0,20190816.0,20190822,20190822,EXP,GB-MHRA-TPP979367C579002YC1561971754336,GB-GILEAD-2019-0424575,GILEAD,,75.0,YR,E,M,Y,94.0,KG,20190822.0,,MD,GB,GB,2019,Q3,Elderly
167322001,16732200,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,152.958,DF,,,,,,,,,,2019,Q3,Malaise,,2019,Q3,1,I,20190701.0,20190816.0,20190822,20190822,EXP,GB-MHRA-TPP979367C579002YC1561971754336,GB-GILEAD-2019-0424575,GILEAD,,75.0,YR,E,M,Y,94.0,KG,20190822.0,,MD,GB,GB,2019,Q3,Elderly
167323032,16732303,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Abdominal pain,,2019,Q3,2,F,,20190829.0,20190822,20190829,EXP,,PHHY2019ES191983,SANDOZ,,52.0,YR,,M,Y,70.0,KG,20190829.0,,OT,ES,ES,2019,Q3,Adult
167323032,16732303,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Acute kidney injury,,2019,Q3,2,F,,20190829.0,20190822,20190829,EXP,,PHHY2019ES191983,SANDOZ,,52.0,YR,,M,Y,70.0,KG,20190829.0,,OT,ES,ES,2019,Q3,Adult
167323032,16732303,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,2,F,,20190829.0,20190822,20190829,EXP,,PHHY2019ES191983,SANDOZ,,52.0,YR,,M,Y,70.0,KG,20190829.0,,OT,ES,ES,2019,Q3,Adult
167323032,16732303,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Dyspnoea,,2019,Q3,2,F,,20190829.0,20190822,20190829,EXP,,PHHY2019ES191983,SANDOZ,,52.0,YR,,M,Y,70.0,KG,20190829.0,,OT,ES,ES,2019,Q3,Adult
167323032,16732303,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Hyperglycaemia,,2019,Q3,2,F,,20190829.0,20190822,20190829,EXP,,PHHY2019ES191983,SANDOZ,,52.0,YR,,M,Y,70.0,KG,20190829.0,,OT,ES,ES,2019,Q3,Adult
167323032,16732303,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Hypokalaemia,,2019,Q3,2,F,,20190829.0,20190822,20190829,EXP,,PHHY2019ES191983,SANDOZ,,52.0,YR,,M,Y,70.0,KG,20190829.0,,OT,ES,ES,2019,Q3,Adult
167323032,16732303,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Leukocytosis,,2019,Q3,2,F,,20190829.0,20190822,20190829,EXP,,PHHY2019ES191983,SANDOZ,,52.0,YR,,M,Y,70.0,KG,20190829.0,,OT,ES,ES,2019,Q3,Adult
167323032,16732303,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Mental status changes,,2019,Q3,2,F,,20190829.0,20190822,20190829,EXP,,PHHY2019ES191983,SANDOZ,,52.0,YR,,M,Y,70.0,KG,20190829.0,,OT,ES,ES,2019,Q3,Adult
167323032,16732303,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Metabolic acidosis,,2019,Q3,2,F,,20190829.0,20190822,20190829,EXP,,PHHY2019ES191983,SANDOZ,,52.0,YR,,M,Y,70.0,KG,20190829.0,,OT,ES,ES,2019,Q3,Adult
167323032,16732303,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Nausea,,2019,Q3,2,F,,20190829.0,20190822,20190829,EXP,,PHHY2019ES191983,SANDOZ,,52.0,YR,,M,Y,70.0,KG,20190829.0,,OT,ES,ES,2019,Q3,Adult
167323032,16732303,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Neutrophilia,,2019,Q3,2,F,,20190829.0,20190822,20190829,EXP,,PHHY2019ES191983,SANDOZ,,52.0,YR,,M,Y,70.0,KG,20190829.0,,OT,ES,ES,2019,Q3,Adult
167323032,16732303,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Therapeutic response decreased,,2019,Q3,2,F,,20190829.0,20190822,20190829,EXP,,PHHY2019ES191983,SANDOZ,,52.0,YR,,M,Y,70.0,KG,20190829.0,,OT,ES,ES,2019,Q3,Adult
167323032,16732303,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Vomiting,,2019,Q3,2,F,,20190829.0,20190822,20190829,EXP,,PHHY2019ES191983,SANDOZ,,52.0,YR,,M,Y,70.0,KG,20190829.0,,OT,ES,ES,2019,Q3,Adult
167370881,16737088,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD(IN THE MORNING.)",,,U,,,,,25.0,MG,TABLET,QD,2019,Q3,Dyspnoea,,2019,Q3,1,I,20190416.0,20190819.0,20190823,20190823,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,PHHY2019GB194093,SANDOZ,,69.0,YR,,F,Y,,,20190823.0,,OT,GB,GB,2019,Q3,Elderly
167370881,16737088,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD(IN THE MORNING.)",,,U,,,,,25.0,MG,TABLET,QD,2019,Q3,Interstitial lung disease,,2019,Q3,1,I,20190416.0,20190819.0,20190823,20190823,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,PHHY2019GB194093,SANDOZ,,69.0,YR,,F,Y,,,20190823.0,,OT,GB,GB,2019,Q3,Elderly
167370881,16737088,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD(IN THE MORNING.)",,,U,,,,,25.0,MG,TABLET,QD,2019,Q3,Left ventricular dysfunction,,2019,Q3,1,I,20190416.0,20190819.0,20190823,20190823,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,PHHY2019GB194093,SANDOZ,,69.0,YR,,F,Y,,,20190823.0,,OT,GB,GB,2019,Q3,Elderly
167384522,16738452,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Blood glucose increased,,2019,Q3,2,F,20160507.0,20190915.0,20190826,20190920,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004279",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,79.3,KG,20190920.0,,MD,JP,JP,2019,Q3,Elderly
167384522,16738452,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Blood pressure increased,,2019,Q3,2,F,20160507.0,20190915.0,20190826,20190920,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004279",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,79.3,KG,20190920.0,,MD,JP,JP,2019,Q3,Elderly
167384522,16738452,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Diabetic ketosis,,2019,Q3,2,F,20160507.0,20190915.0,20190826,20190920,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004279",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,79.3,KG,20190920.0,,MD,JP,JP,2019,Q3,Elderly
167384522,16738452,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Pruritus,,2019,Q3,2,F,20160507.0,20190915.0,20190826,20190920,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004279",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,79.3,KG,20190920.0,,MD,JP,JP,2019,Q3,Elderly
167384522,16738452,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Blood glucose increased,,2019,Q3,2,F,20160507.0,20190915.0,20190826,20190920,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004279",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,79.3,KG,20190920.0,,MD,JP,JP,2019,Q3,Elderly
167384522,16738452,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Blood pressure increased,,2019,Q3,2,F,20160507.0,20190915.0,20190826,20190920,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004279",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,79.3,KG,20190920.0,,MD,JP,JP,2019,Q3,Elderly
167384522,16738452,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Diabetic ketosis,,2019,Q3,2,F,20160507.0,20190915.0,20190826,20190920,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004279",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,79.3,KG,20190920.0,,MD,JP,JP,2019,Q3,Elderly
167384522,16738452,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,TABLET,,2019,Q3,Pruritus,,2019,Q3,2,F,20160507.0,20190915.0,20190826,20190920,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004279",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,79.3,KG,20190920.0,,MD,JP,JP,2019,Q3,Elderly
167385031,16738503,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,20 MG PER DAY,,,,,,,,,,,,2019,Q3,Gastrointestinal disorder,,2019,Q3,1,I,,20190131.0,20190826,20190826,PER,,US-STRIDES ARCOLAB LIMITED-2019SP000978,STRIDES,"JIALAL I, SINGH R. ORAL PHARMACOTHERAPY AS ALTERNATIVE TREATMENT FOR TYPE 2 DIABETES MELLITUS IN A 61 YEAR OLD ETHNIC FILIPINO MAN WITH INSULIN ALLERGIES. LAB-MED. 2019;50(1):93-95",61.0,YR,,M,Y,,,20190826.0,,MD,US,US,2019,Q3,Adult
167385031,16738503,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,TITRATED UP TO 25 MG PER DAY,,,,,,,,,,,,2019,Q3,Gastrointestinal disorder,,2019,Q3,1,I,,20190131.0,20190826,20190826,PER,,US-STRIDES ARCOLAB LIMITED-2019SP000978,STRIDES,"JIALAL I, SINGH R. ORAL PHARMACOTHERAPY AS ALTERNATIVE TREATMENT FOR TYPE 2 DIABETES MELLITUS IN A 61 YEAR OLD ETHNIC FILIPINO MAN WITH INSULIN ALLERGIES. LAB-MED. 2019;50(1):93-95",61.0,YR,,M,Y,,,20190826.0,,MD,US,US,2019,Q3,Adult
167396931,16739693,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,IN THE MORNING,,,U,,,,,25.0,MG,TABLET,,2019,Q3,Dyspnoea,,2019,Q3,1,I,20190416.0,20190820.0,20190826,20190826,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-TORRENT-00021675,TORRENT,,69.0,YR,E,F,Y,,,20190826.0,,PH,GB,GB,2019,Q3,Elderly
167396931,16739693,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,IN THE MORNING,,,U,,,,,25.0,MG,TABLET,,2019,Q3,Interstitial lung disease,,2019,Q3,1,I,20190416.0,20190820.0,20190826,20190826,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-TORRENT-00021675,TORRENT,,69.0,YR,E,F,Y,,,20190826.0,,PH,GB,GB,2019,Q3,Elderly
167396931,16739693,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,IN THE MORNING,,,U,,,,,25.0,MG,TABLET,,2019,Q3,Left ventricular dysfunction,,2019,Q3,1,I,20190416.0,20190820.0,20190826,20190826,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-TORRENT-00021675,TORRENT,,69.0,YR,E,F,Y,,,20190826.0,,PH,GB,GB,2019,Q3,Elderly
167397972,16739797,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 MG, DAILY",,,,,,,,25.0,MG,TABLET,QD,2019,Q3,Cardiac disorder,,2019,Q3,2,F,,20190904.0,20190826,20190910,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201908010055,ELI LILLY AND CO,,73.0,YR,,F,Y,,,20190910.0,,CN,JP,JP,2019,Q3,Elderly
167418671,16741867,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Acute kidney injury,,2019,Q3,1,I,,20190822.0,20190826,20190826,EXP,,PT-MYLANLABS-2019M1079326,MYLAN,"GOUVEIA C, DUQUE S, CAMPOS L.. HYPOVOLEMIC LIPOTHYMIA - A CASE OF IATROGENIC TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-74",71.0,YR,,M,Y,,,20190826.0,,MD,PT,PT,2019,Q3,Elderly
167418671,16741867,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Hypovolaemia,,2019,Q3,1,I,,20190822.0,20190826,20190826,EXP,,PT-MYLANLABS-2019M1079326,MYLAN,"GOUVEIA C, DUQUE S, CAMPOS L.. HYPOVOLEMIC LIPOTHYMIA - A CASE OF IATROGENIC TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-74",71.0,YR,,M,Y,,,20190826.0,,MD,PT,PT,2019,Q3,Elderly
167418671,16741867,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Presyncope,,2019,Q3,1,I,,20190822.0,20190826,20190826,EXP,,PT-MYLANLABS-2019M1079326,MYLAN,"GOUVEIA C, DUQUE S, CAMPOS L.. HYPOVOLEMIC LIPOTHYMIA - A CASE OF IATROGENIC TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-74",71.0,YR,,M,Y,,,20190826.0,,MD,PT,PT,2019,Q3,Elderly
167421762,16742176,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Acidosis,,2019,Q3,2,F,,20190903.0,20190826,20190909,EXP,,PT-MYLANLABS-2019M1078474,MYLAN,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL.. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190909.0,,OT,PT,PT,2019,Q3,Elderly
167421762,16742176,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Acute kidney injury,,2019,Q3,2,F,,20190903.0,20190826,20190909,EXP,,PT-MYLANLABS-2019M1078474,MYLAN,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL.. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190909.0,,OT,PT,PT,2019,Q3,Elderly
167421762,16742176,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,C-reactive protein increased,,2019,Q3,2,F,,20190903.0,20190826,20190909,EXP,,PT-MYLANLABS-2019M1078474,MYLAN,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL.. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190909.0,,OT,PT,PT,2019,Q3,Elderly
167421762,16742176,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Euglycaemic diabetic ketoacidosis,,2019,Q3,2,F,,20190903.0,20190826,20190909,EXP,,PT-MYLANLABS-2019M1078474,MYLAN,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL.. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190909.0,,OT,PT,PT,2019,Q3,Elderly
167421762,16742176,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Food intolerance,,2019,Q3,2,F,,20190903.0,20190826,20190909,EXP,,PT-MYLANLABS-2019M1078474,MYLAN,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL.. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190909.0,,OT,PT,PT,2019,Q3,Elderly
167421762,16742176,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Glycosuria,,2019,Q3,2,F,,20190903.0,20190826,20190909,EXP,,PT-MYLANLABS-2019M1078474,MYLAN,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL.. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190909.0,,OT,PT,PT,2019,Q3,Elderly
167421762,16742176,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Hypokalaemia,,2019,Q3,2,F,,20190903.0,20190826,20190909,EXP,,PT-MYLANLABS-2019M1078474,MYLAN,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL.. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190909.0,,OT,PT,PT,2019,Q3,Elderly
167421762,16742176,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Hypophosphataemia,,2019,Q3,2,F,,20190903.0,20190826,20190909,EXP,,PT-MYLANLABS-2019M1078474,MYLAN,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL.. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190909.0,,OT,PT,PT,2019,Q3,Elderly
167421762,16742176,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Ketonuria,,2019,Q3,2,F,,20190903.0,20190826,20190909,EXP,,PT-MYLANLABS-2019M1078474,MYLAN,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL.. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190909.0,,OT,PT,PT,2019,Q3,Elderly
167421762,16742176,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Leukocytosis,,2019,Q3,2,F,,20190903.0,20190826,20190909,EXP,,PT-MYLANLABS-2019M1078474,MYLAN,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL.. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190909.0,,OT,PT,PT,2019,Q3,Elderly
167421762,16742176,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Metabolic acidosis,,2019,Q3,2,F,,20190903.0,20190826,20190909,EXP,,PT-MYLANLABS-2019M1078474,MYLAN,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL.. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190909.0,,OT,PT,PT,2019,Q3,Elderly
167421762,16742176,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Nausea,,2019,Q3,2,F,,20190903.0,20190826,20190909,EXP,,PT-MYLANLABS-2019M1078474,MYLAN,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL.. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190909.0,,OT,PT,PT,2019,Q3,Elderly
167421762,16742176,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Neutrophilia,,2019,Q3,2,F,,20190903.0,20190826,20190909,EXP,,PT-MYLANLABS-2019M1078474,MYLAN,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL.. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190909.0,,OT,PT,PT,2019,Q3,Elderly
167421762,16742176,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Vomiting,,2019,Q3,2,F,,20190903.0,20190826,20190909,EXP,,PT-MYLANLABS-2019M1078474,MYLAN,"PEREIRA F G, PINTO J, MEIRELES D, ALMEIDA P, PINHEIRO B, ARAUJO A R, ET.AL.. EUGLICAEMIC DIABETIC KETOACIDOSIS: SGLT2 INHIBITORS MAY BE GUILTY.. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1SUPPL):47-122",70.0,YR,,M,Y,,,20190909.0,,OT,PT,PT,2019,Q3,Elderly
167446951,16744695,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Acute kidney injury,,2019,Q3,1,I,2019.0,20190820.0,20190827,20190827,EXP,,PT-MYLANLABS-2019M1078968,MYLAN,"GOUVEIA C. C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,,M,Y,,,20190827.0,,MD,PT,PT,2019,Q3,Elderly
167446951,16744695,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Bradycardia,,2019,Q3,1,I,2019.0,20190820.0,20190827,20190827,EXP,,PT-MYLANLABS-2019M1078968,MYLAN,"GOUVEIA C. C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,,M,Y,,,20190827.0,,MD,PT,PT,2019,Q3,Elderly
167446951,16744695,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Hypotension,,2019,Q3,1,I,2019.0,20190820.0,20190827,20190827,EXP,,PT-MYLANLABS-2019M1078968,MYLAN,"GOUVEIA C. C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,,M,Y,,,20190827.0,,MD,PT,PT,2019,Q3,Elderly
167446951,16744695,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Hypovolaemia,,2019,Q3,1,I,2019.0,20190820.0,20190827,20190827,EXP,,PT-MYLANLABS-2019M1078968,MYLAN,"GOUVEIA C. C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,,M,Y,,,20190827.0,,MD,PT,PT,2019,Q3,Elderly
167446951,16744695,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Presyncope,,2019,Q3,1,I,2019.0,20190820.0,20190827,20190827,EXP,,PT-MYLANLABS-2019M1078968,MYLAN,"GOUVEIA C. C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):74-P050",71.0,YR,,M,Y,,,20190827.0,,MD,PT,PT,2019,Q3,Elderly
167449741,16744974,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD",,,,,,,,25.0,MG,TABLET,QD,2019,Q3,Dyspnoea,,2019,Q3,1,I,20190416.0,20190820.0,20190827,20190827,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-TAKEDA-2019TEU009912,TAKEDA,,69.0,YR,,F,Y,,,20190827.0,,OT,GB,GB,2019,Q3,Elderly
167449741,16744974,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD",,,,,,,,25.0,MG,TABLET,QD,2019,Q3,Interstitial lung disease,,2019,Q3,1,I,20190416.0,20190820.0,20190827,20190827,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-TAKEDA-2019TEU009912,TAKEDA,,69.0,YR,,F,Y,,,20190827.0,,OT,GB,GB,2019,Q3,Elderly
167449741,16744974,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD",,,,,,,,25.0,MG,TABLET,QD,2019,Q3,Left ventricular dysfunction,,2019,Q3,1,I,20190416.0,20190820.0,20190827,20190827,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-TAKEDA-2019TEU009912,TAKEDA,,69.0,YR,,F,Y,,,20190827.0,,OT,GB,GB,2019,Q3,Elderly
167516861,16751686,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,IN THE MORNING.,,,,,,,,25.0,MG,TABLET,QD,2019,Q3,Dyspnoea,,2019,Q3,1,I,20190416.0,20190817.0,20190828,20190828,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-BAUSCH-BL-2019-024009,BAUSCH AND LOMB,,69.0,YR,,F,Y,,,20190828.0,,PH,GB,GB,2019,Q3,Elderly
167516861,16751686,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,IN THE MORNING.,,,,,,,,25.0,MG,TABLET,QD,2019,Q3,Interstitial lung disease,,2019,Q3,1,I,20190416.0,20190817.0,20190828,20190828,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-BAUSCH-BL-2019-024009,BAUSCH AND LOMB,,69.0,YR,,F,Y,,,20190828.0,,PH,GB,GB,2019,Q3,Elderly
167516861,16751686,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,IN THE MORNING.,,,,,,,,25.0,MG,TABLET,QD,2019,Q3,Left ventricular dysfunction,,2019,Q3,1,I,20190416.0,20190817.0,20190828,20190828,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-BAUSCH-BL-2019-024009,BAUSCH AND LOMB,,69.0,YR,,F,Y,,,20190828.0,,PH,GB,GB,2019,Q3,Elderly
167596371,16759637,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,TABLET,QD,2019,Q3,Dyspnoea,,2019,Q3,1,I,20190416.0,20190826.0,20190830,20190830,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-PFIZER INC-2019366617,PFIZER,,69.0,YR,,F,Y,,,20190830.0,,PH,GB,GB,2019,Q3,Elderly
167596371,16759637,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,TABLET,QD,2019,Q3,Interstitial lung disease,,2019,Q3,1,I,20190416.0,20190826.0,20190830,20190830,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-PFIZER INC-2019366617,PFIZER,,69.0,YR,,F,Y,,,20190830.0,,PH,GB,GB,2019,Q3,Elderly
167596371,16759637,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,TABLET,QD,2019,Q3,Left ventricular dysfunction,,2019,Q3,1,I,20190416.0,20190826.0,20190830,20190830,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-PFIZER INC-2019366617,PFIZER,,69.0,YR,,F,Y,,,20190830.0,,PH,GB,GB,2019,Q3,Elderly
167596371,16759637,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,TABLET,QD,2019,Q3,Pneumonia streptococcal,,2019,Q3,1,I,20190416.0,20190826.0,20190830,20190830,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-PFIZER INC-2019366617,PFIZER,,69.0,YR,,F,Y,,,20190830.0,,PH,GB,GB,2019,Q3,Elderly
167609491,16760949,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,, UNK,,,,,UNKNOWN,,2019,Q3,Chronic kidney disease,,2019,Q3,1,I,20190721.0,20190828.0,20190830,20190830,EXP,ES-AEMPS-535463,ES-FRESENIUS KABI-FK201909551,FRESENIUS KABI,,68.0,YR,,F,Y,,,20190830.0,,OT,NL,ES,2019,Q3,Elderly
167609491,16760949,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,, UNK,,,,,UNKNOWN,,2019,Q3,Hyperkalaemia,,2019,Q3,1,I,20190721.0,20190828.0,20190830,20190830,EXP,ES-AEMPS-535463,ES-FRESENIUS KABI-FK201909551,FRESENIUS KABI,,68.0,YR,,F,Y,,,20190830.0,,OT,NL,ES,2019,Q3,Elderly
167640191,16764019,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2019,Q3,Chronic kidney disease,,2019,Q3,1,I,20190721.0,20190828.0,20190902,20190902,EXP,ES-AEMPS-535463,PHHY2019ES201044,SANDOZ,,68.0,YR,,F,Y,,,20190902.0,,OT,ES,ES,2019,Q3,Elderly
167640191,16764019,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2019,Q3,Hyperkalaemia,,2019,Q3,1,I,20190721.0,20190828.0,20190902,20190902,EXP,ES-AEMPS-535463,PHHY2019ES201044,SANDOZ,,68.0,YR,,F,Y,,,20190902.0,,OT,ES,ES,2019,Q3,Elderly
167652621,16765262,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q3,Abdominal pain,,2019,Q3,1,I,,20190819.0,20190903,20190903,EXP,,ES-ZYDUS-040269,ZYDUS PHARM,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURR-DIABET-REV 2019;15(4):259-262.",52.0,YR,,M,Y,70.0,KG,20190903.0,,OT,ES,ES,2019,Q3,Adult
167652621,16765262,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q3,Acute kidney injury,,2019,Q3,1,I,,20190819.0,20190903,20190903,EXP,,ES-ZYDUS-040269,ZYDUS PHARM,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURR-DIABET-REV 2019;15(4):259-262.",52.0,YR,,M,Y,70.0,KG,20190903.0,,OT,ES,ES,2019,Q3,Adult
167652621,16765262,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190819.0,20190903,20190903,EXP,,ES-ZYDUS-040269,ZYDUS PHARM,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURR-DIABET-REV 2019;15(4):259-262.",52.0,YR,,M,Y,70.0,KG,20190903.0,,OT,ES,ES,2019,Q3,Adult
167652621,16765262,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q3,Dyspnoea,,2019,Q3,1,I,,20190819.0,20190903,20190903,EXP,,ES-ZYDUS-040269,ZYDUS PHARM,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURR-DIABET-REV 2019;15(4):259-262.",52.0,YR,,M,Y,70.0,KG,20190903.0,,OT,ES,ES,2019,Q3,Adult
167652621,16765262,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q3,Hyperglycaemia,,2019,Q3,1,I,,20190819.0,20190903,20190903,EXP,,ES-ZYDUS-040269,ZYDUS PHARM,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURR-DIABET-REV 2019;15(4):259-262.",52.0,YR,,M,Y,70.0,KG,20190903.0,,OT,ES,ES,2019,Q3,Adult
167652621,16765262,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q3,Hypokalaemia,,2019,Q3,1,I,,20190819.0,20190903,20190903,EXP,,ES-ZYDUS-040269,ZYDUS PHARM,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURR-DIABET-REV 2019;15(4):259-262.",52.0,YR,,M,Y,70.0,KG,20190903.0,,OT,ES,ES,2019,Q3,Adult
167652621,16765262,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q3,Leukocytosis,,2019,Q3,1,I,,20190819.0,20190903,20190903,EXP,,ES-ZYDUS-040269,ZYDUS PHARM,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURR-DIABET-REV 2019;15(4):259-262.",52.0,YR,,M,Y,70.0,KG,20190903.0,,OT,ES,ES,2019,Q3,Adult
167652621,16765262,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q3,Mental status changes,,2019,Q3,1,I,,20190819.0,20190903,20190903,EXP,,ES-ZYDUS-040269,ZYDUS PHARM,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURR-DIABET-REV 2019;15(4):259-262.",52.0,YR,,M,Y,70.0,KG,20190903.0,,OT,ES,ES,2019,Q3,Adult
167652621,16765262,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q3,Metabolic acidosis,,2019,Q3,1,I,,20190819.0,20190903,20190903,EXP,,ES-ZYDUS-040269,ZYDUS PHARM,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURR-DIABET-REV 2019;15(4):259-262.",52.0,YR,,M,Y,70.0,KG,20190903.0,,OT,ES,ES,2019,Q3,Adult
167652621,16765262,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q3,Nausea,,2019,Q3,1,I,,20190819.0,20190903,20190903,EXP,,ES-ZYDUS-040269,ZYDUS PHARM,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURR-DIABET-REV 2019;15(4):259-262.",52.0,YR,,M,Y,70.0,KG,20190903.0,,OT,ES,ES,2019,Q3,Adult
167652621,16765262,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q3,Neutrophilia,,2019,Q3,1,I,,20190819.0,20190903,20190903,EXP,,ES-ZYDUS-040269,ZYDUS PHARM,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURR-DIABET-REV 2019;15(4):259-262.",52.0,YR,,M,Y,70.0,KG,20190903.0,,OT,ES,ES,2019,Q3,Adult
167652621,16765262,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q3,Vomiting,,2019,Q3,1,I,,20190819.0,20190903,20190903,EXP,,ES-ZYDUS-040269,ZYDUS PHARM,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURR-DIABET-REV 2019;15(4):259-262.",52.0,YR,,M,Y,70.0,KG,20190903.0,,OT,ES,ES,2019,Q3,Adult
167653981,16765398,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2019,Q3,Chronic kidney disease,,2019,Q3,1,I,20190721.0,20190826.0,20190903,20190903,EXP,ES-AEMPS-535463,ES-ACCORD-153550,ACCORD,,68.0,YR,E,F,Y,,,20190903.0,,MD,ES,ES,2019,Q3,Elderly
167653981,16765398,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2019,Q3,Hyperkalaemia,,2019,Q3,1,I,20190721.0,20190826.0,20190903,20190903,EXP,ES-AEMPS-535463,ES-ACCORD-153550,ACCORD,,68.0,YR,E,F,Y,,,20190903.0,,MD,ES,ES,2019,Q3,Elderly
167678401,16767840,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2019,Q3,Dehydration,,2019,Q3,1,I,,20190827.0,20190903,20190903,EXP,,PT-MYLANLABS-2019M1081775,MYLAN,"GOUVEIA CC, DUQUE S, CAMPOS L. LIPOT?MIA POR HIPOVOL?MIA ? UM CASO DE IATROGENIA ? EMPAGLIFLOZINA?. REV PORT DIABETES. 2019;14(1):75",71.0,YR,,M,Y,,,20190903.0,,MD,PT,PT,2019,Q3,Elderly
167678401,16767840,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2019,Q3,Dizziness,,2019,Q3,1,I,,20190827.0,20190903,20190903,EXP,,PT-MYLANLABS-2019M1081775,MYLAN,"GOUVEIA CC, DUQUE S, CAMPOS L. LIPOT?MIA POR HIPOVOL?MIA ? UM CASO DE IATROGENIA ? EMPAGLIFLOZINA?. REV PORT DIABETES. 2019;14(1):75",71.0,YR,,M,Y,,,20190903.0,,MD,PT,PT,2019,Q3,Elderly
167678401,16767840,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2019,Q3,Drug interaction,,2019,Q3,1,I,,20190827.0,20190903,20190903,EXP,,PT-MYLANLABS-2019M1081775,MYLAN,"GOUVEIA CC, DUQUE S, CAMPOS L. LIPOT?MIA POR HIPOVOL?MIA ? UM CASO DE IATROGENIA ? EMPAGLIFLOZINA?. REV PORT DIABETES. 2019;14(1):75",71.0,YR,,M,Y,,,20190903.0,,MD,PT,PT,2019,Q3,Elderly
167678401,16767840,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2019,Q3,Presyncope,,2019,Q3,1,I,,20190827.0,20190903,20190903,EXP,,PT-MYLANLABS-2019M1081775,MYLAN,"GOUVEIA CC, DUQUE S, CAMPOS L. LIPOT?MIA POR HIPOVOL?MIA ? UM CASO DE IATROGENIA ? EMPAGLIFLOZINA?. REV PORT DIABETES. 2019;14(1):75",71.0,YR,,M,Y,,,20190903.0,,MD,PT,PT,2019,Q3,Elderly
167678401,16767840,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2019,Q3,Renal injury,,2019,Q3,1,I,,20190827.0,20190903,20190903,EXP,,PT-MYLANLABS-2019M1081775,MYLAN,"GOUVEIA CC, DUQUE S, CAMPOS L. LIPOT?MIA POR HIPOVOL?MIA ? UM CASO DE IATROGENIA ? EMPAGLIFLOZINA?. REV PORT DIABETES. 2019;14(1):75",71.0,YR,,M,Y,,,20190903.0,,MD,PT,PT,2019,Q3,Elderly
167711631,16771163,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING.",,,,, UNKNOWN,,,25.0,MG,TABLET,,2019,Q3,Dyspnoea,,2019,Q3,1,I,20190416.0,20190826.0,20190904,20190904,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-TEVA-2019-GB-1100468,TEVA,,69.0,YR,,F,Y,,,20190904.0,,PH,GB,GB,2019,Q3,Elderly
167711631,16771163,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING.",,,,, UNKNOWN,,,25.0,MG,TABLET,,2019,Q3,Interstitial lung disease,,2019,Q3,1,I,20190416.0,20190826.0,20190904,20190904,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-TEVA-2019-GB-1100468,TEVA,,69.0,YR,,F,Y,,,20190904.0,,PH,GB,GB,2019,Q3,Elderly
167711631,16771163,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING.",,,,, UNKNOWN,,,25.0,MG,TABLET,,2019,Q3,Left ventricular dysfunction,,2019,Q3,1,I,20190416.0,20190826.0,20190904,20190904,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-TEVA-2019-GB-1100468,TEVA,,69.0,YR,,F,Y,,,20190904.0,,PH,GB,GB,2019,Q3,Elderly
167777811,16777781,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2019,Q3,Atrioventricular block complete,,2019,Q3,1,I,20190812.0,20190827.0,20190905,20190905,EXP,GB-MHRA-EYC 00206271,GB-ELI_LILLY_AND_COMPANY-GB201908013655,ELI LILLY AND CO,,66.0,YR,,M,Y,100.0,KG,20190905.0,,CN,GB,GB,2019,Q3,Elderly
167777811,16777781,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2019,Q3,Cardiac arrest,,2019,Q3,1,I,20190812.0,20190827.0,20190905,20190905,EXP,GB-MHRA-EYC 00206271,GB-ELI_LILLY_AND_COMPANY-GB201908013655,ELI LILLY AND CO,,66.0,YR,,M,Y,100.0,KG,20190905.0,,CN,GB,GB,2019,Q3,Elderly
167791141,16779114,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q3,Acute myocardial infarction,,2019,Q3,1,I,,20190829.0,20190906,20190906,EXP,,JP-009507513-1909JPN000117J,MERCK,,50.0,YR,,M,Y,,,20190906.0,,MD,JP,JP,2019,Q3,Adult
167796021,16779602,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 DOSAGE FORMS 1 DAYS,178.95833,DF,,, UNKNOWN,,,1.0,DF,,,2019,Q3,Abdominal pain,,2019,Q3,1,I,20190802.0,20190829.0,20190906,20190906,EXP,GB-MHRA-TPP10592814C7009506YC1564739331181,GB-TEVA-2019-GB-1102608,TEVA,,52.0,YR,,F,Y,97.0,KG,20190906.0,,MD,GB,GB,2019,Q3,Adult
167796021,16779602,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 DOSAGE FORMS 1 DAYS,178.95833,DF,,, UNKNOWN,,,1.0,DF,,,2019,Q3,Vomiting,,2019,Q3,1,I,20190802.0,20190829.0,20190906,20190906,EXP,GB-MHRA-TPP10592814C7009506YC1564739331181,GB-TEVA-2019-GB-1102608,TEVA,,52.0,YR,,F,Y,97.0,KG,20190906.0,,MD,GB,GB,2019,Q3,Adult
167847121,16784712,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q3,Acute kidney injury,,2019,Q3,1,I,20190529.0,,20190717,20190717,DIR,,,FDA-CTU,,57.0,YR,,M,N,,,20190717.0,N,PH,US,US,2019,Q3,Adult
167847121,16784712,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q3,Ventricular tachycardia,,2019,Q3,1,I,20190529.0,,20190717,20190717,DIR,,,FDA-CTU,,57.0,YR,,M,N,,,20190717.0,N,PH,US,US,2019,Q3,Adult
167847121,16784712,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q3,Acute kidney injury,,2019,Q3,1,I,20190529.0,,20190717,20190717,DIR,,,FDA-CTU,,57.0,YR,,M,N,,,20190717.0,N,PH,US,US,2019,Q3,Adult
167847121,16784712,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q3,Ventricular tachycardia,,2019,Q3,1,I,20190529.0,,20190717,20190717,DIR,,,FDA-CTU,,57.0,YR,,M,N,,,20190717.0,N,PH,US,US,2019,Q3,Adult
167849421,16784942,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,U, UNKNOWN,,,,,,,2019,Q3,Acute kidney injury,,2019,Q3,1,I,,20190828.0,20190909,20190909,EXP,,"ES-ATLAS PHARMACEUTICALS, LLC-2074179",ATLAS PHARMACEUTICALS,"HERNANDEZ-QUILES C, ET AL.,?KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE.?JOURNAL: CURRENT DIABETES REVIEWS,YEAR: 2019, VOLUME: 15 (NO. 4),PAGE NO: 259-262.",52.0,YR,,M,Y,,,20190909.0,,OT,ES,ES,2019,Q3,Adult
167849421,16784942,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,U, UNKNOWN,,,,,,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190828.0,20190909,20190909,EXP,,"ES-ATLAS PHARMACEUTICALS, LLC-2074179",ATLAS PHARMACEUTICALS,"HERNANDEZ-QUILES C, ET AL.,?KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE.?JOURNAL: CURRENT DIABETES REVIEWS,YEAR: 2019, VOLUME: 15 (NO. 4),PAGE NO: 259-262.",52.0,YR,,M,Y,,,20190909.0,,OT,ES,ES,2019,Q3,Adult
167849421,16784942,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,U, UNKNOWN,,,,,,,2019,Q3,Leukocytosis,,2019,Q3,1,I,,20190828.0,20190909,20190909,EXP,,"ES-ATLAS PHARMACEUTICALS, LLC-2074179",ATLAS PHARMACEUTICALS,"HERNANDEZ-QUILES C, ET AL.,?KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE.?JOURNAL: CURRENT DIABETES REVIEWS,YEAR: 2019, VOLUME: 15 (NO. 4),PAGE NO: 259-262.",52.0,YR,,M,Y,,,20190909.0,,OT,ES,ES,2019,Q3,Adult
167849421,16784942,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,U, UNKNOWN,,,,,,,2019,Q3,Neutrophilia,,2019,Q3,1,I,,20190828.0,20190909,20190909,EXP,,"ES-ATLAS PHARMACEUTICALS, LLC-2074179",ATLAS PHARMACEUTICALS,"HERNANDEZ-QUILES C, ET AL.,?KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE.?JOURNAL: CURRENT DIABETES REVIEWS,YEAR: 2019, VOLUME: 15 (NO. 4),PAGE NO: 259-262.",52.0,YR,,M,Y,,,20190909.0,,OT,ES,ES,2019,Q3,Adult
167853131,16785313,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",166958.0,DF,U,,,,,1.0,DF,,QD,2019,Q3,Pruritus generalised,,2019,Q3,1,I,20190819.0,20190905.0,20190909,20190909,EXP,GB-MHRA-TPP30738493C5984567YC1566199154760,GB-GLAXOSMITHKLINE-GB2019161620,GLAXOSMITHKLINE,,77.0,YR,,F,Y,83.0,KG,20190909.0,,MD,GB,GB,2019,Q3,Elderly
167878591,16787859,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Breast cancer female,,2019,Q3,1,I,201612.0,20190525.0,20190909,20190909,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002303",BOEHRINGER INGELHEIM,,49.0,YR,,F,Y,73.2,KG,20190909.0,,MD,JP,JP,2019,Q3,Adult
167901081,16790108,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2019,Q3,Pollakiuria,,2019,Q3,1,I,20190610.0,,20190719,20190719,DIR,,,FDA-CTU,,72.0,YR,,M,N,,,20190617.0,N,PH,UM,UM,2019,Q3,Elderly
167925974,16792597,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Concussion,,2019,Q3,4,F,20190902.0,20190920.0,20190910,20190927,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-101221",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,96.0,KG,20190927.0,,MD,DE,DE,2019,Q3,Elderly
167925974,16792597,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Gangrene,,2019,Q3,4,F,20190902.0,20190920.0,20190910,20190927,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-101221",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,96.0,KG,20190927.0,,MD,DE,DE,2019,Q3,Elderly
167925974,16792597,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Nocardiosis,,2019,Q3,4,F,20190902.0,20190920.0,20190910,20190927,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-101221",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,96.0,KG,20190927.0,,MD,DE,DE,2019,Q3,Elderly
167925974,16792597,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Skin ulcer,,2019,Q3,4,F,20190902.0,20190920.0,20190910,20190927,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-101221",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,96.0,KG,20190927.0,,MD,DE,DE,2019,Q3,Elderly
167981341,16798134,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q3,Renal impairment,,2019,Q3,1,I,20190320.0,,20190722,20190722,DIR,,,FDA-CTU,,75.0,YR,,M,N,,,20190618.0,N,PH,US,US,2019,Q3,Elderly
167992221,16799222,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q3,Urinary tract infection,,2019,Q3,1,I,20190416.0,,20190722,20190722,DIR,,,FDA-CTU,,65.0,YR,,F,N,,,20190618.0,N,PH,US,US,2019,Q3,Elderly
168019601,16801960,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2019,Q3,Pruritus generalised,,2019,Q3,1,I,20190819.0,20190905.0,20190912,20190912,EXP,GB-MHRA-TPP30738493C5984567YC1566199154760,GB-PERRIGO-19GB010808,PERRIGO,,77.0,YR,,F,Y,83.0,KG,20190912.0,,MD,GB,GB,2019,Q3,Elderly
168032791,16803279,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Cognitive disorder,,2019,Q3,1,I,20190716.0,20190903.0,20190913,20190913,EXP,GB-MHRA-ADR 24427516,GB-BIOGEN-2019BI00782892,BIOGEN,,49.0,YR,,F,Y,,,20190913.0,,PH,GB,GB,2019,Q3,Adult
168032791,16803279,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Confusional state,,2019,Q3,1,I,20190716.0,20190903.0,20190913,20190913,EXP,GB-MHRA-ADR 24427516,GB-BIOGEN-2019BI00782892,BIOGEN,,49.0,YR,,F,Y,,,20190913.0,,PH,GB,GB,2019,Q3,Adult
168032791,16803279,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Delirium,,2019,Q3,1,I,20190716.0,20190903.0,20190913,20190913,EXP,GB-MHRA-ADR 24427516,GB-BIOGEN-2019BI00782892,BIOGEN,,49.0,YR,,F,Y,,,20190913.0,,PH,GB,GB,2019,Q3,Adult
168032791,16803279,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Hallucination,,2019,Q3,1,I,20190716.0,20190903.0,20190913,20190913,EXP,GB-MHRA-ADR 24427516,GB-BIOGEN-2019BI00782892,BIOGEN,,49.0,YR,,F,Y,,,20190913.0,,PH,GB,GB,2019,Q3,Adult
168032791,16803279,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Headache,,2019,Q3,1,I,20190716.0,20190903.0,20190913,20190913,EXP,GB-MHRA-ADR 24427516,GB-BIOGEN-2019BI00782892,BIOGEN,,49.0,YR,,F,Y,,,20190913.0,,PH,GB,GB,2019,Q3,Adult
168032791,16803279,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Herpes simplex encephalitis,,2019,Q3,1,I,20190716.0,20190903.0,20190913,20190913,EXP,GB-MHRA-ADR 24427516,GB-BIOGEN-2019BI00782892,BIOGEN,,49.0,YR,,F,Y,,,20190913.0,,PH,GB,GB,2019,Q3,Adult
168032791,16803279,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Incontinence,,2019,Q3,1,I,20190716.0,20190903.0,20190913,20190913,EXP,GB-MHRA-ADR 24427516,GB-BIOGEN-2019BI00782892,BIOGEN,,49.0,YR,,F,Y,,,20190913.0,,PH,GB,GB,2019,Q3,Adult
168032791,16803279,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Pneumonia,,2019,Q3,1,I,20190716.0,20190903.0,20190913,20190913,EXP,GB-MHRA-ADR 24427516,GB-BIOGEN-2019BI00782892,BIOGEN,,49.0,YR,,F,Y,,,20190913.0,,PH,GB,GB,2019,Q3,Adult
168032791,16803279,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Pyrexia,,2019,Q3,1,I,20190716.0,20190903.0,20190913,20190913,EXP,GB-MHRA-ADR 24427516,GB-BIOGEN-2019BI00782892,BIOGEN,,49.0,YR,,F,Y,,,20190913.0,,PH,GB,GB,2019,Q3,Adult
168032791,16803279,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Seizure,,2019,Q3,1,I,20190716.0,20190903.0,20190913,20190913,EXP,GB-MHRA-ADR 24427516,GB-BIOGEN-2019BI00782892,BIOGEN,,49.0,YR,,F,Y,,,20190913.0,,PH,GB,GB,2019,Q3,Adult
168032791,16803279,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Speech disorder,,2019,Q3,1,I,20190716.0,20190903.0,20190913,20190913,EXP,GB-MHRA-ADR 24427516,GB-BIOGEN-2019BI00782892,BIOGEN,,49.0,YR,,F,Y,,,20190913.0,,PH,GB,GB,2019,Q3,Adult
168032791,16803279,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2019,Q3,Visual impairment,,2019,Q3,1,I,20190716.0,20190903.0,20190913,20190913,EXP,GB-MHRA-ADR 24427516,GB-BIOGEN-2019BI00782892,BIOGEN,,49.0,YR,,F,Y,,,20190913.0,,PH,GB,GB,2019,Q3,Adult
168041111,16804111,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,TABLET,,2019,Q3,Sudden death,,2019,Q3,1,I,20181218.0,20190912.0,20190913,20190913,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-102137",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,57.0,KG,20190913.0,,MD,JP,JP,2019,Q3,Elderly
168054001,16805400,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q3,Acute kidney injury,,2019,Q3,1,I,,20190906.0,20190913,20190913,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,,71.0,YR,,M,Y,,,20190913.0,,MD,PT,PT,2019,Q3,Elderly
168054001,16805400,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q3,Arrhythmia,,2019,Q3,1,I,,20190906.0,20190913,20190913,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,,71.0,YR,,M,Y,,,20190913.0,,MD,PT,PT,2019,Q3,Elderly
168054001,16805400,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q3,Bradycardia,,2019,Q3,1,I,,20190906.0,20190913,20190913,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,,71.0,YR,,M,Y,,,20190913.0,,MD,PT,PT,2019,Q3,Elderly
168054001,16805400,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q3,Dehydration,,2019,Q3,1,I,,20190906.0,20190913,20190913,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,,71.0,YR,,M,Y,,,20190913.0,,MD,PT,PT,2019,Q3,Elderly
168054001,16805400,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q3,Hypotension,,2019,Q3,1,I,,20190906.0,20190913,20190913,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,,71.0,YR,,M,Y,,,20190913.0,,MD,PT,PT,2019,Q3,Elderly
168054001,16805400,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q3,Presyncope,,2019,Q3,1,I,,20190906.0,20190913,20190913,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,,71.0,YR,,M,Y,,,20190913.0,,MD,PT,PT,2019,Q3,Elderly
168054001,16805400,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q3,Syncope,,2019,Q3,1,I,,20190906.0,20190913,20190913,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,,71.0,YR,,M,Y,,,20190913.0,,MD,PT,PT,2019,Q3,Elderly
168088801,16808880,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 DOSAGE FORM DAILY,166.958,DF,,,,,,1.0,DF,,,2019,Q3,Pruritus generalised,,2019,Q3,1,I,20190819.0,20190903.0,20190916,20190916,EXP,GB-MHRA-ADR 24430015,GB-EMCURE PHARMACEUTICALS LTD-2019-EPL-0669,EMCURE,,77.0,YR,,F,Y,83.0,KG,20190916.0,,MD,GB,GB,2019,Q3,Elderly
168108291,16810829,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Angioedema,,2019,Q3,1,I,20190321.0,20190906.0,20190916,20190916,EXP,GB-MHRA-EYC 00197768,GB-MYLANLABS-2019M1085703,MYLAN,,56.0,YR,,M,Y,163.0,KG,20190916.0,,OT,GB,GB,2019,Q3,Adult
168108291,16810829,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Rash maculo-papular,,2019,Q3,1,I,20190321.0,20190906.0,20190916,20190916,EXP,GB-MHRA-EYC 00197768,GB-MYLANLABS-2019M1085703,MYLAN,,56.0,YR,,M,Y,163.0,KG,20190916.0,,OT,GB,GB,2019,Q3,Adult
168147631,16814763,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 DOSAGE FORM/ DAY,166.95833,DF,,, UNKNOWN,,,1.0,DF,,,2019,Q3,Pruritus generalised,,2019,Q3,1,I,20190819.0,20190909.0,20190917,20190917,EXP,GB-MHRA-TPP30738493C5984567YC1566199154760,GB-TEVA-2019-GB-1106993,TEVA,,77.0,YR,,F,Y,83.0,KG,20190917.0,,MD,GB,GB,2019,Q3,Elderly
168165551,16816555,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Chronic kidney disease,,2019,Q3,1,I,20190621.0,20190731.0,20190917,20190917,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-032051",BOEHRINGER INGELHEIM,,63.0,YR,,F,Y,65.2,KG,20190917.0,,MD,US,US,2019,Q3,Adult
168194971,16819497,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Acute kidney injury,Acute kidney injury,2019,Q3,1,I,20181024.0,20181025.0,20190917,20190917,EXP,,"SG-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-052665",BOEHRINGER INGELHEIM,,58.0,YR,,F,Y,70.0,KG,20190917.0,,MD,SG,SG,2019,Q3,Adult
168194971,16819497,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q3,Acute pulmonary oedema,,2019,Q3,1,I,20181024.0,20181025.0,20190917,20190917,EXP,,"SG-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-052665",BOEHRINGER INGELHEIM,,58.0,YR,,F,Y,70.0,KG,20190917.0,,MD,SG,SG,2019,Q3,Adult
168194993,16819499,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,TABLETS,,2019,Q3,Anaemia,,2019,Q3,3,F,20190906.0,20190918.0,20190917,20190927,PER,,DE-EISAI MEDICAL RESEARCH-EC-2019-062230,EISAI,,63.0,YR,,F,Y,100.0,KG,20190927.0,,MD,DE,DE,2019,Q3,Adult
168315891,16831589,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DOSAGE FORM, DAILY",166.958,DF,,,,,,1.0,DF,,,2019,Q3,Pruritus generalised,,2019,Q3,1,I,20190819.0,20190909.0,20190920,20190920,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-221369,RANBAXY,,77.0,YR,,F,Y,83.0,KG,20190920.0,,OT,NL,GB,2019,Q3,Elderly
168418681,16841868,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNKNOWN",,,,,,,,10.0,MG,,,2019,Q3,Dementia,,2019,Q3,1,I,,20190916.0,20190923,20190923,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201909007018,ELI LILLY AND CO,,84.0,YR,,F,Y,,,20190923.0,,MD,DE,DE,2019,Q3,Elderly
168418681,16841868,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNKNOWN",,,,,,,,10.0,MG,,,2019,Q3,Glycosylated haemoglobin increased,,2019,Q3,1,I,,20190916.0,20190923,20190923,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201909007018,ELI LILLY AND CO,,84.0,YR,,F,Y,,,20190923.0,,MD,DE,DE,2019,Q3,Elderly
168418681,16841868,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNKNOWN",,,,,,,,10.0,MG,,,2019,Q3,Hyperglycaemia,,2019,Q3,1,I,,20190916.0,20190923,20190923,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201909007018,ELI LILLY AND CO,,84.0,YR,,F,Y,,,20190923.0,,MD,DE,DE,2019,Q3,Elderly
168418681,16841868,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNKNOWN",,,,,,,,10.0,MG,,,2019,Q3,Hypoglycaemia,,2019,Q3,1,I,,20190916.0,20190923,20190923,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201909007018,ELI LILLY AND CO,,84.0,YR,,F,Y,,,20190923.0,,MD,DE,DE,2019,Q3,Elderly
168443421,16844342,9,C,Empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Flushing,,2019,Q3,1,I,20190517.0,,20190802,20190802,DIR,,,FDA-CTU,,39.0,YR,,M,N,,,20190606.0,N,PH,US,US,2019,Q3,Adult
168443421,16844342,9,C,Empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Infusion related reaction,,2019,Q3,1,I,20190517.0,,20190802,20190802,DIR,,,FDA-CTU,,39.0,YR,,M,N,,,20190606.0,N,PH,US,US,2019,Q3,Adult
168671261,16867126,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Papillary thyroid cancer,,2019,Q3,1,I,,20190917.0,20190930,20190930,EXP,,AR-NOVOPROD-686074,NOVO NORDISK,,60.0,YR,,M,Y,,,20190930.0,,MD,AR,AR,2019,Q3,Adult
168691711,16869171,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,,,,,,25.0,MG,,QD,2019,Q3,Drug ineffective for unapproved indication,,2019,Q3,1,I,,20190917.0,20190930,20190930,EXP,,CA-BAYER-2019-173328,BAYER,"ABDI H, LOCKE E, FITZPATRICK R, OAKE JS. CASE - FUNGAL UROSEPSIS AFTER URETEROSCOPY IN A PATIENT ON NEW GENERATION OF ANTIHYPERGLYCEMIC MEDICATION. CANADIAN UROLOGICAL ASSOCIATION JOURNAL. 2019;13:7:E226-E228",59.0,YR,A,M,Y,,,20190930.0,,MD,CA,CA,2019,Q3,Adult
168691711,16869171,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,,,,,,25.0,MG,,QD,2019,Q3,Off label use,,2019,Q3,1,I,,20190917.0,20190930,20190930,EXP,,CA-BAYER-2019-173328,BAYER,"ABDI H, LOCKE E, FITZPATRICK R, OAKE JS. CASE - FUNGAL UROSEPSIS AFTER URETEROSCOPY IN A PATIENT ON NEW GENERATION OF ANTIHYPERGLYCEMIC MEDICATION. CANADIAN UROLOGICAL ASSOCIATION JOURNAL. 2019;13:7:E226-E228",59.0,YR,A,M,Y,,,20190930.0,,MD,CA,CA,2019,Q3,Adult
168691711,16869171,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,,,,,,25.0,MG,,QD,2019,Q3,Urosepsis,,2019,Q3,1,I,,20190917.0,20190930,20190930,EXP,,CA-BAYER-2019-173328,BAYER,"ABDI H, LOCKE E, FITZPATRICK R, OAKE JS. CASE - FUNGAL UROSEPSIS AFTER URETEROSCOPY IN A PATIENT ON NEW GENERATION OF ANTIHYPERGLYCEMIC MEDICATION. CANADIAN UROLOGICAL ASSOCIATION JOURNAL. 2019;13:7:E226-E228",59.0,YR,A,M,Y,,,20190930.0,,MD,CA,CA,2019,Q3,Adult
168695031,16869503,5,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2019,Q3,Haematochezia,,2019,Q3,1,I,20190802.0,20190814.0,20190930,20190930,EXP,,JP-CELGENEUS-JPN-20190806017,CELGENE,,72.0,YR,,M,Y,64.4,KG,20190930.0,,OT,JP,JP,2019,Q3,Elderly
168695031,16869503,5,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2019,Q3,Pyrexia,,2019,Q3,1,I,20190802.0,20190814.0,20190930,20190930,EXP,,JP-CELGENEUS-JPN-20190806017,CELGENE,,72.0,YR,,M,Y,64.4,KG,20190930.0,,OT,JP,JP,2019,Q3,Elderly
168695031,16869503,5,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2019,Q3,Sepsis,,2019,Q3,1,I,20190802.0,20190814.0,20190930,20190930,EXP,,JP-CELGENEUS-JPN-20190806017,CELGENE,,72.0,YR,,M,Y,64.4,KG,20190930.0,,OT,JP,JP,2019,Q3,Elderly
168695661,16869566,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Device malfunction,,2019,Q3,1,I,20190901.0,20190903.0,20190930,20190930,PER,,US-ASTRAZENECA-2019SF26590,ASTRAZENECA,,23566.0,DY,,M,Y,90.7,KG,20190930.0,,,US,US,2019,Q3,Elderly
168695661,16869566,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Injection site discolouration,,2019,Q3,1,I,20190901.0,20190903.0,20190930,20190930,PER,,US-ASTRAZENECA-2019SF26590,ASTRAZENECA,,23566.0,DY,,M,Y,90.7,KG,20190930.0,,,US,US,2019,Q3,Elderly
168695661,16869566,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Injection site haemorrhage,,2019,Q3,1,I,20190901.0,20190903.0,20190930,20190930,PER,,US-ASTRAZENECA-2019SF26590,ASTRAZENECA,,23566.0,DY,,M,Y,90.7,KG,20190930.0,,,US,US,2019,Q3,Elderly
168695661,16869566,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Injection site mass,,2019,Q3,1,I,20190901.0,20190903.0,20190930,20190930,PER,,US-ASTRAZENECA-2019SF26590,ASTRAZENECA,,23566.0,DY,,M,Y,90.7,KG,20190930.0,,,US,US,2019,Q3,Elderly
168695661,16869566,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Multiple use of single-use product,,2019,Q3,1,I,20190901.0,20190903.0,20190930,20190930,PER,,US-ASTRAZENECA-2019SF26590,ASTRAZENECA,,23566.0,DY,,M,Y,90.7,KG,20190930.0,,,US,US,2019,Q3,Elderly
130699507,13069950,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Acute myocardial infarction,,2019,Q4,7,F,20161203.0,20191208.0,20161228,20191211,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001503",BOEHRINGER INGELHEIM,,61.0,YR,,M,Y,67.4,KG,20191211.0,,MD,JP,JP,2019,Q4,Adult
130852957,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Cerebral infarction,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
130852957,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Decreased appetite,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
130852957,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Diabetes mellitus,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
130852957,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Diabetes mellitus inadequate control,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
130852957,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Electrocardiogram T wave abnormal,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
130852957,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Myocardial infarction,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
130852957,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Sleep disorder,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
130852957,13085295,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Ventricular extrasystoles,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
130852957,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q4,Cerebral infarction,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
130852957,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q4,Decreased appetite,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
130852957,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q4,Diabetes mellitus,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
130852957,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q4,Diabetes mellitus inadequate control,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
130852957,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q4,Electrocardiogram T wave abnormal,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
130852957,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q4,Myocardial infarction,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
130852957,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q4,Sleep disorder,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
130852957,13085295,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q4,Ventricular extrasystoles,,2019,Q4,7,F,20160930.0,20191101.0,20170104,20191107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001442",BOEHRINGER INGELHEIM,,67.0,YR,,F,Y,71.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Elderly
136486456,13648645,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Hyperphosphatasaemia,,2019,Q4,6,F,20161117.0,20190930.0,20170613,20191007,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003274",BOEHRINGER INGELHEIM,,51.0,YR,,M,Y,87.9,KG,20191007.0,,MD,JP,JP,2019,Q4,Adult
136486456,13648645,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Urine ketone body present,,2019,Q4,6,F,20161117.0,20190930.0,20170613,20191007,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003274",BOEHRINGER INGELHEIM,,51.0,YR,,M,Y,87.9,KG,20191007.0,,MD,JP,JP,2019,Q4,Adult
138683897,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Blood ketone body increased,,2019,Q4,7,F,20170728.0,20191008.0,20170815,20191013,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20191014.0,,MD,JP,JP,2019,Q4,Adult
138683897,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Hypercholesterolaemia,,2019,Q4,7,F,20170728.0,20191008.0,20170815,20191013,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20191014.0,,MD,JP,JP,2019,Q4,Adult
138683897,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Hyperuricaemia,,2019,Q4,7,F,20170728.0,20191008.0,20170815,20191013,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20191014.0,,MD,JP,JP,2019,Q4,Adult
138683897,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Leukocytosis,,2019,Q4,7,F,20170728.0,20191008.0,20170815,20191013,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20191014.0,,MD,JP,JP,2019,Q4,Adult
141135738,14113573,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2019,Q4,Bladder neoplasm,,2019,Q4,8,F,20171012.0,20191111.0,20171023,20191113,EXP,,DE-ROCHE-2009932,ROCHE,,69.0,YR,,M,Y,112.0,KG,20191113.0,,MD,DE,DE,2019,Q4,Elderly
141135738,14113573,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2019,Q4,Intervertebral disc protrusion,,2019,Q4,8,F,20171012.0,20191111.0,20171023,20191113,EXP,,DE-ROCHE-2009932,ROCHE,,69.0,YR,,M,Y,112.0,KG,20191113.0,,MD,DE,DE,2019,Q4,Elderly
1463541110,14635411,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q4,Dehydration,,2019,Q4,10,F,20180308.0,20191216.0,20180314,20191220,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-013543",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,56.0,KG,20191220.0,,MD,DE,DE,2019,Q4,Elderly
1463541110,14635411,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q4,Extranodal marginal zone B-cell lymphoma (MALT type),,2019,Q4,10,F,20180308.0,20191216.0,20180314,20191220,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-013543",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,56.0,KG,20191220.0,,MD,DE,DE,2019,Q4,Elderly
1463541110,14635411,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q4,Macular degeneration,,2019,Q4,10,F,20180308.0,20191216.0,20180314,20191220,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-013543",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,56.0,KG,20191220.0,,MD,DE,DE,2019,Q4,Elderly
1463541110,14635411,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q4,Dehydration,,2019,Q4,10,F,20180308.0,20191216.0,20180314,20191220,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-013543",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,56.0,KG,20191220.0,,MD,DE,DE,2019,Q4,Elderly
1463541110,14635411,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q4,Extranodal marginal zone B-cell lymphoma (MALT type),,2019,Q4,10,F,20180308.0,20191216.0,20180314,20191220,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-013543",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,56.0,KG,20191220.0,,MD,DE,DE,2019,Q4,Elderly
1463541110,14635411,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q4,Macular degeneration,,2019,Q4,10,F,20180308.0,20191216.0,20180314,20191220,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-013543",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,56.0,KG,20191220.0,,MD,DE,DE,2019,Q4,Elderly
150501915,15050191,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Angina pectoris,,2019,Q4,5,F,20160708.0,20190930.0,20180622,20191004,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000929",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,70.0,KG,20191004.0,,MD,JP,JP,2019,Q4,Elderly
150501915,15050191,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Arrhythmia,,2019,Q4,5,F,20160708.0,20190930.0,20180622,20191004,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000929",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,70.0,KG,20191004.0,,MD,JP,JP,2019,Q4,Elderly
150501915,15050191,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Embolic cerebral infarction,,2019,Q4,5,F,20160708.0,20190930.0,20180622,20191004,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000929",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,70.0,KG,20191004.0,,MD,JP,JP,2019,Q4,Elderly
150501915,15050191,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Hypertension,,2019,Q4,5,F,20160708.0,20190930.0,20180622,20191004,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000929",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,70.0,KG,20191004.0,,MD,JP,JP,2019,Q4,Elderly
150501915,15050191,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Hyperuricaemia,,2019,Q4,5,F,20160708.0,20190930.0,20180622,20191004,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000929",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,70.0,KG,20191004.0,,MD,JP,JP,2019,Q4,Elderly
150501915,15050191,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Lacunar infarction,,2019,Q4,5,F,20160708.0,20190930.0,20180622,20191004,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000929",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,70.0,KG,20191004.0,,MD,JP,JP,2019,Q4,Elderly
150501915,15050191,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Nephropathy,,2019,Q4,5,F,20160708.0,20190930.0,20180622,20191004,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000929",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,70.0,KG,20191004.0,,MD,JP,JP,2019,Q4,Elderly
150934976,15093497,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q4,Renal impairment,,2019,Q4,6,F,20180202.0,20191218.0,20180629,20191224,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-008515",BOEHRINGER INGELHEIM,,78.0,YR,,F,Y,60.0,KG,20191224.0,,MD,DE,DE,2019,Q4,Elderly
150934976,15093497,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q4,Systemic inflammatory response syndrome,,2019,Q4,6,F,20180202.0,20191218.0,20180629,20191224,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-008515",BOEHRINGER INGELHEIM,,78.0,YR,,F,Y,60.0,KG,20191224.0,,MD,DE,DE,2019,Q4,Elderly
150934976,15093497,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2019,Q4,Urosepsis,,2019,Q4,6,F,20180202.0,20191218.0,20180629,20191224,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-008515",BOEHRINGER INGELHEIM,,78.0,YR,,F,Y,60.0,KG,20191224.0,,MD,DE,DE,2019,Q4,Elderly
151134032,15113403,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,1.0,DF,TABLET,QD,2019,Q4,Pancreatitis,,2019,Q4,2,F,,20190926.0,20180706,20191001,EXP,,"HU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-033965",BOEHRINGER INGELHEIM,SZL?DEK H. PRACTICAL EXPERIENCES WITH IMPLEMENTATION OF A COMBINED TREATMENT IN THE THERAPY. METABOLIZMUS 2018/2. 2018;23:243-245.,65.0,YR,,M,Y,,,20191001.0,,MD,HU,HU,2019,Q4,Elderly
152187435,15218743,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,FILM-COATED TABLET,,2019,Q4,Cardiac failure,,2019,Q4,5,F,20180620.0,20191220.0,20180731,20191226,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-037662",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,109.7,KG,20191226.0,,MD,BR,BR,2019,Q4,Elderly
152187435,15218743,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,FILM-COATED TABLET,,2019,Q4,Hemiparesis,,2019,Q4,5,F,20180620.0,20191220.0,20180731,20191226,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-037662",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,109.7,KG,20191226.0,,MD,BR,BR,2019,Q4,Elderly
155457323,15545732,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Urine ketone body present,,2019,Q4,3,F,20181018.0,20191210.0,20181024,20191215,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-005537",BOEHRINGER INGELHEIM,,56.0,YR,,F,Y,52.5,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Abscess,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Alopecia,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Anxiety,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Asthenia,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Back pain,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Blood pressure increased,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Cyst,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Depression,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Dizziness,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Dry eye,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Emotional distress,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Fatigue,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Frustration tolerance decreased,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Hair growth abnormal,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Headache,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Logorrhoea,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Malaise,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Muscle spasms,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Muscular weakness,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Myalgia,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Nail discolouration,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Nerve injury,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Neuralgia,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Pain,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Pain in extremity,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Peripheral swelling,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Poor quality sleep,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Spinal cord neoplasm,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155610266,15561026,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Weight increased,,2019,Q4,6,F,,20191209.0,20181029,20191213,EXP,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20191213.0,,CN,US,US,2019,Q4,Elderly
155722445,15572244,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q4,Acute myocardial infarction,,2019,Q4,5,F,200508.0,20191213.0,20181031,20191219,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20191219.0,,MD,SK,SK,2019,Q4,Elderly
155722445,15572244,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q4,Diabetes mellitus,,2019,Q4,5,F,200508.0,20191213.0,20181031,20191219,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20191219.0,,MD,SK,SK,2019,Q4,Elderly
155722445,15572244,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q4,Drug ineffective,,2019,Q4,5,F,200508.0,20191213.0,20181031,20191219,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20191219.0,,MD,SK,SK,2019,Q4,Elderly
155722445,15572244,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q4,Glycosylated haemoglobin decreased,,2019,Q4,5,F,200508.0,20191213.0,20181031,20191219,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20191219.0,,MD,SK,SK,2019,Q4,Elderly
155722445,15572244,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q4,Glycosylated haemoglobin increased,,2019,Q4,5,F,200508.0,20191213.0,20181031,20191219,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20191219.0,,MD,SK,SK,2019,Q4,Elderly
155722445,15572244,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q4,Hyperlipidaemia,,2019,Q4,5,F,200508.0,20191213.0,20181031,20191219,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20191219.0,,MD,SK,SK,2019,Q4,Elderly
155722445,15572244,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q4,Hypertension,,2019,Q4,5,F,200508.0,20191213.0,20181031,20191219,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20191219.0,,MD,SK,SK,2019,Q4,Elderly
155722445,15572244,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q4,Myocardial infarction,,2019,Q4,5,F,200508.0,20191213.0,20181031,20191219,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20191219.0,,MD,SK,SK,2019,Q4,Elderly
155722445,15572244,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2019,Q4,Weight increased,,2019,Q4,5,F,200508.0,20191213.0,20181031,20191219,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20191219.0,,MD,SK,SK,2019,Q4,Elderly
157557353,15755735,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Blood urine present,,2019,Q4,3,F,20161001.0,20191027.0,20181224,20191101,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004809",BOEHRINGER INGELHEIM,,44.0,YR,,F,Y,67.5,KG,20191101.0,,MD,JP,JP,2019,Q4,Adult
157557353,15755735,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Visual field defect,,2019,Q4,3,F,20161001.0,20191027.0,20181224,20191101,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004809",BOEHRINGER INGELHEIM,,44.0,YR,,F,Y,67.5,KG,20191101.0,,MD,JP,JP,2019,Q4,Adult
158531163,15853116,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Cardiovascular somatic symptom disorder,,2019,Q4,3,F,20180126.0,20191211.0,20190122,20191218,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-000162",BOEHRINGER INGELHEIM,,84.0,YR,,M,Y,65.7,KG,20191218.0,,MD,JP,JP,2019,Q4,Elderly
158531163,15853116,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Pancreatitis necrotising,,2019,Q4,3,F,20180126.0,20191211.0,20190122,20191218,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-000162",BOEHRINGER INGELHEIM,,84.0,YR,,M,Y,65.7,KG,20191218.0,,MD,JP,JP,2019,Q4,Elderly
158531163,15853116,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Weight decreased,,2019,Q4,3,F,20180126.0,20191211.0,20190122,20191218,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-000162",BOEHRINGER INGELHEIM,,84.0,YR,,M,Y,65.7,KG,20191218.0,,MD,JP,JP,2019,Q4,Elderly
1586031315,15860313,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Fournier's gangrene,,2019,Q4,15,F,20181226.0,20191227.0,20190123,20191230,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-062218",BOEHRINGER INGELHEIM,,87.0,YR,,M,Y,81.4,KG,20191230.0,,MD,US,US,2019,Q4,Elderly
1586031315,15860313,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Urinary tract infection,,2019,Q4,15,F,20181226.0,20191227.0,20190123,20191230,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-062218",BOEHRINGER INGELHEIM,,87.0,YR,,M,Y,81.4,KG,20191230.0,,MD,US,US,2019,Q4,Elderly
1586031315,15860313,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,,,FILM-COATED TABLET,,2019,Q4,Fournier's gangrene,,2019,Q4,15,F,20181226.0,20191227.0,20190123,20191230,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-062218",BOEHRINGER INGELHEIM,,87.0,YR,,M,Y,81.4,KG,20191230.0,,MD,US,US,2019,Q4,Elderly
1586031315,15860313,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,,,FILM-COATED TABLET,,2019,Q4,Urinary tract infection,,2019,Q4,15,F,20181226.0,20191227.0,20190123,20191230,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-062218",BOEHRINGER INGELHEIM,,87.0,YR,,M,Y,81.4,KG,20191230.0,,MD,US,US,2019,Q4,Elderly
1598631310,15986313,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Abdominal mass,,2019,Q4,10,F,20190107.0,20191213.0,20190220,20191216,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-006107",BOEHRINGER INGELHEIM,,78.0,YR,,F,Y,73.8,KG,20191216.0,,MD,BR,BR,2019,Q4,Elderly
1598631310,15986313,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Cardiac failure,,2019,Q4,10,F,20190107.0,20191213.0,20190220,20191216,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-006107",BOEHRINGER INGELHEIM,,78.0,YR,,F,Y,73.8,KG,20191216.0,,MD,BR,BR,2019,Q4,Elderly
1598631310,15986313,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Syncope,,2019,Q4,10,F,20190107.0,20191213.0,20190220,20191216,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-006107",BOEHRINGER INGELHEIM,,78.0,YR,,F,Y,73.8,KG,20191216.0,,MD,BR,BR,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Acute kidney injury,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Arrhythmia,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Atrial fibrillation,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Bradycardia,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Dehydration,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Dizziness,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Haematocrit increased,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Haemoglobin increased,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Heart rate irregular,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Hypotension,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Hypovolaemia,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Left atrial dilatation,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Mucosal dryness,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Oedema peripheral,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Presyncope,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Pulmonary congestion,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Renal disorder,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Renal injury,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Skin disorder,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,17,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Syncope,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Acute kidney injury,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Arrhythmia,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Atrial fibrillation,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Bradycardia,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Dehydration,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Dizziness,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Haematocrit increased,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Haemoglobin increased,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Heart rate irregular,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Hypotension,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Hypovolaemia,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Left atrial dilatation,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Mucosal dryness,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Oedema peripheral,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Presyncope,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Pulmonary congestion,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Renal disorder,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Renal injury,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Skin disorder,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
1608836710,16088367,18,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Syncope,,2019,Q4,10,F,2018.0,20191218.0,20190319,20191226,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,,71.0,YR,,M,Y,,,20191226.0,,OT,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Acute kidney injury,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Arrhythmia,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Atrial fibrillation,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Bradycardia,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Dehydration,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Dizziness,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Drug interaction,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Haematocrit increased,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Haemoglobin increased,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Heart rate irregular,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Hypotension,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Hypovolaemia,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Left atrial dilatation,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Mucosal dryness,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Presyncope,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Skin disorder,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Syncope,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Acute kidney injury,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Arrhythmia,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Atrial fibrillation,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Bradycardia,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Dehydration,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Dizziness,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Drug interaction,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Haematocrit increased,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Haemoglobin increased,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Heart rate irregular,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Hypotension,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Hypovolaemia,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Left atrial dilatation,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Mucosal dryness,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Presyncope,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Skin disorder,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161236886,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2019,Q4,Syncope,,2019,Q4,6,F,2018.0,20191203.0,20190327,20191210,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"GOUVEIA C. C, DUQUE S. CAMPOS L. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZINE. REVISTA PORTUGUESA DE DIABETES. 2019;14 (1):74-P050",71.0,YR,,M,Y,,,20191210.0,,MD,PT,PT,2019,Q4,Elderly
161521154,16152115,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q4,Diabetic nephropathy,,2019,Q4,4,F,20190326.0,20191202.0,20190403,20191204,EXP,,"AR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-014846",BOEHRINGER INGELHEIM,,64.0,YR,,F,Y,91.8,KG,20191204.0,,MD,AR,AR,2019,Q4,Adult
161627822,16162782,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Renal cell carcinoma,,2019,Q4,2,F,20181026.0,20191007.0,20190405,20191009,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-001568",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,71.4,KG,20191009.0,,MD,JP,JP,2019,Q4,Elderly
163062892,16306289,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q4,Abdominal pain upper,,2019,Q4,2,F,201902.0,20191205.0,20190513,20191211,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20191211.0,,CN,GT,GT,2019,Q4,Elderly
163062892,16306289,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q4,Cardiac failure,,2019,Q4,2,F,201902.0,20191205.0,20190513,20191211,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20191211.0,,CN,GT,GT,2019,Q4,Elderly
163062892,16306289,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q4,Decreased appetite,,2019,Q4,2,F,201902.0,20191205.0,20190513,20191211,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20191211.0,,CN,GT,GT,2019,Q4,Elderly
163062892,16306289,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q4,Diabetes mellitus,,2019,Q4,2,F,201902.0,20191205.0,20190513,20191211,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20191211.0,,CN,GT,GT,2019,Q4,Elderly
163062892,16306289,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q4,Dizziness,,2019,Q4,2,F,201902.0,20191205.0,20190513,20191211,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20191211.0,,CN,GT,GT,2019,Q4,Elderly
163062892,16306289,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q4,Hypertension,,2019,Q4,2,F,201902.0,20191205.0,20190513,20191211,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20191211.0,,CN,GT,GT,2019,Q4,Elderly
163062892,16306289,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q4,Hypoglycaemia,,2019,Q4,2,F,201902.0,20191205.0,20190513,20191211,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20191211.0,,CN,GT,GT,2019,Q4,Elderly
163062892,16306289,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q4,Insomnia,,2019,Q4,2,F,201902.0,20191205.0,20190513,20191211,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20191211.0,,CN,GT,GT,2019,Q4,Elderly
163062892,16306289,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q4,Nausea,,2019,Q4,2,F,201902.0,20191205.0,20190513,20191211,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20191211.0,,CN,GT,GT,2019,Q4,Elderly
163062892,16306289,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q4,Neoplasm malignant,,2019,Q4,2,F,201902.0,20191205.0,20190513,20191211,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20191211.0,,CN,GT,GT,2019,Q4,Elderly
163062892,16306289,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q4,Red blood cell count decreased,,2019,Q4,2,F,201902.0,20191205.0,20190513,20191211,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20191211.0,,CN,GT,GT,2019,Q4,Elderly
163062892,16306289,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DF,,,U,,,,,1.0,DF,TABLET,,2019,Q4,Renal failure,,2019,Q4,2,F,201902.0,20191205.0,20190513,20191211,EXP,,GT-SA-2019SA122564,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20191211.0,,CN,GT,GT,2019,Q4,Elderly
164604573,16460457,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q4,Cerebral infarction,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q4,Cholangitis acute,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q4,Cholelithiasis,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q4,Dermatitis,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q4,Cerebral infarction,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q4,Cholangitis acute,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q4,Cholelithiasis,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q4,Dermatitis,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q4,Cerebral infarction,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q4,Cholangitis acute,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q4,Cholelithiasis,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q4,Dermatitis,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q4,Cerebral infarction,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q4,Cholangitis acute,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q4,Cholelithiasis,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q4,Dermatitis,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q4,Cerebral infarction,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q4,Cholangitis acute,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q4,Cholelithiasis,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164604573,16460457,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,,2019,Q4,Dermatitis,,2019,Q4,3,F,20170322.0,20191014.0,20190620,20191021,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004537",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,71.9,KG,20191021.0,,MD,JP,JP,2019,Q4,Elderly
164775742,16477574,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q4,Carotid artery stenosis,,2019,Q4,2,F,20180919.0,20191101.0,20190626,20191105,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002911",BOEHRINGER INGELHEIM,,79.0,YR,,M,Y,66.8,KG,20191106.0,,MD,JP,JP,2019,Q4,Elderly
164775742,16477574,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q4,Cerebral infarction,,2019,Q4,2,F,20180919.0,20191101.0,20190626,20191105,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002911",BOEHRINGER INGELHEIM,,79.0,YR,,M,Y,66.8,KG,20191106.0,,MD,JP,JP,2019,Q4,Elderly
164775742,16477574,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q4,Carotid artery stenosis,,2019,Q4,2,F,20180919.0,20191101.0,20190626,20191105,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002911",BOEHRINGER INGELHEIM,,79.0,YR,,M,Y,66.8,KG,20191106.0,,MD,JP,JP,2019,Q4,Elderly
164775742,16477574,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,,2019,Q4,Cerebral infarction,,2019,Q4,2,F,20180919.0,20191101.0,20190626,20191105,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002911",BOEHRINGER INGELHEIM,,79.0,YR,,M,Y,66.8,KG,20191106.0,,MD,JP,JP,2019,Q4,Elderly
164940422,16494042,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Pancreatic carcinoma,Pancreatic carcinoma,2019,Q4,2,F,20190618.0,20190925.0,20190628,20191009,EXP,,US-ALVOGEN-2019-ALVOGEN-100318,ALVOGEN,,69.0,YR,,M,Y,,,20191009.0,,OT,US,US,2019,Q4,Elderly
165287139,16528713,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Cardiac failure congestive,,2019,Q4,9,F,20190416.0,20191217.0,20190703,20191223,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-026253",BOEHRINGER INGELHEIM,,76.0,YR,,F,Y,108.4,KG,20191223.0,,MD,CA,CA,2019,Q4,Elderly
165287139,16528713,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Urosepsis,,2019,Q4,9,F,20190416.0,20191217.0,20190703,20191223,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-026253",BOEHRINGER INGELHEIM,,76.0,YR,,F,Y,108.4,KG,20191223.0,,MD,CA,CA,2019,Q4,Elderly
165342543,16534254,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Blood glucose increased,,2019,Q4,3,F,,20190625.0,20190705,20191011,EXP,,DK-009507513-1906DNK009957,MERCK,,51.0,YR,,M,Y,,,20191011.0,,OT,DK,DK,2019,Q4,Adult
165342543,16534254,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Decreased appetite,,2019,Q4,3,F,,20190625.0,20190705,20191011,EXP,,DK-009507513-1906DNK009957,MERCK,,51.0,YR,,M,Y,,,20191011.0,,OT,DK,DK,2019,Q4,Adult
165342543,16534254,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,3,F,,20190625.0,20190705,20191011,EXP,,DK-009507513-1906DNK009957,MERCK,,51.0,YR,,M,Y,,,20191011.0,,OT,DK,DK,2019,Q4,Adult
165342543,16534254,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Hypotension,,2019,Q4,3,F,,20190625.0,20190705,20191011,EXP,,DK-009507513-1906DNK009957,MERCK,,51.0,YR,,M,Y,,,20191011.0,,OT,DK,DK,2019,Q4,Adult
165342543,16534254,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Metabolic acidosis,,2019,Q4,3,F,,20190625.0,20190705,20191011,EXP,,DK-009507513-1906DNK009957,MERCK,,51.0,YR,,M,Y,,,20191011.0,,OT,DK,DK,2019,Q4,Adult
165342543,16534254,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2019,Q4,Nausea,,2019,Q4,3,F,,20190625.0,20190705,20191011,EXP,,DK-009507513-1906DNK009957,MERCK,,51.0,YR,,M,Y,,,20191011.0,,OT,DK,DK,2019,Q4,Adult
166701228,16670122,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Abdominal pain upper,,2019,Q4,8,F,20180707.0,20190927.0,20190805,20191001,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-039309",BOEHRINGER INGELHEIM,,65.0,YR,,F,Y,53.0,KG,20191001.0,,MD,BR,BR,2019,Q4,Elderly
166701228,16670122,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Sepsis,,2019,Q4,8,F,20180707.0,20190927.0,20190805,20191001,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-039309",BOEHRINGER INGELHEIM,,65.0,YR,,F,Y,53.0,KG,20191001.0,,MD,BR,BR,2019,Q4,Elderly
166701228,16670122,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,204629.0,,,,,2019,Q4,Abdominal pain upper,,2019,Q4,8,F,20180707.0,20190927.0,20190805,20191001,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-039309",BOEHRINGER INGELHEIM,,65.0,YR,,F,Y,53.0,KG,20191001.0,,MD,BR,BR,2019,Q4,Elderly
166701228,16670122,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,204629.0,,,,,2019,Q4,Sepsis,,2019,Q4,8,F,20180707.0,20190927.0,20190805,20191001,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-039309",BOEHRINGER INGELHEIM,,65.0,YR,,F,Y,53.0,KG,20191001.0,,MD,BR,BR,2019,Q4,Elderly
1669801814,16698018,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,TABLETS,,2019,Q4,Rash,,2019,Q4,14,F,20190806.0,20191011.0,20190813,20191017,PER,,DE-EISAI MEDICAL RESEARCH-EC-2019-060585,EISAI,,63.0,YR,,F,Y,100.0,KG,20191017.0,,MD,DE,DE,2019,Q4,Adult
167100287,16710028,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,TABLETS,,2019,Q4,Intestinal haemorrhage,,2019,Q4,7,F,20190805.0,20191122.0,20190816,20191126,EXP,,JP-CELGENEUS-JPN-20190804062,CELGENE,,72.0,YR,,M,Y,64.4,KG,20191126.0,,MD,JP,JP,2019,Q4,Elderly
167102497,16710249,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,Y,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Oedema peripheral,Oedema peripheral,2019,Q4,7,F,20180426.0,20191009.0,20190816,20191010,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-033227",BOEHRINGER INGELHEIM,,55.0,YR,,M,Y,83.0,KG,20191010.0,,MD,MX,MX,2019,Q4,Adult
167102497,16710249,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,Y,,,204629.0,,,FILM-COATED TABLET,,2019,Q4,Oedema peripheral,Oedema peripheral,2019,Q4,7,F,20180426.0,20191009.0,20190816,20191010,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-033227",BOEHRINGER INGELHEIM,,55.0,YR,,M,Y,83.0,KG,20191010.0,,MD,MX,MX,2019,Q4,Adult
167148235,16714823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Abdominal pain,,2019,Q4,5,F,20190515.0,20191219.0,20190819,20191226,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-033229",BOEHRINGER INGELHEIM,,55.0,YR,,M,Y,135.0,KG,20191226.0,,MD,US,US,2019,Q4,Adult
167148235,16714823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Polyp,,2019,Q4,5,F,20190515.0,20191219.0,20190819,20191226,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-033229",BOEHRINGER INGELHEIM,,55.0,YR,,M,Y,135.0,KG,20191226.0,,MD,US,US,2019,Q4,Adult
167439062,16743906,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, DAILY",,,,,,,,10.0,MG,,QD,2019,Q4,Blood glucose decreased,,2019,Q4,2,F,20190811.0,20191008.0,20190827,20191107,EXP,,US-ELI_LILLY_AND_COMPANY-US201908010080,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20191107.0,,CN,US,US,2019,Q4,Elderly
167439062,16743906,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, DAILY",,,,,,,,10.0,MG,,QD,2019,Q4,Injection site haemorrhage,,2019,Q4,2,F,20190811.0,20191008.0,20190827,20191107,EXP,,US-ELI_LILLY_AND_COMPANY-US201908010080,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20191107.0,,CN,US,US,2019,Q4,Elderly
167439062,16743906,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, DAILY",,,,,,,,10.0,MG,,QD,2019,Q4,Memory impairment,,2019,Q4,2,F,20190811.0,20191008.0,20190827,20191107,EXP,,US-ELI_LILLY_AND_COMPANY-US201908010080,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20191107.0,,CN,US,US,2019,Q4,Elderly
167595954,16759595,26,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,2500 MICROGRAM,,,,,,,,1250.0,UG,UNKNOWN,BID,2019,Q4,Pseudomembranous colitis,,2019,Q4,4,F,20190813.0,20190926.0,20190830,20191002,EXP,,AU-CELGENEUS-AUS-20190808804,CELGENE,,30.0,YR,,F,Y,100.0,KG,20191002.0,,MD,AU,AU,2019,Q4,Young Adult
167878592,16787859,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Breast cancer female,,2019,Q4,2,F,201612.0,20191026.0,20190909,20191104,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002303",BOEHRINGER INGELHEIM,,49.0,YR,,F,Y,73.2,KG,20191103.0,,MD,JP,JP,2019,Q4,Adult
167903061,16790306,1,PS,EMPAGLIFLOZIN/METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,D,,,,1.0,TOT,,QD,2019,Q4,Chest pain,,2019,Q4,1,I,20190904.0,,20190909,20190909,DIR,,,FDA-CTU,,38.0,YR,,M,N,105.6,KG,20190909.0,N,PH,US,US,2019,Q4,Adult
167903061,16790306,1,PS,EMPAGLIFLOZIN/METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,D,,,,1.0,TOT,,QD,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20190904.0,,20190909,20190909,DIR,,,FDA-CTU,,38.0,YR,,M,N,105.6,KG,20190909.0,N,PH,US,US,2019,Q4,Adult
167925975,16792597,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Concussion,,2019,Q4,5,F,20190902.0,20190920.0,20190910,20191220,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-101221",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,96.0,KG,20191220.0,,MD,DE,DE,2019,Q4,Elderly
167925975,16792597,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Nocardiosis,,2019,Q4,5,F,20190902.0,20190920.0,20190910,20191220,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-101221",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,96.0,KG,20191220.0,,MD,DE,DE,2019,Q4,Elderly
167925975,16792597,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Skin ulcer,,2019,Q4,5,F,20190902.0,20190920.0,20190910,20191220,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-101221",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,96.0,KG,20191220.0,,MD,DE,DE,2019,Q4,Elderly
168026114,16802611,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Device information output issue,,2019,Q4,4,F,,20191113.0,20190912,20191122,EXP,,GB-NOVOPROD-683802,NOVO NORDISK,,71.0,YR,,M,Y,,,20191122.0,,CN,GB,GB,2019,Q4,Elderly
168026114,16802611,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Device malfunction,,2019,Q4,4,F,,20191113.0,20190912,20191122,EXP,,GB-NOVOPROD-683802,NOVO NORDISK,,71.0,YR,,M,Y,,,20191122.0,,CN,GB,GB,2019,Q4,Elderly
168026114,16802611,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,4,F,,20191113.0,20190912,20191122,EXP,,GB-NOVOPROD-683802,NOVO NORDISK,,71.0,YR,,M,Y,,,20191122.0,,CN,GB,GB,2019,Q4,Elderly
168026114,16802611,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Incorrect dose administered by device,,2019,Q4,4,F,,20191113.0,20190912,20191122,EXP,,GB-NOVOPROD-683802,NOVO NORDISK,,71.0,YR,,M,Y,,,20191122.0,,CN,GB,GB,2019,Q4,Elderly
168026114,16802611,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Needle issue,,2019,Q4,4,F,,20191113.0,20190912,20191122,EXP,,GB-NOVOPROD-683802,NOVO NORDISK,,71.0,YR,,M,Y,,,20191122.0,,CN,GB,GB,2019,Q4,Elderly
168026114,16802611,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Product leakage,,2019,Q4,4,F,,20191113.0,20190912,20191122,EXP,,GB-NOVOPROD-683802,NOVO NORDISK,,71.0,YR,,M,Y,,,20191122.0,,CN,GB,GB,2019,Q4,Elderly
168054003,16805400,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Acute kidney injury,,2019,Q4,3,F,2018.0,20191031.0,20190913,20191105,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,"GOUVEIA, C C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20191105.0,,MD,PT,PT,2019,Q4,Elderly
168054003,16805400,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Arrhythmia,,2019,Q4,3,F,2018.0,20191031.0,20190913,20191105,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,"GOUVEIA, C C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20191105.0,,MD,PT,PT,2019,Q4,Elderly
168054003,16805400,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Atrial fibrillation,,2019,Q4,3,F,2018.0,20191031.0,20190913,20191105,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,"GOUVEIA, C C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20191105.0,,MD,PT,PT,2019,Q4,Elderly
168054003,16805400,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Bradycardia,,2019,Q4,3,F,2018.0,20191031.0,20190913,20191105,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,"GOUVEIA, C C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20191105.0,,MD,PT,PT,2019,Q4,Elderly
168054003,16805400,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Dehydration,,2019,Q4,3,F,2018.0,20191031.0,20190913,20191105,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,"GOUVEIA, C C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20191105.0,,MD,PT,PT,2019,Q4,Elderly
168054003,16805400,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Dizziness,,2019,Q4,3,F,2018.0,20191031.0,20190913,20191105,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,"GOUVEIA, C C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20191105.0,,MD,PT,PT,2019,Q4,Elderly
168054003,16805400,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Haematocrit increased,,2019,Q4,3,F,2018.0,20191031.0,20190913,20191105,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,"GOUVEIA, C C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20191105.0,,MD,PT,PT,2019,Q4,Elderly
168054003,16805400,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Haemoglobin increased,,2019,Q4,3,F,2018.0,20191031.0,20190913,20191105,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,"GOUVEIA, C C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20191105.0,,MD,PT,PT,2019,Q4,Elderly
168054003,16805400,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Hypotension,,2019,Q4,3,F,2018.0,20191031.0,20190913,20191105,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,"GOUVEIA, C C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20191105.0,,MD,PT,PT,2019,Q4,Elderly
168054003,16805400,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Hypovolaemia,,2019,Q4,3,F,2018.0,20191031.0,20190913,20191105,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,"GOUVEIA, C C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20191105.0,,MD,PT,PT,2019,Q4,Elderly
168054003,16805400,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Left atrial dilatation,,2019,Q4,3,F,2018.0,20191031.0,20190913,20191105,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,"GOUVEIA, C C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20191105.0,,MD,PT,PT,2019,Q4,Elderly
168054003,16805400,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Mucosal dryness,,2019,Q4,3,F,2018.0,20191031.0,20190913,20191105,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,"GOUVEIA, C C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20191105.0,,MD,PT,PT,2019,Q4,Elderly
168054003,16805400,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Presyncope,,2019,Q4,3,F,2018.0,20191031.0,20190913,20191105,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,"GOUVEIA, C C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20191105.0,,MD,PT,PT,2019,Q4,Elderly
168054003,16805400,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Skin disorder,,2019,Q4,3,F,2018.0,20191031.0,20190913,20191105,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,"GOUVEIA, C C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20191105.0,,MD,PT,PT,2019,Q4,Elderly
168054003,16805400,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Syncope,,2019,Q4,3,F,2018.0,20191031.0,20190913,20191105,EXP,,PT-MYLANLABS-2019M1085548,MYLAN,"GOUVEIA, C C, DUQUE S, CAMPOS L. LIPOTHYMIA BY HYPOVOLAEMIA - A CASE OF IATROGENY TO EMPAGLIFLOZIN. REVISTA PORTUGUESA DE DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20191105.0,,MD,PT,PT,2019,Q4,Elderly
168194999,16819499,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,TABLETS,,2019,Q4,Anaemia,,2019,Q4,9,F,20190906.0,20191122.0,20190917,20191127,PER,,DE-EISAI MEDICAL RESEARCH-EC-2019-062230,EISAI,,63.0,YR,,F,Y,100.0,KG,20191127.0,,MD,DE,DE,2019,Q4,Adult
168331861,16833186,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Acute kidney injury,,2019,Q4,1,I,20190831.0,,20190920,20190920,DIR,,,FDA-CTU,,65.0,YR,,M,N,85.9,KG,20190920.0,N,PH,US,US,2019,Q4,Elderly
168331861,16833186,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Acute myocardial infarction,,2019,Q4,1,I,20190831.0,,20190920,20190920,DIR,,,FDA-CTU,,65.0,YR,,M,N,85.9,KG,20190920.0,N,PH,US,US,2019,Q4,Elderly
168331861,16833186,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20190831.0,,20190920,20190920,DIR,,,FDA-CTU,,65.0,YR,,M,N,85.9,KG,20190920.0,N,PH,US,US,2019,Q4,Elderly
168331861,16833186,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Heart rate increased,,2019,Q4,1,I,20190831.0,,20190920,20190920,DIR,,,FDA-CTU,,65.0,YR,,M,N,85.9,KG,20190920.0,N,PH,US,US,2019,Q4,Elderly
168331861,16833186,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Hyperglycaemia,,2019,Q4,1,I,20190831.0,,20190920,20190920,DIR,,,FDA-CTU,,65.0,YR,,M,N,85.9,KG,20190920.0,N,PH,US,US,2019,Q4,Elderly
168331861,16833186,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Knee operation,,2019,Q4,1,I,20190831.0,,20190920,20190920,DIR,,,FDA-CTU,,65.0,YR,,M,N,85.9,KG,20190920.0,N,PH,US,US,2019,Q4,Elderly
1684464111,16844641,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,TABLETS,,2019,Q4,Diarrhoea,,2019,Q4,11,F,20190912.0,20191121.0,20190924,20191126,PER,,DE-EISAI MEDICAL RESEARCH-EC-2019-062532,EISAI,,63.0,YR,,F,Y,89.5,KG,20191126.0,,MD,DE,DE,2019,Q4,Adult
1684464111,16844641,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,TABLETS,,2019,Q4,Hypertension,,2019,Q4,11,F,20190912.0,20191121.0,20190924,20191126,PER,,DE-EISAI MEDICAL RESEARCH-EC-2019-062532,EISAI,,63.0,YR,,F,Y,89.5,KG,20191126.0,,MD,DE,DE,2019,Q4,Adult
168621711,16862171,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,QD,2019,Q4,Abscess limb,,2019,Q4,1,I,20190917.0,,20190927,20190927,DIR,,,FDA-CTU,,48.0,YR,,M,N,139.2,KG,20190927.0,N,,US,US,2019,Q4,Adult
168621711,16862171,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,QD,2019,Q4,Necrotising fasciitis,,2019,Q4,1,I,20190917.0,,20190927,20190927,DIR,,,FDA-CTU,,48.0,YR,,M,N,139.2,KG,20190927.0,N,,US,US,2019,Q4,Adult
168621711,16862171,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,QD,2019,Q4,Scrotum erosion,,2019,Q4,1,I,20190917.0,,20190927,20190927,DIR,,,FDA-CTU,,48.0,YR,,M,N,139.2,KG,20190927.0,N,,US,US,2019,Q4,Adult
168695662,16869566,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Device malfunction,,2019,Q4,2,F,20190901.0,20191108.0,20190930,20191120,PER,,US-ASTRAZENECA-2019SF26590,ASTRAZENECA,,23566.0,DY,,M,Y,90.7,KG,20191120.0,,,US,US,2019,Q4,Elderly
168695662,16869566,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Injection site discolouration,,2019,Q4,2,F,20190901.0,20191108.0,20190930,20191120,PER,,US-ASTRAZENECA-2019SF26590,ASTRAZENECA,,23566.0,DY,,M,Y,90.7,KG,20191120.0,,,US,US,2019,Q4,Elderly
168695662,16869566,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Injection site haemorrhage,,2019,Q4,2,F,20190901.0,20191108.0,20190930,20191120,PER,,US-ASTRAZENECA-2019SF26590,ASTRAZENECA,,23566.0,DY,,M,Y,90.7,KG,20191120.0,,,US,US,2019,Q4,Elderly
168695662,16869566,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Injection site mass,,2019,Q4,2,F,20190901.0,20191108.0,20190930,20191120,PER,,US-ASTRAZENECA-2019SF26590,ASTRAZENECA,,23566.0,DY,,M,Y,90.7,KG,20191120.0,,,US,US,2019,Q4,Elderly
168695662,16869566,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Injection site swelling,,2019,Q4,2,F,20190901.0,20191108.0,20190930,20191120,PER,,US-ASTRAZENECA-2019SF26590,ASTRAZENECA,,23566.0,DY,,M,Y,90.7,KG,20191120.0,,,US,US,2019,Q4,Elderly
168695662,16869566,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Multiple use of single-use product,,2019,Q4,2,F,20190901.0,20191108.0,20190930,20191120,PER,,US-ASTRAZENECA-2019SF26590,ASTRAZENECA,,23566.0,DY,,M,Y,90.7,KG,20191120.0,,,US,US,2019,Q4,Elderly
168717431,16871743,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,,,,,,10.0,MG,,QD,2019,Q4,Lower gastrointestinal haemorrhage,,2019,Q4,1,I,20190412.0,20190918.0,20191001,20191001,EXP,,ES-AUROBINDO-AUR-APL-2019-062847,AUROBINDO,,83.0,YR,,F,Y,,,20191001.0,,MD,ES,ES,2019,Q4,Elderly
168745622,16874562,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,FILM-COATED TABLET,,2019,Q4,Renal colic,,2019,Q4,2,F,20190925.0,20191213.0,20191001,20191218,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-104572",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,82.0,KG,20191218.0,,MD,BR,BR,2019,Q4,Adult
168810211,16881021,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Acute kidney injury,,2019,Q4,1,I,20190516.0,,20191003,20191003,DIR,,,FDA-CTU,,61.0,YR,,F,N,79.1,KG,20191003.0,N,PH,US,US,2019,Q4,Adult
168810211,16881021,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Acute respiratory failure,,2019,Q4,1,I,20190516.0,,20191003,20191003,DIR,,,FDA-CTU,,61.0,YR,,F,N,79.1,KG,20191003.0,N,PH,US,US,2019,Q4,Adult
168810211,16881021,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Alcohol poisoning,,2019,Q4,1,I,20190516.0,,20191003,20191003,DIR,,,FDA-CTU,,61.0,YR,,F,N,79.1,KG,20191003.0,N,PH,US,US,2019,Q4,Adult
168810211,16881021,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20190516.0,,20191003,20191003,DIR,,,FDA-CTU,,61.0,YR,,F,N,79.1,KG,20191003.0,N,PH,US,US,2019,Q4,Adult
168810211,16881021,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Hypoxia,,2019,Q4,1,I,20190516.0,,20191003,20191003,DIR,,,FDA-CTU,,61.0,YR,,F,N,79.1,KG,20191003.0,N,PH,US,US,2019,Q4,Adult
168810211,16881021,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Metabolic acidosis,,2019,Q4,1,I,20190516.0,,20191003,20191003,DIR,,,FDA-CTU,,61.0,YR,,F,N,79.1,KG,20191003.0,N,PH,US,US,2019,Q4,Adult
168810211,16881021,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Pneumonia aspiration,,2019,Q4,1,I,20190516.0,,20191003,20191003,DIR,,,FDA-CTU,,61.0,YR,,F,N,79.1,KG,20191003.0,N,PH,US,US,2019,Q4,Adult
168810211,16881021,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Septic shock,,2019,Q4,1,I,20190516.0,,20191003,20191003,DIR,,,FDA-CTU,,61.0,YR,,F,N,79.1,KG,20191003.0,N,PH,US,US,2019,Q4,Adult
168825511,16882551,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Angina pectoris,,2019,Q4,1,I,20181104.0,20190927.0,20191003,20191003,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-104902",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,106.7,KG,20191004.0,,MD,JP,JP,2019,Q4,Adult
168832932,16883293,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Sudden death,,2019,Q4,2,F,20190921.0,20191028.0,20191004,20191031,EXP,,DE-GILEAD-2019-0431538,GILEAD,,44.0,YR,A,M,Y,90.0,KG,20191031.0,,MD,DE,DE,2019,Q4,Adult
168862991,16886299,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Dizziness,,2019,Q4,1,I,20190918.0,,20191004,20191004,DIR,,,FDA-CTU,,72.0,YR,,M,N,88.79,KG,20191004.0,N,,US,US,2019,Q4,Elderly
168862991,16886299,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Fall,,2019,Q4,1,I,20190918.0,,20191004,20191004,DIR,,,FDA-CTU,,72.0,YR,,M,N,88.79,KG,20191004.0,N,,US,US,2019,Q4,Elderly
168862991,16886299,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Rib fracture,,2019,Q4,1,I,20190918.0,,20191004,20191004,DIR,,,FDA-CTU,,72.0,YR,,M,N,88.79,KG,20191004.0,N,,US,US,2019,Q4,Elderly
168862991,16886299,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Syncope,,2019,Q4,1,I,20190918.0,,20191004,20191004,DIR,,,FDA-CTU,,72.0,YR,,M,N,88.79,KG,20191004.0,N,,US,US,2019,Q4,Elderly
168872681,16887268,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20190904.0,20191004.0,20191004,20191004,EXP,GB-MHRA-EYC 00207602,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-12-105954",BOEHRINGER INGELHEIM,,58.0,YR,,F,Y,,,20191004.0,,PH,GB,GB,2019,Q4,Adult
168872701,16887270,4,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,,,UNKNOWN,BID,2019,Q4,Arthralgia,,2019,Q4,1,I,20161218.0,20170110.0,20191004,20191004,EXP,,CO-JNJFOC-20170110013,JOHNSON AND JOHNSON,,39.0,YR,,F,Y,60.0,KG,20191004.0,,OT,CO,CO,2019,Q4,Adult
168872701,16887270,4,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,,,UNKNOWN,BID,2019,Q4,Inappropriate schedule of product administration,,2019,Q4,1,I,20161218.0,20170110.0,20191004,20191004,EXP,,CO-JNJFOC-20170110013,JOHNSON AND JOHNSON,,39.0,YR,,F,Y,60.0,KG,20191004.0,,OT,CO,CO,2019,Q4,Adult
168872701,16887270,4,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,,,UNKNOWN,BID,2019,Q4,Sleep disorder,,2019,Q4,1,I,20161218.0,20170110.0,20191004,20191004,EXP,,CO-JNJFOC-20170110013,JOHNSON AND JOHNSON,,39.0,YR,,F,Y,60.0,KG,20191004.0,,OT,CO,CO,2019,Q4,Adult
168874073,16887407,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Peripheral ischaemia,,2019,Q4,3,F,20190709.0,20191010.0,20191004,20191015,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-104885",BOEHRINGER INGELHEIM,,60.0,YR,,M,Y,84.6,KG,20191016.0,,MD,BR,BR,2019,Q4,Adult
168921103,16892110,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Cardiac failure,,2019,Q4,3,F,20190812.0,20191010.0,20191007,20191021,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-105043",BOEHRINGER INGELHEIM,,62.0,YR,,M,Y,79.8,KG,20191021.0,,MD,CA,CA,2019,Q4,Adult
168959771,16895977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q4,Pollakiuria,,2019,Q4,1,I,20190725.0,,20190814,20190814,DIR,,,FDA-CTU,,54.0,YR,,M,N,,,20190814.0,N,PH,US,US,2019,Q4,Adult
168965331,16896533,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,2050.0,MG,Y,,,,,25.0,MG,,QD,2019,Q4,Dehydration,,2019,Q4,1,I,20190831.0,20191004.0,20191008,20191008,EXP,GB-MHRA-EYC 00207470,GB-BAUSCH-BL-2019-057121,BAUSCH AND LOMB,,64.0,YR,,M,Y,,,20191008.0,,OT,GB,GB,2019,Q4,Adult
168965331,16896533,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,2050.0,MG,Y,,,,,25.0,MG,,QD,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20190831.0,20191004.0,20191008,20191008,EXP,GB-MHRA-EYC 00207470,GB-BAUSCH-BL-2019-057121,BAUSCH AND LOMB,,64.0,YR,,M,Y,,,20191008.0,,OT,GB,GB,2019,Q4,Adult
168965331,16896533,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,2050.0,MG,Y,,,,,25.0,MG,,QD,2019,Q4,Lactic acidosis,,2019,Q4,1,I,20190831.0,20191004.0,20191008,20191008,EXP,GB-MHRA-EYC 00207470,GB-BAUSCH-BL-2019-057121,BAUSCH AND LOMB,,64.0,YR,,M,Y,,,20191008.0,,OT,GB,GB,2019,Q4,Adult
168966383,16896638,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Respiratory acidosis,,2019,Q4,3,F,20180927.0,20191028.0,20191008,20191104,EXP,,"CZ-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-009587",BOEHRINGER INGELHEIM,,81.0,YR,,M,Y,75.0,KG,20191104.0,,MD,CZ,CZ,2019,Q4,Elderly
168970151,16897015,44,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2019,Q4,Thyroid cancer,,2019,Q4,1,I,20190924.0,20191001.0,20191009,20191009,EXP,,IT-ROCHE-2429873,ROCHE,,66.0,YR,,M,Y,,,20191009.0,,MD,IT,IT,2019,Q4,Elderly
168994781,16899478,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,,20191002.0,20191009,20191009,EXP,,ES-EMD SERONO-9120799,EMD SERONO INC,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURRENT DIABETES REVIEWS. 2019;15(4):259-262. DOI:10.2174/1573399814666180726114044",52.0,YR,,M,Y,70.0,KG,20191009.0,,OT,ES,ES,2019,Q4,Adult
168994781,16899478,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,,20191002.0,20191009,20191009,EXP,,ES-EMD SERONO-9120799,EMD SERONO INC,"HERNANDEZ-QUILES C, RAMIREZ-DUQUE N, ACOSTA-DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT: CASE REPORT AND REVIEW OF LITERATURE. CURRENT DIABETES REVIEWS. 2019;15(4):259-262. DOI:10.2174/1573399814666180726114044",52.0,YR,,M,Y,70.0,KG,20191009.0,,OT,ES,ES,2019,Q4,Adult
169012771,16901277,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG DAILY,,,U,,,,204629.0,10.0,MG,TABLET,QD,2019,Q4,Blood glucose increased,,2019,Q4,1,I,20190928.0,20191003.0,20191009,20191009,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-US-105689",BOEHRINGER INGELHEIM,,55.0,YR,,F,Y,,,20191010.0,,CN,US,US,2019,Q4,Adult
169012771,16901277,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG DAILY,,,U,,,,204629.0,25.0,MG,TABLET,QD,2019,Q4,Blood glucose increased,,2019,Q4,1,I,20190928.0,20191003.0,20191009,20191009,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-US-105689",BOEHRINGER INGELHEIM,,55.0,YR,,F,Y,,,20191010.0,,CN,US,US,2019,Q4,Adult
169090821,16909082,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2019,Q4,Incontinence,,2019,Q4,1,I,20190704.0,,20190820,20190820,DIR,,,FDA-CTU,,63.0,YR,,M,N,127.0,KG,20190819.0,N,PH,US,US,2019,Q4,Adult
169090821,16909082,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2019,Q4,Pollakiuria,,2019,Q4,1,I,20190704.0,,20190820,20190820,DIR,,,FDA-CTU,,63.0,YR,,M,N,127.0,KG,20190819.0,N,PH,US,US,2019,Q4,Adult
169090821,16909082,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2019,Q4,Post procedural complication,,2019,Q4,1,I,20190704.0,,20190820,20190820,DIR,,,FDA-CTU,,63.0,YR,,M,N,127.0,KG,20190819.0,N,PH,US,US,2019,Q4,Adult
169090821,16909082,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2019,Q4,Weight increased,,2019,Q4,1,I,20190704.0,,20190820,20190820,DIR,,,FDA-CTU,,63.0,YR,,M,N,127.0,KG,20190819.0,N,PH,US,US,2019,Q4,Adult
169116812,16911681,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",2050.0,MG,Y,U,,,,25.0,MG,,QD,2019,Q4,Dehydration,,2019,Q4,2,F,20190831.0,20191202.0,20191013,20191211,EXP,,GB-AUROBINDO-AUR-APL-2019-065732,AUROBINDO,,64.0,YR,,M,Y,,,20191212.0,,OT,GB,GB,2019,Q4,Adult
169116812,16911681,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",2050.0,MG,Y,U,,,,25.0,MG,,QD,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,2,F,20190831.0,20191202.0,20191013,20191211,EXP,,GB-AUROBINDO-AUR-APL-2019-065732,AUROBINDO,,64.0,YR,,M,Y,,,20191212.0,,OT,GB,GB,2019,Q4,Adult
169116812,16911681,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",2050.0,MG,Y,U,,,,25.0,MG,,QD,2019,Q4,Lactic acidosis,,2019,Q4,2,F,20190831.0,20191202.0,20191013,20191211,EXP,,GB-AUROBINDO-AUR-APL-2019-065732,AUROBINDO,,64.0,YR,,M,Y,,,20191212.0,,OT,GB,GB,2019,Q4,Adult
169189843,16918984,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK, UNKNOWN FREQ.",,,,,,,,,,PER ORAL NOS,,2019,Q4,Hypocalcaemia,,2019,Q4,3,F,20191004.0,20191128.0,20191015,20191204,EXP,,JP-ASTELLAS-2019JP022712,ASTELLAS,,78.0,YR,,M,Y,,,20191204.0,,MD,JP,JP,2019,Q4,Elderly
169230461,16923046,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM PER DAY,2050.0,MG,Y,, UNKNOWN,,,25.0,MG,,,2019,Q4,Dehydration,,2019,Q4,1,I,20190831.0,20191009.0,20191016,20191016,EXP,GB-MHRA-EYC 00207470,GB-TEVA-2019-GB-1122065,TEVA,,64.0,YR,,M,Y,,,20191016.0,,OT,GB,GB,2019,Q4,Adult
169230461,16923046,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM PER DAY,2050.0,MG,Y,, UNKNOWN,,,25.0,MG,,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20190831.0,20191009.0,20191016,20191016,EXP,GB-MHRA-EYC 00207470,GB-TEVA-2019-GB-1122065,TEVA,,64.0,YR,,M,Y,,,20191016.0,,OT,GB,GB,2019,Q4,Adult
169230461,16923046,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM PER DAY,2050.0,MG,Y,, UNKNOWN,,,25.0,MG,,,2019,Q4,Lactic acidosis,,2019,Q4,1,I,20190831.0,20191009.0,20191016,20191016,EXP,GB-MHRA-EYC 00207470,GB-TEVA-2019-GB-1122065,TEVA,,64.0,YR,,M,Y,,,20191016.0,,OT,GB,GB,2019,Q4,Adult
169260751,16926075,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2019,Q4,Blood creatinine increased,,2019,Q4,1,I,20190720.0,,20190823,20190823,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20190822.0,N,PH,US,US,2019,Q4,Elderly
169260751,16926075,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2019,Q4,Blood urea increased,,2019,Q4,1,I,20190720.0,,20190823,20190823,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20190822.0,N,PH,US,US,2019,Q4,Elderly
169260751,16926075,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2019,Q4,Urosepsis,,2019,Q4,1,I,20190720.0,,20190823,20190823,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20190822.0,N,PH,US,US,2019,Q4,Elderly
169261161,16926116,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,N,,,,12.5,MG,,QD,2019,Q4,Dehydration,,2019,Q4,1,I,20190715.0,,20190823,20190823,DIR,,,FDA-CTU,,55.0,YR,,M,N,90.0,KG,20190822.0,N,PH,US,US,2019,Q4,Adult
169261161,16926116,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,N,,,,12.5,MG,,QD,2019,Q4,Thirst,,2019,Q4,1,I,20190715.0,,20190823,20190823,DIR,,,FDA-CTU,,55.0,YR,,M,N,90.0,KG,20190822.0,N,PH,US,US,2019,Q4,Adult
169295963,16929596,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2019,Q4,Hypocalcaemia,,2019,Q4,3,F,20191004.0,20191128.0,20191017,20191209,EXP,,JP-FERRINGPH-2019FE06666,FERRING,,78.0,YR,,M,Y,,,20191209.0,,MD,JP,JP,2019,Q4,Elderly
169302191,16930219,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD, IN THE MORNING.",,,,,,,,25.0,MG,TABLET,QD,2019,Q4,Dyspnoea,,2019,Q4,1,I,20190416.0,20191011.0,20191017,20191017,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-MYLANLABS-2019M1097006,MYLAN,,69.0,YR,,F,Y,,,20191017.0,,PH,GB,GB,2019,Q4,Elderly
169302191,16930219,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD, IN THE MORNING.",,,,,,,,25.0,MG,TABLET,QD,2019,Q4,Interstitial lung disease,,2019,Q4,1,I,20190416.0,20191011.0,20191017,20191017,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-MYLANLABS-2019M1097006,MYLAN,,69.0,YR,,F,Y,,,20191017.0,,PH,GB,GB,2019,Q4,Elderly
169302191,16930219,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD, IN THE MORNING.",,,,,,,,25.0,MG,TABLET,QD,2019,Q4,Left ventricular dysfunction,,2019,Q4,1,I,20190416.0,20191011.0,20191017,20191017,EXP,GB-MHRA-MIDB-7B6FB732-CC9C-4072-A1B9-2A2B2A49D619,GB-MYLANLABS-2019M1097006,MYLAN,,69.0,YR,,F,Y,,,20191017.0,,PH,GB,GB,2019,Q4,Elderly
169323801,16932380,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Blood cholesterol increased,,2019,Q4,1,I,201909.0,20191015.0,20191017,20191017,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-US-107885",BOEHRINGER INGELHEIM,,58.0,YR,,F,Y,,,20191018.0,,CN,US,US,2019,Q4,Adult
169323801,16932380,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Fungal skin infection,,2019,Q4,1,I,201909.0,20191015.0,20191017,20191017,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-US-107885",BOEHRINGER INGELHEIM,,58.0,YR,,F,Y,,,20191018.0,,CN,US,US,2019,Q4,Adult
169324261,16932426,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",26298.96,MG,Y,U,,,,25.0,MG,,QD,2019,Q4,Confusional state,,2019,Q4,1,I,20190918.0,20191009.0,20191017,20191017,EXP,GB-MHRA-EYC 00208853,GB-NOVOPROD-689574,NOVO NORDISK,,69.0,YR,,F,Y,83.0,KG,20191018.0,,MD,GB,GB,2019,Q4,Elderly
169324261,16932426,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",26298.96,MG,Y,U,,,,25.0,MG,,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20190918.0,20191009.0,20191017,20191017,EXP,GB-MHRA-EYC 00208853,GB-NOVOPROD-689574,NOVO NORDISK,,69.0,YR,,F,Y,83.0,KG,20191018.0,,MD,GB,GB,2019,Q4,Elderly
169324261,16932426,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",26298.96,MG,Y,U,,,,25.0,MG,,QD,2019,Q4,Incorrect route of product administration,,2019,Q4,1,I,20190918.0,20191009.0,20191017,20191017,EXP,GB-MHRA-EYC 00208853,GB-NOVOPROD-689574,NOVO NORDISK,,69.0,YR,,F,Y,83.0,KG,20191018.0,,MD,GB,GB,2019,Q4,Elderly
169324261,16932426,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",26298.96,MG,Y,U,,,,25.0,MG,,QD,2019,Q4,Pancreatitis acute,,2019,Q4,1,I,20190918.0,20191009.0,20191017,20191017,EXP,GB-MHRA-EYC 00208853,GB-NOVOPROD-689574,NOVO NORDISK,,69.0,YR,,F,Y,83.0,KG,20191018.0,,MD,GB,GB,2019,Q4,Elderly
169324261,16932426,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",26298.96,MG,Y,U,,,,25.0,MG,,QD,2019,Q4,Somnolence,,2019,Q4,1,I,20190918.0,20191009.0,20191017,20191017,EXP,GB-MHRA-EYC 00208853,GB-NOVOPROD-689574,NOVO NORDISK,,69.0,YR,,F,Y,83.0,KG,20191018.0,,MD,GB,GB,2019,Q4,Elderly
169358481,16935848,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q4,Urinary tract infection,,2019,Q4,1,I,20190603.0,,20190827,20190827,DIR,,,FDA-CTU,,37.0,YR,,F,N,,,20190816.0,N,PH,US,US,2019,Q4,Adult
169390402,16939040,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,2,F,,20191204.0,20191020,20191216,EXP,,CO-NOVOPROD-690482,NOVO NORDISK,,55.0,YR,,F,Y,,,20191216.0,,MD,CO,CO,2019,Q4,Adult
169390402,16939040,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Incorrect dose administered,,2019,Q4,2,F,,20191204.0,20191020,20191216,EXP,,CO-NOVOPROD-690482,NOVO NORDISK,,55.0,YR,,F,Y,,,20191216.0,,MD,CO,CO,2019,Q4,Adult
169397622,16939762,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,, UNK,,204629.0,10.0,MG,,QD,2019,Q4,Diabetes mellitus inadequate control,,2019,Q4,2,F,,20191216.0,20191021,20191223,EXP,,"SI-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-12-107489",BOEHRINGER INGELHEIM,,75.0,YR,,M,Y,124.0,KG,20191223.0,,OT,SI,SI,2019,Q4,Elderly
169408791,16940879,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DOSAGE FORM, QD",178.958,DF,,,,,,1.0,DF,,QD,2019,Q4,Abdominal pain,,2019,Q4,1,I,20190802.0,20191014.0,20191021,20191021,EXP,GB-MHRA-TPP10592814C7009506YC1564739331181,GB-MYLANLABS-2019M1098077,MYLAN,,52.0,YR,,F,Y,97.0,KG,20191021.0,,MD,GB,GB,2019,Q4,Adult
169408791,16940879,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DOSAGE FORM, QD",178.958,DF,,,,,,1.0,DF,,QD,2019,Q4,Vomiting,,2019,Q4,1,I,20190802.0,20191014.0,20191021,20191021,EXP,GB-MHRA-TPP10592814C7009506YC1564739331181,GB-MYLANLABS-2019M1098077,MYLAN,,52.0,YR,,F,Y,97.0,KG,20191021.0,,MD,GB,GB,2019,Q4,Adult
169411001,16941100,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DOSAGE FORM, QD",166.958,DF,,,,,,1.0,DF,,QD,2019,Q4,Pruritus,,2019,Q4,1,I,20190819.0,20191014.0,20191021,20191021,EXP,GB-MHRA-TPP30738493C5984567YC1566199154760,GB-MYLANLABS-2019M1098303,MYLAN,,77.0,YR,,F,Y,83.0,KG,20191021.0,,MD,GB,GB,2019,Q4,Elderly
169428291,16942829,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Lung neoplasm,,2019,Q4,1,I,201902.0,20190315.0,20191021,20191021,EXP,,"IT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-012145",BOEHRINGER INGELHEIM,,86.0,YR,,M,Y,80.0,KG,20191021.0,,MD,IT,IT,2019,Q4,Elderly
169448181,16944818,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, UNKNOWN",,,,,,,,25.0,MG,,,2019,Q4,Blood glucose increased,,2019,Q4,1,I,2015.0,20191017.0,20191022,20191022,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-STRIDES ARCOLAB LIMITED-2019SP010325,STRIDES,,63.0,YR,,M,Y,,,20191022.0,,,NL,HU,2019,Q4,Adult
169448181,16944818,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, UNKNOWN",,,,,,,,25.0,MG,,,2019,Q4,Blood pressure inadequately controlled,,2019,Q4,1,I,2015.0,20191017.0,20191022,20191022,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-STRIDES ARCOLAB LIMITED-2019SP010325,STRIDES,,63.0,YR,,M,Y,,,20191022.0,,,NL,HU,2019,Q4,Adult
169448181,16944818,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, UNKNOWN",,,,,,,,25.0,MG,,,2019,Q4,Blood pressure systolic increased,,2019,Q4,1,I,2015.0,20191017.0,20191022,20191022,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-STRIDES ARCOLAB LIMITED-2019SP010325,STRIDES,,63.0,YR,,M,Y,,,20191022.0,,,NL,HU,2019,Q4,Adult
169448181,16944818,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, UNKNOWN",,,,,,,,25.0,MG,,,2019,Q4,Dyslipidaemia,,2019,Q4,1,I,2015.0,20191017.0,20191022,20191022,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-STRIDES ARCOLAB LIMITED-2019SP010325,STRIDES,,63.0,YR,,M,Y,,,20191022.0,,,NL,HU,2019,Q4,Adult
169448181,16944818,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, UNKNOWN",,,,,,,,25.0,MG,,,2019,Q4,Eating disorder,,2019,Q4,1,I,2015.0,20191017.0,20191022,20191022,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-STRIDES ARCOLAB LIMITED-2019SP010325,STRIDES,,63.0,YR,,M,Y,,,20191022.0,,,NL,HU,2019,Q4,Adult
169448181,16944818,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, UNKNOWN",,,,,,,,25.0,MG,,,2019,Q4,Glycosylated haemoglobin increased,,2019,Q4,1,I,2015.0,20191017.0,20191022,20191022,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-STRIDES ARCOLAB LIMITED-2019SP010325,STRIDES,,63.0,YR,,M,Y,,,20191022.0,,,NL,HU,2019,Q4,Adult
169448181,16944818,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, UNKNOWN",,,,,,,,25.0,MG,,,2019,Q4,Mobility decreased,,2019,Q4,1,I,2015.0,20191017.0,20191022,20191022,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-STRIDES ARCOLAB LIMITED-2019SP010325,STRIDES,,63.0,YR,,M,Y,,,20191022.0,,,NL,HU,2019,Q4,Adult
169448181,16944818,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, UNKNOWN",,,,,,,,25.0,MG,,,2019,Q4,Obesity,,2019,Q4,1,I,2015.0,20191017.0,20191022,20191022,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-STRIDES ARCOLAB LIMITED-2019SP010325,STRIDES,,63.0,YR,,M,Y,,,20191022.0,,,NL,HU,2019,Q4,Adult
169448181,16944818,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, UNKNOWN",,,,,,,,25.0,MG,,,2019,Q4,Sleep apnoea syndrome,,2019,Q4,1,I,2015.0,20191017.0,20191022,20191022,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-STRIDES ARCOLAB LIMITED-2019SP010325,STRIDES,,63.0,YR,,M,Y,,,20191022.0,,,NL,HU,2019,Q4,Adult
169448181,16944818,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, UNKNOWN",,,,,,,,25.0,MG,,,2019,Q4,Stress,,2019,Q4,1,I,2015.0,20191017.0,20191022,20191022,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-STRIDES ARCOLAB LIMITED-2019SP010325,STRIDES,,63.0,YR,,M,Y,,,20191022.0,,,NL,HU,2019,Q4,Adult
169448181,16944818,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, UNKNOWN",,,,,,,,25.0,MG,,,2019,Q4,Type 2 diabetes mellitus,,2019,Q4,1,I,2015.0,20191017.0,20191022,20191022,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-STRIDES ARCOLAB LIMITED-2019SP010325,STRIDES,,63.0,YR,,M,Y,,,20191022.0,,,NL,HU,2019,Q4,Adult
169515213,16951521,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Cardiac failure,,2019,Q4,3,F,20191015.0,20191204.0,20191023,20191210,EXP,,"AR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-108695",BOEHRINGER INGELHEIM,,58.0,YR,,F,Y,77.7,KG,20191210.0,,MD,AR,AR,2019,Q4,Adult
169516841,16951684,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q4,Genital rash,,2019,Q4,1,I,20190821.0,,20190903,20190903,DIR,,,FDA-CTU,,72.0,YR,,M,N,,,20190830.0,N,PH,US,US,2019,Q4,Elderly
169516841,16951684,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q4,Rash,,2019,Q4,1,I,20190821.0,,20190903,20190903,DIR,,,FDA-CTU,,72.0,YR,,M,N,,,20190830.0,N,PH,US,US,2019,Q4,Elderly
169521741,16952174,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20190718.0,,20190903,20190903,DIR,,,FDA-CTU,,70.0,YR,,M,N,68.04,KG,20190724.0,N,PH,US,US,2019,Q4,Elderly
169544562,16954456,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2019,Q4,Hepatitis,,2019,Q4,2,F,2019.0,20191104.0,20191023,20191111,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201910007881,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20191111.0,,CN,ES,ES,2019,Q4,Adult
169574221,16957422,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,DAILY DOSE: 1 DF DOSAGE FORM EVERY DAYS,,,,,,,,1.0,DF,,QD,2019,Q4,Abdominal pain,,2019,Q4,1,I,20190627.0,20191021.0,20191024,20191024,EXP,,DE-009507513-1910DEU013262,MERCK,,54.0,YR,,M,Y,106.0,KG,20191024.0,,MD,DE,DE,2019,Q4,Adult
169574221,16957422,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,DAILY DOSE: 1 DF DOSAGE FORM EVERY DAYS,,,,,,,,1.0,DF,,QD,2019,Q4,Cholestasis,,2019,Q4,1,I,20190627.0,20191021.0,20191024,20191024,EXP,,DE-009507513-1910DEU013262,MERCK,,54.0,YR,,M,Y,106.0,KG,20191024.0,,MD,DE,DE,2019,Q4,Adult
169574221,16957422,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,DAILY DOSE: 1 DF DOSAGE FORM EVERY DAYS,,,,,,,,1.0,DF,,QD,2019,Q4,Diarrhoea,,2019,Q4,1,I,20190627.0,20191021.0,20191024,20191024,EXP,,DE-009507513-1910DEU013262,MERCK,,54.0,YR,,M,Y,106.0,KG,20191024.0,,MD,DE,DE,2019,Q4,Adult
169574221,16957422,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,DAILY DOSE: 1 DF DOSAGE FORM EVERY DAYS,,,,,,,,1.0,DF,,QD,2019,Q4,Pancreatitis,,2019,Q4,1,I,20190627.0,20191021.0,20191024,20191024,EXP,,DE-009507513-1910DEU013262,MERCK,,54.0,YR,,M,Y,106.0,KG,20191024.0,,MD,DE,DE,2019,Q4,Adult
169582061,16958206,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2019,Q4,Squamous cell carcinoma,,2019,Q4,1,I,20190315.0,20191016.0,20191024,20191024,EXP,,GB-JNJFOC-20191025521,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,105.0,KG,20191024.0,,OT,GB,GB,2019,Q4,Elderly
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Alanine aminotransferase increased,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Aortic arteriosclerosis,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Aspartate aminotransferase increased,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Basophil count increased,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Blood alkaline phosphatase increased,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Blood creatine phosphokinase increased,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Blood glucose increased,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Eosinophil count increased,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Left ventricular dysfunction,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Left ventricular hypertrophy,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Oedema peripheral,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Protein total increased,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Pulmonary valve incompetence,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Red cell distribution width increased,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Right ventricular hypertrophy,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Sinus tachycardia,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Systolic dysfunction,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169620451,16962045,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, IN THE MORNING",,,,,,,,25.0,MG,,,2019,Q4,Ventricular hypokinesia,,2019,Q4,1,I,20190917.0,20191018.0,20191025,20191025,EXP,,AU-PFIZER INC-2019455357,PFIZER,,58.0,YR,,M,Y,,,20191025.0,,MD,AU,AU,2019,Q4,Adult
169640201,16964020,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q4,Blood glucose increased,,2019,Q4,1,I,2015.0,20191021.0,20191026,20191026,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-ACCORD-159035,ACCORD,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20191026.0,,OT,HU,HU,2019,Q4,Adult
169640201,16964020,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q4,Blood pressure inadequately controlled,,2019,Q4,1,I,2015.0,20191021.0,20191026,20191026,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-ACCORD-159035,ACCORD,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20191026.0,,OT,HU,HU,2019,Q4,Adult
169640201,16964020,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q4,Blood pressure systolic increased,,2019,Q4,1,I,2015.0,20191021.0,20191026,20191026,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-ACCORD-159035,ACCORD,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20191026.0,,OT,HU,HU,2019,Q4,Adult
169640201,16964020,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q4,Dyslipidaemia,,2019,Q4,1,I,2015.0,20191021.0,20191026,20191026,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-ACCORD-159035,ACCORD,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20191026.0,,OT,HU,HU,2019,Q4,Adult
169640201,16964020,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q4,Eating disorder,,2019,Q4,1,I,2015.0,20191021.0,20191026,20191026,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-ACCORD-159035,ACCORD,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20191026.0,,OT,HU,HU,2019,Q4,Adult
169640201,16964020,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q4,Glycosylated haemoglobin increased,,2019,Q4,1,I,2015.0,20191021.0,20191026,20191026,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-ACCORD-159035,ACCORD,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20191026.0,,OT,HU,HU,2019,Q4,Adult
169640201,16964020,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q4,Mobility decreased,,2019,Q4,1,I,2015.0,20191021.0,20191026,20191026,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-ACCORD-159035,ACCORD,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20191026.0,,OT,HU,HU,2019,Q4,Adult
169640201,16964020,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q4,Obesity,,2019,Q4,1,I,2015.0,20191021.0,20191026,20191026,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-ACCORD-159035,ACCORD,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20191026.0,,OT,HU,HU,2019,Q4,Adult
169640201,16964020,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q4,Sleep apnoea syndrome,,2019,Q4,1,I,2015.0,20191021.0,20191026,20191026,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-ACCORD-159035,ACCORD,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20191026.0,,OT,HU,HU,2019,Q4,Adult
169640201,16964020,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q4,Stress,,2019,Q4,1,I,2015.0,20191021.0,20191026,20191026,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-ACCORD-159035,ACCORD,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20191026.0,,OT,HU,HU,2019,Q4,Adult
169640201,16964020,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,,,2019,Q4,Type 2 diabetes mellitus,,2019,Q4,1,I,2015.0,20191021.0,20191026,20191026,EXP,HU-EMA-DD-20191016-KHARE_I-140134,HU-ACCORD-159035,ACCORD,"KATONA, G.. HYPERTENSION TREATMENT OF PATIENT WITH DIABETES. MAGYAR CSALADORVOSOK LAPJA. 2019;1:17-18",63.0,YR,,M,Y,,,20191026.0,,OT,HU,HU,2019,Q4,Adult
169647921,16964792,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,15.0,DF,,, UNKNOWN,,,1.0,DF,,,2019,Q4,Swelling face,,2019,Q4,1,I,20191001.0,20191022.0,20191028,20191028,EXP,GB-MHRA-TPP51533152C6120645YC1569943139320,GB-TEVA-2019-GB-1127711,TEVA,,67.0,YR,,F,Y,89.0,KG,20191028.0,,MD,GB,GB,2019,Q4,Elderly
169665401,16966540,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;?,,,Y,N,,,,,,,QD,2019,Q4,Acute kidney injury,,2019,Q4,1,I,20190628.0,,20190909,20190909,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20190906.0,N,PH,US,US,2019,Q4,Elderly
169665401,16966540,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;?,,,Y,N,,,,,,,QD,2019,Q4,Carotid artery stenosis,,2019,Q4,1,I,20190628.0,,20190909,20190909,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20190906.0,N,PH,US,US,2019,Q4,Elderly
169665401,16966540,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;?,,,Y,N,,,,,,,QD,2019,Q4,Hypophagia,,2019,Q4,1,I,20190628.0,,20190909,20190909,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20190906.0,N,PH,US,US,2019,Q4,Elderly
169665401,16966540,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;?,,,Y,N,,,,,,,QD,2019,Q4,Orthostatic hypotension,,2019,Q4,1,I,20190628.0,,20190909,20190909,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20190906.0,N,PH,US,US,2019,Q4,Elderly
169665401,16966540,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;?,,,Y,N,,,,,,,QD,2019,Q4,Syncope,,2019,Q4,1,I,20190628.0,,20190909,20190909,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20190906.0,N,PH,US,US,2019,Q4,Elderly
169669801,16966980,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Hyperglycaemia,,2019,Q4,1,I,20190830.0,,20190910,20190910,DIR,,,FDA-CTU,,38.0,YR,,M,N,,,20190909.0,N,PH,US,US,2019,Q4,Adult
169670721,16967072,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2019,Q4,Urosepsis,,2019,Q4,1,I,20190805.0,,20190910,20190910,DIR,,,FDA-CTU,,70.0,YR,,M,N,,,20190831.0,N,PH,US,US,2019,Q4,Elderly
169672491,16967249,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2019,Q4,Asthenia,,2019,Q4,1,I,20190701.0,,20190910,20190910,DIR,,,FDA-CTU,,75.0,YR,,M,N,93.0,KG,20190908.0,N,PH,US,US,2019,Q4,Elderly
169672491,16967249,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2019,Q4,Decreased appetite,,2019,Q4,1,I,20190701.0,,20190910,20190910,DIR,,,FDA-CTU,,75.0,YR,,M,N,93.0,KG,20190908.0,N,PH,US,US,2019,Q4,Elderly
169672491,16967249,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2019,Q4,Fatigue,,2019,Q4,1,I,20190701.0,,20190910,20190910,DIR,,,FDA-CTU,,75.0,YR,,M,N,93.0,KG,20190908.0,N,PH,US,US,2019,Q4,Elderly
169673271,16967327,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,25.0,MG,,QD,2019,Q4,Urinary tract infection,,2019,Q4,1,I,20190325.0,,20190910,20190910,DIR,,,FDA-CTU,,67.0,YR,,M,N,98.0,KG,20190411.0,N,PH,US,US,2019,Q4,Elderly
169692081,16969208,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,315.958,DF,U,,,,,1.0,DF,,QD,2019,Q4,Abdominal pain,,2019,Q4,1,I,20191003.0,20191017.0,20191029,20191029,EXP,GB-MHRA-TPP14268155C304213YC1570096988675,GB-ELI_LILLY_AND_COMPANY-GB201910009309,ELI LILLY AND CO,,58.0,YR,,F,Y,98.0,KG,20191029.0,,CN,GB,GB,2019,Q4,Adult
169692081,16969208,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,315.958,DF,U,,,,,1.0,DF,,QD,2019,Q4,Musculoskeletal pain,,2019,Q4,1,I,20191003.0,20191017.0,20191029,20191029,EXP,GB-MHRA-TPP14268155C304213YC1570096988675,GB-ELI_LILLY_AND_COMPANY-GB201910009309,ELI LILLY AND CO,,58.0,YR,,F,Y,98.0,KG,20191029.0,,CN,GB,GB,2019,Q4,Adult
169692081,16969208,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,315.958,DF,U,,,,,1.0,DF,,QD,2019,Q4,Nausea,,2019,Q4,1,I,20191003.0,20191017.0,20191029,20191029,EXP,GB-MHRA-TPP14268155C304213YC1570096988675,GB-ELI_LILLY_AND_COMPANY-GB201910009309,ELI LILLY AND CO,,58.0,YR,,F,Y,98.0,KG,20191029.0,,CN,GB,GB,2019,Q4,Adult
169692152,16969215,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,300 MG,,,,,,,,300.0,MG,,,2019,Q4,Hypoglycaemia,,2019,Q4,2,F,20190516.0,20191111.0,20191029,20191122,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201910011812AA,ELI LILLY AND CO,,48.0,YR,,M,Y,65.0,KG,20191122.0,,CN,JP,JP,2019,Q4,Adult
169692152,16969215,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,300 MG,,,,,,,,300.0,MG,,,2019,Q4,Incorrect dose administered,,2019,Q4,2,F,20190516.0,20191111.0,20191029,20191122,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201910011812AA,ELI LILLY AND CO,,48.0,YR,,M,Y,65.0,KG,20191122.0,,CN,JP,JP,2019,Q4,Adult
169692152,16969215,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,300 MG,,,,,,,,300.0,MG,,,2019,Q4,Lactic acidosis,,2019,Q4,2,F,20190516.0,20191111.0,20191029,20191122,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201910011812AA,ELI LILLY AND CO,,48.0,YR,,M,Y,65.0,KG,20191122.0,,CN,JP,JP,2019,Q4,Adult
169692152,16969215,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,300 MG,,,,,,,,300.0,MG,,,2019,Q4,Pneumonia aspiration,,2019,Q4,2,F,20190516.0,20191111.0,20191029,20191122,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201910011812AA,ELI LILLY AND CO,,48.0,YR,,M,Y,65.0,KG,20191122.0,,CN,JP,JP,2019,Q4,Adult
169692152,16969215,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,300 MG,,,,,,,,300.0,MG,,,2019,Q4,Suicide attempt,,2019,Q4,2,F,20190516.0,20191111.0,20191029,20191122,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201910011812AA,ELI LILLY AND CO,,48.0,YR,,M,Y,65.0,KG,20191122.0,,CN,JP,JP,2019,Q4,Adult
169722591,16972259,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,204629.0,,,TABLET,,2019,Q4,Genital infection bacterial,,2019,Q4,1,I,201909.0,20191022.0,20191029,20191029,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-US-109321",BOEHRINGER INGELHEIM,,42.0,YR,,F,Y,,,20191030.0,,CN,US,US,2019,Q4,Adult
169727191,16972719,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Acute myocardial infarction,,2019,Q4,1,I,20181017.0,20191024.0,20191030,20191030,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-110013",BOEHRINGER INGELHEIM,,51.0,YR,,M,Y,73.5,KG,20191030.0,,MD,JP,JP,2019,Q4,Adult
169768152,16976815,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q4,Renal impairment,,2019,Q4,2,F,20171117.0,20191220.0,20191030,20191224,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-110784",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,100.0,KG,20191224.0,,MD,JP,JP,2019,Q4,Adult
169828791,16982879,1,PS,empagliflozin,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20191029.0,,20191030,20191030,DIR,,,FDA-CTU,,51.0,YR,,T,N,87.5,KG,20191030.0,N,,US,US,2019,Q4,Adult
169857731,16985773,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,1.0,DF,,QD,2019,Q4,Fungal infection,,2019,Q4,1,I,20190604.0,,20190917,20190917,DIR,,,FDA-CTU,,75.0,YR,,M,N,100.7,KG,20190816.0,N,PH,US,US,2019,Q4,Elderly
169857731,16985773,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,1.0,DF,,QD,2019,Q4,Urinary tract infection,,2019,Q4,1,I,20190604.0,,20190917,20190917,DIR,,,FDA-CTU,,75.0,YR,,M,N,100.7,KG,20190816.0,N,PH,US,US,2019,Q4,Elderly
169859081,16985908,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Encephalopathy,,2019,Q4,1,I,20190419.0,,20191031,20191031,DIR,,,FDA-CTU,,65.0,YR,,F,N,79.0,KG,20191031.0,N,PH,US,US,2019,Q4,Elderly
169859081,16985908,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20190419.0,,20191031,20191031,DIR,,,FDA-CTU,,65.0,YR,,F,N,79.0,KG,20191031.0,N,PH,US,US,2019,Q4,Elderly
169859081,16985908,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Hypophagia,,2019,Q4,1,I,20190419.0,,20191031,20191031,DIR,,,FDA-CTU,,65.0,YR,,F,N,79.0,KG,20191031.0,N,PH,US,US,2019,Q4,Elderly
169859081,16985908,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Nausea,,2019,Q4,1,I,20190419.0,,20191031,20191031,DIR,,,FDA-CTU,,65.0,YR,,F,N,79.0,KG,20191031.0,N,PH,US,US,2019,Q4,Elderly
169859081,16985908,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Vomiting,,2019,Q4,1,I,20190419.0,,20191031,20191031,DIR,,,FDA-CTU,,65.0,YR,,F,N,79.0,KG,20191031.0,N,PH,US,US,2019,Q4,Elderly
169945611,16994561,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Cellulitis,,2019,Q4,1,I,20190204.0,20191024.0,20191105,20191105,EXP,,GB-JNJFOC-20191039833,JOHNSON AND JOHNSON,,53.0,YR,,M,Y,159.9,KG,20191105.0,,OT,GB,GB,2019,Q4,Adult
169945611,16994561,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Pyelonephritis,,2019,Q4,1,I,20190204.0,20191024.0,20191105,20191105,EXP,,GB-JNJFOC-20191039833,JOHNSON AND JOHNSON,,53.0,YR,,M,Y,159.9,KG,20191105.0,,OT,GB,GB,2019,Q4,Adult
169945611,16994561,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Urinary tract infection enterococcal,,2019,Q4,1,I,20190204.0,20191024.0,20191105,20191105,EXP,,GB-JNJFOC-20191039833,JOHNSON AND JOHNSON,,53.0,YR,,M,Y,159.9,KG,20191105.0,,OT,GB,GB,2019,Q4,Adult
169981471,16998147,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,222.0,DF,,,,,,1.0,DF,,QD,2019,Q4,Glossodynia,,2019,Q4,1,I,20180521.0,20191030.0,20191106,20191106,EXP,GB-MHRA-TPP28502604C1470748YC1526893895702,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-12-110908",BOEHRINGER INGELHEIM,,71.0,YR,,F,Y,77.0,KG,20191106.0,,MD,GB,GB,2019,Q4,Elderly
169981471,16998147,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,222.0,DF,,,,,,1.0,DF,,QD,2019,Q4,Oral mucosal blistering,,2019,Q4,1,I,20180521.0,20191030.0,20191106,20191106,EXP,GB-MHRA-TPP28502604C1470748YC1526893895702,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-12-110908",BOEHRINGER INGELHEIM,,71.0,YR,,F,Y,77.0,KG,20191106.0,,MD,GB,GB,2019,Q4,Elderly
169990181,16999018,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2019,Q4,Abdominal pain,,2019,Q4,1,I,201706.0,20171128.0,20191106,20191106,EXP,,PHJP2017JP035137,NOVARTIS,,55.0,YR,,F,Y,74.6,KG,20191106.0,,CN,COUNTRY NOT SPECIFIED,JP,2019,Q4,Adult
169990181,16999018,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2019,Q4,Appendicitis,,2019,Q4,1,I,201706.0,20171128.0,20191106,20191106,EXP,,PHJP2017JP035137,NOVARTIS,,55.0,YR,,F,Y,74.6,KG,20191106.0,,CN,COUNTRY NOT SPECIFIED,JP,2019,Q4,Adult
169990181,16999018,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2019,Q4,Diabetes mellitus inadequate control,,2019,Q4,1,I,201706.0,20171128.0,20191106,20191106,EXP,,PHJP2017JP035137,NOVARTIS,,55.0,YR,,F,Y,74.6,KG,20191106.0,,CN,COUNTRY NOT SPECIFIED,JP,2019,Q4,Adult
169990181,16999018,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2019,Q4,Peritoneal abscess,,2019,Q4,1,I,201706.0,20171128.0,20191106,20191106,EXP,,PHJP2017JP035137,NOVARTIS,,55.0,YR,,F,Y,74.6,KG,20191106.0,,CN,COUNTRY NOT SPECIFIED,JP,2019,Q4,Adult
169990181,16999018,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2019,Q4,Pyrexia,,2019,Q4,1,I,201706.0,20171128.0,20191106,20191106,EXP,,PHJP2017JP035137,NOVARTIS,,55.0,YR,,F,Y,74.6,KG,20191106.0,,CN,COUNTRY NOT SPECIFIED,JP,2019,Q4,Adult
170000061,17000006,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,FROM PREVIOUS 2 WEEKS,,,,,,,,,,,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,,20191031.0,20191106,20191106,EXP,,PT-MYLANLABS-2019M1104637,MYLAN,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZIN",71.0,YR,,M,Y,,,20191106.0,,MD,PT,PT,2019,Q4,Elderly
170000061,17000006,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,FROM PREVIOUS 2 WEEKS,,,,,,,,,,,,2019,Q4,Dizziness,,2019,Q4,1,I,,20191031.0,20191106,20191106,EXP,,PT-MYLANLABS-2019M1104637,MYLAN,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZIN",71.0,YR,,M,Y,,,20191106.0,,MD,PT,PT,2019,Q4,Elderly
170000061,17000006,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,FROM PREVIOUS 2 WEEKS,,,,,,,,,,,,2019,Q4,Hypovolaemia,,2019,Q4,1,I,,20191031.0,20191106,20191106,EXP,,PT-MYLANLABS-2019M1104637,MYLAN,"GOUVEIA C. C., DUQUE S., CAMPOS L.. LIPOTHYMIA DUE TO HYPOVOLAEMIA - A CASE OF IATROGENESIS TO EMPAGLIFLOZIN",71.0,YR,,M,Y,,,20191106.0,,MD,PT,PT,2019,Q4,Elderly
170054171,17005417,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q4,Urinary tract infection,,2019,Q4,1,I,20190725.0,,20190926,20190926,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20190918.0,N,PH,US,US,2019,Q4,Elderly
170107381,17010738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,Y,D,,,,,,,QD,2019,Q4,Blood creatinine increased,,2019,Q4,1,I,20190516.0,,20190930,20190930,DIR,,,FDA-CTU,,70.0,YR,,M,N,,,20190718.0,N,PH,US,US,2019,Q4,Elderly
170107381,17010738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,Y,D,,,,,,,QD,2019,Q4,Blood urea increased,,2019,Q4,1,I,20190516.0,,20190930,20190930,DIR,,,FDA-CTU,,70.0,YR,,M,N,,,20190718.0,N,PH,US,US,2019,Q4,Elderly
170107381,17010738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,Y,D,,,,,,,QD,2019,Q4,Dizziness,,2019,Q4,1,I,20190516.0,,20190930,20190930,DIR,,,FDA-CTU,,70.0,YR,,M,N,,,20190718.0,N,PH,US,US,2019,Q4,Elderly
170107381,17010738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,Y,D,,,,,,,QD,2019,Q4,Hallucination,,2019,Q4,1,I,20190516.0,,20190930,20190930,DIR,,,FDA-CTU,,70.0,YR,,M,N,,,20190718.0,N,PH,US,US,2019,Q4,Elderly
170107381,17010738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,Y,D,,,,,,,QD,2019,Q4,Urinary tract infection,,2019,Q4,1,I,20190516.0,,20190930,20190930,DIR,,,FDA-CTU,,70.0,YR,,M,N,,,20190718.0,N,PH,US,US,2019,Q4,Elderly
170157982,17015798,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Atrial tachycardia,,2019,Q4,2,F,201806.0,20191125.0,20191111,20191202,EXP,,"RS-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-111966",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,,,20191202.0,,MD,RS,RS,2019,Q4,Adult
170157982,17015798,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Atrial thrombosis,,2019,Q4,2,F,201806.0,20191125.0,20191111,20191202,EXP,,"RS-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-111966",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,,,20191202.0,,MD,RS,RS,2019,Q4,Adult
170157982,17015798,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Drug interaction,,2019,Q4,2,F,201806.0,20191125.0,20191111,20191202,EXP,,"RS-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-111966",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,,,20191202.0,,MD,RS,RS,2019,Q4,Adult
170157982,17015798,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Gastrointestinal haemorrhage,,2019,Q4,2,F,201806.0,20191125.0,20191111,20191202,EXP,,"RS-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-111966",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,,,20191202.0,,MD,RS,RS,2019,Q4,Adult
170157982,17015798,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Glycosylated haemoglobin increased,,2019,Q4,2,F,201806.0,20191125.0,20191111,20191202,EXP,,"RS-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-111966",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,,,20191202.0,,MD,RS,RS,2019,Q4,Adult
170174091,17017409,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2019,Q4,Transient ischaemic attack,,2019,Q4,1,I,20190801.0,,20191004,20191004,DIR,,,FDA-CTU,,58.0,YR,,M,N,111.0,KG,20191003.0,N,PH,US,US,2019,Q4,Adult
170178381,17017838,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,U,,,,,,,,QD,2019,Q4,Rash,,2019,Q4,1,I,,20191107.0,20191111,20191111,EXP,GB-MHRA-TPP25139373C5315413YC1571762952091,GB-TAKEDA-2019TEU013262,TAKEDA,,53.0,YR,,F,Y,72.0,KG,20191111.0,,OT,GB,GB,2019,Q4,Adult
170178381,17017838,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,U,,,,,,,,QD,2019,Q4,Throat tightness,,2019,Q4,1,I,,20191107.0,20191111,20191111,EXP,GB-MHRA-TPP25139373C5315413YC1571762952091,GB-TAKEDA-2019TEU013262,TAKEDA,,53.0,YR,,F,Y,72.0,KG,20191111.0,,OT,GB,GB,2019,Q4,Adult
170184241,17018424,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, UNK",,,,,,,,10.0,MG,,,2019,Q4,Pancreatitis acute,,2019,Q4,1,I,20180529.0,20180627.0,20191111,20191111,EXP,,PHHO2018PT007933,NOVARTIS,,46.0,YR,,F,Y,,,20191112.0,,OT,PT,PT,2019,Q4,Adult
170185012,17018501,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Osteonecrosis of jaw,,2019,Q4,2,F,20180605.0,20191127.0,20191111,20191203,EXP,,PHHO2019ES009322,NOVARTIS,,66.0,YR,,F,Y,78.0,KG,20191203.0,,OT,ES,ES,2019,Q4,Elderly
170195591,17019559,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Myalgia,,2019,Q4,1,I,20190701.0,20191001.0,20191112,20191112,PER,GB-MHRA-EYC 00205350,GB-LUPIN PHARMACEUTICALS INC.-2019-06438,LUPIN,,64.0,YR,,M,Y,75.0,KG,20191112.0,,CN,GB,GB,2019,Q4,Adult
170195613,17019561,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Blood creatinine increased,,2019,Q4,3,F,20191102.0,20191202.0,20191112,20191206,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-112197",BOEHRINGER INGELHEIM,,15.0,YR,,F,Y,96.0,KG,20191206.0,,MD,US,US,2019,Q4,Youth
170195613,17019561,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Colitis,,2019,Q4,3,F,20191102.0,20191202.0,20191112,20191206,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-112197",BOEHRINGER INGELHEIM,,15.0,YR,,F,Y,96.0,KG,20191206.0,,MD,US,US,2019,Q4,Youth
170195613,17019561,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Tubulointerstitial nephritis,,2019,Q4,3,F,20191102.0,20191202.0,20191112,20191206,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-112197",BOEHRINGER INGELHEIM,,15.0,YR,,F,Y,96.0,KG,20191206.0,,MD,US,US,2019,Q4,Youth
170338921,17033892,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5MG;?,,,Y,D,,,,125.0,MG,,QD,2019,Q4,Urinary tract infection,,2019,Q4,1,I,20190913.0,,20191015,20191015,DIR,,,FDA-CTU,,81.0,YR,,M,N,,,20191010.0,N,PH,US,US,2019,Q4,Elderly
170399361,17039936,3,C,EMPAGLIFLOZIN/METFORMIN,,2,,,,,,,,,,,,,,2019,Q4,Anaphylactic reaction,,2019,Q4,1,I,,20191104.0,20191116,20191116,EXP,,AU-BION-008384,BIONPHARMA,"LEE A, SMITH A, KRUMMENACHER M, HUGHES T. AN UNUSUAL CASE OF LOPERAMIDE ANAPHYLAXIS. ANN ALLERGY ASTHMA IMMUNOL. 2019 OCT 26. PII: S1081-1206(19)31350-X.",75.0,YR,E,M,Y,,,20191116.0,,MD,AU,AU,2019,Q4,Elderly
170399361,17039936,3,C,EMPAGLIFLOZIN/METFORMIN,,2,,,,,,,,,,,,,,2019,Q4,Diarrhoea,,2019,Q4,1,I,,20191104.0,20191116,20191116,EXP,,AU-BION-008384,BIONPHARMA,"LEE A, SMITH A, KRUMMENACHER M, HUGHES T. AN UNUSUAL CASE OF LOPERAMIDE ANAPHYLAXIS. ANN ALLERGY ASTHMA IMMUNOL. 2019 OCT 26. PII: S1081-1206(19)31350-X.",75.0,YR,E,M,Y,,,20191116.0,,MD,AU,AU,2019,Q4,Elderly
170433291,17043329,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2019,Q4,Urinary tract infection,,2019,Q4,1,I,20191007.0,,20191017,20191017,DIR,,,FDA-CTU,,72.0,YR,,M,N,,,20191007.0,N,PH,US,US,2019,Q4,Elderly
170436291,17043629,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q4,Flushing,,2019,Q4,1,I,20190901.0,,20191017,20191017,DIR,,,FDA-CTU,,72.0,YR,,M,N,102.51,KG,20191016.0,N,PH,US,US,2019,Q4,Elderly
170436291,17043629,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q4,Muscle spasms,,2019,Q4,1,I,20190901.0,,20191017,20191017,DIR,,,FDA-CTU,,72.0,YR,,M,N,102.51,KG,20191016.0,N,PH,US,US,2019,Q4,Elderly
170436291,17043629,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q4,Therapy cessation,,2019,Q4,1,I,20190901.0,,20191017,20191017,DIR,,,FDA-CTU,,72.0,YR,,M,N,102.51,KG,20191016.0,N,PH,US,US,2019,Q4,Elderly
170439321,17043932,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,Y,,,,,,,QD,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20191112.0,,20191115,20191115,DIR,,,FDA-CTU,,44.0,YR,,M,N,136.3,KG,20191115.0,N,PH,US,US,2019,Q4,Adult
170442302,17044230,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Abdominal pain,,2019,Q4,2,F,,20191119.0,20191118,20191126,EXP,,ES-GILEAD-2019-0437785,GILEAD,,70.0,YR,E,F,Y,,,20191125.0,,MD,ES,ES,2019,Q4,Elderly
170442302,17044230,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Diarrhoea,,2019,Q4,2,F,,20191119.0,20191118,20191126,EXP,,ES-GILEAD-2019-0437785,GILEAD,,70.0,YR,E,F,Y,,,20191125.0,,MD,ES,ES,2019,Q4,Elderly
170442302,17044230,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Haematochezia,,2019,Q4,2,F,,20191119.0,20191118,20191126,EXP,,ES-GILEAD-2019-0437785,GILEAD,,70.0,YR,E,F,Y,,,20191125.0,,MD,ES,ES,2019,Q4,Elderly
170442302,17044230,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Portal vein thrombosis,,2019,Q4,2,F,,20191119.0,20191118,20191126,EXP,,ES-GILEAD-2019-0437785,GILEAD,,70.0,YR,E,F,Y,,,20191125.0,,MD,ES,ES,2019,Q4,Elderly
170453291,17045329,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Asthma,,2019,Q4,1,I,,20191105.0,20191118,20191118,EXP,,CA-PFIZER INC-2019491331,PFIZER,,50.0,YR,,M,Y,83.0,KG,20191118.0,,CN,CA,CA,2019,Q4,Adult
170453291,17045329,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Blood count abnormal,,2019,Q4,1,I,,20191105.0,20191118,20191118,EXP,,CA-PFIZER INC-2019491331,PFIZER,,50.0,YR,,M,Y,83.0,KG,20191118.0,,CN,CA,CA,2019,Q4,Adult
170453291,17045329,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Chest discomfort,,2019,Q4,1,I,,20191105.0,20191118,20191118,EXP,,CA-PFIZER INC-2019491331,PFIZER,,50.0,YR,,M,Y,83.0,KG,20191118.0,,CN,CA,CA,2019,Q4,Adult
170453291,17045329,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Dyspnoea,,2019,Q4,1,I,,20191105.0,20191118,20191118,EXP,,CA-PFIZER INC-2019491331,PFIZER,,50.0,YR,,M,Y,83.0,KG,20191118.0,,CN,CA,CA,2019,Q4,Adult
170453291,17045329,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Tremor,,2019,Q4,1,I,,20191105.0,20191118,20191118,EXP,,CA-PFIZER INC-2019491331,PFIZER,,50.0,YR,,M,Y,83.0,KG,20191118.0,,CN,CA,CA,2019,Q4,Adult
170456821,17045682,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD",,,,,,,,25.0,MG,,QD,2019,Q4,Confusional state,,2019,Q4,1,I,20191028.0,20191030.0,20191118,20191118,EXP,,CA-TAKEDA-2019TUS065073,TAKEDA,,77.0,YR,,M,Y,73.4,KG,20191119.0,,MD,CA,CA,2019,Q4,Elderly
170456821,17045682,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD",,,,,,,,25.0,MG,,QD,2019,Q4,Fall,,2019,Q4,1,I,20191028.0,20191030.0,20191118,20191118,EXP,,CA-TAKEDA-2019TUS065073,TAKEDA,,77.0,YR,,M,Y,73.4,KG,20191119.0,,MD,CA,CA,2019,Q4,Elderly
170456821,17045682,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD",,,,,,,,25.0,MG,,QD,2019,Q4,Influenza like illness,,2019,Q4,1,I,20191028.0,20191030.0,20191118,20191118,EXP,,CA-TAKEDA-2019TUS065073,TAKEDA,,77.0,YR,,M,Y,73.4,KG,20191119.0,,MD,CA,CA,2019,Q4,Elderly
170456821,17045682,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD",,,,,,,,25.0,MG,,QD,2019,Q4,Neck pain,,2019,Q4,1,I,20191028.0,20191030.0,20191118,20191118,EXP,,CA-TAKEDA-2019TUS065073,TAKEDA,,77.0,YR,,M,Y,73.4,KG,20191119.0,,MD,CA,CA,2019,Q4,Elderly
170516351,17051635,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2019,Q4,Asthma,,2019,Q4,1,I,,20191108.0,20191120,20191120,EXP,,CA-AUROBINDO-AUR-APL-2019-073684,AUROBINDO,,50.0,YR,,M,Y,83.0,KG,20191120.0,,OT,CA,CA,2019,Q4,Adult
170516351,17051635,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2019,Q4,Blood count abnormal,,2019,Q4,1,I,,20191108.0,20191120,20191120,EXP,,CA-AUROBINDO-AUR-APL-2019-073684,AUROBINDO,,50.0,YR,,M,Y,83.0,KG,20191120.0,,OT,CA,CA,2019,Q4,Adult
170516351,17051635,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2019,Q4,Chest discomfort,,2019,Q4,1,I,,20191108.0,20191120,20191120,EXP,,CA-AUROBINDO-AUR-APL-2019-073684,AUROBINDO,,50.0,YR,,M,Y,83.0,KG,20191120.0,,OT,CA,CA,2019,Q4,Adult
170516351,17051635,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2019,Q4,Dyspnoea,,2019,Q4,1,I,,20191108.0,20191120,20191120,EXP,,CA-AUROBINDO-AUR-APL-2019-073684,AUROBINDO,,50.0,YR,,M,Y,83.0,KG,20191120.0,,OT,CA,CA,2019,Q4,Adult
170516351,17051635,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2019,Q4,Tremor,,2019,Q4,1,I,,20191108.0,20191120,20191120,EXP,,CA-AUROBINDO-AUR-APL-2019-073684,AUROBINDO,,50.0,YR,,M,Y,83.0,KG,20191120.0,,OT,CA,CA,2019,Q4,Adult
170579601,17057960,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2019,Q4,Chronic obstructive pulmonary disease,,2019,Q4,1,I,20191015.0,20191021.0,20191121,20191121,EXP,,CA-JNJFOC-20191035705,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,90.0,KG,20191121.0,,MD,CA,CA,2019,Q4,Elderly
170579601,17057960,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,UNKNOWN,QD,2019,Q4,Chronic obstructive pulmonary disease,,2019,Q4,1,I,20191015.0,20191021.0,20191121,20191121,EXP,,CA-JNJFOC-20191035705,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,90.0,KG,20191121.0,,MD,CA,CA,2019,Q4,Elderly
170582173,17058217,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Dementia,,2019,Q4,3,F,20190625.0,20191210.0,20191121,20191212,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-113242",BOEHRINGER INGELHEIM,,89.0,YR,,M,Y,,,20191212.0,,MD,US,US,2019,Q4,Elderly
170605782,17060578,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Dyspepsia,,2019,Q4,2,F,,20191114.0,20191121,20191127,EXP,,CZ-MYLANLABS-2019M1110591,MYLAN,TOMANEK P. PRVN? ZKUSENOST S T??DENN? HLADOVKOU U OB?ZN? DIABETI?KY 2. TYPU S V?ZNAMNOU INZULINOREZISTENC?. KAZUISTIKY V DIABETOLOGII. 2019;17(3):30-2,66.0,YR,,F,Y,,,20191127.0,,MD,CZ,CZ,2019,Q4,Elderly
170617301,17061730,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,,, UNKNOWN,,,25.0,MG,,QD,2019,Q4,Sudden death,,2019,Q4,1,I,20191105.0,20191108.0,20191121,20191121,EXP,,GB-NOVOPROD-695921,NOVO NORDISK,,73.0,YR,,M,Y,107.6,KG,20191121.0,,MD,GB,GB,2019,Q4,Elderly
170622502,17062250,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,,,,,,25.0,MG,,,2019,Q4,Drug intolerance,,2019,Q4,2,F,,20191118.0,20191122,20191129,EXP,,IN-LUPIN LIMITED-2019-07491,LUPIN,ANEESH GHOSH MS. A CASE OF EUGLYCEMIC DIABETIC KETO ACIDOSIS. INDIAN JOURNAL OF ENDOCRINOLOGY AND METABOLISM. 2019;23 (4):500-501,52.0,YR,,M,Y,,,20191129.0,,MD,IN,IN,2019,Q4,Adult
170622502,17062250,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,,,,,,25.0,MG,,,2019,Q4,Gastric disorder,,2019,Q4,2,F,,20191118.0,20191122,20191129,EXP,,IN-LUPIN LIMITED-2019-07491,LUPIN,ANEESH GHOSH MS. A CASE OF EUGLYCEMIC DIABETIC KETO ACIDOSIS. INDIAN JOURNAL OF ENDOCRINOLOGY AND METABOLISM. 2019;23 (4):500-501,52.0,YR,,M,Y,,,20191129.0,,MD,IN,IN,2019,Q4,Adult
170623111,17062311,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,25.0,MG,,,2019,Q4,Abdominal discomfort,,2019,Q4,1,I,,20191112.0,20191122,20191122,EXP,,IN-EMD SERONO-9128927,EMD SERONO INC,GHOSH A. 10.4103/IJEM.IJEM_302_19; A CASE OF EUGLYCEMIC DIABETIC KETO ACIDOSIS. INDIAN JOURNAL OF ENDOCRINOLOGY AND METABOLISM. 2019 AUG 01;23(4):500-501.,52.0,YR,,M,Y,,,20191122.0,,MD,IN,IN,2019,Q4,Adult
170623111,17062311,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,25.0,MG,,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,,20191112.0,20191122,20191122,EXP,,IN-EMD SERONO-9128927,EMD SERONO INC,GHOSH A. 10.4103/IJEM.IJEM_302_19; A CASE OF EUGLYCEMIC DIABETIC KETO ACIDOSIS. INDIAN JOURNAL OF ENDOCRINOLOGY AND METABOLISM. 2019 AUG 01;23(4):500-501.,52.0,YR,,M,Y,,,20191122.0,,MD,IN,IN,2019,Q4,Adult
170627314,17062731,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,QD,2019,Q4,Haemorrhagic stroke,,2019,Q4,4,F,20191105.0,20191206.0,20191122,20191213,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-111059,BRISTOL MYERS SQUIBB,,78.0,YR,,M,Y,84.0,KG,20191213.0,,MD,CA,CA,2019,Q4,Elderly
170698132,17069813,6,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,D,,,,,,,,,2019,Q4,Anaphylactic reaction,,2019,Q4,2,F,20190415.0,20191205.0,20191125,20191217,EXP,,AU-APOTEX-2019AP024930,APOTEX,"LEE AYS, SMITH AJF, KRUMMENACHER M, HUGHES TL.. AN UNUSUAL CASE OF LOPERAMIDE ANAPHYLAXIS. DOI: 10.1016/J.ANAI.2019.10.017. ANNALS OF ALLERGY, ASTHMA AND IMMUNOLOGY. 2019;1-6",75.0,YR,,M,Y,,,20191217.0,,MD,AU,AU,2019,Q4,Elderly
170698982,17069898,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,U,,,,,25.0,MG,,,2019,Q4,Asthenia,,2019,Q4,2,F,,20191118.0,20191125,20191129,EXP,,IN-SA-2019SA318046,SANOFI AVENTIS,,52.0,YR,A,M,Y,,,20191129.0,,OT,IN,IN,2019,Q4,Adult
170698982,17069898,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,U,,,,,25.0,MG,,,2019,Q4,Blood ketone body present,,2019,Q4,2,F,,20191118.0,20191125,20191129,EXP,,IN-SA-2019SA318046,SANOFI AVENTIS,,52.0,YR,A,M,Y,,,20191129.0,,OT,IN,IN,2019,Q4,Adult
170698982,17069898,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,U,,,,,25.0,MG,,,2019,Q4,Chest discomfort,,2019,Q4,2,F,,20191118.0,20191125,20191129,EXP,,IN-SA-2019SA318046,SANOFI AVENTIS,,52.0,YR,A,M,Y,,,20191129.0,,OT,IN,IN,2019,Q4,Adult
170698982,17069898,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,U,,,,,25.0,MG,,,2019,Q4,Drug intolerance,,2019,Q4,2,F,,20191118.0,20191125,20191129,EXP,,IN-SA-2019SA318046,SANOFI AVENTIS,,52.0,YR,A,M,Y,,,20191129.0,,OT,IN,IN,2019,Q4,Adult
170698982,17069898,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,U,,,,,25.0,MG,,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,2,F,,20191118.0,20191125,20191129,EXP,,IN-SA-2019SA318046,SANOFI AVENTIS,,52.0,YR,A,M,Y,,,20191129.0,,OT,IN,IN,2019,Q4,Adult
170698982,17069898,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,U,,,,,25.0,MG,,,2019,Q4,Gastrointestinal disorder,,2019,Q4,2,F,,20191118.0,20191125,20191129,EXP,,IN-SA-2019SA318046,SANOFI AVENTIS,,52.0,YR,A,M,Y,,,20191129.0,,OT,IN,IN,2019,Q4,Adult
170698982,17069898,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,U,,,,,25.0,MG,,,2019,Q4,Hypophagia,,2019,Q4,2,F,,20191118.0,20191125,20191129,EXP,,IN-SA-2019SA318046,SANOFI AVENTIS,,52.0,YR,A,M,Y,,,20191129.0,,OT,IN,IN,2019,Q4,Adult
170698982,17069898,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,U,,,,,25.0,MG,,,2019,Q4,Ketonuria,,2019,Q4,2,F,,20191118.0,20191125,20191129,EXP,,IN-SA-2019SA318046,SANOFI AVENTIS,,52.0,YR,A,M,Y,,,20191129.0,,OT,IN,IN,2019,Q4,Adult
170698982,17069898,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,U,,,,,25.0,MG,,,2019,Q4,Malaise,,2019,Q4,2,F,,20191118.0,20191125,20191129,EXP,,IN-SA-2019SA318046,SANOFI AVENTIS,,52.0,YR,A,M,Y,,,20191129.0,,OT,IN,IN,2019,Q4,Adult
170698982,17069898,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,U,,,,,25.0,MG,,,2019,Q4,Nausea,,2019,Q4,2,F,,20191118.0,20191125,20191129,EXP,,IN-SA-2019SA318046,SANOFI AVENTIS,,52.0,YR,A,M,Y,,,20191129.0,,OT,IN,IN,2019,Q4,Adult
170698982,17069898,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,U,,,,,25.0,MG,,,2019,Q4,Retching,,2019,Q4,2,F,,20191118.0,20191125,20191129,EXP,,IN-SA-2019SA318046,SANOFI AVENTIS,,52.0,YR,A,M,Y,,,20191129.0,,OT,IN,IN,2019,Q4,Adult
170698982,17069898,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,U,,,,,25.0,MG,,,2019,Q4,Vomiting,,2019,Q4,2,F,,20191118.0,20191125,20191129,EXP,,IN-SA-2019SA318046,SANOFI AVENTIS,,52.0,YR,A,M,Y,,,20191129.0,,OT,IN,IN,2019,Q4,Adult
170708672,17070867,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Dermatitis bullous,,2019,Q4,2,F,20180610.0,20191219.0,20191125,20191226,EXP,,"KR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-115047",BOEHRINGER INGELHEIM,,75.0,YR,,M,Y,70.2,KG,20191226.0,,MD,KR,KR,2019,Q4,Elderly
170708672,17070867,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,,,FILM-COATED TABLET,,2019,Q4,Dermatitis bullous,,2019,Q4,2,F,20180610.0,20191219.0,20191125,20191226,EXP,,"KR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-115047",BOEHRINGER INGELHEIM,,75.0,YR,,M,Y,70.2,KG,20191226.0,,MD,KR,KR,2019,Q4,Elderly
170730452,17073045,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2019,Q4,Cardiac failure,,2019,Q4,2,F,20191115.0,20191115.0,20191125,20191126,EXP,,JP-VIFOR (INTERNATIONAL) INC.-VIT-2019-14177,VIFOR,,67.0,YR,,F,Y,,,20191126.0,,MD,JP,JP,2019,Q4,Elderly
170737472,17073747,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, DAILY",,,U,,,,,10.0,MG,,,2019,Q4,Death,,2019,Q4,2,F,,20191126.0,20191126,20191205,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-113898,BRISTOL MYERS SQUIBB,,78.0,YR,,M,Y,,,20191205.0,,MD,CA,CA,2019,Q4,Elderly
170750662,17075066,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Cardiac failure,,2019,Q4,2,F,20180914.0,20191206.0,20191126,20191211,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-006704",BOEHRINGER INGELHEIM,,58.0,YR,,M,Y,98.0,KG,20191211.0,,MD,JP,JP,2019,Q4,Adult
170750662,17075066,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Oedema peripheral,,2019,Q4,2,F,20180914.0,20191206.0,20191126,20191211,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-006704",BOEHRINGER INGELHEIM,,58.0,YR,,M,Y,98.0,KG,20191211.0,,MD,JP,JP,2019,Q4,Adult
170750662,17075066,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q4,Cardiac failure,,2019,Q4,2,F,20180914.0,20191206.0,20191126,20191211,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-006704",BOEHRINGER INGELHEIM,,58.0,YR,,M,Y,98.0,KG,20191211.0,,MD,JP,JP,2019,Q4,Adult
170750662,17075066,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,,2019,Q4,Oedema peripheral,,2019,Q4,2,F,20180914.0,20191206.0,20191126,20191211,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-006704",BOEHRINGER INGELHEIM,,58.0,YR,,M,Y,98.0,KG,20191211.0,,MD,JP,JP,2019,Q4,Adult
170779881,17077988,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,Y,U,,,,,,,,2019,Q4,Ketoacidosis,,2019,Q4,1,I,20190821.0,20191115.0,20191126,20191126,EXP,,DE-NOVOPROD-697140,NOVO NORDISK,,60.0,YR,,F,Y,108.0,KG,20191126.0,,MD,DE,DE,2019,Q4,Adult
170779881,17077988,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,Y,U,,,,,,,,2019,Q4,Pancreatitis,,2019,Q4,1,I,20190821.0,20191115.0,20191126,20191126,EXP,,DE-NOVOPROD-697140,NOVO NORDISK,,60.0,YR,,F,Y,108.0,KG,20191126.0,,MD,DE,DE,2019,Q4,Adult
170812571,17081257,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Anion gap increased,,2019,Q4,1,I,20191120.0,,20191126,20191126,DIR,,,FDA-CTU,,61.0,YR,,M,N,85.5,KG,20191126.0,N,PH,US,US,2019,Q4,Adult
170812571,17081257,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20191120.0,,20191126,20191126,DIR,,,FDA-CTU,,61.0,YR,,M,N,85.5,KG,20191126.0,N,PH,US,US,2019,Q4,Adult
170812571,17081257,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Hyperglycaemia,,2019,Q4,1,I,20191120.0,,20191126,20191126,DIR,,,FDA-CTU,,61.0,YR,,M,N,85.5,KG,20191126.0,N,PH,US,US,2019,Q4,Adult
170812571,17081257,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Starvation ketoacidosis,,2019,Q4,1,I,20191120.0,,20191126,20191126,DIR,,,FDA-CTU,,61.0,YR,,M,N,85.5,KG,20191126.0,N,PH,US,US,2019,Q4,Adult
170812571,17081257,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2019,Q4,Treatment noncompliance,,2019,Q4,1,I,20191120.0,,20191126,20191126,DIR,,,FDA-CTU,,61.0,YR,,M,N,85.5,KG,20191126.0,N,PH,US,US,2019,Q4,Adult
170868891,17086889,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q4,Headache,,2019,Q4,1,I,20190807.0,,20191031,20191031,DIR,,,FDA-CTU,,70.0,YR,,M,N,,,20191017.0,N,PH,US,US,2019,Q4,Elderly
170881361,17088136,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,,20191125.0,20191128,20191128,EXP,,CA-APOTEX-2019AP025420,APOTEX,,54.0,YR,,M,Y,70.0,KG,20191128.0,,CN,CA,CA,2019,Q4,Adult
170881361,17088136,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2019,Q4,Metabolic acidosis,,2019,Q4,1,I,,20191125.0,20191128,20191128,EXP,,CA-APOTEX-2019AP025420,APOTEX,,54.0,YR,,M,Y,70.0,KG,20191128.0,,CN,CA,CA,2019,Q4,Adult
170881361,17088136,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2019,Q4,Respiratory acidosis,,2019,Q4,1,I,,20191125.0,20191128,20191128,EXP,,CA-APOTEX-2019AP025420,APOTEX,,54.0,YR,,M,Y,70.0,KG,20191128.0,,CN,CA,CA,2019,Q4,Adult
170882372,17088237,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,2,F,,20191206.0,20191128,20191218,EXP,,CA-APOTEX-2019AP025437,APOTEX,,58.0,YR,,M,Y,71.0,KG,20191218.0,,CN,CA,CA,2019,Q4,Adult
170882372,17088237,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2019,Q4,Metabolic acidosis,,2019,Q4,2,F,,20191206.0,20191128,20191218,EXP,,CA-APOTEX-2019AP025437,APOTEX,,58.0,YR,,M,Y,71.0,KG,20191218.0,,CN,CA,CA,2019,Q4,Adult
170913661,17091366,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2019,Q4,Pollakiuria,,2019,Q4,1,I,20190823.0,,20191031,20191031,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20191017.0,N,PH,US,US,2019,Q4,Elderly
170935451,17093545,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,QD,2019,Q4,Pruritus,,2019,Q4,1,I,20190801.0,,20191101,20191101,DIR,,,FDA-CTU,,62.0,YR,,M,N,101.15,KG,20191017.0,N,PH,US,US,2019,Q4,Adult
170935451,17093545,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,QD,2019,Q4,Rash,,2019,Q4,1,I,20190801.0,,20191101,20191101,DIR,,,FDA-CTU,,62.0,YR,,M,N,101.15,KG,20191017.0,N,PH,US,US,2019,Q4,Adult
170935451,17093545,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,QD,2019,Q4,Urticaria,,2019,Q4,1,I,20190801.0,,20191101,20191101,DIR,,,FDA-CTU,,62.0,YR,,M,N,101.15,KG,20191017.0,N,PH,US,US,2019,Q4,Adult
170939561,17093956,21,C,EMPAGLIFLOZIN-LINAGLIPTIN,,2,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q4,Headache,,2019,Q4,1,I,20190314.0,20190315.0,20191129,20191129,EXP,,AE-ASTRAZENECA-2019SE42766,ASTRAZENECA,,67.0,YR,,M,Y,,,20191129.0,,MD,US,US,2019,Q4,Elderly
170939561,17093956,21,C,EMPAGLIFLOZIN-LINAGLIPTIN,,2,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q4,Herpes zoster meningoencephalitis,,2019,Q4,1,I,20190314.0,20190315.0,20191129,20191129,EXP,,AE-ASTRAZENECA-2019SE42766,ASTRAZENECA,,67.0,YR,,M,Y,,,20191129.0,,MD,US,US,2019,Q4,Elderly
170939561,17093956,22,C,EMPAGLIFLOZIN-LINAGLIPTIN,,2,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q4,Headache,,2019,Q4,1,I,20190314.0,20190315.0,20191129,20191129,EXP,,AE-ASTRAZENECA-2019SE42766,ASTRAZENECA,,67.0,YR,,M,Y,,,20191129.0,,MD,US,US,2019,Q4,Elderly
170939561,17093956,22,C,EMPAGLIFLOZIN-LINAGLIPTIN,,2,Oral,,,,,,,,,1.0,DF,TABLET,QD,2019,Q4,Herpes zoster meningoencephalitis,,2019,Q4,1,I,20190314.0,20190315.0,20191129,20191129,EXP,,AE-ASTRAZENECA-2019SE42766,ASTRAZENECA,,67.0,YR,,M,Y,,,20191129.0,,MD,US,US,2019,Q4,Elderly
170950261,17095026,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",2050.0,MG,Y,,,,,25.0,MG,,QD,2019,Q4,Dehydration,,2019,Q4,1,I,20190831.0,20191127.0,20191130,20191130,EXP,GB-MHRA-EYC 00207470,NVSC2019GB050617,NOVARTIS,,64.0,YR,,M,Y,,,20191130.0,,OT,GB,GB,2019,Q4,Adult
170950261,17095026,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",2050.0,MG,Y,,,,,25.0,MG,,QD,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20190831.0,20191127.0,20191130,20191130,EXP,GB-MHRA-EYC 00207470,NVSC2019GB050617,NOVARTIS,,64.0,YR,,M,Y,,,20191130.0,,OT,GB,GB,2019,Q4,Adult
170950261,17095026,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",2050.0,MG,Y,,,,,25.0,MG,,QD,2019,Q4,Lactic acidosis,,2019,Q4,1,I,20190831.0,20191127.0,20191130,20191130,EXP,GB-MHRA-EYC 00207470,NVSC2019GB050617,NOVARTIS,,64.0,YR,,M,Y,,,20191130.0,,OT,GB,GB,2019,Q4,Adult
171014892,17101489,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD",,,U,,,,,25.0,MG,,QD,2019,Q4,Febrile neutropenia,,2019,Q4,2,F,20191116.0,20191128.0,20191202,20191204,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-111831,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,186.0,KG,20191204.0,,OT,DE,DE,2019,Q4,Adult
171016821,17101682,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Renal failure,,2019,Q4,1,I,20191119.0,20191126.0,20191202,20191202,EXP,,"PL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-116380",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,101.0,KG,20191202.0,,MD,PL,PL,2019,Q4,Elderly
171063471,17106347,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD (1-0-0-0)",,,,,,,,10.0,MG,TABLET,QD,2019,Q4,Agitation,,2019,Q4,1,I,,20191125.0,20191203,20191203,EXP,DE-BFARM-19007959,DE-MYLANLABS-2019M1116730,MYLAN,,56.0,YR,,M,Y,84.0,KG,20191203.0,,MD,DE,DE,2019,Q4,Adult
171063471,17106347,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD (1-0-0-0)",,,,,,,,10.0,MG,TABLET,QD,2019,Q4,Depressed level of consciousness,,2019,Q4,1,I,,20191125.0,20191203,20191203,EXP,DE-BFARM-19007959,DE-MYLANLABS-2019M1116730,MYLAN,,56.0,YR,,M,Y,84.0,KG,20191203.0,,MD,DE,DE,2019,Q4,Adult
171063471,17106347,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD (1-0-0-0)",,,,,,,,10.0,MG,TABLET,QD,2019,Q4,General physical health deterioration,,2019,Q4,1,I,,20191125.0,20191203,20191203,EXP,DE-BFARM-19007959,DE-MYLANLABS-2019M1116730,MYLAN,,56.0,YR,,M,Y,84.0,KG,20191203.0,,MD,DE,DE,2019,Q4,Adult
171063471,17106347,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD (1-0-0-0)",,,,,,,,10.0,MG,TABLET,QD,2019,Q4,Product prescribing error,,2019,Q4,1,I,,20191125.0,20191203,20191203,EXP,DE-BFARM-19007959,DE-MYLANLABS-2019M1116730,MYLAN,,56.0,YR,,M,Y,84.0,KG,20191203.0,,MD,DE,DE,2019,Q4,Adult
171063471,17106347,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD (1-0-0-0)",,,,,,,,10.0,MG,TABLET,QD,2019,Q4,Syncope,,2019,Q4,1,I,,20191125.0,20191203,20191203,EXP,DE-BFARM-19007959,DE-MYLANLABS-2019M1116730,MYLAN,,56.0,YR,,M,Y,84.0,KG,20191203.0,,MD,DE,DE,2019,Q4,Adult
171072821,17107282,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0, TABLETTEN",,,,,,,,10.0,MG,TABLET,,2019,Q4,Haematochezia,,2019,Q4,1,I,20180226.0,20191125.0,20191203,20191203,EXP,DE-BFARM-19008123,DE-MYLANLABS-2019M1116224,MYLAN,,74.0,YR,,M,Y,89.0,KG,20191203.0,,MD,DE,DE,2019,Q4,Elderly
171072821,17107282,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0, TABLETTEN",,,,,,,,10.0,MG,TABLET,,2019,Q4,Medication error,,2019,Q4,1,I,20180226.0,20191125.0,20191203,20191203,EXP,DE-BFARM-19008123,DE-MYLANLABS-2019M1116224,MYLAN,,74.0,YR,,M,Y,89.0,KG,20191203.0,,MD,DE,DE,2019,Q4,Elderly
171096291,17109629,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,,,,,12.5,MG,,,2019,Q4,Pancreatitis,,2019,Q4,1,I,20191025.0,,20191108,20191108,DIR,,,FDA-CTU,,53.0,YR,,M,N,,,20191108.0,N,PH,US,US,2019,Q4,Adult
171100401,17110040,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Fatigue,,2019,Q4,1,I,20190108.0,,20191108,20191108,DIR,,,FDA-CTU,,70.0,YR,,M,N,110.0,KG,20191018.0,N,PH,US,US,2019,Q4,Elderly
171100401,17110040,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Lethargy,,2019,Q4,1,I,20190108.0,,20191108,20191108,DIR,,,FDA-CTU,,70.0,YR,,M,N,110.0,KG,20191018.0,N,PH,US,US,2019,Q4,Elderly
171100401,17110040,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Muscle spasms,,2019,Q4,1,I,20190108.0,,20191108,20191108,DIR,,,FDA-CTU,,70.0,YR,,M,N,110.0,KG,20191018.0,N,PH,US,US,2019,Q4,Elderly
171100401,17110040,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Nervousness,,2019,Q4,1,I,20190108.0,,20191108,20191108,DIR,,,FDA-CTU,,70.0,YR,,M,N,110.0,KG,20191018.0,N,PH,US,US,2019,Q4,Elderly
171100401,17110040,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Pollakiuria,,2019,Q4,1,I,20190108.0,,20191108,20191108,DIR,,,FDA-CTU,,70.0,YR,,M,N,110.0,KG,20191018.0,N,PH,US,US,2019,Q4,Elderly
171100831,17110083,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,,,,,12.5,MG,,,2019,Q4,Pollakiuria,,2019,Q4,1,I,20191001.0,,20191108,20191108,DIR,,,FDA-CTU,,67.0,YR,,M,N,,,20191108.0,N,PH,US,US,2019,Q4,Elderly
171100842,17110084,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Colon cancer,,2019,Q4,2,F,20190329.0,20191216.0,20191204,20191218,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-117766",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,55.0,KG,20191218.0,,MD,JP,JP,2019,Q4,Elderly
171100842,17110084,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,,2019,Q4,Cystitis,,2019,Q4,2,F,20190329.0,20191216.0,20191204,20191218,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-117766",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,55.0,KG,20191218.0,,MD,JP,JP,2019,Q4,Elderly
171102631,17110263,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,,,,,12.5,MG,,QD,2019,Q4,Genital rash,,2019,Q4,1,I,20191101.0,,20191108,20191108,DIR,,,FDA-CTU,,59.0,YR,,M,N,,,20191108.0,N,PH,US,US,2019,Q4,Adult
171102631,17110263,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,,,,,12.5,MG,,QD,2019,Q4,Pollakiuria,,2019,Q4,1,I,20191101.0,,20191108,20191108,DIR,,,FDA-CTU,,59.0,YR,,M,N,,,20191108.0,N,PH,US,US,2019,Q4,Adult
171102631,17110263,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,,,,,12.5,MG,,QD,2019,Q4,Rash,,2019,Q4,1,I,20191101.0,,20191108,20191108,DIR,,,FDA-CTU,,59.0,YR,,M,N,,,20191108.0,N,PH,US,US,2019,Q4,Adult
171105121,17110512,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,,,,,12.5,MG,,,2019,Q4,Genital rash,,2019,Q4,1,I,20191024.0,,20191108,20191108,DIR,,,FDA-CTU,,79.0,YR,,M,N,,,20191108.0,N,PH,US,US,2019,Q4,Elderly
171105121,17110512,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,,,,,12.5,MG,,,2019,Q4,Rash,,2019,Q4,1,I,20191024.0,,20191108,20191108,DIR,,,FDA-CTU,,79.0,YR,,M,N,,,20191108.0,N,PH,US,US,2019,Q4,Elderly
171105191,17110519,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,,,,,12.5,MG,,,2019,Q4,Pollakiuria,,2019,Q4,1,I,20191108.0,,20191108,20191108,DIR,,,FDA-CTU,,74.0,YR,,M,N,,,20191108.0,N,PH,US,US,2019,Q4,Elderly
171113532,17111353,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DOSAGE FORM, DAILY",,,,,,,,1.0,DF,TABLET,QD,2019,Q4,Abdominal distension,,2019,Q4,2,F,20191203.0,20191205.0,20191204,20191217,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201911012330,ELI LILLY AND CO,,69.0,YR,,F,Y,78.0,KG,20191217.0,,CN,CN,CN,2019,Q4,Elderly
171113532,17111353,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DOSAGE FORM, DAILY",,,,,,,,1.0,DF,TABLET,QD,2019,Q4,Blood glucose fluctuation,,2019,Q4,2,F,20191203.0,20191205.0,20191204,20191217,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201911012330,ELI LILLY AND CO,,69.0,YR,,F,Y,78.0,KG,20191217.0,,CN,CN,CN,2019,Q4,Elderly
171113532,17111353,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DOSAGE FORM, DAILY",,,,,,,,1.0,DF,TABLET,QD,2019,Q4,Blood glucose increased,,2019,Q4,2,F,20191203.0,20191205.0,20191204,20191217,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201911012330,ELI LILLY AND CO,,69.0,YR,,F,Y,78.0,KG,20191217.0,,CN,CN,CN,2019,Q4,Elderly
171113532,17111353,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DOSAGE FORM, DAILY",,,,,,,,1.0,DF,TABLET,QD,2019,Q4,Gastric ulcer,,2019,Q4,2,F,20191203.0,20191205.0,20191204,20191217,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201911012330,ELI LILLY AND CO,,69.0,YR,,F,Y,78.0,KG,20191217.0,,CN,CN,CN,2019,Q4,Elderly
171113532,17111353,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DOSAGE FORM, DAILY",,,,,,,,1.0,DF,TABLET,QD,2019,Q4,Gastrointestinal disorder,,2019,Q4,2,F,20191203.0,20191205.0,20191204,20191217,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201911012330,ELI LILLY AND CO,,69.0,YR,,F,Y,78.0,KG,20191217.0,,CN,CN,CN,2019,Q4,Elderly
171113532,17111353,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DOSAGE FORM, DAILY",,,,,,,,1.0,DF,TABLET,QD,2019,Q4,Generalised oedema,,2019,Q4,2,F,20191203.0,20191205.0,20191204,20191217,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201911012330,ELI LILLY AND CO,,69.0,YR,,F,Y,78.0,KG,20191217.0,,CN,CN,CN,2019,Q4,Elderly
171113532,17111353,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DOSAGE FORM, DAILY",,,,,,,,1.0,DF,TABLET,QD,2019,Q4,Hypertension,,2019,Q4,2,F,20191203.0,20191205.0,20191204,20191217,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201911012330,ELI LILLY AND CO,,69.0,YR,,F,Y,78.0,KG,20191217.0,,CN,CN,CN,2019,Q4,Elderly
171113532,17111353,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DOSAGE FORM, DAILY",,,,,,,,1.0,DF,TABLET,QD,2019,Q4,Neuropathy peripheral,,2019,Q4,2,F,20191203.0,20191205.0,20191204,20191217,EXP,,CN-ELI_LILLY_AND_COMPANY-CN201911012330,ELI LILLY AND CO,,69.0,YR,,F,Y,78.0,KG,20191217.0,,CN,CN,CN,2019,Q4,Elderly
171155891,17115589,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,10.0,MG,,QD,2019,Q4,Fournier's gangrene,,2019,Q4,1,I,20190507.0,,20191112,20191112,DIR,,,FDA-CTU,,69.0,YR,,M,N,94.35,KG,20191112.0,N,PH,US,US,2019,Q4,Elderly
171174901,17117490,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q4,Abdominal pain,,2019,Q4,1,I,20190815.0,20191129.0,20191205,20191205,EXP,,NVSC2019DE053967,NOVARTIS,,56.0,YR,,F,Y,87.0,KG,20191205.0,,OT,DE,DE,2019,Q4,Adult
171174901,17117490,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q4,Anaemia,,2019,Q4,1,I,20190815.0,20191129.0,20191205,20191205,EXP,,NVSC2019DE053967,NOVARTIS,,56.0,YR,,F,Y,87.0,KG,20191205.0,,OT,DE,DE,2019,Q4,Adult
171174901,17117490,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q4,Anuria,,2019,Q4,1,I,20190815.0,20191129.0,20191205,20191205,EXP,,NVSC2019DE053967,NOVARTIS,,56.0,YR,,F,Y,87.0,KG,20191205.0,,OT,DE,DE,2019,Q4,Adult
171174901,17117490,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q4,Cerebral haemorrhage,,2019,Q4,1,I,20190815.0,20191129.0,20191205,20191205,EXP,,NVSC2019DE053967,NOVARTIS,,56.0,YR,,F,Y,87.0,KG,20191205.0,,OT,DE,DE,2019,Q4,Adult
171174901,17117490,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q4,Diarrhoea,,2019,Q4,1,I,20190815.0,20191129.0,20191205,20191205,EXP,,NVSC2019DE053967,NOVARTIS,,56.0,YR,,F,Y,87.0,KG,20191205.0,,OT,DE,DE,2019,Q4,Adult
171174901,17117490,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q4,Febrile neutropenia,,2019,Q4,1,I,20190815.0,20191129.0,20191205,20191205,EXP,,NVSC2019DE053967,NOVARTIS,,56.0,YR,,F,Y,87.0,KG,20191205.0,,OT,DE,DE,2019,Q4,Adult
171174901,17117490,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q4,Malaise,,2019,Q4,1,I,20190815.0,20191129.0,20191205,20191205,EXP,,NVSC2019DE053967,NOVARTIS,,56.0,YR,,F,Y,87.0,KG,20191205.0,,OT,DE,DE,2019,Q4,Adult
171174901,17117490,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q4,Pneumonia,,2019,Q4,1,I,20190815.0,20191129.0,20191205,20191205,EXP,,NVSC2019DE053967,NOVARTIS,,56.0,YR,,F,Y,87.0,KG,20191205.0,,OT,DE,DE,2019,Q4,Adult
171174901,17117490,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q4,Respiratory failure,,2019,Q4,1,I,20190815.0,20191129.0,20191205,20191205,EXP,,NVSC2019DE053967,NOVARTIS,,56.0,YR,,F,Y,87.0,KG,20191205.0,,OT,DE,DE,2019,Q4,Adult
171174901,17117490,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q4,Sepsis,,2019,Q4,1,I,20190815.0,20191129.0,20191205,20191205,EXP,,NVSC2019DE053967,NOVARTIS,,56.0,YR,,F,Y,87.0,KG,20191205.0,,OT,DE,DE,2019,Q4,Adult
171174901,17117490,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q4,Tachycardia,,2019,Q4,1,I,20190815.0,20191129.0,20191205,20191205,EXP,,NVSC2019DE053967,NOVARTIS,,56.0,YR,,F,Y,87.0,KG,20191205.0,,OT,DE,DE,2019,Q4,Adult
171174901,17117490,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q4,Thrombocytopenia,,2019,Q4,1,I,20190815.0,20191129.0,20191205,20191205,EXP,,NVSC2019DE053967,NOVARTIS,,56.0,YR,,F,Y,87.0,KG,20191205.0,,OT,DE,DE,2019,Q4,Adult
171206621,17120662,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2019,Q4,Haemodynamic instability,,2019,Q4,1,I,,20191127.0,20191206,20191206,EXP,,JP-MYLANLABS-2019M1119525,MYLAN,"YAMAMOTO S, IWAMURO M, MIYAKE M, NISHIMURA N, MIZUNO M, OKADA H. SEVERE BLEEDING DUE TO CYTOMEGALOVIRUS ESOPHAGITIS IN A PATIENT WITH DIABETES AFTER INTERBODY FUSION SURGERY. INTERN-MED 2019;58(20):2949-2955.. 2019;58(20):2949-2955",49.0,YR,,M,Y,,,20191206.0,,MD,JP,JP,2019,Q4,Adult
171206621,17120662,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2019,Q4,Oesophageal ulcer haemorrhage,,2019,Q4,1,I,,20191127.0,20191206,20191206,EXP,,JP-MYLANLABS-2019M1119525,MYLAN,"YAMAMOTO S, IWAMURO M, MIYAKE M, NISHIMURA N, MIZUNO M, OKADA H. SEVERE BLEEDING DUE TO CYTOMEGALOVIRUS ESOPHAGITIS IN A PATIENT WITH DIABETES AFTER INTERBODY FUSION SURGERY. INTERN-MED 2019;58(20):2949-2955.. 2019;58(20):2949-2955",49.0,YR,,M,Y,,,20191206.0,,MD,JP,JP,2019,Q4,Adult
171349942,17134994,7,C,EMPAGLIFLOZIN/LINAGLIPTIN,,2,,TRADIANCE,,,,,,,,,,,,2019,Q4,Sepsis,,2019,Q4,2,F,20191118.0,20191212.0,20191210,20191220,EXP,,JP-PFIZER INC-2019523052,PFIZER,,68.0,YR,,F,Y,63.0,KG,20191220.0,,MD,JP,JP,2019,Q4,Elderly
171386211,17138621,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,D,D,,,,12.5,MG,,,2019,Q4,Abdominal discomfort,,2019,Q4,1,I,20191018.0,,20191119,20191119,DIR,,,FDA-CTU,,68.0,YR,,M,N,82.0,KG,20191114.0,N,PH,US,US,2019,Q4,Elderly
171392841,17139284,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Balanoposthitis,,2019,Q4,1,I,20191115.0,,20191119,20191119,DIR,,,FDA-CTU,,57.0,YR,,M,N,107.0,KG,20191118.0,N,PH,US,US,2019,Q4,Adult
171392841,17139284,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2019,Q4,Rash,,2019,Q4,1,I,20191115.0,,20191119,20191119,DIR,,,FDA-CTU,,57.0,YR,,M,N,107.0,KG,20191118.0,N,PH,US,US,2019,Q4,Adult
171409252,17140925,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Ileus,,2019,Q4,2,F,20191206.0,20191217.0,20191211,20191220,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-119014",BOEHRINGER INGELHEIM,,83.0,YR,,M,Y,63.8,KG,20191220.0,,MD,JP,JP,2019,Q4,Elderly
171430321,17143032,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2019,Q4,Ventricular tachycardia,,2019,Q4,1,I,20190403.0,20191118.0,20191211,20191211,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-114923",BOEHRINGER INGELHEIM,,78.0,YR,,M,Y,64.0,KG,20191211.0,,MD,GB,GB,2019,Q4,Elderly
171444641,17144464,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2019,Q4,Erythema,,2019,Q4,1,I,20181225.0,,20191119,20191119,DIR,,,FDA-CTU,,51.0,YR,,M,N,161.93,KG,20191027.0,N,PH,US,US,2019,Q4,Adult
171444641,17144464,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2019,Q4,Penile pain,,2019,Q4,1,I,20181225.0,,20191119,20191119,DIR,,,FDA-CTU,,51.0,YR,,M,N,161.93,KG,20191027.0,N,PH,US,US,2019,Q4,Adult
171444641,17144464,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2019,Q4,Pruritus,,2019,Q4,1,I,20181225.0,,20191119,20191119,DIR,,,FDA-CTU,,51.0,YR,,M,N,161.93,KG,20191027.0,N,PH,US,US,2019,Q4,Adult
171444641,17144464,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2019,Q4,Testicular pain,,2019,Q4,1,I,20181225.0,,20191119,20191119,DIR,,,FDA-CTU,,51.0,YR,,M,N,161.93,KG,20191027.0,N,PH,US,US,2019,Q4,Adult
171452042,17145204,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,,QD,2019,Q4,Diabetes mellitus management,,2019,Q4,2,F,20191010.0,20191212.0,20191212,20191223,EXP,,CN-NOVOPROD-700295,NOVO NORDISK,,51.0,YR,,M,Y,85.0,KG,20191220.0,,OT,CN,CN,2019,Q4,Adult
171452042,17145204,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,,,,,,1.0,DF,,QD,2019,Q4,Weight increased,,2019,Q4,2,F,20191010.0,20191212.0,20191212,20191223,EXP,,CN-NOVOPROD-700295,NOVO NORDISK,,51.0,YR,,M,Y,85.0,KG,20191220.0,,OT,CN,CN,2019,Q4,Adult
171457241,17145724,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,,2019,Q4,Ketoacidosis,,2019,Q4,1,I,,20191204.0,20191212,20191212,EXP,,CN-009507513-1912CHN003025,MERCK,,60.0,YR,,F,Y,,,20191212.0,,MD,CN,CN,2019,Q4,Adult
171501211,17150121,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Chest pain,,2019,Q4,1,I,,20191206.0,20191213,20191213,EXP,,NVSC2019MX066917,NOVARTIS,"GOMEZ CH, REYES JM, RAGLE DH. TAKOTSUBO SYNDROME IN MALE PATIENT. MEDIGRAPHIC",52.0,YR,,M,Y,,,20191213.0,,OT,MX,MX,2019,Q4,Adult
171501211,17150121,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Dizziness,,2019,Q4,1,I,,20191206.0,20191213,20191213,EXP,,NVSC2019MX066917,NOVARTIS,"GOMEZ CH, REYES JM, RAGLE DH. TAKOTSUBO SYNDROME IN MALE PATIENT. MEDIGRAPHIC",52.0,YR,,M,Y,,,20191213.0,,OT,MX,MX,2019,Q4,Adult
171501211,17150121,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Dyskinesia,,2019,Q4,1,I,,20191206.0,20191213,20191213,EXP,,NVSC2019MX066917,NOVARTIS,"GOMEZ CH, REYES JM, RAGLE DH. TAKOTSUBO SYNDROME IN MALE PATIENT. MEDIGRAPHIC",52.0,YR,,M,Y,,,20191213.0,,OT,MX,MX,2019,Q4,Adult
171501211,17150121,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Dyspnoea,,2019,Q4,1,I,,20191206.0,20191213,20191213,EXP,,NVSC2019MX066917,NOVARTIS,"GOMEZ CH, REYES JM, RAGLE DH. TAKOTSUBO SYNDROME IN MALE PATIENT. MEDIGRAPHIC",52.0,YR,,M,Y,,,20191213.0,,OT,MX,MX,2019,Q4,Adult
171501211,17150121,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Hypokinesia,,2019,Q4,1,I,,20191206.0,20191213,20191213,EXP,,NVSC2019MX066917,NOVARTIS,"GOMEZ CH, REYES JM, RAGLE DH. TAKOTSUBO SYNDROME IN MALE PATIENT. MEDIGRAPHIC",52.0,YR,,M,Y,,,20191213.0,,OT,MX,MX,2019,Q4,Adult
171501211,17150121,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Palpitations,,2019,Q4,1,I,,20191206.0,20191213,20191213,EXP,,NVSC2019MX066917,NOVARTIS,"GOMEZ CH, REYES JM, RAGLE DH. TAKOTSUBO SYNDROME IN MALE PATIENT. MEDIGRAPHIC",52.0,YR,,M,Y,,,20191213.0,,OT,MX,MX,2019,Q4,Adult
171501211,17150121,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Stress,,2019,Q4,1,I,,20191206.0,20191213,20191213,EXP,,NVSC2019MX066917,NOVARTIS,"GOMEZ CH, REYES JM, RAGLE DH. TAKOTSUBO SYNDROME IN MALE PATIENT. MEDIGRAPHIC",52.0,YR,,M,Y,,,20191213.0,,OT,MX,MX,2019,Q4,Adult
171501211,17150121,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Stress cardiomyopathy,,2019,Q4,1,I,,20191206.0,20191213,20191213,EXP,,NVSC2019MX066917,NOVARTIS,"GOMEZ CH, REYES JM, RAGLE DH. TAKOTSUBO SYNDROME IN MALE PATIENT. MEDIGRAPHIC",52.0,YR,,M,Y,,,20191213.0,,OT,MX,MX,2019,Q4,Adult
171501211,17150121,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Troponin increased,,2019,Q4,1,I,,20191206.0,20191213,20191213,EXP,,NVSC2019MX066917,NOVARTIS,"GOMEZ CH, REYES JM, RAGLE DH. TAKOTSUBO SYNDROME IN MALE PATIENT. MEDIGRAPHIC",52.0,YR,,M,Y,,,20191213.0,,OT,MX,MX,2019,Q4,Adult
171581421,17158142,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,,20191209.0,20191216,20191216,EXP,,CA-PFIZER INC-2019536377,PFIZER,,54.0,YR,,M,Y,97.0,KG,20191216.0,,OT,CA,CA,2019,Q4,Adult
171581421,17158142,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2019,Q4,Metabolic acidosis,,2019,Q4,1,I,,20191209.0,20191216,20191216,EXP,,CA-PFIZER INC-2019536377,PFIZER,,54.0,YR,,M,Y,97.0,KG,20191216.0,,OT,CA,CA,2019,Q4,Adult
171581421,17158142,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2019,Q4,Respiratory acidosis,,2019,Q4,1,I,,20191209.0,20191216,20191216,EXP,,CA-PFIZER INC-2019536377,PFIZER,,54.0,YR,,M,Y,97.0,KG,20191216.0,,OT,CA,CA,2019,Q4,Adult
171589301,17158930,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 QD,,,,,,,,,,,,2019,Q4,Abdominal discomfort,,2019,Q4,1,I,,20191203.0,20191216,20191216,EXP,GB-MHRA-TPP34673888C1753076YC1574330452715,GB-NOVOPROD-700210,NOVO NORDISK,,69.0,YR,,F,Y,69.0,KG,20191216.0,,OT,GB,GB,2019,Q4,Elderly
171589301,17158930,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 QD,,,,,,,,,,,,2019,Q4,Eructation,,2019,Q4,1,I,,20191203.0,20191216,20191216,EXP,GB-MHRA-TPP34673888C1753076YC1574330452715,GB-NOVOPROD-700210,NOVO NORDISK,,69.0,YR,,F,Y,69.0,KG,20191216.0,,OT,GB,GB,2019,Q4,Elderly
171589301,17158930,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 QD,,,,,,,,,,,,2019,Q4,Hypotension,,2019,Q4,1,I,,20191203.0,20191216,20191216,EXP,GB-MHRA-TPP34673888C1753076YC1574330452715,GB-NOVOPROD-700210,NOVO NORDISK,,69.0,YR,,F,Y,69.0,KG,20191216.0,,OT,GB,GB,2019,Q4,Elderly
171589301,17158930,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 QD,,,,,,,,,,,,2019,Q4,Loss of consciousness,,2019,Q4,1,I,,20191203.0,20191216,20191216,EXP,GB-MHRA-TPP34673888C1753076YC1574330452715,GB-NOVOPROD-700210,NOVO NORDISK,,69.0,YR,,F,Y,69.0,KG,20191216.0,,OT,GB,GB,2019,Q4,Elderly
171621671,17162167,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q4,Penile rash,,2019,Q4,1,I,20190927.0,,20191122,20191122,DIR,,,FDA-CTU,,77.0,YR,,M,N,,,20191118.0,N,PH,US,US,2019,Q4,Elderly
171621671,17162167,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q4,Rash,,2019,Q4,1,I,20190927.0,,20191122,20191122,DIR,,,FDA-CTU,,77.0,YR,,M,N,,,20191118.0,N,PH,US,US,2019,Q4,Elderly
171633001,17163300,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2019,Q4,Rash,,2019,Q4,1,I,20190828.0,,20191124,20191124,DIR,,,FDA-CTU,,64.0,YR,,M,N,,,20191118.0,N,PH,US,US,2019,Q4,Adult
171850381,17185038,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2019,Q4,Chronic kidney disease,,2019,Q4,1,I,20190721.0,20191214.0,20191220,20191220,EXP,ES-AEMPS-535463,ES-MYLANLABS-2019M1125895,MYLAN,,68.0,YR,,F,Y,,,20191220.0,,MD,ES,ES,2019,Q4,Elderly
171850381,17185038,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2019,Q4,Hyperkalaemia,,2019,Q4,1,I,20190721.0,20191214.0,20191220,20191220,EXP,ES-AEMPS-535463,ES-MYLANLABS-2019M1125895,MYLAN,,68.0,YR,,F,Y,,,20191220.0,,MD,ES,ES,2019,Q4,Elderly
171866962,17186696,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Mixed deafness,,2019,Q4,2,F,20190930.0,20191224.0,20191220,20191227,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-120796",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,60.95,KG,20191227.0,,MD,JP,JP,2019,Q4,Elderly
171906791,17190679,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q4,Genital infection,,2019,Q4,1,I,20190916.0,,20191129,20191129,DIR,,,FDA-CTU,,69.0,YR,,M,N,108.86,KG,20191129.0,N,PH,US,US,2019,Q4,Elderly
171906791,17190679,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2019,Q4,Genital rash,,2019,Q4,1,I,20190916.0,,20191129,20191129,DIR,,,FDA-CTU,,69.0,YR,,M,N,108.86,KG,20191129.0,N,PH,US,US,2019,Q4,Elderly
171907621,17190762,3,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Angioedema,,2019,Q4,1,I,20191220.0,,20191220,20191220,DIR,,,FDA-CTU,,52.0,YR,,F,N,89.0,KG,20191220.0,N,PH,US,US,2019,Q4,Adult
171907621,17190762,3,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Neck pain,,2019,Q4,1,I,20191220.0,,20191220,20191220,DIR,,,FDA-CTU,,52.0,YR,,F,N,89.0,KG,20191220.0,N,PH,US,US,2019,Q4,Adult
171907661,17190766,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,25.0,MG,,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20191013.0,,20191220,20191220,DIR,,,FDA-CTU,,59.0,YR,,M,N,122.0,KG,20191220.0,N,PH,US,US,2019,Q4,Adult
171907661,17190766,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,25.0,MG,,QD,2019,Q4,Pain,,2019,Q4,1,I,20191013.0,,20191220,20191220,DIR,,,FDA-CTU,,59.0,YR,,M,N,122.0,KG,20191220.0,N,PH,US,US,2019,Q4,Adult
171907891,17190789,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2019,Q4,Rash,,2019,Q4,1,I,20191126.0,,20191129,20191129,DIR,,,FDA-CTU,,67.0,YR,,M,N,,,20191126.0,N,PH,US,US,2019,Q4,Elderly
171907971,17190797,18,C,empagliflozin 25mg,,2,,,,,,,,,,,,,,2019,Q4,Nausea,,2019,Q4,1,I,20191219.0,,20191220,20191220,DIR,,,FDA-CTU,,69.0,YR,,M,N,110.25,KG,20191220.0,N,PH,US,US,2019,Q4,Elderly
171907971,17190797,18,C,empagliflozin 25mg,,2,,,,,,,,,,,,,,2019,Q4,Vomiting,,2019,Q4,1,I,20191219.0,,20191220,20191220,DIR,,,FDA-CTU,,69.0,YR,,M,N,110.25,KG,20191220.0,N,PH,US,US,2019,Q4,Elderly
172030341,17203034,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,5.0,MG,TABLET,,2019,Q4,Knee operation,,2019,Q4,1,I,20170501.0,20190504.0,20191226,20191226,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002014",BOEHRINGER INGELHEIM,,66.0,YR,,F,Y,68.0,KG,20191226.0,,MD,JP,JP,2019,Q4,Elderly
172030341,17203034,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,5.0,MG,TABLET,,2019,Q4,Osteoporosis,,2019,Q4,1,I,20170501.0,20190504.0,20191226,20191226,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-NB-002014",BOEHRINGER INGELHEIM,,66.0,YR,,F,Y,68.0,KG,20191226.0,,MD,JP,JP,2019,Q4,Elderly
172049571,17204957,3,C,Empagliflozin;Metformin,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,U,,,,,,,,,2019,Q4,Daydreaming,,2019,Q4,1,I,,20191213.0,20191227,20191227,EXP,,ES-AUROBINDO-AUR-APL-2019-107559,AUROBINDO,,60.0,YR,,F,Y,,,20191227.0,,CN,ES,ES,2019,Q4,Adult
172049571,17204957,3,C,Empagliflozin;Metformin,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,U,,,,,,,,,2019,Q4,Disorientation,,2019,Q4,1,I,,20191213.0,20191227,20191227,EXP,,ES-AUROBINDO-AUR-APL-2019-107559,AUROBINDO,,60.0,YR,,F,Y,,,20191227.0,,CN,ES,ES,2019,Q4,Adult
172049571,17204957,3,C,Empagliflozin;Metformin,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,U,,,,,,,,,2019,Q4,Vitamin B12 deficiency,,2019,Q4,1,I,,20191213.0,20191227,20191227,EXP,,ES-AUROBINDO-AUR-APL-2019-107559,AUROBINDO,,60.0,YR,,F,Y,,,20191227.0,,CN,ES,ES,2019,Q4,Adult
172138081,17213808,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,,20191219.0,20191230,20191230,EXP,,GR-EMD SERONO-9136962,EMD SERONO INC,"MPOULMPOU A, GRIVA T, KATSIGIANNI I, KYRIAKOU I, LILIOS C, MANGANARI E, TSAVOUSOGLOU X, DOURLIOU V, KARAGOUNIS K, MACHAIRA K. EUGLYCEMIC DIABETIC KETOACIDOSIS WITHIN ANTIDIABETIC TREATMENT WITH EMPAGLIFLOZIN: CASE REPORT. HELLENIC DIABETOLOGICAL CHRONICLE. 2019;32 (2):.",53.0,YR,,M,Y,,,20191230.0,,MD,GR,GR,2019,Q4,Adult
172163411,17216341,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,,10.0,MG,,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,,20191224.0,20191230,20191230,EXP,GB-MHRA-EYC 00214176,GB-ELI_LILLY_AND_COMPANY-GB201912012691,ELI LILLY AND CO,,65.0,YR,,F,Y,,,20191230.0,,CN,GB,GB,2019,Q4,Elderly
172193831,17219383,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,20191004.0,,20191209,20191209,DIR,,,FDA-CTU,,59.0,YR,,M,N,,,20191129.0,N,PH,US,US,2019,Q4,Adult
172193831,17219383,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2019,Q4,Dehydration,,2019,Q4,1,I,20191004.0,,20191209,20191209,DIR,,,FDA-CTU,,59.0,YR,,M,N,,,20191129.0,N,PH,US,US,2019,Q4,Adult
172238411,17223841,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2019,Q4,Urinary tract infection,,2019,Q4,1,I,20190628.0,,20191209,20191209,DIR,,,FDA-CTU,,73.0,YR,,M,N,133.0,KG,20191206.0,N,PH,US,US,2019,Q4,Elderly
172246901,17224690,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2019,Q4,Anorectal disorder,,2019,Q4,1,I,20191119.0,,20191209,20191209,DIR,,,FDA-CTU,,68.0,YR,,M,N,,,20191202.0,N,PH,US,US,2019,Q4,Elderly
172246901,17224690,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2019,Q4,Proctalgia,,2019,Q4,1,I,20191119.0,,20191209,20191209,DIR,,,FDA-CTU,,68.0,YR,,M,N,,,20191202.0,N,PH,US,US,2019,Q4,Elderly
172246901,17224690,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2019,Q4,Rash,,2019,Q4,1,I,20191119.0,,20191209,20191209,DIR,,,FDA-CTU,,68.0,YR,,M,N,,,20191202.0,N,PH,US,US,2019,Q4,Elderly
172251241,17225124,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2019,Q4,Dysuria,,2019,Q4,1,I,20191004.0,,20191209,20191209,DIR,,,FDA-CTU,,62.0,YR,,F,N,81.65,KG,20191129.0,N,PH,US,US,2019,Q4,Adult
172251241,17225124,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2019,Q4,Therapy cessation,,2019,Q4,1,I,20191004.0,,20191209,20191209,DIR,,,FDA-CTU,,62.0,YR,,F,N,81.65,KG,20191129.0,N,PH,US,US,2019,Q4,Adult
172252641,17225264,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,TABLET,QD,2019,Q4,Pollakiuria,,2019,Q4,1,I,20190628.0,,20191209,20191209,DIR,,,FDA-CTU,,73.0,YR,,M,N,133.0,KG,20191206.0,N,PH,US,US,2019,Q4,Elderly
172252641,17225264,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,TABLET,QD,2019,Q4,Urinary tract infection,,2019,Q4,1,I,20190628.0,,20191209,20191209,DIR,,,FDA-CTU,,73.0,YR,,M,N,133.0,KG,20191206.0,N,PH,US,US,2019,Q4,Elderly
172280131,17228013,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,12.5,MG,,QD,2019,Q4,Hyperglycaemia,,2019,Q4,1,I,20191121.0,,20191209,20191209,DIR,,,FDA-CTU,,71.0,YR,,M,N,108.0,KG,20191204.0,N,PH,US,US,2019,Q4,Elderly
91168517,9116851,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2019,Q4,Abdominal pain,,2019,Q4,7,F,201302.0,20191108.0,20130225,20191115,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20191115.0,,MD,CA,CA,2019,Q4,Adult
91168517,9116851,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2019,Q4,Abdominal pain upper,,2019,Q4,7,F,201302.0,20191108.0,20130225,20191115,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20191115.0,,MD,CA,CA,2019,Q4,Adult
91168517,9116851,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2019,Q4,Blood pressure systolic increased,,2019,Q4,7,F,201302.0,20191108.0,20130225,20191115,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20191115.0,,MD,CA,CA,2019,Q4,Adult
91168517,9116851,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2019,Q4,Blood prolactin abnormal,,2019,Q4,7,F,201302.0,20191108.0,20130225,20191115,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20191115.0,,MD,CA,CA,2019,Q4,Adult
91168517,9116851,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2019,Q4,Brain neoplasm,,2019,Q4,7,F,201302.0,20191108.0,20130225,20191115,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20191115.0,,MD,CA,CA,2019,Q4,Adult
91168517,9116851,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2019,Q4,Cerebrospinal fluid leakage,,2019,Q4,7,F,201302.0,20191108.0,20130225,20191115,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20191115.0,,MD,CA,CA,2019,Q4,Adult
91168517,9116851,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2019,Q4,Diabetes mellitus,,2019,Q4,7,F,201302.0,20191108.0,20130225,20191115,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20191115.0,,MD,CA,CA,2019,Q4,Adult
91168517,9116851,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2019,Q4,Fatigue,,2019,Q4,7,F,201302.0,20191108.0,20130225,20191115,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20191115.0,,MD,CA,CA,2019,Q4,Adult
91168517,9116851,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2019,Q4,Heart rate decreased,,2019,Q4,7,F,201302.0,20191108.0,20130225,20191115,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20191115.0,,MD,CA,CA,2019,Q4,Adult
91168517,9116851,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2019,Q4,Hormone level abnormal,,2019,Q4,7,F,201302.0,20191108.0,20130225,20191115,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20191115.0,,MD,CA,CA,2019,Q4,Adult
91168517,9116851,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2019,Q4,Memory impairment,,2019,Q4,7,F,201302.0,20191108.0,20130225,20191115,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20191115.0,,MD,CA,CA,2019,Q4,Adult
91168517,9116851,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2019,Q4,Nausea,,2019,Q4,7,F,201302.0,20191108.0,20130225,20191115,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20191115.0,,MD,CA,CA,2019,Q4,Adult
91168517,9116851,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2019,Q4,Needle issue,,2019,Q4,7,F,201302.0,20191108.0,20130225,20191115,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20191115.0,,MD,CA,CA,2019,Q4,Adult
91168517,9116851,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2019,Q4,Urinary tract infection,,2019,Q4,7,F,201302.0,20191108.0,20130225,20191115,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20191115.0,,MD,CA,CA,2019,Q4,Adult
